<SEC-DOCUMENT>0001654954-25-005610.txt : 20250514
<SEC-HEADER>0001654954-25-005610.hdr.sgml : 20250514
<ACCEPTANCE-DATETIME>20250514170030
ACCESSION NUMBER:		0001654954-25-005610
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		66
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250514
DATE AS OF CHANGE:		20250514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PALATIN TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0000911216
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				954078884
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15543
		FILM NUMBER:		25946864

	BUSINESS ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		609-495-2200

	MAIL ADDRESS:	
		STREET 1:		4B CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERFILM INC
		DATE OF NAME CHANGE:	19930825
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ptn_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ffd="http://xbrl.sec.gov/ffd/2024q2" xmlns:ptn="http://ptn.com/20250331"><head><title>ptn_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2024-07-01to2025-03-31" id="ixv-9337">0000911216</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2024-07-01to2025-03-31" format="ixt:booleanfalse" id="ixv-9338">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2024-07-01to2025-03-31" id="ixv-9339">--06-30</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2024-07-01to2025-03-31" id="ixv-9340">Q3</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2024-07-01to2025-03-31" id="ixv-9341">2025</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" unitRef="USDPShares" decimals="INF" id="ixv-9342">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-9343">10000000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-9344">4030</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" unitRef="USDPShares" decimals="INF" id="ixv-9345">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-9346">300000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-03-31" unitRef="Shares" decimals="0" id="ixv-9347">28557246</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" unitRef="Shares" decimals="0" id="ixv-9348">17926640</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-9349">4030</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-9350">4030</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" unitRef="Shares" decimals="0" id="ixv-9351">4030</ix:nonFraction><ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" contextRef="From2024-07-01to2025-03-31" id="ixv-9352">false</ix:nonNumeric><ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" contextRef="From2024-07-01to2025-03-31" id="ixv-9353">false</ix:nonNumeric><ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" contextRef="From2024-07-01to2025-03-31" id="ixv-9354">false</ix:nonNumeric><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" contextRef="From2024-07-01to2025-03-31" id="ixv-9355">false</ix:nonNumeric><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-01-01to2025-03-31" unitRef="Shares" decimals="0" id="ixv-9356">17749116</ix:nonFraction><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-03-31" unitRef="Shares" decimals="0" id="ixv-9357">8520332</ix:nonFraction><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" contextRef="From2023-07-01to2024-03-31" unitRef="Shares" decimals="0" id="ixv-9358">279700</ix:nonFraction><ix:nonFraction name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" contextRef="From2024-07-01to2025-03-31" unitRef="Shares" decimals="0" sign="-" format="ixt:numdotdecimal" id="ixv-9359">14338</ix:nonFraction><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-06-20_ptn_StockWarrantsMember" unitRef="USDPShares" decimals="INF" id="ixv-9360">1.88</ix:nonFraction><ix:nonFraction name="ptn:PurchaseOfWarrantOfCommonStockSeriesA" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember" unitRef="Shares" decimals="0" id="ixv-9361">4849915</ix:nonFraction><ix:nonFraction name="ptn:PurchaseOfWarrantOfCommonStockSeriesA" contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember" unitRef="Shares" decimals="0" id="ixv-9362">3907679</ix:nonFraction><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember" unitRef="USD" decimals="0" id="ixv-9363">6078561</ix:nonFraction><ix:nonFraction name="ptn:WarrantsToPurchaseShares" contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember" unitRef="Shares" decimals="0" id="ixv-9364">1953839</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ptn-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="From2024-07-01to2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-05-08_us-gaap_SubsequentEventMember_ptn_SeriesFWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesFWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-05-08_us-gaap_SubsequentEventMember_ptn_SeriesGWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesGWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-05-01to2025-05-08_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-04-01to2025-05-14_us-gaap_SubsequentEventMember_ptn_TwoThousandTwentyFiveSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptn:TwoThousandTwentyFiveSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-05-08_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_ptn_TwoThousandTwentyFiveSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptn:TwoThousandTwentyFiveSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-01-29_ptn_PrivateWarrantSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptn:PrivateWarrantSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-01-29_ptn_PrivateWarrantSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptn:PrivateWarrantSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-02-10_us-gaap_PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2025-02-01to2025-02-10_us-gaap_PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-01-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-02-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-04-01to2023-04-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-12-01to2024-12-13_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-13_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-20_ptn_StockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-10-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-10-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-01-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2023-10-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-07-01to2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2022-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-02-01to2025-02-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptn:TwentyTwentyThreeEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptn:TwentyTwentyThreeEquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:FebruaryTwoZeroTwoFiveSeriesEWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoZeroTwoThreePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:DecemberToZeroTwoFourSeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JuneTwoThousandTwentyFourSerisBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:DecemberTwoThousandTwentyFourSerisCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_MayTwoThousandTwentyTwoWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:MayTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CumulativeFromInceptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_ptn_OneToThreeYearsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OneToThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_ptn_CurrentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_ptn_FourToFiveYearsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:FourToFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2017-11-01to2017-11-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2017-09-01to2017-09-06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2024-03-31_us-gaap_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_ptn_ContingentlyRedeemableWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-07-01to2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-01-01to2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2025-01-01to2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStocksMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-05-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000911216</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2024-07-01to2025-03-31" id="ixv-10206">10-Q</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:boolballotbox" id="ixv-10207">&#9746;</ix:nonNumeric>&#160;</strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">For the quarterly period ended <strong><span style="text-decoration:underline"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2024-07-01to2025-03-31" format="ixt:datemonthdayyearen" id="ixv-10208">March 31, 2025</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">or</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:boolballotbox" id="ixv-10209">&#9744;</ix:nonNumeric> </strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">For the transition period from ___________ to __________</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Commission file number: <strong><span style="text-decoration:underline"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2024-07-01to2025-03-31" id="ixv-10210">001-15543</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_10qimg18.jpg" alt="ptn_10qimg18.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2024-07-01to2025-03-31" id="ixv-10211">PALATIN TECHNOLOGIES, INC.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:stateprovnameen" id="ixv-10212">Delaware</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2024-07-01to2025-03-31" id="ixv-10213">95-4078884</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(State or other jurisdiction of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">incorporation or organization)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(I.R.S. Employer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Identification No.)</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2024-07-01to2025-03-31" id="ixv-10214">4B Cedar Brook Drive</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2024-07-01to2025-03-31" id="ixv-10215">Cranbury</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:stateprovnameen" id="ixv-10216">New Jersey</ix:nonNumeric></strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2024-07-01to2025-03-31" id="ixv-10217">08512</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Address of principal executive offices)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2024-07-01to2025-03-31" id="ixv-10218">609</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2024-07-01to2025-03-31" id="ixv-10219">495&#8209;2200</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Registrant&#8217;s telephone number, including area code)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Title of Each Class</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Trading Symbol</strong></p></td><td style="width:5%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Name of Each Exchange </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>on Which Registered</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2024-07-01to2025-03-31" id="ixv-10220">Common Stock, par value $0.01 per share</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2024-07-01to2025-03-31" id="ixv-149">PTN<sup style="vertical-align:super">1</sup></ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:exchnameen" id="ixv-10221">NYSE</ix:nonNumeric> American</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="From2024-07-01to2025-03-31" id="ixv-10222">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="From2024-07-01to2025-03-31" id="ixv-10223">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;No&#160;&#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act: </p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:entityfilercategoryen" id="ixv-10224">Non-accelerated filer</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller reporting company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:boolballotbox" id="ixv-10225">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging growth company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:boolballotbox" id="ixv-10226">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; Yes <ix:nonNumeric name="dei:EntityShellCompany" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:boolballotbox" id="ixv-10227">&#9744;</ix:nonNumeric>&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate the number of shares outstanding of each of the registrant&#8217;s classes of common stock, as of the latest practicable date (May 14, 2025): <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-05-14" format="ixt:numdotdecimal" unitRef="Shares" decimals="INF" id="ixv-10228">46,479,861</ix:nonFraction></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">__________________________________________&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><sup style="vertical-align:super">1</sup> Palatin Technologies, Inc. (the &#8220;Company&#8221;) has received a notice from the&#160;NYSE American&#160;LLC (&#8220;NYSE American&#8221;) stating that the NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company&#8217;s Common Stock. NYSE American commenced delisting proceedings in connection with the foregoing determination, and trading the Company&#8217;s common stock was suspended on May 7, 2025. Since May 8, 2025, the Company&#8217;s common stock has traded on the Pink Market of the OTC Markets Group under the trading symbol &#8220;PTNT&#8221;. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC</strong>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="TOC">Table of Contents</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Page</strong></p></td><td style="width:1%;"/></tr><tr style="height:15px"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px"><td colspan="2" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><a href="#p1">PART I &#8211; FINANCIAL INFORMATION</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><a href="#i1">Item 1. Financial Statements (Unaudited)</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#bs">Consolidated Balance Sheets as of March 31, 2025 and June 30, 2024</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#cso">Consolidated Statements of Operations for the Three and Nine Months Ended March 31, 2025 and 2024</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#defict">Consolidated Statements of Changes in Stockholders&#8217; Deficiency for the Three and Nine Months Ended March 31, 2025 </a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#equity">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficiency) for the Three and Nine Months Ended March 31, 2024</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#cf">Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2025 and 2024</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">9</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:left;"><a href="#notes">Notes to Consolidated Financial Statements</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><a href="#i2">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">22</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><a href="#i3">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">26</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><a href="#i4">Item 4. Controls and Procedures</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">26</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><a href="#p2">PART II &#8211; OTHER INFORMATION</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#p2i1">Item 1. Legal Proceedings</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">27</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#p2i1a">Item 1A. Risk Factors</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">27</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#p2i2">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">28</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#p2i3">Item 3. Defaults Upon Senior Securities</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">28</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#p2i4">Item 4. Mine Safety Disclosures</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">28</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#p2i5">Item 5. Other Information</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">28</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong><a href="#i6">Item 6. Exhibits</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">29</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><a href="#sig">Signatures</a></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">30</p></td><td/></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Special Note Regarding Forward-Looking Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In this Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; the &#8220;Company&#8221; or &#8220;Palatin&#8221; mean Palatin Technologies, Inc. and its subsidiary. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Statements in this Quarterly Report, as well as oral statements that may be made by us or by our officers, directors, or employees acting on our behalf, that are not historical facts constitute &#8220;forward-looking statements,&#8221; which are made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The forward-looking statements in this Quarterly Report do not constitute guarantees of future performance. Investors are cautioned that statements that are not strictly historical facts contained in this Quarterly Report, including, without limitation, the following are forward looking statements:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our significant operating losses since our inception and our need to obtain additional financing has caused management to determine there is substantial doubt regarding our ability to continue as a going concern;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays in receiving funds as a result of economic disruptions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectation that we will incur losses for the foreseeable future and may never achieve or maintain profitability;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our business, financial condition, and results of operations may be adversely affected by increases in costs of and delays in conducting human clinical trials and the performance of our contractors and suppliers, reduction in our productivity or the productivity of our contractors and suppliers, supply chain constraints, and labor shortages;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">whether Cosette Pharmaceuticals, Inc. (&#8220;Cosette&#8221;), which acquired our product Vyleesi&#174; (the trade name for bremelanotide for treatment of hyperactive sexual desire disorder in premenopausal women) in December 2023, will have sufficient sales to generate significant milestone payments under our purchase agreement with Cosette;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the results of clinical trials with our late-stage products, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024 with topline results announced in March 2025, in which co-administration demonstrated an increased weight loss over tirzepatide alone; PL9643, an ophthalmic peptide solution for dry eye disease (&#8220;DED&#8221;), which completed a first Phase 3 clinical trials with top line results announced from the Phase 3 clinical trial in the first quarter of calendar year 2024 and which has concluded a positive Type C meeting with the FDA and can, depending on financial resources and product development priority, commence patient enrollment as early as the first half of calendar year 2025; and PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials in the third quarter of calendar year 2022 and announced topline results in March 2025, with one-third of patients dosed with PL8177 achieving clinical remission while the placebo group saw no clinical remission;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">estimates of our expenses, future revenue and capital requirements;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to achieve profitability;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to advance product candidates into, and successfully complete, clinical trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the timing or likelihood of regulatory filings and approvals;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectations regarding the clinical efficacy and utility of our melanocortin agonist product candidates for treatment of inflammatory and autoimmune related diseases and disorders, including ocular indications;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to compete with other products and technologies treating the same or similar indications as our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the ability of our third-party collaborators to timely carry out their duties under their agreements with us;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to recognize the potential value of our licensing arrangements with third parties;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the potential to achieve revenues from the sale of our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to obtain adequate reimbursement from private insurers and other healthcare payers;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to maintain product liability insurance at a reasonable cost or in sufficient amounts, if at all;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the performance and retention of our management team, senior staff professionals, other employees, and third-party contractors and consultants;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology in the United States and throughout the world;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our compliance with federal and state laws and regulations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the timing and costs associated with obtaining regulatory approval for our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the impact of fluctuations in foreign exchange rates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the impact of any geopolitical instability, economic uncertainty, inflationary pressure, supply chain disruptions, tariffs, financial markets volatility, or capital markets disruption resulting from the ongoing Russia-Ukraine and Israel-Hamas military conflicts or otherwise, and any resulting effects on our revenue, financial condition, or results of operations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the impact of legislative or regulatory healthcare reforms in the United States; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">our ability to adapt to changes in global economic conditions as well as competing products and technologies.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Such forward-looking statements involve risks, uncertainties and other factors that could cause our actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Our future operating results are subject to risks and uncertainties and are dependent upon many factors, including, without limitation, the risks identified under the caption &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report, and any of those made in our other reports filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Except as required by law, we do not intend, and undertake no obligation, to publicly update forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><span class="atag" style="display: inline" id="p1"><strong>PART I</strong> <strong>&#8211; FINANCIAL INFORMATION</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span class="atag" style="display: inline" id="i1"><strong>Item 1.&#160; Financial Statements.</strong> </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC</strong>.</p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and Subsidiary</strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="bs">Consolidated Balance Sheets</span></strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(unaudited)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>ASSETS</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2795" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,520,062</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2796" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,527,396</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other receivables</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2797" name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">271,037</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2798" name="us-gaap:OtherReceivablesNetCurrent" contextRef="AsOf2024-06-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses and other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2799" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">442,178</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2800" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">242,272</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2801" name="us-gaap:AssetsCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,233,277</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2802" name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,769,668</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2803" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">182,437</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2804" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">388,361</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right-of-use assets - operating leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2805" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">255,863</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2806" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">527,321</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2807" name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">56,916</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2808" name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">56,916</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2809" name="us-gaap:Assets" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,728,493</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2810" name="us-gaap:Assets" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,742,266</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>LIABILITIES AND STOCKHOLDERS&#8217; DEFICIENCY</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2813" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,770,567</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2814" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,101,929</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2815" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">506,460</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2816" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,185,046</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Short-term operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2817" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">194,972</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2818" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">380,542</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Short-term finance lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2819" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2820" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">46,014</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2821" name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,576,350</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2822" name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">944,150</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2823" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,048,349</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2824" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,657,681</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Long-term operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2825" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">67,248</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2826" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">163,782</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other long-term liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2827" name="us-gaap:OtherLongTermDebt" contextRef="AsOf2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2828" name="us-gaap:OtherLongTermDebt" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,032,300</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2829" name="us-gaap:Liabilities" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,115,597</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2830" name="us-gaap:Liabilities" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,853,763</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commitments and contingencies (Note 12)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stockholders&#8217; deficiency:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock of $<ix:nonFraction id="fid_348" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction> par value &#8211; authorized <ix:nonFraction id="fid_350" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,000,000</ix:nonFraction> shares: shares issued and outstanding designated as follows:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Series A Convertible: authorized <ix:nonFraction id="fid_351" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction> shares as of March 31, 2025: issued and outstanding <ix:nonFraction id="fid_362" name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction> shares as of March 31, 2025 and June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2833" name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2834" name="us-gaap:PreferredStockValue" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common stock of $<ix:nonFraction id="fid_354" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction> par value &#8211; authorized <ix:nonFraction id="fid_356" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">300,000,000</ix:nonFraction> shares: issued and outstanding <ix:nonFraction id="fid_359" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">28,557,246</ix:nonFraction> shares as of March 31, 2025 and <ix:nonFraction id="fid_358" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,926,640</ix:nonFraction> shares as of June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2835" name="us-gaap:CommonStockValue" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">285,572</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2836" name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">179,266</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2837" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">450,171,385</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2838" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">441,475,747</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2839" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">456,844,101</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2840" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">441,766,550</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total stockholders&#8217; deficiency</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2841" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,387,104</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2842" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">111,497</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total liabilities and stockholders&#8217; deficiency</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2843" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,728,493</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2844" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,742,266</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="17" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p></td></tr><tr style="height:15px"><td colspan="17" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and Subsidiary</strong></p></td></tr><tr style="height:15px"><td colspan="17" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="cso">Consolidated Statements of Operations</span></strong></p></td></tr><tr style="height:15px"><td colspan="17" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(unaudited)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended March 31</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Nine Months Ended March 31</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">REVENUES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Product revenue, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2914" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2915" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2916" name="us-gaap:Revenues" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2917" name="us-gaap:Revenues" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,140,090</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">OPERATING EXPENSES</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cost of products sold</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2919" name="us-gaap:ProductionCosts" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2920" name="us-gaap:ProductionCosts" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2921" name="us-gaap:ProductionCosts" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2922" name="us-gaap:ProductionCosts" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">97,637</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2923" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,755,158</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2924" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,159,686</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2925" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,928,391</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2926" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">17,728,516</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Selling, general and administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2927" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,474,019</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2928" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,033,410</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2929" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,176,794</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2930" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,266,267</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Loss (Gain) on sale of Vyleesi</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2931" name="ptn:GainLossOnSaleOfVylessi" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2932" name="ptn:GainLossOnSaleOfVylessi" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">25,202</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2933" name="ptn:GainLossOnSaleOfVylessi" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,500,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2934" name="ptn:GainLossOnSaleOfVylessi" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,798,280</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Gain on purchase commitment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2935" name="ptn:GainLossOnPurchaseCommitment" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">416,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2936" name="ptn:GainLossOnPurchaseCommitment" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2937" name="ptn:GainLossOnPurchaseCommitment" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">416,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2938" name="ptn:GainLossOnPurchaseCommitment" contextRef="From2023-07-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2939" name="us-gaap:OperatingExpenses" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,813,177</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2940" name="us-gaap:OperatingExpenses" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,218,298</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2941" name="us-gaap:OperatingExpenses" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,189,185</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2942" name="us-gaap:OperatingExpenses" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,294,140</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Loss from operations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2943" name="us-gaap:OperatingIncomeLoss" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,813,177</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2944" name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">9,218,298</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2945" name="us-gaap:OperatingIncomeLoss" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">15,189,185</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2946" name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">14,154,050</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">OTHER INCOME (EXPENSE)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Investment income</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2948" name="us-gaap:InvestmentIncomeNet" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">31,452</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2949" name="us-gaap:InvestmentIncomeNet" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">139,273</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2950" name="us-gaap:InvestmentIncomeNet" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">139,072</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2951" name="us-gaap:InvestmentIncomeNet" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">272,929</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Foreign currency transaction (loss) gain</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2952" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">27,900</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2953" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">215,600</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2954" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">15,900</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2955" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">68,653</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Interest expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2956" name="us-gaap:InterestExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,795</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2957" name="us-gaap:InterestExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,254</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2958" name="us-gaap:InterestExpense" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,538</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2959" name="us-gaap:InterestExpense" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,741</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Offering expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2960" name="us-gaap:OtherExpenses" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2961" name="us-gaap:OtherExpenses" contextRef="From2024-01-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2962" name="us-gaap:OtherExpenses" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2963" name="us-gaap:OtherExpenses" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">696,912</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Change in fair value of warrant liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2964" name="ptn:WarrantsGainLossOnWarrantsNet" contextRef="From2025-01-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2965" name="ptn:WarrantsGainLossOnWarrantsNet" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">429,029</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2966" name="ptn:WarrantsGainLossOnWarrantsNet" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2967" name="ptn:WarrantsGainLossOnWarrantsNet" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,962,562</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total other income (expense), net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2968" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,757</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2969" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">782,648</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2970" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">111,634</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2971" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,331,633</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NET LOSS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2972" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,811,420</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2973" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,435,650</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2974" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">15,077,551</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2975" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">21,485,683</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted net loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2976" name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.18</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2977" name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.53</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2978" name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.68</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2979" name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">1.53</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2980" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">26,344,584</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2981" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">15,792,421</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2982" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">22,245,153</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2983" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">14,013,848</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="29" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p></td></tr><tr style="height:15px"><td colspan="29" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and Subsidiary</strong></p></td></tr><tr style="height:15px"><td colspan="29" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="defict">Consolidated Statements of Changes in Stockholders&#8217; Deficiency</span></strong></p></td></tr><tr style="height:15px"><td colspan="29" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(unaudited)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Three Months Ended March 31, 2025</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stockholders' Deficiency</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Series A Convertible</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Additional</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Accumulated </strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Paid-in Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance December 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2984" name="us-gaap:SharesIssued" contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2986" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2985" name="us-gaap:SharesIssued" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">23,455,846</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2987" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">234,558</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2988" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">445,416,974</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2989" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">452,032,681</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2990" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,381,109</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2991" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2992" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2993" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">347,691</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2994" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2995" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">347,691</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Sale of common stock, net of costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2998" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2025-01-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2997" name="ptn:SaleOfCommonStockNetOfCostsShares" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,101,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2999" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">51,014</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3000" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,406,506</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3001" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3002" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,457,520</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3003" name="ptn:WarrantExercisesAmount" contextRef="From2025-01-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3004" name="ptn:WarrantExercisesAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3005" name="ptn:WarrantExercisesAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">214</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3006" name="ptn:WarrantExercisesAmount" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3007" name="ptn:WarrantExercisesAmount" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">214</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3008" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3009" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3010" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3011" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,811,420</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3012" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,811,420</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3013" name="us-gaap:SharesIssued" contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3015" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3014" name="us-gaap:SharesIssued" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">28,557,246</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3016" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">285,572</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3017" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">450,171,385</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3018" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">456,844,101</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3019" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,387,104</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Nine Months Ended March 31, 2025</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stockholders' Deficiency</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Series A Convertible</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><strong>Additional</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Accumulated </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Paid-in Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3020" name="us-gaap:SharesIssued" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3022" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3021" name="us-gaap:SharesIssued" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,926,640</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3023" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">179,266</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3024" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">441,475,747</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3025" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">441,766,550</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3026" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">111,497</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3029" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3028" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">232,941</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3030" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,329</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3031" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,043,340</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3032" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3033" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,045,669</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Withholding taxes related to restricted stock units</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3036" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3035" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">54,691</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3037" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">547</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3038" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">98,935</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3039" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3040" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">99,482</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Shares released from abeyance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3043" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3042" name="ptn:SharesReleasedFromAbeyanceShares" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,443,277</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3044" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,433</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3045" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">14,433</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3046" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3047" name="ptn:SharesReleasedFromAbeyanceAmount" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Sale of common stock, net of costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3050" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3049" name="ptn:SaleOfCommonStockNetOfCostsShares" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,101,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3051" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">51,014</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3052" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,406,506</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3053" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3054" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,457,520</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3057" name="ptn:WarrantExercisesAmount" contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3056" name="ptn:WarrantExercisesShares" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,907,679</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3058" name="ptn:WarrantExercisesAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">39,077</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3059" name="ptn:WarrantExercisesAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,359,160</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3060" name="ptn:WarrantExercisesAmount" contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3061" name="ptn:WarrantExercisesAmount" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,398,237</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3062" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3063" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3064" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3065" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">15,077,551</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3066" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">15,077,551</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3067" name="us-gaap:SharesIssued" contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3069" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3068" name="us-gaap:SharesIssued" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">28,557,246</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3070" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">285,572</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3071" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">450,171,385</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3072" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">456,844,101</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3073" name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">6,387,104</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="33" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p></td></tr><tr style="height:15px"><td colspan="33" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and Subsidiary</strong></p></td></tr><tr style="height:15px"><td colspan="33" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="equity">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficiency)</span></strong></p></td></tr><tr style="height:15px"><td colspan="33" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(unaudited)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Three Months Ended March 31, 2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stockholders' Equity (Deficiency)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><strong>Contingently Redeemable</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Series A Convertible</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Additional</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Paid-in</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><strong>Accumulated</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3076" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">423,100</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3074" name="us-gaap:SharesIssued" contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3077" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3075" name="us-gaap:SharesIssued" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">14,305,137</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3078" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">143,051</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3079" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">413,552,953</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3080" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">425,080,470</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3081" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">11,384,426</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Stock-based compensation</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3082" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3083" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3084" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3085" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">390,195</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3086" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3087" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">390,195</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Conversion of liability classified warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3088" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3089" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3090" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3091" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,423,203</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3092" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3093" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,423,203</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Sale of common stock, net of costs</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_3200" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td style="BORDER-TOP: #000000 0px solid; BORDER-RIGHT: #000000 0px solid; BORDER-BOTTOM: #000000 0px solid; BORDER-LEFT: #000000 0px solid; background-color:#000000;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;-</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_3193" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_3195" name="ptn:SaleOfCommonStockNetOfCostsShares" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,831,503</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_3196" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,315</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_3197" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,144,198</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_3198" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;<ix:nonFraction id="fid_3199" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,162,513</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Reclassification of contingently redeemable warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3094" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">423,100</ix:nonFraction></td><td style="vertical-align:bottom;white-space: nowrap;">)</td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3095" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3096" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3097" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">423,100</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3098" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3099" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">423,100</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Net loss</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3100" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3101" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3102" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3103" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3104" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,435,650</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3105" name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">8,435,650</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance March 31, 2024</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3108" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3106" name="us-gaap:SharesIssued" contextRef="AsOf2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3109" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3107" name="us-gaap:SharesIssued" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">16,136,640</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3110" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">161,366</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3111" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">434,933,649</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3112" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">433,516,120</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;">)</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3113" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,578,935</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Nine Months Ended March 31, 2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"/><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="26"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Stockholders' Equity (Deficiency)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Contingently Redeemable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Series A Convertible</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid-in</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Warrants</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style=" background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Capital</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Deficit</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance June 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3116" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">263,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3114" name="us-gaap:SharesIssued" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3117" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3115" name="us-gaap:SharesIssued" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">11,656,714</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3118" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">116,567</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3119" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">409,933,959</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3120" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">412,030,437</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3121" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,979,871</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3124" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3125" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3123" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">98,372</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3126" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">984</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3127" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,329,518</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3128" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3129" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,330,502</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Withholding taxes related to restricted stock units</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3132" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3133" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3131" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">25,467</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3134" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">255</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3135" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">56,146</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3136" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3137" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">56,401</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Sale of common stock, net of costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3140" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3141" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3139" name="ptn:SaleOfCommonStockNetOfCostsShares" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,048,530</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3142" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,485</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3143" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,673,397</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3144" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3145" name="ptn:SaleOfCommonStockNetOfCostsAmount" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,693,882</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Conversion of liability classified warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3146" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3147" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3148" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3149" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,423,203</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3150" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3151" name="ptn:ConversionOfLiabilityClassifiedWarrant" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,423,203</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Conversion of liability classified warrants upon warrant exercise</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3154" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3155" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3153" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,358,491</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3156" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,585</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3157" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,366,318</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3158" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3159" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,389,903</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Reclassification of contingently redeemable warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3160" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">263,400</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3161" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3162" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3163" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">263,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3164" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3165" name="ptn:ReclassificationOfContingentlyRedeemableWarrants" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">263,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:8pt">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3166" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3167" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3168" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3169" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3170" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">21,485,683</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3171" name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">21,485,683</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Balance March 31, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3174" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_ptn_ContingentlyRedeemableWarrantsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%; background-color:#000000;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3172" name="us-gaap:SharesIssued" contextRef="AsOf2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3175" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_ptn_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3173" name="us-gaap:SharesIssued" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">16,136,640</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3176" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">161,366</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3177" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">434,933,649</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_3178" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">433,516,120</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3179" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,578,935</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>and Subsidiary</strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="cf">Consolidated Statements of Cash Flows</span></strong></p></td></tr><tr style="height:15px"><td colspan="9" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(unaudited)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Nine Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2846" name="us-gaap:ProfitLoss" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">15,077,551</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2847" name="us-gaap:ProfitLoss" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">21,485,683</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2849" name="us-gaap:DepreciationAndAmortization" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">205,924</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2850" name="us-gaap:DepreciationAndAmortization" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">257,115</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Decrease in right-of-use asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2851" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">271,458</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2852" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">260,832</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Unrealized foreign currency transaction loss (gain)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2853" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">15,900</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2854" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">68,653</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Stock-based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2855" name="us-gaap:ShareBasedCompensation" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,045,669</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2856" name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,330,502</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Change in fair value of liability classified warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2857" name="ptn:ChangeInFairValueOfLiabilityClassifiedWarrants" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2858" name="ptn:ChangeInFairValueOfLiabilityClassifiedWarrants" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,962,562</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Gain on sale of Vyleesi</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2859" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,500,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2860" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,798,280</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Gain on purchase commitment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2861" name="ptn:GainLossOnPurchaseCommitment" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">416,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2862" name="ptn:GainLossOnPurchaseCommitment" contextRef="From2023-07-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Changes in operating assets and liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:30pt">Accounts receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2864" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2865" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,915,760</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:30pt">Other receivables</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2866" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">271,037</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2867" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="From2023-07-01to2024-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:30pt">Prepaid expenses and other assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2868" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">199,906</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2869" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">1,206,564</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:30pt">Inventories</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2870" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2871" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,154,355</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:30pt">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2872" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,668,638</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2873" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">860,280</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:30pt">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2874" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">3,678,586</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2875" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,171,297</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:30pt">Operating lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2876" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">282,104</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2877" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">264,875</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:30pt">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2878" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2879" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,118,897</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:40pt">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2880" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">17,217,595</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2881" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">24,988,985</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Maturity of marketable securities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2883" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2884" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,992,890</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Proceeds from sale of Vyleesi</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2885" name="ptn:ProceedsFromSaleOfOtherAssets" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,500,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2886" name="ptn:ProceedsFromSaleOfOtherAssets" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,500,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2887" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2888" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">37,615</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:40pt">Net cash provided by investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2889" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,500,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2890" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,455,275</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Payment of withholding taxes related to restricted stock units</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2892" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">99,482</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2893" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">56,401</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Proceeds from the sale of common stock and warrants, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2894" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,457,520</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2895" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,693,779</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Payment of finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2896" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">46,014</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2897" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">79,265</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Proceeds from exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2898" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,398,237</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2899" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">103</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:40pt">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2900" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,710,261</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2901" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,558,216</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2902" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">7,007,334</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2903" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,024,506</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH AND CASH EQUIVALENTS, beginning of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2904" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,527,396</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2905" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,989,582</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">CASH AND CASH EQUIVALENTS, end of period</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2906" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,520,062</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2907" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,014,088</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">SUPPLEMENTAL CASH FLOW INFORMATION:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2909" name="us-gaap:InterestPaidNet" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,538</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2910" name="us-gaap:InterestPaidNet" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,741</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Conversion of liability classified warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2912" name="ptn:ConversionOfLiabilityClassifiedWarrants" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,423,203</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:20pt">Conversion of liability classified warrants upon warrant exercise</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3180" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_3181" name="ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,389,903</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="notes">Notes to Consolidated Financial Statements</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1937" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true" continuedAt="cont_587a4a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(1) ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Nature of Business </em>- Palatin Technologies, Inc. (&#8220;Palatin&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company&#8217;s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Melanocortin Receptor System.</em> The melanocortin receptor system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s prior commercial product, Vyleesi&#174;, was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2019 for the treatment of hypoactive sexual desire disorder (&#8220;HSDD&#8221;) in premenopausal women. As disclosed in Note 5, this product was acquired by Cosette Pharmaceuticals, Inc. (&#8220;Cosette&#8221;) on December 19, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our new product development activities focus primarily on use of bremelanotide, or other MC4r agonists, with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, with topline results announced in March 2025, in which co-administration of bremelanotide and tirzepatide demonstrated an increased weight loss over tirzepatide alone.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is also developing, dependent on resources for development activities, MC1r agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1r agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Business Risks and Liquidity &#8211; </em>The Company has incurred operating losses and negative cash flows from operations since inception and will need additional funding to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit as of March 31, 2025 of $<ix:nonFraction id="fid_1444" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">456,844,101</ix:nonFraction> and a net loss for the three and nine months ended March 31, 2025 of $<ix:nonFraction id="fid_2317" name="us-gaap:NetIncomeLoss" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,811,420</ix:nonFraction> and $<ix:nonFraction id="fid_1445" name="us-gaap:NetIncomeLoss" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">15,077,551</ix:nonFraction>, respectively. The Company anticipates incurring significant expenses in the future as a result of spending on its development programs and will require substantial additional financing or revenues to continue to fund its planned activities. To achieve sustained profitability, if ever, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals, and successfully manufacture and market such technologies and proposed products. The time required to reach sustained profitability is highly uncertain, and the Company may never be able to achieve profitability on a sustained basis, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of March 31, 2025, the Company&#8217;s cash and cash equivalents were $<ix:nonFraction id="fid_1447" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,520,602</ix:nonFraction> and current liabilities were $<ix:nonFraction id="fid_1448" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,048,349</ix:nonFraction>. Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the Company&#8217;s MC1r and MC4r programs, and development of other portfolio products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company follows the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, <em>Presentation of Financial Statements &#8212; Going Concern</em>, which requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company&#8217;s ability to meet its obligations for the next year.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:continuation id="cont_587a4a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Based on our available cash and cash equivalents as of March 31, 2025, management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. The Company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm the Company&#8217;s business, results of operations, and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company could be forced to make additional reductions in certain expenditures. This could include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If the Company is unable to raise capital when needed or enter into a strategic transaction, then the Company could be required to cease operations, which could cause its stockholders to lose all or part of their investment. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Assuming no additional funding and based on its current operating and development plans, the Company expects that existing cash and cash equivalents as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the second half of calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company may receive contingent, sales-based milestone payments of up to $<ix:nonFraction id="fid_2162" name="ptn:SalesBasedMilestonePayments" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">159,000,000</ix:nonFraction> on sales of Vyleesi by Cosette and its licensees.<em> </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Concentrations &#8211;</em> Concentrations in the Company&#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are primarily invested in one investment account sponsored by a large financial institution.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1945" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(2) BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three and nine months ended March 31, 2025, may not necessarily be indicative of the results of operations expected for the full fiscal year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2024, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), which includes consolidated financial statements as of June 30, 2024 and 2023 and for the fiscal years then ended.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1938" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true" continuedAt="cont_bc3f4e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1953" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Principles of Consolidation</em> &#8211; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1954" name="us-gaap:UseOfEstimates" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1955" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Cash, Cash Equivalents</em> &#8211; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $<ix:nonFraction id="fid_282" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,097,618</ix:nonFraction> and $<ix:nonFraction id="fid_2040" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,089,113</ix:nonFraction> in a money market account at March 31, 2025 and June 30, 2024, respectively.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1957" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Fair Value of Financial Instruments</em> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1958" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Credit Risk</em> &#8211; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company.</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_bc3f4e" continuedAt="cont_48676e"><ix:nonNumeric id="fid_1961" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1962" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Impairment of Long-Lived Assets</em> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1963" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Leases</em> - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#8217;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#8217;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1989" name="ptn:RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" contextRef="From2024-07-01to2025-03-31" escape="true" continuedAt="cont_d2de75"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition (Prior to the sale of Vyleesi)</em> &#8211; The Company recognized product revenues in accordance with FASB ASC Topic 606, <em>Revenue from Contracts with Customers</em>. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. </p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_48676e" continuedAt="cont_a61835"><ix:continuation id="cont_d2de75"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligations were satisfied by transferring control of the product to a customer. Per the Company&#8217;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Gross product sales offset by product sales allowances for the three and nine months ended March 31, 2025 and 2024 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1971" name="ptn:ScheduleOfSalesTableTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended March 31</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Nine Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2326" name="ptn:RevenuesGross" contextRef="From2025-01-01to2025-03-31_us-gaap_ProductMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2327" name="ptn:RevenuesGross" contextRef="From2024-01-01to2024-03-31_us-gaap_ProductMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_12" name="ptn:RevenuesGross" contextRef="From2024-07-01to2025-03-31_us-gaap_ProductMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2325" name="ptn:RevenuesGross" contextRef="From2023-07-01to2024-03-31_us-gaap_ProductMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,875,153</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Product sales allowances and accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2328" name="ptn:ProductSalesAllowancesAndAccruals" contextRef="From2025-01-01to2025-03-31_us-gaap_ProductMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2329" name="ptn:ProductSalesAllowancesAndAccruals" contextRef="From2024-01-01to2024-03-31_us-gaap_ProductMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_605" name="ptn:ProductSalesAllowancesAndAccruals" contextRef="From2024-07-01to2025-03-31_us-gaap_ProductMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2331" name="ptn:ProductSalesAllowancesAndAccruals" contextRef="From2023-07-01to2024-03-31_us-gaap_ProductMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">4,735,063</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2333" name="us-gaap:Revenues" contextRef="From2025-01-01to2025-03-31_us-gaap_ProductMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2330" name="us-gaap:Revenues" contextRef="From2024-01-01to2024-03-31_us-gaap_ProductMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_264" name="us-gaap:Revenues" contextRef="From2024-07-01to2025-03-31_us-gaap_ProductMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2332" name="us-gaap:Revenues" contextRef="From2023-07-01to2024-03-31_us-gaap_ProductMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,140,090</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1964" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition &#8212;</em>&#8211; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company determines if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the non-refundable, upfront license fees will be recognized over time, the Company assesses the appropriate method of measuring proportional performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1965" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Research and Development Costs</em> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1966" name="ptn:AccruedLiabilitiesPolicyTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Accrued Expenses &#8211;</em> Third parties perform a significant portion of the Company&#8217;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_a61835"><ix:nonNumeric id="fid_1967" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock-Based Compensation &#8211; </em>The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1968" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Income Taxes</em> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1969" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Net Loss per Common Share </em>&#8211;<em> </em>Basic and diluted loss per common share (&#8220;EPS&#8221;) are calculated in accordance with the provisions of FASB ASC Topic 260, <em>Earnings per Share</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the three months ended March 31, 2025 and 2024, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three and nine months ended March 31, 2025 and 2024 were <ix:nonFraction id="fid_287" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,749,116</ix:nonFraction> and <ix:nonFraction id="fid_1415" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">8,520,332</ix:nonFraction>, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the weighted average common shares used in computing basic and diluted net loss per common share are <ix:nonFraction id="fid_1416" name="us-gaap:WeightedAverageNumberOfSharesRestrictedStock" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">279,700</ix:nonFraction> vested restricted stock units that had not been issued as of March 31, 2025 and 2024 due to a provision in the restricted stock unit agreements to delay delivery.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1970" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Translation of foreign currencies </em>&#8211; Transactions denominated in currencies other than the Company&#8217;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1939" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(4)</strong> <strong>New Accounting Pronouncements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of the adoption on the consolidated financial statements and accompanying footnotes.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1940" name="ptn:AssetPurchaseAgreementTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true" continuedAt="cont_0e8501"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(5) ASSET PURCHASE AGREEMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On December 19, 2023, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Cosette pursuant to which Cosette acquired from the Company worldwide rights to Vyleesi&#174;.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_0e8501"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under the terms of the Purchase Agreement, the Company sold certain assets (the &#8220;Purchased Assets&#8221;) to Cosette, comprising the exclusive right to market and sell Vyleesi for treatment of hypoactive sexual desire disorder in women, and contracts relating to manufacturing and distribution of Vyleesi. The Purchased Assets include applicable intellectual property pertaining to the marketing and sale of Vyleesi, including patents, patent applications, trademarks and copyrights. In addition, Cosette acquired records pertaining to the historical sales and distribution of Vyleesi, as well as quality control and pharmacovigilance records and other records. The Company will receive up to $<ix:nonFraction id="fid_1450" name="us-gaap:AccountsReceivablePurchase" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">171,000,000</ix:nonFraction>, consisting of an upfront purchase price of $<ix:nonFraction id="fid_1452" name="us-gaap:SupplementalDeferredPurchasePrice" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,500,000</ix:nonFraction>, $<ix:nonFraction id="fid_1449" name="us-gaap:PaymentsForPurchaseOfOtherAssets1" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,500,000</ix:nonFraction> payable upon the settlement of certain purchase commitments, which was received November 1, 2024, and sales-based milestone payments of up to $<ix:nonFraction id="fid_1451" name="ptn:PaymentsToSalesBasedMilestonePayments" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">159,000,000</ix:nonFraction>. As of March 31, 2025, none of the sales-based milestones have been achieved. The closing of the transaction took place simultaneously with the signing of the Purchase Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The parties have also entered into a transition service agreement pursuant to which the Company provided certain transition services to Cosette through May 31, 2024, and the Company was reimbursed for the costs of the transition services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is also eligible to receive regulatory approval milestones associated with previous licensing of Vyleesi to Kwangdong for the Republic of Korea (&#8220;Korea&#8221;) (see Note 8).</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1988" name="ptn:ManufacturingSupplyAgreementsTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(6) MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has transferred to Cosette its right, title and interest in contracts and agreements to manufacture Vyleesi, including manufacturing contracts with Catalent Belgium S.A. (&#8220;Catalent&#8221;), a subsidiary of Catalent Pharma Solutions, Inc., to manufacture drug product and prefilled syringes and assemble prefilled syringes into an auto-injector device; Ypsomed AG (&#8220;Ypsomed&#8221;), to manufacture the auto-injector device (the &#8220;Ypsomed Agreement&#8221;); and Lonza Ltd. (&#8220;Lonza&#8221;), to manufacture the active pharmaceutical ingredient peptide (the &#8220;Lonza Agreement&#8221;).</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1941" name="ptn:AgreementWithFosunTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun&#8221;) for exclusive rights to commercialize Vyleesi in China (the &#8220;Fosun License Agreement&#8221;). Under the terms of the Fosun License Agreement, the Company received $<ix:nonFraction id="fid_1618" name="us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" contextRef="From2017-09-01to2017-09-06" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,500,000</ix:nonFraction> in October 2017, which consisted of an upfront payment of $<ix:nonFraction id="fid_1619" name="us-gaap:PaymentsForRestructuring" contextRef="From2017-09-01to2017-09-06" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,000,000</ix:nonFraction> less $<ix:nonFraction id="fid_1626" name="ptn:UpfrontPaymentOfLess" contextRef="From2017-09-01to2017-09-06" format="ixt:numdotdecimal" unitRef="USD" decimals="0">500,000</ix:nonFraction> that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. In July 2024, Fosun, Cosette and Palatin entered into a termination agreement, effective as of May 20, 2024, terminating the Fosun License Agreement and ancillary agreements.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1942" name="ptn:AgreementWithKwangdongTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(8) AGREEMENT WITH KWANGDONG</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 21, 2017, the Company entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. (&#8220;Kwangdong&#8221;) for exclusive rights to commercialize Vyleesi in Korea (the &#8220;Kwangdong License Agreement&#8221;). Under the terms of the Kwangdong License Agreement, the Company received $<ix:nonFraction id="fid_631" name="us-gaap:OfficersCompensation" contextRef="From2017-11-01to2017-11-21" format="ixt:numdotdecimal" unitRef="USD" decimals="0">417,500</ix:nonFraction> in December 2017, consisting of an upfront payment of $<ix:nonFraction id="fid_633" name="us-gaap:PaymentsForRestructuring" contextRef="From2017-11-01to2017-11-21" format="ixt:numdotdecimal" unitRef="USD" decimals="0">500,000</ix:nonFraction>, less $<ix:nonFraction id="fid_634" name="ptn:taxexpenses" contextRef="From2017-11-01to2017-11-21" format="ixt:numdotdecimal" unitRef="USD" decimals="0">82,500</ix:nonFraction>, which was withheld in accordance with tax withholding requirements in Korea and recorded as an expense during the year ended June 30, 2018. The Company has assigned the Kwangdong License Agreement to Cosette, provided that the Company retains the right to receive a $<ix:nonFraction id="fid_636" name="us-gaap:PaymentsToAcquireReceivables" contextRef="From2017-11-01to2017-11-21" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,000,000</ix:nonFraction> milestone payment based on the first commercial sale in Korea which has not occurred as of March 31, 2025.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1943" name="us-gaap:OtherCurrentAssetsTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(9) PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid expenses<strong> </strong>and other current assets consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1972" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_637" name="ptn:PrepaidClinicalStudyCosts" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">45,118</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_575" name="ptn:PrepaidClinicalStudyCosts" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,926</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Insurance premiums</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_638" name="ptn:PrepaidInsurancePremiums" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">95,327</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_577" name="ptn:PrepaidInsurancePremiums" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">71,097</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_640" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">301,733</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_581" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">147,249</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_641" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">442,178</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_583" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">242,272</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1944" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(10) FAIR VALUE MEASUREMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The fair value of cash equivalents is classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&#8217;s own assumptions used to measure assets and liabilities at fair value. A financial asset&#8217;s or liability&#8217;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table provides the assets carried at fair value:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1973" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carrying Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Quoted prices in </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>active markets</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(Level 1)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Other quoted/observable inputs (Level 2)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Significant unobservable inputs</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(Level 3)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">March 31, 2025:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1460" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,097,618</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1471" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,097,618</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1461" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1466" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 30, 2024:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2042" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,089,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2041" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,089,113</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2043" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2044" name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><ix:nonNumeric id="fid_1948" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(11) ACCRUED EXPENSES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Accrued expenses<strong> </strong>consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1981" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_661" name="ptn:AccruedClinicalRegulatoryCosts" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">378,592</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_660" name="ptn:AccruedClinicalRegulatoryCosts" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,509,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other research related expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_663" name="ptn:OtherAccruedResearchRelatedExpenses" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40,509</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_662" name="ptn:OtherAccruedResearchRelatedExpenses" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">65,972</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Professional Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_665" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">55,040</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_664" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">284,215</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_667" name="ptn:AccruedPersonalCost" contextRef="AsOf2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_666" name="ptn:AccruedPersonalCost" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,771,694</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Selling expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_669" name="ptn:AccruedSellingExpenses" contextRef="AsOf2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_668" name="ptn:AccruedSellingExpenses" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">351,485</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_671" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">32,319</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_670" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">201,883</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_673" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">506,460</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_672" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,185,046</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><ix:nonNumeric id="fid_1949" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true" continuedAt="cont_dee477"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(12) COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Inventory Purchases </em>- The Company had certain supply agreements with manufacturers and suppliers, including the manufacturing agreement with Catalent entered into in September 2020 (the &#8220;Catalent Agreement&#8221;), Ypsomed Agreement, and Lonza Agreement, all of which have been transferred to Cosette. As a result of the sale of Vyleesi to Cosette, the Company is still required to make certain payments for the manufacture and supply of Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes the contractual obligations under the Catalent Agreement and Ypsomed Agreement as of March 31, 2025:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1982" name="ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Current</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>1 - 3 Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>4 - 5 Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inventory purchase commitments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_865" name="us-gaap:AdvancesOnInventoryPurchases" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,101,800</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_866" name="us-gaap:AdvancesOnInventoryPurchases" contextRef="AsOf2025-03-31_ptn_CurrentMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,101,800</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_867" name="us-gaap:AdvancesOnInventoryPurchases" contextRef="AsOf2025-03-31_ptn_OneToThreeYearsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2335" name="us-gaap:AdvancesOnInventoryPurchases" contextRef="AsOf2025-03-31_ptn_FourToFiveYearsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of March 31, 2025, the Company has $<ix:nonFraction id="fid_870" name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,576,350</ix:nonFraction> accrued within other current liabilities in the consolidated balance sheet related to estimated losses for firm commitment contractual obligations under these agreements. As of June 30, 2024, $<ix:nonFraction id="fid_869" name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">944,150</ix:nonFraction> and $<ix:nonFraction id="fid_871" name="us-gaap:OtherLongTermDebt" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,032,300</ix:nonFraction> was accrued within other current and long-term liabilities, respectively. Losses on these firm commitment contractual obligations are recognized based upon the terms of the respective agreement and similar factors considered for the write-down of inventory, including expected sales requirements as determined by internal sales forecasts.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_dee477"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The commitment contractual obligation amounts above are denominated in Swiss Francs and Euros and have been translated using period end exchange rates. The Company may experience a negative impact on future earnings and equity solely as a result of future foreign currency exchange rate fluctuations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Contingencies</em> - The Company accounts for litigation losses in accordance with ASC 450-20, <em>Loss Contingencies</em>. In addition, the Company is subject to other contingencies, such as product liability, arising in the ordinary course of business. Loss contingency provisions are recorded for probable losses when management is able to reasonably estimate the loss. Any outcome upon settlement that deviates from the Company&#8217;s best estimate may result in additional expense or in a reduction in expense in a future accounting period. The Company records legal expenses associated with such contingencies as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. The Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1950" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true" continuedAt="cont_40fb2c"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(13) STOCKHOLDERS&#8217; DEFICIENCY</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Series A Convertible Preferred Stock</em> &#8211; As of March 31, 2025, <ix:nonFraction id="fid_2704" name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,030</ix:nonFraction> shares of Series A Convertible Preferred Stock were outstanding. Each share of Series A Convertible Preferred Stock is convertible at any time, at the option of the holder, into the number of shares of common stock equal to $<ix:nonFraction id="fid_2708" name="us-gaap:CashAvailableForDistributions" contextRef="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">100</ix:nonFraction> divided by the Series A Conversion Price. As of March 31, 2025, the Series A Conversion Price was $<ix:nonFraction id="fid_2706" name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">60.33</ix:nonFraction>, and each share of Series A Convertible Preferred Stock is convertible into approximately <ix:nonFraction id="fid_2707" name="us-gaap:DebtInstrumentConvertibleLiquidationPreferencePerShare" contextRef="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.66</ix:nonFraction> shares of common stock. The Series A Conversion Price is subject to adjustment, under certain circumstances, upon the sale or issuance of common stock for consideration per share less than either (i) the Series A Conversion Price in effect on the date of such sale or issuance, or (ii) the market price of the common stock as of the date of such sale or issuance. The Series A Conversion Price is also subject to adjustment upon the occurrence of a merger, reorganization, consolidation, reclassification, stock dividend or stock split which will result in an increase or decrease in the number of shares of common stock outstanding. Shares of Series A Convertible Preferred Stock have a preference in liquidation, including certain merger transactions, of $<ix:nonFraction id="fid_2710" name="ptn:DistributableValueOfDividendPerShare" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">100</ix:nonFraction> per share, or $<ix:nonFraction id="fid_2705" name="ptn:AggregateValue" contextRef="From2024-07-01to2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">403,000</ix:nonFraction> in the aggregate as of March 31, 2025. Additionally, the Company may not pay a dividend or make any distribution to holders of any class of stock unless the Company first pays a special dividend or distribution of $<ix:nonFraction id="fid_2709" name="ptn:DividendAdditionalPerShare" contextRef="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">100</ix:nonFraction> per share to holders of the Series A Convertible Preferred Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Financing Transactions &#8211; </em>On February 10, 2025, the Company entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of <ix:nonFraction id="fid_2767" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-02-01to2025-02-10" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,688,000</ix:nonFraction> shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the &#8220; February 2025 RD Offering&#8221;) at a purchase price of $<ix:nonFraction id="fid_2766" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2025-02-10" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.00</ix:nonFraction> per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company also agreed to issue to the same investor in a concurrent private placement warrants to purchase up to an aggregate of <ix:nonFraction id="fid_2770" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-02-01to2025-02-10_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,688,000</ix:nonFraction> shares of common stock (the &#8220;February 2025 Private Placement&#8221; and, together with the February 2025 RD Offering, the &#8220;February 2025 Offering&#8221;). The warrants issued in the concurrent February 2025 Private Placement will have an exercise price of $<ix:nonFraction id="fid_2771" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-02-10_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.00</ix:nonFraction> per share, will be exercisable 181 days after their issuance and will expire approximately five and a half years from the date of issuance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The gross proceeds from the February 2025 Offering totaled $<ix:nonFraction id="fid_2768" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-02-01to2025-02-10" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,687,786</ix:nonFraction>, with net proceeds after deducting the placement agent fees and offering expenses amounting to $<ix:nonFraction id="fid_3202" name="ptn:OfferingExpensesAmount" contextRef="From2025-02-01to2025-02-10" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,309,641</ix:nonFraction>.&#160;The Company intends to use the net proceeds from the Offering for general corporate purposes.&#160; The Company paid the placement agents a cash fee equal to 7.0% of the aggregate gross proceeds of the February 2025 Offering. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 29, 2024, the Company entered into a securities purchase agreement (the &#8220;January 2024 Purchase Agreement&#8221;) to sell in a registered direct offering (the &#8220;January 2024 RD Offering&#8221;), an aggregate of <ix:nonFraction id="fid_2772" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-01to2024-01-29" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,831,503</ix:nonFraction> shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#8220;January 2024 Private Warrants&#8221;) to purchase up to <ix:nonFraction id="fid_2776" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2024-01-01to2024-01-29_ptn_PrivateWarrantSharesMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,831,503</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;January 2024 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;Private Offering&#8221; and together with the January 2024 RD Offering, the &#8220;January 2024 Offering&#8221;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $<ix:nonFraction id="fid_2774" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-29_ptn_PrivateWarrantSharesMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">5.46</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The January 2024 Private Warrants are exercisable on the six-month anniversary of the issuance date for a period of four years from the issuance date, at an exercise price equal to $<ix:nonFraction id="fid_2700" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">5.46</ix:nonFraction> per January 2024 Private Warrant Share. The January 2024 Private Warrants are exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the January 2024 Private Warrant Shares issuable upon exercise of the January 2024 Private Warrants to or by the holder of such January 2024 Private Warrants is not in effect, on a cashless basis. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_40fb2c" continuedAt="cont_24477c"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company paid the placement agent a cash fee equal to <ix:nonFraction id="fid_3189" name="ptn:EquityIssuanceCostsPercentage" contextRef="AsOf2025-03-31" unitRef="Pure" decimals="INF" scale="-2">7.0</ix:nonFraction>% of the aggregate gross proceeds of the January 2024 Offering and for certain expenses and legal fees in connection with the January 2024 Offering. In addition, the Company also issued to the placement agent or its designees warrants (the &#8220;2024 Placement Agent Warrants&#8221;) to purchase up to <ix:nonFraction id="fid_2716" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2025-03-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">91,575</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;January 2024 Placement Agent Warrant Shares&#8221;) as part of the compensation payable to the placement agent. The January 2024 Placement Agent Warrants have substantially the same terms as the January 2024 Private Warrants, except that the January 2024 Placement Agent Warrants have an exercise price of $<ix:nonFraction id="fid_2717" name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2025-03-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.825</ix:nonFraction> per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On March 14, 2024, the Company filed a registration statement on Form S-1 to register the January 2024 Private Warrants and the January 2024 Placement Agent Warrants, which registration statement was declared effective on March 28, 2024 and a prospectus was filed on the same date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The gross proceeds from the January 2024 Offering totaled $<ix:nonFraction id="fid_2777" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,000,006</ix:nonFraction>, with net proceeds from the January 2024 Offering, after deducting the placement agent fees and offering expenses, amounting to $<ix:nonFraction id="fid_2699" name="us-gaap:CostsAndExpenses" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,224,056</ix:nonFraction>. The Company intends to use the net proceeds received from the January 2024 Offering for general working capital purposes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October 20, 2023, the Company entered into a securities purchase agreement (the &#8220;October 2023 Purchase Agreement&#8221;) with a certain institutional investor, to sell in a registered direct offering (the &#8220;October 2023 RD Offering&#8221;), <ix:nonNumeric id="fid_2718" name="ptn:DescriptionOfSecuritiesPurchaseAgreement" contextRef="From2023-10-01to2023-10-20">an aggregate of (i) 1,325,000 shares of common stock (the &#8220;October 2023 Shares&#8221;), of the Company and (ii) pre-funded warrants (the &#8220;October 2023 Pre-Funded Warrants&#8221;) to purchase up to 1,033,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Pre-Funded Warrant Shares&#8221;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#8220;October 2023 Private Warrants&#8221;) to purchase up to 2,358,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;October 2023 Private Offering&#8221; and together with the October 2023 RD Offering, the &#8220;October 2023 Offering&#8221;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The October 2023 Private Warrants are exercisable on the six-month anniversary of issuance for a period of five and one-half years from the issuance date, at an exercise price equal to $<ix:nonFraction id="fid_2701" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-10-20" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.12</ix:nonFraction> per October 2023 Private Warrant Share. The October 2023 Private Warrants will be exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the October 2023 Private Warrant Shares issuable upon exercise of the October 2023 Private Warrants to or by the holder of such October 2023 Private Warrants is not in effect, on a cashless basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The October 2023 Pre-Funded Warrants had an exercise price of $<ix:nonFraction id="fid_2702" name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-10-20" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.0001</ix:nonFraction> per October 2023 Pre-Funded Warrant Share, were exercisable upon issuance, and during the three months ended December 31, 2023, the institutional investor exercised the outstanding October 2023 Pre-Funded Warrants to purchase <ix:nonFraction id="fid_2719" name="ptn:PurchaseOfWarrantShares" contextRef="From2024-07-01to2025-03-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,033,491</ix:nonFraction> shares of the Company&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The net proceeds from the October 2023 Offering, after deducting the placement agent fees and offering expenses, were $<ix:nonFraction id="fid_2712" name="us-gaap:CostsAndExpenses" contextRef="From2023-10-01to2023-10-20" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,573,948</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The placement agent warrants were issued to non-employees in exchange for services related to the offering are accounted for in accordance with ASC 718 which requires the fair value of the warrants to be recognized as an offering expense. The placement agent warrants contain certain contingent cash settlement features that are not probable of occurring and not within the control of the Company, therefore the placement agent warrants are classified out of permanent equity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 24, 2024, the Company and warrant holders amended the terms of warrants related to the October 2023 financings. As a result, all liability classified warrants were reclassified to additional paid-in capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 11, 2025, the Company entered into a sales agreement (the &#8220;2025 Sales Agreement&#8221;) with A.G.P./Alliance Global Partners (&#8220;A.G.P.&#8221;), pursuant to which the Company may, from time to time, sell shares of the Company&#8217;s common stock at market prices by methods deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended(the &#8220;Securities Act&#8221;). <ix:nonNumeric id="fid_2720" name="ptn:DescriptionOfSecuritiesPurchaseAgreement" contextRef="From2023-04-01to2023-04-12">The 2025 Sales Agreement and related prospectus is limited to sales of up to an aggregate maximum of $6.0 million of shares of the Company&#8217;s common stock. The Company pays A.G.P. 3.0% of the gross proceeds as a commission</ix:nonNumeric>.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_24477c" continuedAt="cont_a29f6a"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the three months ended March 31, 2025, a total of <ix:nonFraction id="fid_2782" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-01-01to2025-03-31_ptn_TwoThousandTwentyFiveSalesAgreementMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">413,400</ix:nonFraction> shares of common stock were sold through A.G.P. under the 2025 Sales Agreement for net proceeds of $<ix:nonFraction id="fid_2783" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-01-01to2025-03-31_ptn_TwoThousandTwentyFiveSalesAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">271,037</ix:nonFraction> after payment of commission fees of $<ix:nonFraction id="fid_2784" name="us-gaap:PaymentsForCommissions" contextRef="From2025-01-01to2025-03-31_ptn_TwoThousandTwentyFiveSalesAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,837</ix:nonFraction> and other related expenses of $<ix:nonFraction id="fid_2785" name="us-gaap:OtherExpenses" contextRef="From2025-01-01to2025-03-31_ptn_TwoThousandTwentyFiveSalesAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">164,054</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended March 31, 2025, the equity distribution agreement (the &#8220;2023 Equity Distribution Agreement&#8221;) that the Company entered into with Canaccord Genuity LLC (&#8220;Canaccord&#8221;) on April 12, 2023, was terminated.&#160; The 2023 Equity Distribution Agreement and related prospectus was limited to sales, from time to time in an &#8220;at-the-market offering&#8221; (as defined in Rule 415 promulgated under the Securities Act), of up to an aggregate maximum $<ix:nonFraction id="fid_2779" name="ptn:PurchaseOfWarrantShares" contextRef="From2025-01-01to2025-03-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">50.0</ix:nonFraction> million of shares of the Company&#8217;s common stock. The Company paid Canaccord 3.0% of the gross proceeds as a commission.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Proceeds raised under the 2023 Equity Distribution Agreement are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2105" name="ptn:ScheduleOfEquityDistributionAgreementTableTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Nine Months Ended&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31, 2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Cumulative from</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>inception</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Gross proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2395" name="ptn:EquityGrossProceedsShares" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">217,027</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2394" name="us-gaap:ProceedsFromOtherEquity" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">547,803</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2403" name="ptn:EquityNetProceedsShares" contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">721,061</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2408" name="us-gaap:ProceedsFromOtherEquity" contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,744,542</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Fees</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2397" name="us-gaap:ProceedsFromFeesReceived" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">16,434</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2406" name="us-gaap:ProceedsFromFeesReceived" contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52,336</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2399" name="ptn:EquityExpensesProceeds" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2404" name="ptn:EquityExpensesProceeds" contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">126,800</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2400" name="ptn:EquityNetProceedsShares" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">217,027</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2401" name="ptn:EquityNetProceedsProceeds" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">531,369</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2409" name="ptn:EquityGrossProceedsShares" contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">721,061</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2402" name="ptn:EquityNetProceedsProceeds" contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,565,406</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">No proceeds were raised under the 2023 Equity Distribution Agreement during the three and nine months ended March 31, 2025.&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock Warrants</em> &#8211; On December 13, 2024, the Company entered into a letter agreement (the &#8220;December 2024 Inducement Letter&#8221;) with a holder (the &#8220;December 2024 Exercising Holder&#8221;) of outstanding common stock purchase warrants that the Company issued on June 24, 2024, with an initial exercise price of $<ix:nonFraction id="fid_2749" name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-12-13_ptn_StockWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.88</ix:nonFraction>, and October 24, 2023, with an initial exercise price of $2.12 (the &#8220;December 2024 Existing Warrants&#8221;). To induce the exercise of a portion of the December 2024 Existing Warrants by the December 2024 Exercising Holder, <ix:nonNumeric id="fid_2751" name="ptn:DescriptionOfExistingHolderPurchaseOfWarrants" contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember">the Company agreed to adjust the exercise price of such portion of the December 2024 Existing Warrants to $0.875. Pursuant to the December 2024 Inducement Letter, the December 2024 Exercising Holder agreed to exercise, for cash, the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company&#8217;s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock (the &#8220;Series C Warrants&#8221;) and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock (the &#8220;Series D Warrants&#8221; and together with the Series C Warrants, the &#8220;December 2024 Inducement Warrants,&#8221; and the shares issuable upon exercise of the December 2024 Inducement Warrants, the &#8220;December 2024 Inducement Warrant Shares&#8221;)</ix:nonNumeric>. The Company received aggregate gross proceeds of $<ix:nonFraction id="fid_2753" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,419,219</ix:nonFraction> from the exercise of the December 2024 Existing Warrants by the December 2024 Exercising Holder (the &#8220;December 2024 Warrant Inducement&#8221;). The incremental value of the December 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On June 20, 2024, the Company entered into a letter agreement (the &#8220;June 2024 Inducement Letter&#8221;) with a holder (the &#8220;June 2024 Exercising Holder&#8221;) of outstanding common stock purchase warrants that the Company issued on November 2, 2022, and October 24, 2023 (the &#8220;June 2024 Existing Warrants&#8221;). Pursuant to the June 2024 Inducement Letter, the June 2024 Exercising Holder agreed to exercise, for cash, June 2024 Existing Warrants to purchase, in the aggregate, <ix:nonFraction id="fid_2714" name="ptn:WarrantsToPurchaseShares" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,233,277</ix:nonFraction> shares of common stock in exchange for the Company&#8217;s agreement to <ix:nonNumeric id="fid_2723" name="ptn:DescriptionOfExistingHolderPurchaseOfWarrants" contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember">(i) lower the exercise price to $1.88 per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#8220;June 2024 Series A Warrants&#8221;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#8220;June 2024 Series B Warrants&#8221; and together with the June 2024 Series A Warrants, the &#8220;June 2024 Inducement Warrants&#8221;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the &#8220;Warrant Inducement&#8221;)</ix:nonNumeric>. As part of the agreement, <ix:nonFraction id="fid_2724" name="ptn:ExercisingHolderReleasedShares" contextRef="From2024-07-01to2025-03-31_ptn_StockWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,443,277</ix:nonFraction> shares of common stock were held in abeyance on behalf of the June 2024 Exercising Holder. During the three months ended March 31, 2025, at the request of the June 2024 Exercising Holder, <ix:nonFraction id="fid_2786" name="ptn:ExercisingHolderReleasedShares" contextRef="From2025-01-01to2025-03-31_ptn_StockWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,443,277</ix:nonFraction> shares were released from abeyance. The incremental value of the June 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_a29f6a" continuedAt="cont_65c161"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of March 31, 2025, the Company had outstanding warrants for shares of common stock as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2106" name="ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares of Common</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise Price per</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Latest Expiration</strong></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Date</strong></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">May 2022 Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2410" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2025-03-31_ptn_MayTwoThousandTwentyTwoWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">66,666</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2413" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2025-03-31_ptn_MayTwoThousandTwentyTwoWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">12.50</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2416" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2025-03-31_ptn_MayTwoThousandTwentyTwoWarrantsMember">May 11, 2026</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2022 Placement Agent Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2412" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">90,909</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2415" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.88</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2418" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember">October 31, 2027</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2023 Placement Agent Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2423" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">117,925</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2422" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2421" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember">October 20, 2028</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Private Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2426" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,831,503</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2425" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">5.46</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2424" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember">February 1, 2028</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Placement Agent Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2429" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">91,575</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2428" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.83</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2427" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember">February 1, 2028</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 2024 Series B Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2432" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2025-03-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,885,632</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2431" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2025-03-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.88</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_2430" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2025-03-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember">June24,2029</ix:nonNumeric>*</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series C Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2411" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2025-03-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,907,679</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2414" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2025-03-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.88</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2417" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2025-03-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember">December 17, 2029</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series D Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2420" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2025-03-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,953,839</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2419" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2025-03-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.88</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">**</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 2025 Series E Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2764" name="ptn:SharesOfCommonStock" contextRef="From2024-07-01to2025-03-31_ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,688,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2763" name="ptn:ExercisePricePerShareWarrantsOutstanding" contextRef="From2024-07-01to2025-03-31_ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><ix:nonNumeric id="fid_2765" name="ptn:LatestTerminationDate" contextRef="From2024-07-01to2025-03-31_ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember">August 12, 2030</ix:nonNumeric></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="11" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">* <ix:nonFraction id="fid_2742" name="ptn:WarrantIssuanceShares" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,624,201</ix:nonFraction> shares expire on the five year anniversary following stockholder approval of the warrant issuance and the balance expire on June 24, 2029.</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="4" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">** <ix:nonFraction id="fid_2743" name="ptn:WarrantIssuance" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,953,839</ix:nonFraction> shares expire on the five year anniversary following stockholder approval of the warrant issuance.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5" style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock Options &#8211;</em> For the three and nine months ended March 31, 2025, the Company recorded stock-based compensation related to stock options of $<ix:nonFraction id="fid_2744" name="us-gaap:StockOptionPlanExpense" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">176,410</ix:nonFraction> and $<ix:nonFraction id="fid_2725" name="us-gaap:StockOptionPlanExpense" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">531,817</ix:nonFraction>, respectively. For the three and nine months ended March 31, 2024, the Company recorded stock-based compensation related to stock options of $<ix:nonFraction id="fid_2745" name="us-gaap:StockOptionPlanExpense" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">205,176</ix:nonFraction> and $<ix:nonFraction id="fid_2726" name="us-gaap:StockOptionPlanExpense" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">615,716</ix:nonFraction>, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A summary of stock option activity is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2107" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average Remaining</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Term in </strong><strong>Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Aggregate Intrinsic</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2433" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,263,440</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2436" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.11</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2444" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:duryear">8.2</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2437" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USDPShares" decimals="INF">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2438" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USDPShares" decimals="INF">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2439" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USDPShares" decimals="INF">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,338</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">4.50</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2453" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,249,102</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2441" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.12</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2445" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:duryear">7.5</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2450" name="ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2454" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">937,894</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2442" name="ptn:shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">10.77</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2446" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:duryear">5.9</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2449" name="ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected to vest at March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2455" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,311,208</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2443" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.80</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2447" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="From2024-07-01to2025-03-31" format="ixt-sec:duryear">8.6</ix:nonNumeric></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2448" name="ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock options granted to the Company&#8217;s executive officers and employees generally vest over a 48-month period, while stock options granted to its non-employee directors vest over a 12-month period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the outstanding options in the table above are <ix:nonFraction id="fid_2754" name="ptn:UnvestedPerformanceBasedStockOptionsGranted" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">418,945</ix:nonFraction> and <ix:nonFraction id="fid_2727" name="ptn:UnvestedPerformanceBasedStockOptionsGranted" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">88,911</ix:nonFraction> unvested performance-based stock options granted to executive officers and other employees, respectively, which were granted in June 2020, 2021, 2022 and 2023. Grants in June 2021, 2022, 2023 and 2024 were <ix:nonFraction id="fid_2728" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">95,167</ix:nonFraction>, <ix:nonFraction id="fid_2729" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-07-01to2022-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">60,566</ix:nonFraction>, <ix:nonFraction id="fid_2730" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">238,838</ix:nonFraction> and <ix:nonFraction id="fid_2731" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-07-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">264,945</ix:nonFraction>, respectively. The performance-based stock options vest on annual performance criteria through the fiscal years ending June 30, 2028 relating to advancement of MC1r programs, including initiation of clinical trials and licensing of Vyleesi in additional countries or regions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Restricted Stock Units &#8211; </em>For the three and nine months ended March 31, 2025, the Company recorded stock-based compensation related to restricted stock units of $<ix:nonFraction id="fid_2746" name="ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" contextRef="From2025-01-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">171,281</ix:nonFraction> and $<ix:nonFraction id="fid_2732" name="ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">513,852</ix:nonFraction> respectively. For the three and nine months ended March 31, 2024, the Company recorded stock-based compensation related to restricted stock units of $<ix:nonFraction id="fid_2747" name="ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" contextRef="From2024-01-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">185,019</ix:nonFraction> and $<ix:nonFraction id="fid_2733" name="ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">555,057</ix:nonFraction>, respectively. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PALATIN TECHNOLOGIES, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>and Subsidiary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Notes to Consolidated Financial Statements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_65c161"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A summary of restricted stock unit activity is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2109" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2456" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" contextRef="AsOf2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,374,980</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2457" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="Shares" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2458" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2024-07-01to2025-03-31" format="ixt:zerodash" unitRef="Shares" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Vested </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2459" name="ptn:RestrictedStockVestedInPeriod" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">232,941</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Expirations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,726</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2460" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,139,313</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in outstanding restricted stock units in the table above are <ix:nonFraction id="fid_2734" name="ptn:NumberOfOutstandingSharesOfRestrictedStockUnits" contextRef="AsOf2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">279,700</ix:nonFraction> vested shares that have not been issued as of March 31, 2025, due to a provision in the restricted stock unit agreements to delay delivery.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Time-based restricted stock units granted to the Company&#8217;s executive officers, other employees, and non-employee directors generally vest over 48 months, 48 months, and 12 months, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the outstanding restricted stock units in the table above are <ix:nonFraction id="fid_2735" name="ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">274,549</ix:nonFraction> and <ix:nonFraction id="fid_2736" name="ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" contextRef="From2023-07-01to2024-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">59,842</ix:nonFraction> unvested performance-based restricted stock units granted to executive officers and other employees, respectively, which were granted in June 2021, 2022, 2023, and 2024. Grants in June 2021, 2022, 2023 and 2024 were <ix:nonFraction id="fid_2738" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" contextRef="From2020-07-01to2021-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">22,343</ix:nonFraction>, <ix:nonFraction id="fid_2739" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" contextRef="From2021-07-01to2022-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">40,707</ix:nonFraction>, <ix:nonFraction id="fid_2740" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" contextRef="From2022-07-01to2023-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">152,432</ix:nonFraction> and <ix:nonFraction id="fid_2737" name="ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" contextRef="From2023-07-01to2024-06-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">184,443</ix:nonFraction> restricted stock units, respectively. The performance-based restricted stock units vest on annual performance criteria through the fiscal years ending June 30, 2026 relating to advancement of MC1r programs, including initiation of clinical trials, and licensing of Vyleesi in additional countries or regions</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In connection with the vesting of restricted share units during the nine months ended March 31, 2025, the Company withheld <ix:nonFraction id="fid_2741" name="ptn:StockIssuedDuringPeriodValueRestrictedStockUnitshares" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">54,691</ix:nonFraction> shares, with an aggregate value of $<ix:nonFraction id="fid_2748" name="ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" contextRef="From2024-07-01to2025-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0">99,482</ix:nonFraction>, in satisfaction of minimum tax withholding obligations.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2393" name="us-gaap:SubsequentEventsTextBlock" contextRef="From2024-07-01to2025-03-31" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(14) SUBSEQUENT EVENTS</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Sales Under 2025 Sales Agreement</em> &#8211; As disclosed in Note 13 above, the Company entered into the 2025 Sales Agreement. During the period from April 1, 2025 through and until May 14, 2025, the Company has sold <ix:nonFraction id="fid_2787" name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2025-04-01to2025-05-14_us-gaap_SubsequentEventMember_ptn_TwoThousandTwentyFiveSalesAgreementMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,598,496</ix:nonFraction> shares for gross proceeds of $<ix:nonFraction id="fid_2788" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2025-04-01to2025-05-14_us-gaap_SubsequentEventMember_ptn_TwoThousandTwentyFiveSalesAgreementMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,296,532</ix:nonFraction> under the at-the-market offering&#8221; pursuant to the 2025 Sales Agreement and related prospectus.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>May 2025 Public Offering</em> &#8211; On May 8, 2025, the Company completed a <ix:nonNumeric id="fid_2789" name="ptn:DescriptionOfPublicOffering" contextRef="From2025-05-01to2025-05-08_us-gaap_SubsequentEventMember">public offering with participation from institutional and accredited investors of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the &#8220;Series F Warrants&#8220;), Series G warrants to purchase up to 7,324,119 shares of common stock (the &#8220;Series G Warrants&#8220;), and Series H warrants to purchase up to 7,324,119 shares of common stock (the &#8220;Series H Warrants&#8220;), at a combined public offering price of $0.15 per share of common stock and accompanying warrants (the &#8220;Offering&#8220;)</ix:nonNumeric>. The Offering was made pursuant to the Company&#8217;s registration statement on Form S-1 (Registration No. 333-286280) previously filed with the SEC and declared effective on May 6, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Series F Warrants have an exercise price of $<ix:nonFraction id="fid_2759" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-08_us-gaap_SubsequentEventMember_ptn_SeriesFWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.30</ix:nonFraction> per share, are immediately exercisable and expire on the five-year anniversary of the original issuance date, subject to the certain terms as defined in such warrant. The Series G Warrants have an exercise price of $<ix:nonFraction id="fid_2791" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-08_us-gaap_SubsequentEventMember_ptn_SeriesGWarrantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.15</ix:nonFraction> per share, are immediately exercisable and expire on the earlier of (i) the 24-month anniversary of the original issuance date or (ii) the expiration of the FDA Exercise Period (as such term is defined in the Series G Warrant). The Series H Warrants will be issuable to the holder upon their exercise of the Series G Warrants, will have an exercise price of $<ix:nonFraction id="fid_2792" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-05-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.225</ix:nonFraction> per share, will be immediately exercisable upon issuance and will expire on the 24-month anniversary of its issuance date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A.G.P. acted as lead placement agent and Laidlaw &amp; Company (UK) Ltd., as co-placement agent in the Offering. The Company paid the placement agents a cash fee equal to <ix:nonFraction id="fid_3187" name="ptn:EquityIssuanceCostsPercentage" contextRef="AsOf2025-05-08_us-gaap_SubsequentEventMember" unitRef="Pure" decimals="INF" scale="-2">7.0</ix:nonFraction>% of the gross proceeds raised in the Offering and reimbursed the placement agents for out-of-pocket expenses, including the reasonable fees of legal counsel, in an amount equal to $<ix:nonFraction id="fid_2758" name="us-gaap:LegalFees" contextRef="From2025-05-01to2025-05-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">85,000</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company received aggregate net proceeds from the Offering of $<ix:nonFraction id="fid_2760" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2025-05-01to2025-05-08_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">931,715</ix:nonFraction>. The Company intends to use the net proceeds from the Offering primarily for working capital and general corporate purposes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>NYSE American Delisting</em> &#8211; On May 7, 2025, the Company announced that it has received a notice from the NYSE American LLC (&#8220;NYSE American&#8221;) stating that the NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company&#8217;s common stock. NYSE American commenced delisting proceedings in connection with the foregoing determination, and trading in the Company&#8217;s common stock was suspended on May 7, 2025. Since May 8, 2025 the Company&#8217;s common stock has traded on the Pink Market of the OTC Markets Group under the trading symbol &#8220;PTNT&#8221;. The Company has a right to a review of NYSE Regulation&#8217;s determination to delist the Company&#8217;s common stock by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. The Company is currently assessing the viability of such an appeal.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="i2">Item 2.&#160; Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>The following discussion and analysis should be read in conjunction with the consolidated financial statements and notes to the consolidated financial statements filed as part of this report and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended June 30, 2024.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>The following discussion and analysis contain forward-looking statements within the meaning of the federal securities laws. You are urged to carefully review our description and examples of forward-looking statements included earlier in this Quarterly Report immediately prior to Part I, under the heading &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Forward-looking statements are subject to risk that could cause actual results to differ materially from those expressed in the forward-looking statements. You are urged to carefully review the disclosures we make concerning risks and other factors that may affect our business and operating results, including those made in this Quarterly Report and our Annual Report on Form 10-K for the year ended June 30, 2024, as well as any of those made in our other reports filed with the SEC. You are cautioned not to place undue reliance on the forward-looking statements included herein, which speak only as of the date of this document. We do not intend, and undertake no obligation, to publish revised forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Critical Accounting Policies and Estimates</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our significant accounting policies, which are described in the notes to our consolidated financial statements included in this report and in our Annual Report on Form 10-K for the year ended June 30, 2024, have not changed during the three and nine months ended March 31, 2025. We believe that our accounting policies and estimates relating to the carrying value of inventory, revenue recognition, accrued expenses, purchase commitment liabilities, warrants and stock-based compensation are the most critical.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Our Business</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Melanocortin Receptor System.</em> The melanocortin receptor (&#8220;MCr&#8221;) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our prior commercial product, Vyleesi&#174;, was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2019 and was being marketed in the United States by AMAG Pharmaceuticals, Inc. (&#8220;AMAG&#8221;) for the treatment of hypoactive sexual desire disorder (&#8220;HSDD&#8221;) in premenopausal women pursuant to a license agreement between them for Vyleesi for North America, which was entered into on January 8, 2017 (the &#8220;AMAG License Agreement&#8221;). The AMAG License Agreement was terminated effective July 24, 2020, and we commenced marketing Vyleesi in North America. As disclosed in Note 5 to the Consolidated Financial Statements, effective December 19, 2023, Cosette acquired all rights to Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our new product development activities focus on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity, which has completed Phase 2 in the fourth quarter of calendar year 2024, with topline results expected in the first quarter of calendar year 2025 announced in March 2025, in which co-administration demonstrated an increased weight loss over tirzepatide alone; and secondarily on ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (&#8220;DED&#8221;), which completed Phase 3 clinical trials and announced top line results from the first Phase 3 clinical trial in the first quarter of calendar year 2024; ulcerative colitis, including PL8177, an oral peptide formulation, which entered Phase 2 ulcerative colitis clinical trials in the third quarter of calendar year 2022 and announced topline results in March 2025, with one-third of patients dosed with PL8177 achieving clinical remission while the placebo group saw no clinical remission is expected to report topline results later this quarter. We are actively engaged in discussions with potential partners and licensees that have the financial and operational resources to progress our products for ocular conditions through development, approval and commercialization. &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Pipeline Overview</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following chart illustrates the status of our drug development programs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_10qimg19.jpg" alt="ptn_10qimg19.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Our Strategy</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Key elements of our business strategy include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Maintaining a team to create, develop and commercialize MCr products addressing unmet medical needs;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Entering into strategic alliances and partnerships with pharmaceutical companies to facilitate the development, manufacture, marketing, sale, and distribution of product candidates that we are developing;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Partially funding our product development programs with the cash flow generated from the sale of Vyleesi to Cosette and existing license agreements, as well as any future research, collaboration, or license agreements; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Completing development and seeking regulatory approval of certain of our other product candidates.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Corporate Information</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We were incorporated under the laws of the State of Delaware on November 21, 1986 and commenced operations in the biopharmaceutical area in 1996. Our corporate offices are located at 4B Cedar Brook Drive, Cedar Brook Corporate Center, Cranbury, New Jersey 08512, and our telephone number is (609) 495-2200. We maintain an Internet site, where among other things, we make available free of charge on and through this website our Forms 3, 4 and 5, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) and Section 16 of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our website and the information contained in it or connected to it are not incorporated into this Quarterly Report on Form 10-Q. The reference to our website is an inactive textual reference only. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC (<em>www.sec.gov</em>).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Results of Operations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As we continue to explore commercial opportunities and partners in both U.S. and international markets, we remain attentive to evolving global economic conditions, including uncertainties related to international trade policies, tariffs, and supply chain dynamics. Although these factors have not had a material impact on our operations to date, future changes in trade regulations, tariff structures, or logistical constraints could influence the cost, availability, or timing of materials, services and other components associated with the development of our product candidates and manufacturing capabilities. We continue to monitor these developments closely to maintain operational efficiency and help mitigate potential future impacts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Three and Nine Months Ended March 31, 2025, Compared to the Three and Nine Months Ended March 31, 2024:</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenues &#8211;</em> For the nine months ended March 31, 2025, we recognized $0 in product revenue, net of allowances. For the nine months ended March 31, 2024, we recognized $4,140,090 in product revenue, net of allowances, respectively. The decrease in product revenue, net of allowances is a result of the sale to Cosette of worldwide rights to Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Cost of Products Sold &#8211; </em>Cost of products sold was $0 for the nine months ended March 31, 2025 compared to $97,637 for the nine months ended March 31, 2024. The decrease is a result of the sale to Cosette of worldwide rights to Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Research and Development</em> &#8211; Research and development expenses were $3,755,158 and $12,928,391 for the three and nine months ended March 31, 2025, respectively, compared to $7,159,686 and $17,728,516 for the three and nine months ended March 31, 2024, respectively. The decrease was primarily related to a decrease in spending on our MCr programs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Research and development expenses related to our MCr other preclinical programs were $1,853,851 and $7,822,953 for the three and nine months ended March 31, 2025, respectively compared to $5,487,259 and $12,775,229 for the three and nine months ended March 31, 2024, respectively. The decrease was primarily related to a decrease in spending on our MCr programs. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The amounts of project spending above exclude general research and development spending, which was $1,901,307 and $5,105,438 for the three and nine months ended March 31, 2025, respectively, compared to $1,672,427 and $4,953,286 for the three and nine months ended March 31, 2024, respectively. The decrease is primarily attributable to an decrease in compensation-related expenses. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Cumulative spending from inception to March 31, 2025, was approximately $311,900,000 on our Vyleesi program and approximately $246,800,000 on all our other programs (which include PL3994, melanocortin receptor agonists, other discovery programs and terminated programs). Due to various risk factors described in our Annual Report on Form 10-K for the year ended June 30, 2024, under &#8220;Risk Factors,&#8221; including the difficulty in currently estimating the costs and timing of future Phase 1 clinical trials and larger-scale Phase 2 and Phase 3 clinical trials for any product under development, we cannot predict with reasonable certainty when, if ever, a program will advance to the next stage of development or be successfully completed, or when, if ever, related net cash inflows will be generated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Selling, General and Administrative</em> &#8211; Selling, general and administrative expenses, which consist mainly of compensation and related costs, were $1,474,019 and $5,176,794 for the three and nine months ended March 31, 2025, respectively, compared to $2,033,410 and $8,266,267 for the three and nine months ended March 31, 2024, respectively. The decrease is a result of the elimination of selling expenses relating to Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Gain on Sale of Vyleesi</em> &#8211; For the nine months ended March 31, 2025, the Company recorded a gain of $2,500,000 on the sale of Vyleesi as a result of the settlement of certain purchase commitments. For the three and nine months ended March 31, 2024, the Company recorded a loss of $25,202 and a gain of $7,798,280 on the sale of Vyleesi. The gain represents the upfront purchase price of $9,500,000 less the cost of net assets transferred to the purchaser. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Gain on Purchase Commitment</em> - Gain on purchase commitments were $416,000 for the three and nine months ended March 31, 2025 as a result of the completion of certain inventory production runs by Cosette. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Other Income (Expense) &#8211; </em>For the three and nine months ended, March 31, 2025, total other income (expense), net was $1,757 and $111,634, respectively. For the three and nine months ended March 31, 2024, other income (expense) income was $782,648 and $(7,331,633), respectively. The decrease in other income (expense) for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was driven primarily by the change in fair values of the warrant liability and foreign currency transaction gains. &#160;The increase in other income (expense), net for the nine months ended March 31, 2025 compared to the nine months ended March 31, 2024 was primarily driven by the an increase in the change in fair value of warrant liabilities and offering expenses.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Liquidity and Capital Resources</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Since inception, we have generally incurred net operating losses, primarily related to spending on our research and development programs. We have financed our net operating losses primarily through debt and equity financings and amounts received under collaborative and license agreements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our product candidates are at various stages of development and will require significant further research, development, and testing and some may never be successfully developed or commercialized. We may experience uncertainties, delays, difficulties, and expenses commonly experienced by early-stage biopharmaceutical companies, which may include unanticipated problems and additional costs relating to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the development and testing of products in animals and humans;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product approval or clearance;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">regulatory compliance;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">good manufacturing practices (&#8220;GMP&#8221;) compliance;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">intellectual property rights;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">product introduction;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">marketing, sales, and competition; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">obtaining sufficient capital.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Failure to enter into or successfully perform under collaboration agreements and obtain timely regulatory approval for our product candidates and indications would impact our ability to generate revenues and could make it more difficult to attract investment capital for funding our operations. Any of these possibilities could materially and adversely affect our operations and require us to curtail or cease certain programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the nine months ended March 31, 2025, net cash used in operating activities was $17,217,595 compared to $24,988,985 for the nine months ended March 31, 2024. The decrease was primarily related to a decrease in net loss during the period and working capital changes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the nine months ended March 31, 2025, net cash provided by investing activities was $2,500,000, which consisted of proceeds from the sale of Vyleesi. During the nine months ended March 31, 2024, net cash provided by investing activities was $12,455,275, which consisted of $9,500,000 of proceeds from the sale of Vyleesi and $2,992,890 proceeds from the maturity of marketable securities, offset by $37,615 used for the purchase of property and equipment. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the nine months ended March 31, 2025, net cash provided by financing activities was $7,710,261, which consisted of $3,398,237 of proceeds from the exercise of warrants and 4,457,520 from the sale of common stock, offset by $99,482 for payment of withholding taxes related to restricted stock units and $46,014 for payment of finance lease obligations. During the nine months ended March 31, 2024, net cash provided by financing activities was $14,558,216, which consisted of proceeds from the sale of common stock of $14,693,779, proceeds from the exercise of warrants of $103, offset by $56,401 for payment of withholding taxes related to restricted stock units and $79,265 for payment of finance lease obligations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We have incurred cumulative negative cash flows from operations since our inception, and have expended substantial funds to advance our planned product development efforts. Continued operations are dependent upon our ability to complete equity or debt financing activities and to enter into additional licensing or collaboration arrangements. As of March 31, 2025, our cash and cash equivalents were $2,520,062, and our current liabilities were $10,048,349. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Current liabilities include short-term lease obligations in an aggregate amount of $194,972 and inventory purchase commitments in an aggregate amount of $1,576,350. Our long-term obligations consist of $67,248 in long-term lease liabilities. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">There have been no material changes outside the ordinary course of business to our contractual obligations and commitments, as disclosed in our Annual Report on Form 10-K for the year ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We intend to utilize existing capital resources for general corporate purposes and working capital requirements, including preclinical and clinical development of our MC1r and MC4r programs, and development of other portfolio products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As a result of our sale of worldwide rights to Vyleesi pursuant to the Purchase Agreement, we currently do not have a recurring source of revenue. Based on our available cash and cash equivalents as of March 31, 2025, the Company has concluded that substantial doubt exists about our ability to continue as a going concern for one year from the date our consolidated financial statements are issued. We are evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm our business, results of operations, and future prospects. If we are not able to secure adequate additional funding in future periods, we would be forced to make additional reductions in certain expenditures. This may include liquidating assets and suspending or curtailing planned programs. We may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If we are unable to raise capital when needed or enter into a strategic transaction, then we may be required to cease operations, which could cause our stockholders to lose all or part of their investment. Based on our current operating and development plans, we expect that our existing cash and cash equivalents as of the date of this filing will be sufficient to enable the Company to fund its operations into the second half of the calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We will need additional funding to complete required clinical trials for our product candidates and development programs and, if those clinical trials are successful (which we cannot predict), to complete submission of required regulatory applications to the FDA. However, current economic conditions (including current economic uncertainty, high interest rates, rising inflation, tariffs, and the potential for local and/or global economic recession) may negatively impact our operations, including possible effects on our financial condition, ability to access the capital markets on attractive terms or at all, liquidity, operations, suppliers, industry, and workforce. We will continue to evaluate the impact that these events could have on the operations, financial position, and the results of operations and cash flows during fiscal year 2025 and beyond.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="i3">Item 3. &#160;Quantitative and Qualitative Disclosures About Market Risk.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Not required to be provided by smaller reporting companies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><span class="atag" style="display: inline" id="i4"><strong>Item 4. &#160;Controls and Procedures</strong><strong>.</strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as defined in Exchange Act Rules 13a-15(e) and 15d-15(e), as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective due to the previously-reported material weakness in our controls over financial reporting related to the accounting for complex financial instruments. As a result, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. GAAP. Accordingly, Company management believes that the consolidated financial statements included in this Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows for the period presented. We will continue to improve these processes to ensure that the nuances of such significant or non-routine transactions are effectively evaluated in the context of the appropriate accounting standards. There were no other changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span class="atag" style="display: inline" id="p2">PART II &#8211; OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="p2i1">Item 1. Legal Proceedings.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We may be involved, from time to time, in various claims and legal proceedings arising in the ordinary course of our business. On February 13, 2025, a complaint was filed in the Supreme Court of the State of New York, County of New York, captioned <em>H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) v. Palatin Technologies, Inc.</em>, Case No: 650878/2025. The complaint names the Company as defendant, asserting three causes of action for breach of contract and seeking monetary damages and the award of warrants allegedly due under the parties&#8217; agreement. The breach of contract claims each relate to the engagement agreement entered into by the Company and Wainwright on or about January 29, 2024. On March 20, 2025, the Company filed its answer in response to the complaint, in which it denied all liability and asserted several affirmative defenses. The Company plans to vigorously defend against the lawsuit and the action will proceed next to the discovery stage and for further proceedings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We are not currently a party to any other claim or legal proceeding.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="p2i1a">Item 1A. Risk Factors.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">This report and other documents we file with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs, and our management&#8217;s assumptions. These statements are not guarantees of future performance, and they involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties facing our business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Other than set forth below, there have been no material changes to our risk factors disclosed in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended June 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em>We have been&#160;suspended from the NYSE American and are currently not in compliance with the continued listing standards of the NYSE American. Our failure to resume compliance with the continued listing standards or make continued progress toward compliance consistent with a plan of compliance that we submitted to NYSE Regulation may result in the delisting of our common stock.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Previously, we received written notification from the NYSE American that we are not in compliance with Section 1003(a)(i) and (ii) of the NYSE American Company Guide (the &#8220;Company Guide&#8221;). The Company submitted a plan to regain compliance, which was accepted by the NYSE American on December 13, 2023, and was granted a plan period through April 10, 2025, to regain compliance with the foregoing continued listing standards. On October 4, 2024, the Company received written notification from the NYSE American that the Company is not in compliance with Section 1003(a)(iii) of the Company Guide. The Company was not required to submit an additional plan of compliance in response to the additional deficiency identified by the NYSE American but had to regain compliance with Section 1003(a)(iii) of the Company Guide during the plan period under the accepted plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On April 10, 2025, the Company received written notification from the NYSE American stating that the NYSE Regulation determined to commence proceedings to delist the Company&#8217;s common stock from NYSE American. NYSE Regulation has determined the Company is no longer suitable for listing pursuant to Section 1009(a) of the Company Guide as the Company was unable to demonstrate that it had regained compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide by the end of the maximum 18-month compliance plan period, which expired on April 10, 2025. On April 14, 2025, the Company appealed the NYSE Regulation&#8217;s decision, and on April 15, 2025, the Company requested a hearing with the office of the General Counsel of the NYSE American.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On May 7, 2025, the Company received notice from NYSE Regulation that it had suspended trading of the Company&#8217;s common stock on the NYSE American LLC stock exchange (&#8220;NYSE American&#8221;) and determined to commence proceedings to delist the Company&#8217;s common stock from the NYSE American as a result of its determination that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company&#8217;s common stock. Trading of the Company&#8217;s common stock on the NYSE American was suspended on May 7, 2025 and began trading on the OTC Pink Market on May 8, 2025.The Company has a right to a review of NYSE Regulation&#8217;s determination to delist the Company&#8217;s common stock by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. The Company is currently assessing the viability of such an appeal.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Because our common stock has been&#160;suspended from the NYSE American and is now listed on the Pink Market of the OTC Markets Group under the trading symbol &#8220;PTNT&#8221;, we could face significant material adverse consequences, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a limited availability of market quotations for our securities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">reduced liquidity with respect to our securities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a determination that our shares of common stock are &#8220;penny stock&#8221; which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a limited amount of news and analyst coverage for our Company; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a decreased ability to issue additional securities or obtain additional financing in the future.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Such a delisting may also have a negative effect on the price of our common stock and may impair our investors&#8217; ability to sell or purchase our common stock when investors wish to do so.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The National Securities Markets Improvement Act of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Shares of our common stock were considered to be covered securities because they were listed on the NYSE American. Because our common stock is no longer listed on the NYSE American, our common stock would not be deemed covered securities and we are subject to regulation in each state in which we offer our securities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="p2i2">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="p2i3">Item 3. Defaults Upon Senior Securities.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">None.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="p2i4">Item 4. Mine Safety Disclosures.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="p2i5">Item 5. Other Information.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">During the Company&#8217;s fiscal quarter ended March 31, 2025, no director or officer, as defined in Rule 1a-1(f), adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; each as defined in Item 408 of Regulation S-K</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="i6">Item 6.&#160; Exhibits.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Exhibits filed or furnished with this report:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:7%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exhibit</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Description</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filed</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&#160;Herewith</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Form</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Filing Date</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SEC</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>File No.</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495421010197/ptn_ex31.htm">3.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495421010197/ptn_ex31.htm">Amended and Restated Bylaws of Palatin Technologies, Inc.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">September 17, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">3.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Restated Certificate of Incorporation of Palatin Technologies, Inc., as amended.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">September 27, 2013</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422011989/ptn_ex31.htm">3.3</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422011989/ptn_ex31.htm">Certificate of Amendment to the Restated Certificate of Incorporation of Palatin Technologies, Inc., as amended.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">August 31, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422006963/ptn_ex34.htm">3.4</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495422006963/ptn_ex34.htm">Certificate of Decrease of Series A Convertible Preferred Stock.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">10-Q</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">May 16, 2022</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex41.htm">4.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex41.htm">Form of Pre-Funded Common Stock Purchase Warrant.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">February 10, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex42.htm">4.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex42.htm">Form of Series E Common Stock Purchase Warrant.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">February 10, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex101.htm">10.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="http://www.sec.gov/Archives/edgar/data/911216/000165495425001286/ptn_ex101.htm">Placement Agency Agreement, dated February 6, 2025, between A.G.P./Alliance Global Partners, Laidlaw &amp; Company (UK) Ltd., and Palatin Technologies, Inc.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">February 10, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">10.2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Form of Securities Purchase Agreement, dated February 6, 2025, by and between the Company and the Purchasers named therein.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">February 10, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">10.3</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Sales Agreement, dated as of February 11, 2025, by and between Palatin Technologies, Inc. and A.G.P./Alliance Global Partners.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">February 12, 2025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">001-15543</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex311.htm">31.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex311.htm">Certification of Chief Executive Officer.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex312.htm">31.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex312.htm">Certification of Chief Financial Officer.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex321.htm">32.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">*&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex322.htm">32.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><a href="ptn_ex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">*&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.INS</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Instance Document (the instance document does not appear on the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.SCH</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Schema Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.CAL</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.DEF</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">101.LAB</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="ptn_10qimg20.jpg" alt="ptn_10qimg20.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#TOC">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="text-decoration:underline"><span id="sig" class="atag" style="display:inline">SIGNATURES</span></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:50%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="width:3%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="width:35%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>Palatin Technologies, Inc.</strong></p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">(Registrant)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">/s/ Carl Spana</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Date: May 14, 2025</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Carl Spana, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">President and</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Chief Executive Officer (Principal</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Executive Officer)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">/s/ Stephen T. Wills</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Date: May 14, 2025</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Stephen T. Wills, CPA, MST</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Executive Vice President, Chief Financial Officer and Chief Operating Officer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">(Principal Financial and Accounting Officer)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ptn_ex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Certification of Chief Executive Officer</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">I, Carl Spana, certify that:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have reviewed this Quarterly Report on Form 10-Q of Palatin Technologies, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(c)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(d)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Date: May 14, 2025</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Carl Spana</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Carl Spana, President and Chief Executive Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ptn_ex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.2</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Certification of Chief Financial Officer</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">I, Stephen T. Wills, certify that:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I have reviewed this Quarterly Report on Form 10-Q of Palatin Technologies, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(c)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(d)</p></td> <td style="vertical-align:top;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Date: May 14, 2025</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Stephen T. Wills</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen T. Wills, Executive Vice President, Chief Financial Officer and Chief Operating Officer</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ptn_ex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Certification of Principal Executive Officer</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Pursuant to 18 U.S.C. Section 1350</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">I, Carl Spana, President and Chief Executive Officer of Palatin Technologies, Inc., hereby certify, to my knowledge, that the Quarterly Report on Form 10-Q for the period ended March 31, 2025 of Palatin Technologies, Inc. (the &#8220;Form 10-Q&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Palatin Technologies, Inc.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Dated: May 14, 2025</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Carl Spana</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Carl Spana, President and Chief Executive Officer (Principal Executive Officer) </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ptn_ex322.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html><head><title>ptn_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.2</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Certification of Principal Financial Officer</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Pursuant to 18 U.S.C. Section 1350</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">I, Stephen T. Wills, Executive Vice President, Chief Financial Officer and Chief Operating Officer of Palatin Technologies, Inc., hereby certify, to my knowledge, that the Quarterly Report on Form 10-Q for the period ended March 31, 2025 of Palatin Technologies, Inc. (the &#8220;Form 10-Q&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Palatin Technologies, Inc.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Dated: May 14, 2025</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:top;"> <p style="margin:0px">/s/ Stephen T. Wills</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="margin:0px">Stephen T. Wills, Executive Vice President, Chief Financial Officer and Chief Operating Officer (Principal Financial Officer)</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ptn-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/13/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ptn="http://ptn.com/20250331" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://ptn.com/20250331">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://ptn.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>110200 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <link:definition>110201 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" id="ConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>124100 - Statement - Consolidated Statements of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" id="ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited">
        <link:definition>148600 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" id="ConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>170000 - Statement - Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/InsiderTradingArragements" id="InsiderTradingArragements">
        <link:definition>995445 - Disclosure - Insider Trading Arragements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ORGANIZATION" id="ORGANIZATION">
        <link:definition>995446 - Disclosure - ORGANIZATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>995447 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>995448 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/NewAccountingPronouncements" id="NewAccountingPronouncements">
        <link:definition>995449 - Disclosure - New Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AssetPurchaseAgreement" id="AssetPurchaseAgreement">
        <link:definition>995450 - Disclosure - ASSET PURCHASE AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" id="ManufacturingSupplyAgreementsForVyleesi">
        <link:definition>995451 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithFosun" id="AgreementWithFosun">
        <link:definition>995452 - Disclosure - AGREEMENT WITH FOSUN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithKwangdong" id="AgreementWithKwangdong">
        <link:definition>995453 - Disclosure - AGREEMENT WITH KWANGDONG</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
        <link:definition>995454 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995455 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>995456 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995457 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiency" id="StockholdersDeficiency">
        <link:definition>995458 - Disclosure - STOCKHOLDERS DEFICIENCY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>995459 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995460 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995461 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>995462 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>995463 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <link:definition>995464 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>995465 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyTables" id="StockholdersDeficiencyTables">
        <link:definition>995466 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/OrganizationDetailsNarrative" id="OrganizationDetailsNarrative">
        <link:definition>995467 - Disclosure - ORGANIZATION (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>995468 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>995469 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" id="AssetPurchaseAgreementDetailsNarrative">
        <link:definition>995470 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" id="AgreementWithFosunDetailsNarrative">
        <link:definition>995471 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" id="AgreementWithKwangdongDetailsNarrative">
        <link:definition>995472 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>995473 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
        <link:definition>995474 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
        <link:definition>995475 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>995476 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>995477 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" id="StockholdersDeficiencyDetails">
        <link:definition>995478 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" id="StockholdersDeficiencyDetails1">
        <link:definition>995479 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" id="StockholdersDeficiencyDetails2">
        <link:definition>995480 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" id="StockholdersDeficiencyDetails3">
        <link:definition>995481 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" id="StockholdersDeficiencyDetailsNarrative">
        <link:definition>995482 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ptn.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>995483 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ptn-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd" />
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <element id="ptn_GainLossOnSaleOfVylessi" name="GainLossOnSaleOfVylessi" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_GainLossOnPurchaseCommitment" name="GainLossOnPurchaseCommitment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantsGainLossOnWarrantsNet" name="WarrantsGainLossOnWarrantsNet" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" name="WithholdingTaxesRelatedToRestrictedStockUnitsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" name="WithholdingTaxesRelatedToRestrictedStockUnitsAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SaleOfCommonStockNetOfCostsShares" name="SaleOfCommonStockNetOfCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SaleOfCommonStockNetOfCostsAmount" name="SaleOfCommonStockNetOfCostsAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ConversionOfLiabilityClassifiedWarrant" name="ConversionOfLiabilityClassifiedWarrant" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" name="ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" name="ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ReclassificationOfContingentlyRedeemableWarrants" name="ReclassificationOfContingentlyRedeemableWarrants" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SharesReleasedFromAbeyanceShares" name="SharesReleasedFromAbeyanceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SharesReleasedFromAbeyanceAmount" name="SharesReleasedFromAbeyanceAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantExercisesShares" name="WarrantExercisesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantExercisesAmount" name="WarrantExercisesAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" name="ChangeInFairValueOfLiabilityClassifiedWarrants" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ProceedsFromSaleOfOtherAssets" name="ProceedsFromSaleOfOtherAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ConversionOfLiabilityClassifiedWarrants" name="ConversionOfLiabilityClassifiedWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" name="ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AssetPurchaseAgreementTextBlock" name="AssetPurchaseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ManufacturingSupplyAgreementsTextBlock" name="ManufacturingSupplyAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithFosunTextBlock" name="AgreementWithFosunTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithKwangdongTextBlock" name="AgreementWithKwangdongTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" name="RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AccruedLiabilitiesPolicyTextBlock" name="AccruedLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfSalesTableTextBlock" name="ScheduleOfSalesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" name="ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" name="ScheduleOfEquityDistributionAgreementTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" name="ScheduleOfStockPurchaseWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SalesBasedMilestonePayments" name="SalesBasedMilestonePayments" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_RevenuesGross" name="RevenuesGross" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ProductSalesAllowancesAndAccruals" name="ProductSalesAllowancesAndAccruals" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PaymentsToSalesBasedMilestonePayments" name="PaymentsToSalesBasedMilestonePayments" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UpfrontPaymentOfLess" name="UpfrontPaymentOfLess" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_taxexpenses" name="taxexpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PrepaidClinicalStudyCosts" name="PrepaidClinicalStudyCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PrepaidInsurancePremiums" name="PrepaidInsurancePremiums" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AccruedClinicalRegulatoryCosts" name="AccruedClinicalRegulatoryCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_OtherAccruedResearchRelatedExpenses" name="OtherAccruedResearchRelatedExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AccruedPersonalCost" name="AccruedPersonalCost" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AccruedSellingExpenses" name="AccruedSellingExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityGrossProceedsShares" name="EquityGrossProceedsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityFeesShares" name="EquityFeesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityExpensesShares" name="EquityExpensesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityExpensesProceeds" name="EquityExpensesProceeds" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityNetProceedsShares" name="EquityNetProceedsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityNetProceedsProceeds" name="EquityNetProceedsProceeds" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_SharesOfCommonStock" name="SharesOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ExercisePricePerShareWarrantsOutstanding" name="ExercisePricePerShareWarrantsOutstanding" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_LatestTerminationDate" name="LatestTerminationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" name="shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" name="ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_RestrictedStockVestedInPeriod" name="RestrictedStockVestedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PurchaseOfWarrantShares" name="PurchaseOfWarrantShares" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_EquityIssuanceCostsPercentage" name="EquityIssuanceCostsPercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_OfferingExpensesAmount" name="OfferingExpensesAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" name="StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" name="NumberOfOutstandingSharesOfRestrictedStockUnits" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" name="UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" name="StockIssuedDuringPeriodValueRestrictedStockUnitshares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_UnvestedPerformanceBasedStockOptionsGranted" name="UnvestedPerformanceBasedStockOptionsGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" name="WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantIssuanceShares" name="WarrantIssuanceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantIssuance" name="WarrantIssuance" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_PurchaseOfWarrantOfCommonStockSeriesA" name="PurchaseOfWarrantOfCommonStockSeriesA" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_DescriptionOfSecuritiesPurchaseAgreement" name="DescriptionOfSecuritiesPurchaseAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AggregateValue" name="AggregateValue" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_DistributableValueOfDividendPerShare" name="DistributableValueOfDividendPerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_DividendAdditionalPerShare" name="DividendAdditionalPerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_WarrantsToPurchaseShares" name="WarrantsToPurchaseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_DescriptionOfExistingHolderPurchaseOfWarrants" name="DescriptionOfExistingHolderPurchaseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ExercisingHolderReleasedShares" name="ExercisingHolderReleasedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_DescriptionOfPublicOffering" name="DescriptionOfPublicOffering" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_OrganizationAbstract" name="OrganizationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AssetPurchaseAgreementAbstract" name="AssetPurchaseAgreementAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_ManufacturingSupplyAgreementsForVyleesiabstract" name="ManufacturingSupplyAgreementsForVyleesiabstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithFosunAbstract" name="AgreementWithFosunAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_AgreementWithKwangdongAbstract" name="AgreementWithKwangdongAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" name="StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesAConvertiblePreferredStocksMember" id="ptn_SeriesAConvertiblePreferredStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CurrentMember" id="ptn_CurrentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OneToThreeYearsMember" id="ptn_OneToThreeYearsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FourToFiveYearsMember" id="ptn_FourToFiveYearsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DecemberToZeroTwoFourSeriesDWarrantsMember" id="ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesAConvertiblePreferredStockMember" id="ptn_SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="MayTwoThousandTwentyTwoWarrantsMember" id="ptn_MayTwoThousandTwentyTwoWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" id="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" id="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryTwoZeroTwoFourPrivateWarrantsMember" id="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" id="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="JuneTwoThousandTwentyFourSerisBWarrantsMember" id="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwentyTwentyThreeEquityDistributionAgreementMember" id="ptn_TwentyTwentyThreeEquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConvertibleSeriesAPreferredStocksMember" id="ptn_ConvertibleSeriesAPreferredStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CumulativeFromInceptionMember" id="ptn_CumulativeFromInceptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoThousandTwentyFourPlacementAgentWarrantsMember" id="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ContingentlyRedeemableWarrantsMember" id="ptn_ContingentlyRedeemableWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DecemberTwoThousandTwentyFourSerisCWarrantsMember" id="ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FebruaryTwoZeroTwoFiveSeriesEWarrantsMember" id="ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="PrivateWarrantSharesMember" id="ptn_PrivateWarrantSharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoThousandTwentyFiveSalesAgreementMember" id="ptn_TwoThousandTwentyFiveSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesFWarrantsMember" id="ptn_SeriesFWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesGWarrantsMember" id="ptn_SeriesGWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockWarrantsMember" id="ptn_StockWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>ptn-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/13/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_494370" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_494370" xml:lang="en-US">Consolidated Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_9919ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_9919ee" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_a8ba02" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_a8ba02" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl_32efd1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl_32efd1" xml:lang="en-US">Statement Class Of Stock Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="ptn_SeriesAConvertiblePreferredStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SeriesAConvertiblePreferredStocksMember" xlink:to="ptn_SeriesAConvertiblePreferredStocksMember_lbl_c1f57e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SeriesAConvertiblePreferredStocksMember_lbl_c1f57e" xml:lang="en-US">Series A Convertible Preferred Stocks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_98095a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_98095a" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_9dda3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_9dda3f" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_1ae166" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_1ae166" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl_cf3d86" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl_cf3d86" xml:lang="en-US">OtherReceivablesCurrent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_f13f03" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_f13f03" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_e2c236" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_e2c236" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_7" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_82c46d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_82c46d" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_950a3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_950a3e" xml:lang="en-US">Right-of-use assets - operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl_ee11d4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl_ee11d4" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_256554" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_256554" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_11" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_0151b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_0151b1" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIENCY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_7a49b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_7a49b5" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_41c76b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_41c76b" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_681f0a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_681f0a" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_c04039" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_c04039" xml:lang="en-US">Short-term operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_3c578a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_3c578a" xml:lang="en-US">Short-term finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl_45a787" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl_45a787" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_1f140c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_1f140c" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_19" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_b9c93a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_b9c93a" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="us-gaap_OtherLongTermDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl_41703d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebt_lbl_41703d" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_0dea98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_0dea98" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_22" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_f58fcf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_f58fcf" xml:lang="en-US">Stockholders' deficiency:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_f112e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_f112e4" xml:lang="en-US">Series A Convertible: authorized 4,030 shares as of March 31, 2025: issued and outstanding 4,030 shares as of March 31, 2025 and June 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_eb6395" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_eb6395" xml:lang="en-US">Common stock of $0.01 par value - authorized 300,000,000 shares: issued and outstanding 28,557,246 shares as of March 31, 2025 and 17,926,640 shares as of June 30, 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_7d129f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_7d129f" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_b94601" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_b94601" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_18259e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_18259e" xml:lang="en-US">Total stockholders' deficiency</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_28" xml:lang="en-US">[Equity, Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_9a7210" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_9a7210" xml:lang="en-US">Total liabilities and stockholders' deficiency</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_29" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_f6b923" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_f6b923" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_d22b3c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_d22b3c" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_8ee4ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_8ee4ff" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_1e9f8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_1e9f8f" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_909720" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_909720" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_eeec9a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_eeec9a" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_fff529" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_fff529" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_c5050b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_c5050b" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_c02a10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_c02a10" xml:lang="en-US">Consolidated Statements of Operations (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl_926351" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl_926351" xml:lang="en-US">REVENUES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_97f97d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl_97f97d" xml:lang="en-US">Product revenue, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_937c90" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_937c90" xml:lang="en-US">OPERATING EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductionCosts" xlink:label="us-gaap_ProductionCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductionCosts" xlink:to="us-gaap_ProductionCosts_lbl_88905c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductionCosts_lbl_88905c" xml:lang="en-US">Cost of products sold</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_0eb61d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_0eb61d" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_5a2050" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_5a2050" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_GainLossOnSaleOfVylessi" xlink:to="ptn_GainLossOnSaleOfVylessi_lbl_c55cf8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_GainLossOnSaleOfVylessi_lbl_c55cf8" xml:lang="en-US">Loss (Gain) on sale of Vyleesi</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_GainLossOnSaleOfVylessi" xlink:label="ptn_GainLossOnSaleOfVylessi" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_GainLossOnSaleOfVylessi" xlink:to="ptn_GainLossOnSaleOfVylessi_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_GainLossOnSaleOfVylessi_lbl_8" xml:lang="en-US">[Loss (Gain) on sale of Vyleesi]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_GainLossOnPurchaseCommitment" xlink:to="ptn_GainLossOnPurchaseCommitment_lbl_52af21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_GainLossOnPurchaseCommitment_lbl_52af21" xml:lang="en-US">Gain on purchase commitment</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_GainLossOnPurchaseCommitment" xlink:label="ptn_GainLossOnPurchaseCommitment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_GainLossOnPurchaseCommitment" xlink:to="ptn_GainLossOnPurchaseCommitment_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_GainLossOnPurchaseCommitment_lbl_9" xml:lang="en-US">[Gain on purchase commitment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_15cfb5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_15cfb5" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_10" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_11111a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_11111a" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_11" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_bd7735" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_bd7735" xml:lang="en-US">OTHER INCOME (EXPENSE)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl_5527f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl_5527f5" xml:lang="en-US">Investment income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl_79d3a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl_79d3a1" xml:lang="en-US">Foreign currency transaction (loss) gain</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_099759" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl_099759" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl_15" xml:lang="en-US">[Interest Expense, Operating and Nonoperating]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl_dde254" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherExpenses_lbl_dde254" xml:lang="en-US">Offering expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl_16" xml:lang="en-US">[Other Expenses]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantsGainLossOnWarrantsNet" xlink:label="ptn_WarrantsGainLossOnWarrantsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantsGainLossOnWarrantsNet" xlink:to="ptn_WarrantsGainLossOnWarrantsNet_lbl_1d83cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantsGainLossOnWarrantsNet_lbl_1d83cc" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_d041e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_d041e7" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_18" xml:lang="en-US">[Other Nonoperating Income (Expense)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_0936d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_0936d0" xml:lang="en-US">NET LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_19" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl_4485ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl_4485ff" xml:lang="en-US">Basic and diluted net loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_507701" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_507701" xml:lang="en-US">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_5da0b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_5da0b2" xml:lang="en-US">Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_df7e96" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_df7e96" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesAConvertiblePreferredStockMember" xlink:label="ptn_SeriesAConvertiblePreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SeriesAConvertiblePreferredStockMember" xlink:to="ptn_SeriesAConvertiblePreferredStockMember_lbl_23a9fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SeriesAConvertiblePreferredStockMember_lbl_23a9fe" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_bc4379" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_bc4379" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_b5f2f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_b5f2f5" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_8552c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_8552c9" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ContingentlyRedeemableWarrantsMember" xlink:label="ptn_ContingentlyRedeemableWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ContingentlyRedeemableWarrantsMember" xlink:to="ptn_ContingentlyRedeemableWarrantsMember_lbl_e2364b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ContingentlyRedeemableWarrantsMember_lbl_e2364b" xml:lang="en-US">Contingently Redeemable Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_f37bd5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_f37bd5" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_bc1c93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_bc1c93" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_cba482" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl_cba482" xml:lang="en-US">Stock-based compensation, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_92cea3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_92cea3" xml:lang="en-US">Stock-based compensation, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:to="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares_lbl_67cdae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares_lbl_67cdae" xml:lang="en-US">Withholding taxes related to restricted stock units, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:to="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount_lbl_361419" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount_lbl_361419" xml:lang="en-US">Withholding taxes related to restricted stock units, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SaleOfCommonStockNetOfCostsShares" xlink:label="ptn_SaleOfCommonStockNetOfCostsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SaleOfCommonStockNetOfCostsShares" xlink:to="ptn_SaleOfCommonStockNetOfCostsShares_lbl_78eab9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SaleOfCommonStockNetOfCostsShares_lbl_78eab9" xml:lang="en-US">Sale of common stock, net of costs, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SaleOfCommonStockNetOfCostsAmount" xlink:label="ptn_SaleOfCommonStockNetOfCostsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SaleOfCommonStockNetOfCostsAmount" xlink:to="ptn_SaleOfCommonStockNetOfCostsAmount_lbl_148623" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SaleOfCommonStockNetOfCostsAmount_lbl_148623" xml:lang="en-US">Sale of common stock, net of costs, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrant" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConversionOfLiabilityClassifiedWarrant" xlink:to="ptn_ConversionOfLiabilityClassifiedWarrant_lbl_eb14bf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrant_lbl_eb14bf" xml:lang="en-US">Conversion of liability classified warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" xlink:to="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares_lbl_b07cec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares_lbl_b07cec" xml:lang="en-US">Conversion of liability classified warrants upon warrant exercise, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" xlink:to="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount_lbl_acccad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount_lbl_acccad" xml:lang="en-US">Conversion of liability classified warrants upon warrant exercise, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ReclassificationOfContingentlyRedeemableWarrants" xlink:label="ptn_ReclassificationOfContingentlyRedeemableWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ReclassificationOfContingentlyRedeemableWarrants" xlink:to="ptn_ReclassificationOfContingentlyRedeemableWarrants_lbl_9e62a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ReclassificationOfContingentlyRedeemableWarrants_lbl_9e62a1" xml:lang="en-US">Reclassification of contingently redeemable warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_525a85" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_525a85" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl_2226c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl_2226c0" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesReleasedFromAbeyanceShares" xlink:label="ptn_SharesReleasedFromAbeyanceShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesReleasedFromAbeyanceShares" xlink:to="ptn_SharesReleasedFromAbeyanceShares_lbl_f166c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SharesReleasedFromAbeyanceShares_lbl_f166c3" xml:lang="en-US">Shares released from abeyance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesReleasedFromAbeyanceAmount" xlink:label="ptn_SharesReleasedFromAbeyanceAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesReleasedFromAbeyanceAmount" xlink:to="ptn_SharesReleasedFromAbeyanceAmount_lbl_80202e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SharesReleasedFromAbeyanceAmount_lbl_80202e" xml:lang="en-US">Shares released from abeyance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantExercisesShares" xlink:label="ptn_WarrantExercisesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantExercisesShares" xlink:to="ptn_WarrantExercisesShares_lbl_48ef62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantExercisesShares_lbl_48ef62" xml:lang="en-US">Warrant exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantExercisesAmount" xlink:label="ptn_WarrantExercisesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantExercisesAmount" xlink:to="ptn_WarrantExercisesAmount_lbl_103ecf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantExercisesAmount_lbl_103ecf" xml:lang="en-US">Warrant exercises, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_be0b16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_be0b16" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_230c51" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_230c51" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_96a640" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_96a640" xml:lang="en-US">Consolidated Statements of Cash Flows (unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_da101d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_da101d" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_858cea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl_858cea" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_3" xml:lang="en-US">[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_3745d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_3745d7" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_7417b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_7417b1" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_9939b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl_9939b2" xml:lang="en-US">Decrease in right-of-use asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl_2166b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl_2166b6" xml:lang="en-US">Unrealized foreign currency transaction loss (gain)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl_7" xml:lang="en-US">[Unrealized Gain (Loss), Foreign Currency Transaction, before Tax]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_81357b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl_81357b" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_8" xml:lang="en-US">[Share-Based Payment Arrangement, Noncash Expense]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:to="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants_lbl_2cc788" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ChangeInFairValueOfLiabilityClassifiedWarrants_lbl_2cc788" xml:lang="en-US">Change in fair value of liability classified warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl_1acc1f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl_1acc1f" xml:lang="en-US">Gain on sale of Vyleesi</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="us-gaap_GainLossOnSaleOfOtherAssets_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfOtherAssets_lbl_10" xml:lang="en-US">[Gain (Loss) on Disposition of Other Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_f3cec6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl_f3cec6" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_7680dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_7680dc" xml:lang="en-US">Accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl_13" xml:lang="en-US">[Increase (Decrease) in Accounts Receivable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl_6d57a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl_6d57a3" xml:lang="en-US">Other receivables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl_14" xml:lang="en-US">[Increase (Decrease) in Other Receivables]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_bafb66" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_bafb66" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl_15" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense and Other Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_ecc6d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_ecc6d0" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_16" xml:lang="en-US">[Increase (Decrease) in Inventories]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_e3a522" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_e3a522" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_17" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_661804" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_661804" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_18" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_4b5756" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl_4b5756" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl_0e963d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl_0e963d" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_58fded" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_58fded" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_21" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_6dabab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_6dabab" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl_adaf22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl_adaf22" xml:lang="en-US">Maturity of marketable securities</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ProceedsFromSaleOfOtherAssets" xlink:label="ptn_ProceedsFromSaleOfOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ProceedsFromSaleOfOtherAssets" xlink:to="ptn_ProceedsFromSaleOfOtherAssets_lbl_2b137b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ProceedsFromSaleOfOtherAssets_lbl_2b137b" xml:lang="en-US">Proceeds from sale of Vyleesi</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_c29aa8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_c29aa8" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_25" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_977258" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_977258" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_26" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_d79240" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_d79240" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_40c91e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_40c91e" xml:lang="en-US">Payment of withholding taxes related to restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl_28" xml:lang="en-US">[Payment, Tax Withholding, Share-Based Payment Arrangement]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_4a21cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_4a21cf" xml:lang="en-US">Proceeds from the sale of common stock and warrants, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_cc354a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_cc354a" xml:lang="en-US">Payment of finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_30" xml:lang="en-US">[Finance Lease, Principal Payments]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_b127df" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_b127df" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_7cb2c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_7cb2c1" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_32" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_cdfd7c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_cdfd7c" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_33" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_54e83e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_54e83e" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_c76a17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_c76a17" xml:lang="en-US">CASH AND CASH EQUIVALENTS, end of period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_1d8e80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_1d8e80" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_61125e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_61125e" xml:lang="en-US">Cash paid for interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConversionOfLiabilityClassifiedWarrants" xlink:to="ptn_ConversionOfLiabilityClassifiedWarrants_lbl_161299" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrants_lbl_161299" xml:lang="en-US">Conversion of liability classified warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrants" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConversionOfLiabilityClassifiedWarrants" xlink:to="ptn_ConversionOfLiabilityClassifiedWarrants_lbl_38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrants_lbl_38" xml:lang="en-US">[Conversion of liability classified warrants]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" xlink:to="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise_lbl_31f141" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise_lbl_31f141" xml:lang="en-US">Conversion of liability classified warrants upon warrant exercise</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl_40d3c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl_40d3c7" xml:lang="en-US">Insider Trading Arragements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl_c72090" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl_c72090" xml:lang="en-US">Rule 10b5-1 Arragement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl_0ae336" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl_0ae336" xml:lang="en-US">Rule 10b5-1 Arragement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl_0f9732" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl_0f9732" xml:lang="en-US">Non Rule 10b5-1 Arragement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl_145743" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl_145743" xml:lang="en-US">Non Rule 10b5-1 Arragement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OrganizationAbstract" xlink:label="ptn_OrganizationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OrganizationAbstract" xlink:to="ptn_OrganizationAbstract_lbl_4d82a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OrganizationAbstract_lbl_4d82a4" xml:lang="en-US">ORGANIZATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_e74dad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_e74dad" xml:lang="en-US">ORGANIZATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_BasisOfPresentationAbstract" xlink:label="ptn_BasisOfPresentationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_BasisOfPresentationAbstract" xlink:to="ptn_BasisOfPresentationAbstract_lbl_7fe154" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_BasisOfPresentationAbstract_lbl_7fe154" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_590e2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_590e2b" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_902ed3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_902ed3" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_757ac9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_757ac9" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl_be6b5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl_be6b5d" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_cd170d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_cd170d" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl_2" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AssetPurchaseAgreementAbstract" xlink:label="ptn_AssetPurchaseAgreementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AssetPurchaseAgreementAbstract" xlink:to="ptn_AssetPurchaseAgreementAbstract_lbl_ccb557" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AssetPurchaseAgreementAbstract_lbl_ccb557" xml:lang="en-US">ASSET PURCHASE AGREEMENT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AssetPurchaseAgreementTextBlock" xlink:to="ptn_AssetPurchaseAgreementTextBlock_lbl_608e32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_AssetPurchaseAgreementTextBlock_lbl_608e32" xml:lang="en-US">ASSET PURCHASE AGREEMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AssetPurchaseAgreementTextBlock" xlink:label="ptn_AssetPurchaseAgreementTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AssetPurchaseAgreementTextBlock" xlink:to="ptn_AssetPurchaseAgreementTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AssetPurchaseAgreementTextBlock_lbl_2" xml:lang="en-US">[ASSET PURCHASE AGREEMENT]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ManufacturingSupplyAgreementsForVyleesiabstract" xlink:label="ptn_ManufacturingSupplyAgreementsForVyleesiabstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ManufacturingSupplyAgreementsForVyleesiabstract" xlink:to="ptn_ManufacturingSupplyAgreementsForVyleesiabstract_lbl_cfea4f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ManufacturingSupplyAgreementsForVyleesiabstract_lbl_cfea4f" xml:lang="en-US">MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ManufacturingSupplyAgreementsTextBlock" xlink:to="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_e9abda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_e9abda" xml:lang="en-US">MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ManufacturingSupplyAgreementsTextBlock" xlink:label="ptn_ManufacturingSupplyAgreementsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ManufacturingSupplyAgreementsTextBlock" xlink:to="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ManufacturingSupplyAgreementsTextBlock_lbl_2" xml:lang="en-US">[MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AgreementWithFosunAbstract" xlink:label="ptn_AgreementWithFosunAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithFosunAbstract" xlink:to="ptn_AgreementWithFosunAbstract_lbl_8f1581" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithFosunAbstract_lbl_8f1581" xml:lang="en-US">AGREEMENT WITH FOSUN</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithFosunTextBlock" xlink:to="ptn_AgreementWithFosunTextBlock_lbl_ad350d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_AgreementWithFosunTextBlock_lbl_ad350d" xml:lang="en-US">AGREEMENT WITH FOSUN</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AgreementWithFosunTextBlock" xlink:label="ptn_AgreementWithFosunTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithFosunTextBlock" xlink:to="ptn_AgreementWithFosunTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithFosunTextBlock_lbl_2" xml:lang="en-US">[AGREEMENT WITH FOSUN]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AgreementWithKwangdongAbstract" xlink:label="ptn_AgreementWithKwangdongAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithKwangdongAbstract" xlink:to="ptn_AgreementWithKwangdongAbstract_lbl_e571b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithKwangdongAbstract_lbl_e571b9" xml:lang="en-US">AGREEMENT WITH KWANGDONG</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithKwangdongTextBlock" xlink:to="ptn_AgreementWithKwangdongTextBlock_lbl_567e92" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_AgreementWithKwangdongTextBlock_lbl_567e92" xml:lang="en-US">AGREEMENT WITH KWANGDONG</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AgreementWithKwangdongTextBlock" xlink:label="ptn_AgreementWithKwangdongTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AgreementWithKwangdongTextBlock" xlink:to="ptn_AgreementWithKwangdongTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AgreementWithKwangdongTextBlock_lbl_2" xml:lang="en-US">[AGREEMENT WITH KWANGDONG]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl_9c1f21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl_9c1f21" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl_aafa87" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl_aafa87" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl_2" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl_62fd2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl_62fd2d" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_9f97e2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_9f97e2" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_2" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl_2ec121" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl_2ec121" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_a4d34a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_a4d34a" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl_2" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_564927" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_564927" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_e505b3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_e505b3" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:to="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_lbl_cf488b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_lbl_cf488b" xml:lang="en-US">STOCKHOLDERS DEFICIENCY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_7af60e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_7af60e" xml:lang="en-US">STOCKHOLDERS DEFICIENCY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_70ae34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_70ae34" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_afec33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_afec33" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl_285868" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl_285868" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_92a2ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_92a2ad" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_cde37f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_cde37f" xml:lang="en-US">Cash, Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl_3b4fe9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl_3b4fe9" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl_1fd355" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl_1fd355" xml:lang="en-US">Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_8275a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_8275a5" xml:lang="en-US">Property and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_7f267e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_7f267e" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl_e56fe4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl_e56fe4" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" xlink:label="ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" xlink:to="ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock_lbl_4b6012" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock_lbl_4b6012" xml:lang="en-US">Revenue Recognition (Prior to the sale of Vyleesi)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_bb5fcd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl_bb5fcd" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_7ac6cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_7ac6cc" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AccruedLiabilitiesPolicyTextBlock" xlink:label="ptn_AccruedLiabilitiesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AccruedLiabilitiesPolicyTextBlock" xlink:to="ptn_AccruedLiabilitiesPolicyTextBlock_lbl_ff054d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AccruedLiabilitiesPolicyTextBlock_lbl_ff054d" xml:lang="en-US">Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_de3c8e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_de3c8e" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_a48e9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_a48e9c" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_8f23ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_8f23ad" xml:lang="en-US">Net Loss per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl_90cc97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl_90cc97" xml:lang="en-US">Translation of foreign currencies</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ScheduleOfSalesTableTextBlock" xlink:label="ptn_ScheduleOfSalesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfSalesTableTextBlock" xlink:to="ptn_ScheduleOfSalesTableTextBlock_lbl_a58f83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfSalesTableTextBlock_lbl_a58f83" xml:lang="en-US">Schedule of sales</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl_71c58f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl_71c58f" xml:lang="en-US">Schedule of prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl_6ee4a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl_6ee4a0" xml:lang="en-US">Schedule of fair value asset measurement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl_a683d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl_a683d1" xml:lang="en-US">Schdule of Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" xlink:label="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" xlink:to="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock_lbl_3fb0a9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock_lbl_3fb0a9" xml:lang="en-US">Schedule of inventory purchase commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" xlink:label="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" xlink:to="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock_lbl_a91836" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfEquityDistributionAgreementTableTextBlock_lbl_a91836" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" xlink:label="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" xlink:to="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock_lbl_8ffc4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock_lbl_8ffc4c" xml:lang="en-US">Outstanding Stock Purchase Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_ebf0d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_ebf0d1" xml:lang="en-US">Option activity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl_43541a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl_43541a" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_4e9f24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_4e9f24" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_49138c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_49138c" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SalesBasedMilestonePayments" xlink:label="ptn_SalesBasedMilestonePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SalesBasedMilestonePayments" xlink:to="ptn_SalesBasedMilestonePayments_lbl_0e14d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SalesBasedMilestonePayments_lbl_0e14d3" xml:lang="en-US">Sales-based milestone payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_a8d89f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_a8d89f" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_5" xml:lang="en-US">[Cash and Cash Equivalents, at Carrying Value]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_7c6bfd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_7c6bfd" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl_ffaee0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl_ffaee0" xml:lang="en-US">Product Or Service Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl_688894" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl_688894" xml:lang="en-US">Product Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_RevenuesGross" xlink:label="ptn_RevenuesGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RevenuesGross" xlink:to="ptn_RevenuesGross_lbl_728192" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_RevenuesGross_lbl_728192" xml:lang="en-US">Gross product sales</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ProductSalesAllowancesAndAccruals" xlink:label="ptn_ProductSalesAllowancesAndAccruals" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ProductSalesAllowancesAndAccruals" xlink:to="ptn_ProductSalesAllowancesAndAccruals_lbl_6c51ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ProductSalesAllowancesAndAccruals_lbl_6c51ce" xml:lang="en-US">Product sales allowances and accruals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_4036ce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl_4036ce" xml:lang="en-US">Net sales</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_5befd2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_5befd2" xml:lang="en-US">Potential number of common shares excluded from diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:to="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl_eecc11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl_eecc11" xml:lang="en-US">Weighted average vested restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl_42a01d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl_42a01d" xml:lang="en-US">Cash equivalents - Money market funds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:to="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl_5bfbf6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForPurchaseOfOtherAssets1_lbl_5bfbf6" xml:lang="en-US">Payable the settlement of certain purchase commitments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivablePurchase" xlink:label="us-gaap_AccountsReceivablePurchase" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivablePurchase" xlink:to="us-gaap_AccountsReceivablePurchase_lbl_975a62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivablePurchase_lbl_975a62" xml:lang="en-US">Acounts receiveble</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PaymentsToSalesBasedMilestonePayments" xlink:to="ptn_PaymentsToSalesBasedMilestonePayments_lbl_b98697" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_PaymentsToSalesBasedMilestonePayments_lbl_b98697" xml:lang="en-US">Sales-based milestone payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PaymentsToSalesBasedMilestonePayments" xlink:label="ptn_PaymentsToSalesBasedMilestonePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PaymentsToSalesBasedMilestonePayments" xlink:to="ptn_PaymentsToSalesBasedMilestonePayments_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PaymentsToSalesBasedMilestonePayments_lbl_4" xml:lang="en-US">[Sales-based milestone payments]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalDeferredPurchasePrice" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl_339fd6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl_339fd6" xml:lang="en-US">Upfront purchase price amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_lbl_acc1c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_lbl_acc1c7" xml:lang="en-US">Company License Agreement Recievables</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl_c9ff04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl_c9ff04" xml:lang="en-US">Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_UpfrontPaymentOfLess" xlink:label="ptn_UpfrontPaymentOfLess" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UpfrontPaymentOfLess" xlink:to="ptn_UpfrontPaymentOfLess_lbl_d17fc3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UpfrontPaymentOfLess_lbl_d17fc3" xml:lang="en-US">Upfront payment of less</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl_acc3fc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl_acc3fc" xml:lang="en-US">Recievable under company agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl_08f50f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl_08f50f" xml:lang="en-US">Upfront payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_taxexpenses" xlink:label="ptn_taxexpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_taxexpenses" xlink:to="ptn_taxexpenses_lbl_017adc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_taxexpenses_lbl_017adc" xml:lang="en-US">Tax Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireReceivables" xlink:label="us-gaap_PaymentsToAcquireReceivables" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireReceivables" xlink:to="us-gaap_PaymentsToAcquireReceivables_lbl_2dd96e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireReceivables_lbl_2dd96e" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PrepaidClinicalStudyCosts" xlink:label="ptn_PrepaidClinicalStudyCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PrepaidClinicalStudyCosts" xlink:to="ptn_PrepaidClinicalStudyCosts_lbl_c7c176" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PrepaidClinicalStudyCosts_lbl_c7c176" xml:lang="en-US">Clinical / regulatory costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PrepaidInsurancePremiums" xlink:label="ptn_PrepaidInsurancePremiums" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PrepaidInsurancePremiums" xlink:to="ptn_PrepaidInsurancePremiums_lbl_ceb998" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PrepaidInsurancePremiums_lbl_ceb998" xml:lang="en-US">Insurance premiums</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl_43e2f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl_43e2f3" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_9592b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_9592b4" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_f632db" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl_f632db" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl_6bb407" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl_6bb407" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl_38ecb2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl_38ecb2" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl_1d2c6d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl_1d2c6d" xml:lang="en-US">Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl_cb27a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl_cb27a1" xml:lang="en-US">Cash equivalents - Money market funds</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AccruedClinicalRegulatoryCosts" xlink:to="ptn_AccruedClinicalRegulatoryCosts_lbl_ac2cd5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_AccruedClinicalRegulatoryCosts_lbl_ac2cd5" xml:lang="en-US">Clinical / regulatory costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AccruedClinicalRegulatoryCosts" xlink:label="ptn_AccruedClinicalRegulatoryCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AccruedClinicalRegulatoryCosts" xlink:to="ptn_AccruedClinicalRegulatoryCosts_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AccruedClinicalRegulatoryCosts_lbl_2" xml:lang="en-US">[Clinical / regulatory costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OtherAccruedResearchRelatedExpenses" xlink:label="ptn_OtherAccruedResearchRelatedExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OtherAccruedResearchRelatedExpenses" xlink:to="ptn_OtherAccruedResearchRelatedExpenses_lbl_683677" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OtherAccruedResearchRelatedExpenses_lbl_683677" xml:lang="en-US">Other research related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl_bbef35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl_bbef35" xml:lang="en-US">Professional services</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AccruedPersonalCost" xlink:label="ptn_AccruedPersonalCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AccruedPersonalCost" xlink:to="ptn_AccruedPersonalCost_lbl_2d401b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AccruedPersonalCost_lbl_2d401b" xml:lang="en-US">Personal cost</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AccruedSellingExpenses" xlink:label="ptn_AccruedSellingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AccruedSellingExpenses" xlink:to="ptn_AccruedSellingExpenses_lbl_b72580" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AccruedSellingExpenses_lbl_b72580" xml:lang="en-US">Selling expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_d2a36e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_d2a36e" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl_7" xml:lang="en-US">[Other Accrued Liabilities, Current]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_90c1f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_90c1f9" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_0a54a3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_0a54a3" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_CurrentMember" xlink:label="ptn_CurrentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CurrentMember" xlink:to="ptn_CurrentMember_lbl_bbf194" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CurrentMember_lbl_bbf194" xml:lang="en-US">Current [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OneToThreeYearsMember" xlink:label="ptn_OneToThreeYearsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OneToThreeYearsMember" xlink:to="ptn_OneToThreeYearsMember_lbl_9c3002" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OneToThreeYearsMember_lbl_9c3002" xml:lang="en-US">1 - 3 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_FourToFiveYearsMember" xlink:label="ptn_FourToFiveYearsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_FourToFiveYearsMember" xlink:to="ptn_FourToFiveYearsMember_lbl_f95e40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_FourToFiveYearsMember_lbl_f95e40" xml:lang="en-US">4 - 5 Years [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases_lbl_32a198" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl_32a198" xml:lang="en-US">Inventory purchase commitments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl_f9e51d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl_f9e51d" xml:lang="en-US">Other current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebt" xlink:to="us-gaap_OtherLongTermDebt_lbl_95e5ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLongTermDebt_lbl_95e5ba" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_CumulativeFromInceptionMember" xlink:label="ptn_CumulativeFromInceptionMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_CumulativeFromInceptionMember" xlink:to="ptn_CumulativeFromInceptionMember_lbl_513683" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_CumulativeFromInceptionMember_lbl_513683" xml:lang="en-US">Cumulative From Inception</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityGrossProceedsShares" xlink:label="ptn_EquityGrossProceedsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityGrossProceedsShares" xlink:to="ptn_EquityGrossProceedsShares_lbl_71d992" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityGrossProceedsShares_lbl_71d992" xml:lang="en-US">Equity Gross proceeds, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl_1e0de5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl_1e0de5" xml:lang="en-US">Equity Gross proceeds, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityFeesShares" xlink:label="ptn_EquityFeesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityFeesShares" xlink:to="ptn_EquityFeesShares_lbl_b5072d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityFeesShares_lbl_b5072d" xml:lang="en-US">Equity Fees, Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl_a91098" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl_a91098" xml:lang="en-US">Equity Fees, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl_5" xml:lang="en-US">[Proceeds from Fees Received]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityExpensesShares" xlink:label="ptn_EquityExpensesShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityExpensesShares" xlink:to="ptn_EquityExpensesShares_lbl_d7c85d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityExpensesShares_lbl_d7c85d" xml:lang="en-US">Equity Expenses, Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityExpensesProceeds" xlink:to="ptn_EquityExpensesProceeds_lbl_498217" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_EquityExpensesProceeds_lbl_498217" xml:lang="en-US">Equity Expenses, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityExpensesProceeds" xlink:label="ptn_EquityExpensesProceeds" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityExpensesProceeds" xlink:to="ptn_EquityExpensesProceeds_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityExpensesProceeds_lbl_7" xml:lang="en-US">[Equity Expenses, Proceeds]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityNetProceedsShares" xlink:label="ptn_EquityNetProceedsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityNetProceedsShares" xlink:to="ptn_EquityNetProceedsShares_lbl_8a6adb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityNetProceedsShares_lbl_8a6adb" xml:lang="en-US">Equity Net proceeds, Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityNetProceedsProceeds" xlink:label="ptn_EquityNetProceedsProceeds" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityNetProceedsProceeds" xlink:to="ptn_EquityNetProceedsProceeds_lbl_a3ee1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityNetProceedsProceeds_lbl_a3ee1c" xml:lang="en-US">Equity Net proceeds, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" xlink:label="ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" xlink:to="ptn_DecemberToZeroTwoFourSeriesDWarrantsMember_lbl_f8bf2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DecemberToZeroTwoFourSeriesDWarrantsMember_lbl_f8bf2f" xml:lang="en-US">December 2024 Series D Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="ptn_MayTwoThousandTwentyTwoWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:to="ptn_MayTwoThousandTwentyTwoWarrantsMember_lbl_a0a357" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_MayTwoThousandTwentyTwoWarrantsMember_lbl_a0a357" xml:lang="en-US">May 2022 Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:label="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:to="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_lbl_44c309" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_lbl_44c309" xml:lang="en-US">October 2022 Placement Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:label="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:to="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember_lbl_bcd510" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember_lbl_bcd510" xml:lang="en-US">October 2023 Placement Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:label="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:to="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember_lbl_f0a57e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember_lbl_f0a57e" xml:lang="en-US">January 2024 Private Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:label="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:to="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_lbl_6c5794" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_lbl_6c5794" xml:lang="en-US">January 2024 Placement Agent Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:label="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:to="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember_lbl_4d286c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember_lbl_4d286c" xml:lang="en-US">June 2024 Seris B Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" xlink:label="ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" xlink:to="ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember_lbl_1bfa05" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember_lbl_1bfa05" xml:lang="en-US">December 2024 Series C Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember" xlink:label="ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember" xlink:to="ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember_lbl_672fcf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember_lbl_672fcf" xml:lang="en-US">February 2025 Series E Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesOfCommonStock" xlink:label="ptn_SharesOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesOfCommonStock" xlink:to="ptn_SharesOfCommonStock_lbl_2ae714" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SharesOfCommonStock_lbl_2ae714" xml:lang="en-US">Shares of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ExercisePricePerShareWarrantsOutstanding" xlink:label="ptn_ExercisePricePerShareWarrantsOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ExercisePricePerShareWarrantsOutstanding" xlink:to="ptn_ExercisePricePerShareWarrantsOutstanding_lbl_99efcd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ExercisePricePerShareWarrantsOutstanding_lbl_99efcd" xml:lang="en-US">Exercise Price per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_LatestTerminationDate" xlink:label="ptn_LatestTerminationDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_LatestTerminationDate" xlink:to="ptn_LatestTerminationDate_lbl_765d36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_LatestTerminationDate_lbl_765d36" xml:lang="en-US">Latest Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_lbl_b82fdf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_lbl_b82fdf" xml:lang="en-US">Number of Options Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_lbl_66a827" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_lbl_66a827" xml:lang="en-US">Number of Options Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_5f6bde" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_5f6bde" xml:lang="en-US">Number of Options Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_lbl_4" xml:lang="en-US">[Number of Options Forfeited]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_68f380" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_68f380" xml:lang="en-US">Number of Options Exercied</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_lbl_5" xml:lang="en-US">[Number of Options Exercied]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_lbl_a62c79" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_lbl_a62c79" xml:lang="en-US">Number of Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_lbl_7dfc00" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_lbl_7dfc00" xml:lang="en-US">Number of Options Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_lbl_8c11a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_lbl_8c11a8" xml:lang="en-US">Number of Options Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_lbl_da9b3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_lbl_da9b3a" xml:lang="en-US">Number of Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_lbl_d311d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_lbl_d311d7" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_802a70" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_802a70" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_a160f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_a160f7" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_2721b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_2721b2" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl_c8e113" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl_c8e113" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_lbl_e50aca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_lbl_e50aca" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" xlink:label="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" xlink:to="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_lbl_365f3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_lbl_365f3a" xml:lang="en-US">Weighted Average Exercise Price Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_lbl_65b045" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_lbl_65b045" xml:lang="en-US">Weighted Average Exercise Price Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl_ee5d13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl_ee5d13" xml:lang="en-US">Weighted Average Remaining Term in Years Options outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_6aa6c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_6aa6c0" xml:lang="en-US">Weighted Average Remaining Term in Years Options outstanding at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_bfe013" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_bfe013" xml:lang="en-US">Weighted Average Remaining Term in Years Options exercisable at end of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl_501377" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl_501377" xml:lang="en-US">Weighted Average Remaining Term in Years Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" xlink:to="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_lbl_fa8e5a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_lbl_fa8e5a" xml:lang="en-US">Aggregate Intrinsic Value Options Expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" xlink:to="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_lbl_7c9e8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_lbl_7c9e8f" xml:lang="en-US">Aggregate Intrinsic Value Options Expected to outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" xlink:to="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_lbl_ef449e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_lbl_ef449e" xml:lang="en-US">Aggregate Intrinsic Value Options Exercisable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_949a11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_949a11" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_2" xml:lang="en-US">[Outstanding at beginning of year]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_55b632" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_55b632" xml:lang="en-US">Granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_cefda7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_cefda7" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl_4" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_RestrictedStockVestedInPeriod" xlink:label="ptn_RestrictedStockVestedInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_RestrictedStockVestedInPeriod" xlink:to="ptn_RestrictedStockVestedInPeriod_lbl_9673c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_RestrictedStockVestedInPeriod_lbl_9673c9" xml:lang="en-US">Vested</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_a0f08d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_a0f08d" xml:lang="en-US">Expirations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl_6" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_142648" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_lbl_142648" xml:lang="en-US">Outstanding at ending of year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_bff526" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_bff526" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl_0ad6a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl_0ad6a4" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_b1a633" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_b1a633" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:label="ptn_TwentyTwentyThreeEquityDistributionAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:to="ptn_TwentyTwentyThreeEquityDistributionAgreementMember_lbl_2d0b86" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_TwentyTwentyThreeEquityDistributionAgreementMember_lbl_2d0b86" xml:lang="en-US">2023 Equity Distribution Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConvertibleSeriesAPreferredStocksMember" xlink:label="ptn_ConvertibleSeriesAPreferredStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ConvertibleSeriesAPreferredStocksMember" xlink:to="ptn_ConvertibleSeriesAPreferredStocksMember_lbl_ff9ff0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ConvertibleSeriesAPreferredStocksMember_lbl_ff9ff0" xml:lang="en-US">Convertible Series A Preferred Stocks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:to="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember_lbl_f7a947" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember_lbl_f7a947" xml:lang="en-US">2024 Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl_e18c09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl_e18c09" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PrivateWarrantSharesMember" xlink:label="ptn_PrivateWarrantSharesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PrivateWarrantSharesMember" xlink:to="ptn_PrivateWarrantSharesMember_lbl_64a42c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PrivateWarrantSharesMember_lbl_64a42c" xml:lang="en-US">Private Warrant Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwoThousandTwentyFiveSalesAgreementMember" xlink:label="ptn_TwoThousandTwentyFiveSalesAgreementMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TwoThousandTwentyFiveSalesAgreementMember" xlink:to="ptn_TwoThousandTwentyFiveSalesAgreementMember_lbl_e83334" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_TwoThousandTwentyFiveSalesAgreementMember_lbl_e83334" xml:lang="en-US">2025 Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockWarrantsMember" xlink:label="ptn_StockWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockWarrantsMember" xlink:to="ptn_StockWarrantsMember_lbl_3da04e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockWarrantsMember_lbl_3da04e" xml:lang="en-US">Stock Warrants [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SharesOfCommonStock" xlink:to="ptn_SharesOfCommonStock_lbl_203a5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_SharesOfCommonStock_lbl_203a5c" xml:lang="en-US">Shares of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PurchaseOfWarrantShares" xlink:label="ptn_PurchaseOfWarrantShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PurchaseOfWarrantShares" xlink:to="ptn_PurchaseOfWarrantShares_lbl_642994" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PurchaseOfWarrantShares_lbl_642994" xml:lang="en-US">Purchase of warrant shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityIssuanceCostsPercentage" xlink:label="ptn_EquityIssuanceCostsPercentage" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityIssuanceCostsPercentage" xlink:to="ptn_EquityIssuanceCostsPercentage_lbl_471ec8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_EquityIssuanceCostsPercentage_lbl_471ec8" xml:lang="en-US">Cash fee, percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OfferingExpensesAmount" xlink:to="ptn_OfferingExpensesAmount_lbl_eb0408" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_OfferingExpensesAmount_lbl_eb0408" xml:lang="en-US">Offering expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OfferingExpensesAmount" xlink:label="ptn_OfferingExpensesAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_OfferingExpensesAmount" xlink:to="ptn_OfferingExpensesAmount_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_OfferingExpensesAmount_lbl_5" xml:lang="en-US">[Offering expenses]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:label="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:to="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_lbl_891319" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_lbl_891319" xml:lang="en-US">Stock-based compensation related to restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:label="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:to="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits_lbl_b0c8fe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_NumberOfOutstandingSharesOfRestrictedStockUnits_lbl_b0c8fe" xml:lang="en-US">Number of outstanding shares of restricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:to="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_lbl_6fe5b3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_lbl_6fe5b3" xml:lang="en-US">Unvested performance-based stock options granted estricted stock units</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:to="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_lbl_3038c5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_lbl_3038c5" xml:lang="en-US">Restricted stock units number of shares outstanding granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:to="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_5b27d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_5b27d2" xml:lang="en-US">Withholding taxes related to restricted stock units, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:label="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:to="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares_lbl_10" xml:lang="en-US">[Withholding taxes related to restricted stock units, shares]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl_1f48d1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl_1f48d1" xml:lang="en-US">Stock-based compensation to stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:to="ptn_UnvestedPerformanceBasedStockOptionsGranted_lbl_704871" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_UnvestedPerformanceBasedStockOptionsGranted_lbl_704871" xml:lang="en-US">Unvested performance-based stock options granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_1f593d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl_1f593d" xml:lang="en-US">Number of shares outstanding granted</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" xlink:to="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun_lbl_ccf2f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun_lbl_ccf2f1" xml:lang="en-US">Withholding taxes related to restricted stock units, value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl_b59fe1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl_b59fe1" xml:lang="en-US">Fees and expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_c2466b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_c2466b" xml:lang="en-US">Exercise price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl_107d2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl_107d2f" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantIssuanceShares" xlink:label="ptn_WarrantIssuanceShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantIssuanceShares" xlink:to="ptn_WarrantIssuanceShares_lbl_0f20f3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantIssuanceShares_lbl_0f20f3" xml:lang="en-US">Warrant issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantIssuance" xlink:label="ptn_WarrantIssuance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantIssuance" xlink:to="ptn_WarrantIssuance_lbl_2f0dae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantIssuance_lbl_2f0dae" xml:lang="en-US">Warrant issuance year five</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:label="ptn_PurchaseOfWarrantOfCommonStockSeriesA" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:to="ptn_PurchaseOfWarrantOfCommonStockSeriesA_lbl_3b12d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_PurchaseOfWarrantOfCommonStockSeriesA_lbl_3b12d2" xml:lang="en-US">Purchase of warrant of common stock series A</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="ptn_DescriptionOfSecuritiesPurchaseAgreement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:to="ptn_DescriptionOfSecuritiesPurchaseAgreement_lbl_0313e9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DescriptionOfSecuritiesPurchaseAgreement_lbl_0313e9" xml:lang="en-US">Description of securities purchase agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_ee18e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_ee18e0" xml:lang="en-US">Convertible preferred stock were outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AggregateValue" xlink:label="ptn_AggregateValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_AggregateValue" xlink:to="ptn_AggregateValue_lbl_73b9ed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_AggregateValue_lbl_73b9ed" xml:lang="en-US">Aggregate value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl_01c2a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl_01c2a2" xml:lang="en-US">Conversion price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:label="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:to="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare_lbl_495fac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare_lbl_495fac" xml:lang="en-US">Convertible shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAvailableForDistributions" xlink:label="us-gaap_CashAvailableForDistributions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAvailableForDistributions" xlink:to="us-gaap_CashAvailableForDistributions_lbl_011ee1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAvailableForDistributions_lbl_011ee1" xml:lang="en-US">Distributable value of dividend</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DistributableValueOfDividendPerShare" xlink:to="ptn_DistributableValueOfDividendPerShare_lbl_ef6ded" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_DistributableValueOfDividendPerShare_lbl_ef6ded" xml:lang="en-US">Distributable value of dividend</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DistributableValueOfDividendPerShare" xlink:label="ptn_DistributableValueOfDividendPerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DistributableValueOfDividendPerShare" xlink:to="ptn_DistributableValueOfDividendPerShare_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DistributableValueOfDividendPerShare_lbl_27" xml:lang="en-US">[Distributable value of dividend]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DividendAdditionalPerShare" xlink:label="ptn_DividendAdditionalPerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DividendAdditionalPerShare" xlink:to="ptn_DividendAdditionalPerShare_lbl_31be23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DividendAdditionalPerShare_lbl_31be23" xml:lang="en-US">Distributable value of dividend additional</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_89e0f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_89e0f8" xml:lang="en-US">Purchase price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_ec837c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_ec837c" xml:lang="en-US">Common stock share purchased</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_8ea171" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_8ea171" xml:lang="en-US">Gross proceeds from Offering</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantsToPurchaseShares" xlink:label="ptn_WarrantsToPurchaseShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_WarrantsToPurchaseShares" xlink:to="ptn_WarrantsToPurchaseShares_lbl_c3dde9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_WarrantsToPurchaseShares_lbl_c3dde9" xml:lang="en-US">Warrants to purchase</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_67fc40" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_67fc40" xml:lang="en-US">Gross proceeds from exercise of Existing Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:label="ptn_DescriptionOfExistingHolderPurchaseOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:to="ptn_DescriptionOfExistingHolderPurchaseOfWarrants_lbl_4e926e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DescriptionOfExistingHolderPurchaseOfWarrants_lbl_4e926e" xml:lang="en-US">Description of existing holder purchase of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ExercisingHolderReleasedShares" xlink:label="ptn_ExercisingHolderReleasedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_ExercisingHolderReleasedShares" xlink:to="ptn_ExercisingHolderReleasedShares_lbl_38e20f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_ExercisingHolderReleasedShares_lbl_38e20f" xml:lang="en-US">Exercising holder released shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_a29978" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_a29978" xml:lang="en-US">Net proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl_9b0fc7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForCommissions_lbl_9b0fc7" xml:lang="en-US">Payment of commission fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl_930ab0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherExpenses_lbl_930ab0" xml:lang="en-US">Other related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_10ff71" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_10ff71" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_291ba7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_291ba7" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_TwoThousandTwentyFiveSalesAgreementMember" xlink:to="ptn_TwoThousandTwentyFiveSalesAgreementMember_lbl_d674ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_TwoThousandTwentyFiveSalesAgreementMember_lbl_d674ad" xml:lang="en-US">2025 Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesFWarrantsMember" xlink:label="ptn_SeriesFWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SeriesFWarrantsMember" xlink:to="ptn_SeriesFWarrantsMember_lbl_a66b1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SeriesFWarrantsMember_lbl_a66b1c" xml:lang="en-US">Series F Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesGWarrantsMember" xlink:label="ptn_SeriesGWarrantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_SeriesGWarrantsMember" xlink:to="ptn_SeriesGWarrantsMember_lbl_6a2495" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_SeriesGWarrantsMember_lbl_6a2495" xml:lang="en-US">Series G Warrants [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_EquityIssuanceCostsPercentage" xlink:to="ptn_EquityIssuanceCostsPercentage_lbl_7d1905" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptn_EquityIssuanceCostsPercentage_lbl_7d1905" xml:lang="en-US">Cash fee, percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_95ae1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl_95ae1e" xml:lang="en-US">Common stock share sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_ae0fa8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_ae0fa8" xml:lang="en-US">Net proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DescriptionOfPublicOffering" xlink:label="ptn_DescriptionOfPublicOffering" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptn_DescriptionOfPublicOffering" xlink:to="ptn_DescriptionOfPublicOffering_lbl_79b93f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptn_DescriptionOfPublicOffering_lbl_79b93f" xml:lang="en-US">May 2025 Public Offering, Description</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_7ccd9b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_7ccd9b" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl_9bae7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl_9bae7d" xml:lang="en-US">Legal Fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_5807cc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl_5807cc" xml:lang="en-US">Gross proceeds from Offering</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ptn-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/13/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20250331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:href="ptn-20250331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ptn-20250331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptn-20250331.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:href="ptn-20250331.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptn-20250331.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ORGANIZATION" xlink:href="ptn-20250331.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/BasisOfPresentation" xlink:href="ptn-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/NewAccountingPronouncements" xlink:href="ptn-20250331.xsd#NewAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreement" xlink:href="ptn-20250331.xsd#AssetPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:href="ptn-20250331.xsd#ManufacturingSupplyAgreementsForVyleesi" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosun" xlink:href="ptn-20250331.xsd#AgreementWithFosun" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdong" xlink:href="ptn-20250331.xsd#AgreementWithKwangdong" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ptn-20250331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurements" xlink:href="ptn-20250331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpenses" xlink:href="ptn-20250331.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingencies" xlink:href="ptn-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiency" xlink:href="ptn-20250331.xsd#StockholdersDeficiency" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEvents" xlink:href="ptn-20250331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ptn-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsTables" xlink:href="ptn-20250331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesTables" xlink:href="ptn-20250331.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:href="ptn-20250331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyTables" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20250331.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:href="ptn-20250331.xsd#AssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:href="ptn-20250331.xsd#AgreementWithFosunDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:href="ptn-20250331.xsd#AgreementWithKwangdongDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ptn-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20250331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesDetails" xlink:href="ptn-20250331.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:href="ptn-20250331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ptn-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:href="ptn-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:title="110200 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLongTermDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="110201 - Statement - Consolidated Balance Sheets (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="124100 - Statement - Consolidated Statements of Operations (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductionCosts" xlink:label="loc_us-gaapProductionCosts" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProductionCosts" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_GainLossOnSaleOfVylessi" xlink:label="loc_ptnGainLossOnSaleOfVylessi" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_ptnGainLossOnSaleOfVylessi" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_GainLossOnPurchaseCommitment" xlink:label="loc_ptnGainLossOnPurchaseCommitment" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_ptnGainLossOnPurchaseCommitment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantsGainLossOnWarrantsNet" xlink:label="loc_ptnWarrantsGainLossOnWarrantsNet" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_ptnWarrantsGainLossOnWarrantsNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:title="148600 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="170000 - Statement - Consolidated Statements of Cash Flows (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_GainLossOnPurchaseCommitment" xlink:label="loc_ptnGainLossOnPurchaseCommitment" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ptnGainLossOnPurchaseCommitment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ProceedsFromSaleOfOtherAssets" xlink:label="loc_ptnProceedsFromSaleOfOtherAssets" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ptnProceedsFromSaleOfOtherAssets" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ORGANIZATION" xlink:title="995446 - Disclosure - ORGANIZATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/BasisOfPresentation" xlink:title="995447 - Disclosure - BASIS OF PRESENTATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995448 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/NewAccountingPronouncements" xlink:title="995449 - Disclosure - New Accounting Pronouncements" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreement" xlink:title="995450 - Disclosure - ASSET PURCHASE AGREEMENT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:title="995451 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosun" xlink:title="995452 - Disclosure - AGREEMENT WITH FOSUN" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdong" xlink:title="995453 - Disclosure - AGREEMENT WITH KWANGDONG" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="995454 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurements" xlink:title="995455 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpenses" xlink:title="995456 - Disclosure - ACCRUED EXPENSES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingencies" xlink:title="995457 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiency" xlink:title="995458 - Disclosure - STOCKHOLDERS DEFICIENCY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEvents" xlink:title="995459 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995460 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="995461 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="995462 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsTables" xlink:title="995463 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesTables" xlink:title="995464 - Disclosure - ACCRUED EXPENSES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:title="995465 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyTables" xlink:title="995466 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/OrganizationDetailsNarrative" xlink:title="995467 - Disclosure - ORGANIZATION (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="995468 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995469 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:title="995470 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:title="995471 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:title="995472 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="995473 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsDetails" xlink:title="995474 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesDetails" xlink:title="995475 - Disclosure - ACCRUED EXPENSES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:title="995476 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995477 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:title="995478 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:title="995479 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:title="995480 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:title="995481 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:title="995482 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:title="995483 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ptn-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/13/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20250331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:href="ptn-20250331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ptn-20250331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptn-20250331.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:href="ptn-20250331.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptn-20250331.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ORGANIZATION" xlink:href="ptn-20250331.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/BasisOfPresentation" xlink:href="ptn-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/NewAccountingPronouncements" xlink:href="ptn-20250331.xsd#NewAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreement" xlink:href="ptn-20250331.xsd#AssetPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:href="ptn-20250331.xsd#ManufacturingSupplyAgreementsForVyleesi" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosun" xlink:href="ptn-20250331.xsd#AgreementWithFosun" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdong" xlink:href="ptn-20250331.xsd#AgreementWithKwangdong" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ptn-20250331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurements" xlink:href="ptn-20250331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpenses" xlink:href="ptn-20250331.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingencies" xlink:href="ptn-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiency" xlink:href="ptn-20250331.xsd#StockholdersDeficiency" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEvents" xlink:href="ptn-20250331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ptn-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsTables" xlink:href="ptn-20250331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesTables" xlink:href="ptn-20250331.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:href="ptn-20250331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyTables" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20250331.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:href="ptn-20250331.xsd#AssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:href="ptn-20250331.xsd#AgreementWithFosunDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:href="ptn-20250331.xsd#AgreementWithKwangdongDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ptn-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20250331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesDetails" xlink:href="ptn-20250331.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:href="ptn-20250331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ptn-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:href="ptn-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:title="110200 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_606271" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_587441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_606271" xlink:to="loc_us-gaapStatementTable_587441" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9faa8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_587441" xlink:to="loc_us-gaapStatementLineItems_9faa8a" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_d6cfa5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_587441" xlink:to="loc_us-gaapStatementClassOfStockAxis_d6cfa5" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_3fb631" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_d6cfa5" xlink:to="loc_us-gaapClassOfStockDomain_3fb631" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember_201733" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_3fb631" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember_201733" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_4848d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapAssetsAbstract_4848d3" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_57f48e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapAssetsCurrentAbstract_57f48e" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c5509" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7c5509" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent_f2e2b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapOtherReceivablesNetCurrent_f2e2b7" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_3fe01d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_3fe01d" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_aaa04a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapAssetsCurrent_aaa04a" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_6444ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_6444ad" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_0fbd96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_0fbd96" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_b1e4f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapOtherAssetsNoncurrent_b1e4f0" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_dd0c7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapAssets_dd0c7a" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_eb501c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_eb501c" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_a8e7ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_a8e7ac" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_633488" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapAccountsPayableCurrent_633488" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_e9ba26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_e9ba26" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_68074b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_68074b" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_d02ab1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_d02ab1" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_a7bdf7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_a7bdf7" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_4bdadd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapLiabilitiesCurrent_4bdadd" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_38dcd7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_38dcd7" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt_6ad968" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapOtherLongTermDebt_6ad968" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_5a0a79" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapLiabilities_5a0a79" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_842f82" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapStockholdersEquityAbstract_842f82" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_778dfe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapPreferredStockValue_778dfe" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_7fff33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapCommonStockValue_7fff33" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_9d3bff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapAdditionalPaidInCapital_9d3bff" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_f2473f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_f2473f" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_77c14e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapStockholdersEquity_77c14e" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_d945be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9faa8a" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_d945be" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="110201 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_10e043" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_41742d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_10e043" xlink:to="loc_us-gaapStatementTable_41742d" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_b74ed1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_41742d" xlink:to="loc_us-gaapStatementLineItems_b74ed1" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_43534a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_41742d" xlink:to="loc_us-gaapStatementClassOfStockAxis_43534a" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_169792" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_43534a" xlink:to="loc_us-gaapClassOfStockDomain_169792" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember_6022e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_169792" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember_6022e7" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_0c8228" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b74ed1" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_0c8228" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_7cccd0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b74ed1" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_7cccd0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_7c58a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b74ed1" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_7c58a5" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_4ef2d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b74ed1" xlink:to="loc_us-gaapCommonStockSharesAuthorized_4ef2d4" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_eb7647" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b74ed1" xlink:to="loc_us-gaapCommonStockSharesIssued_eb7647" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_e627a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b74ed1" xlink:to="loc_us-gaapCommonStockSharesOutstanding_e627a4" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_c84152" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b74ed1" xlink:to="loc_us-gaapPreferredStockSharesIssued_c84152" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_596c89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_b74ed1" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_596c89" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="124100 - Statement - Consolidated Statements of Operations (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_b3222f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_a63ce2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_us-gaapRevenuesAbstract_a63ce2" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_d3a234" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_a63ce2" xlink:to="loc_us-gaapRevenues_d3a234" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_bcbde7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract_a63ce2" xlink:to="loc_us-gaapOperatingExpensesAbstract_bcbde7" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductionCosts" xlink:label="loc_us-gaapProductionCosts_e918fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_us-gaapProductionCosts_e918fa" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_a1a70c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_a1a70c" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_611fa2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_611fa2" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_GainLossOnSaleOfVylessi" xlink:label="loc_ptnGainLossOnSaleOfVylessi_304837" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_ptnGainLossOnSaleOfVylessi_304837" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_GainLossOnPurchaseCommitment" xlink:label="loc_ptnGainLossOnPurchaseCommitment_aaf169" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_ptnGainLossOnPurchaseCommitment_aaf169" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_4ed12a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_us-gaapOperatingExpenses_4ed12a" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_957b6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_us-gaapOperatingIncomeLoss_957b6b" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_04e80b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_04e80b" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaapInvestmentIncomeNet_687441" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_04e80b" xlink:to="loc_us-gaapInvestmentIncomeNet_687441" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_e94209" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_04e80b" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax_e94209" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_9712ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_04e80b" xlink:to="loc_us-gaapInterestExpense_9712ed" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_428bfd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_04e80b" xlink:to="loc_us-gaapOtherExpenses_428bfd" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantsGainLossOnWarrantsNet" xlink:label="loc_ptnWarrantsGainLossOnWarrantsNet_30e5ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_04e80b" xlink:to="loc_ptnWarrantsGainLossOnWarrantsNet_30e5ab" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_6107ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_04e80b" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_6107ec" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_c5ad20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_us-gaapNetIncomeLoss_c5ad20" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_13e61d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_us-gaapEarningsPerShareDiluted_13e61d" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_02a803" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_b3222f" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_02a803" order="20" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:title="148600 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_41e53c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_62bca7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_41e53c" xlink:to="loc_us-gaapStatementTable_62bca7" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_94f583" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_62bca7" xlink:to="loc_us-gaapStatementLineItems_94f583" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_3750a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_62bca7" xlink:to="loc_us-gaapStatementEquityComponentsAxis_3750a1" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_518b97" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_3750a1" xlink:to="loc_us-gaapEquityComponentDomain_518b97" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesAConvertiblePreferredStockMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStockMember_6eaad7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_518b97" xlink:to="loc_ptnSeriesAConvertiblePreferredStockMember_6eaad7" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_988277" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_518b97" xlink:to="loc_us-gaapCommonStockMember_988277" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_2ffbe2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_518b97" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_2ffbe2" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_795e8e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_518b97" xlink:to="loc_us-gaapRetainedEarningsMember_795e8e" order="24" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ContingentlyRedeemableWarrantsMember" xlink:label="loc_ptnContingentlyRedeemableWarrantsMember_1ef345" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_518b97" xlink:to="loc_ptnContingentlyRedeemableWarrantsMember_1ef345" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_c20514" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_us-gaapSharesIssued_c20514" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_83b28d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_us-gaapStockholdersEquity_83b28d" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_1ebea5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_1ebea5" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_8f84bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_8f84bc" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares_b6abc3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares_b6abc3" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount_e90e18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount_e90e18" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SaleOfCommonStockNetOfCostsShares" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsShares_de6bd6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsShares_de6bd6" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SaleOfCommonStockNetOfCostsAmount" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsAmount_33c6f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsAmount_33c6f5" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrant" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrant_e3cb51" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrant_e3cb51" order="9" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares_4dadfb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares_4dadfb" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount_db6a5b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount_db6a5b" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ReclassificationOfContingentlyRedeemableWarrants" xlink:label="loc_ptnReclassificationOfContingentlyRedeemableWarrants_6c5c70" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnReclassificationOfContingentlyRedeemableWarrants_6c5c70" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_a8a3f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_us-gaapNetIncomeLoss_a8a3f3" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0e3d8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0e3d8a" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesReleasedFromAbeyanceShares" xlink:label="loc_ptnSharesReleasedFromAbeyanceShares_c714a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnSharesReleasedFromAbeyanceShares_c714a2" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesReleasedFromAbeyanceAmount" xlink:label="loc_ptnSharesReleasedFromAbeyanceAmount_beab85" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnSharesReleasedFromAbeyanceAmount_beab85" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantExercisesShares" xlink:label="loc_ptnWarrantExercisesShares_b7bc6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnWarrantExercisesShares_b7bc6d" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantExercisesAmount" xlink:label="loc_ptnWarrantExercisesAmount_b279d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_ptnWarrantExercisesAmount_b279d8" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_e90c96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_us-gaapSharesIssued_e90c96" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_48ff10" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_94f583" xlink:to="loc_us-gaapStockholdersEquity_48ff10" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="170000 - Statement - Consolidated Statements of Cash Flows (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_e32839" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_749acf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_749acf" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_328e75" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_749acf" xlink:to="loc_us-gaapProfitLoss_328e75" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23ecf9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_749acf" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23ecf9" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_8e80f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23ecf9" xlink:to="loc_us-gaapDepreciationAndAmortization_8e80f6" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_f0ebcd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_23ecf9" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_f0ebcd" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized_d909e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossUnrealized_d909e1" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_b0c768" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapShareBasedCompensation_b0c768" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ChangeInFairValueOfLiabilityClassifiedWarrants" xlink:label="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants_5a5aa7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_ptnChangeInFairValueOfLiabilityClassifiedWarrants_5a5aa7" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaapGainLossOnSaleOfOtherAssets_178e27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapGainLossOnSaleOfOtherAssets_178e27" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_GainLossOnPurchaseCommitment" xlink:label="loc_ptnGainLossOnPurchaseCommitment_c29640" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_ptnGainLossOnPurchaseCommitment_c29640" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_342f87" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_342f87" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInOtherReceivables_f920b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" xlink:to="loc_us-gaapIncreaseDecreaseInOtherReceivables_f920b6" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d65387" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d65387" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_d2b8d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_d2b8d1" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_0e5dad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_0e5dad" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_155697" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_155697" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_6e09fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_6e09fa" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities_6770f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities_6770f7" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_a84935" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_5a8092" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_a84935" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4525b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4525b9" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities_5dc46a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4525b9" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities_5dc46a" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ProceedsFromSaleOfOtherAssets" xlink:label="loc_ptnProceedsFromSaleOfOtherAssets_915e53" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4525b9" xlink:to="loc_ptnProceedsFromSaleOfOtherAssets_915e53" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_d584a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4525b9" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_d584a9" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_8ddfaf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_4525b9" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_8ddfaf" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ce6a2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ce6a2f" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_88f292" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ce6a2f" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_88f292" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_acbbe6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ce6a2f" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_acbbe6" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_6c342f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ce6a2f" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_6c342f" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_23c1d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ce6a2f" xlink:to="loc_us-gaapProceedsFromWarrantExercises_23c1d4" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_f9dec7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_ce6a2f" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_f9dec7" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dc7903" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_dc7903" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_990ea0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_990ea0" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24443d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24443d" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_a9de6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e32839" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_a9de6b" order="35" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_aed90c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_a9de6b" xlink:to="loc_us-gaapInterestPaidNet_aed90c" order="36" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrants" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrants_3b2631" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_a9de6b" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrants_3b2631" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExercise_546366" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_a9de6b" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExercise_546366" order="38" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arragements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems_16cbbb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag_4f0a2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_16cbbb" xlink:to="loc_ecdRule10b51ArrAdoptedFlag_4f0a2c" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag_a7beae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_16cbbb" xlink:to="loc_ecdRule10b51ArrTrmntdFlag_a7beae" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag_0c7c06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_16cbbb" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag_0c7c06" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag_940020" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems_16cbbb" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag_940020" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ORGANIZATION" xlink:title="995446 - Disclosure - ORGANIZATION">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OrganizationAbstract" xlink:label="loc_ptnOrganizationAbstract_6f9591" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_13ac0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_6f9591" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_13ac0d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/BasisOfPresentation" xlink:title="995447 - Disclosure - BASIS OF PRESENTATION">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_BasisOfPresentationAbstract" xlink:label="loc_ptnBasisOfPresentationAbstract_822723" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1adb2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnBasisOfPresentationAbstract_822723" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1adb2b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995448 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_8c8045" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_172c5f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_8c8045" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_172c5f" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/NewAccountingPronouncements" xlink:title="995449 - Disclosure - New Accounting Pronouncements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_18a915" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_42d19c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_18a915" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_42d19c" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreement" xlink:title="995450 - Disclosure - ASSET PURCHASE AGREEMENT">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AssetPurchaseAgreementAbstract" xlink:label="loc_ptnAssetPurchaseAgreementAbstract_024aed" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AssetPurchaseAgreementTextBlock" xlink:label="loc_ptnAssetPurchaseAgreementTextBlock_5080aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_024aed" xlink:to="loc_ptnAssetPurchaseAgreementTextBlock_5080aa" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:title="995451 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ManufacturingSupplyAgreementsForVyleesiabstract" xlink:label="loc_ptnManufacturingSupplyAgreementsForVyleesiabstract_e4afcf" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ManufacturingSupplyAgreementsTextBlock" xlink:label="loc_ptnManufacturingSupplyAgreementsTextBlock_15e796" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnManufacturingSupplyAgreementsForVyleesiabstract_e4afcf" xlink:to="loc_ptnManufacturingSupplyAgreementsTextBlock_15e796" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosun" xlink:title="995452 - Disclosure - AGREEMENT WITH FOSUN">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AgreementWithFosunAbstract" xlink:label="loc_ptnAgreementWithFosunAbstract_e7b21b" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AgreementWithFosunTextBlock" xlink:label="loc_ptnAgreementWithFosunTextBlock_15b79e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_e7b21b" xlink:to="loc_ptnAgreementWithFosunTextBlock_15b79e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdong" xlink:title="995453 - Disclosure - AGREEMENT WITH KWANGDONG">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AgreementWithKwangdongAbstract" xlink:label="loc_ptnAgreementWithKwangdongAbstract_d2bc95" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AgreementWithKwangdongTextBlock" xlink:label="loc_ptnAgreementWithKwangdongTextBlock_aa16a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_d2bc95" xlink:to="loc_ptnAgreementWithKwangdongTextBlock_aa16a3" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="995454 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_2dc6cd" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock_02cc7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_2dc6cd" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock_02cc7b" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurements" xlink:title="995455 - Disclosure - FAIR VALUE MEASUREMENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_483d4d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_f5f6e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_483d4d" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_f5f6e3" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpenses" xlink:title="995456 - Disclosure - ACCRUED EXPENSES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_c9fb96" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_7292f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_c9fb96" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_7292f2" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingencies" xlink:title="995457 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d92a4f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_0d4c7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_d92a4f" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_0d4c7a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiency" xlink:title="995458 - Disclosure - STOCKHOLDERS DEFICIENCY">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e96308" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_6d4c44" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e96308" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_6d4c44" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEvents" xlink:title="995459 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_9b4a97" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_750f6d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_9b4a97" xlink:to="loc_us-gaapSubsequentEventsTextBlock_750f6d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995460 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_1246ef" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock_cfd6df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapConsolidationPolicyTextBlock_cfd6df" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_833edb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapUseOfEstimates_833edb" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_e71bf7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_e71bf7" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_f80a14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy_f80a14" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk_f6cc34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapConcentrationRiskCreditRisk_f6cc34" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_9d0c88" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_9d0c88" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_77b122" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_77b122" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock_44569c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock_44569c" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock" xlink:label="loc_ptnRevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock_796009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_ptnRevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock_796009" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock_89820d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock_89820d" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_7861a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_7861a0" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AccruedLiabilitiesPolicyTextBlock" xlink:label="loc_ptnAccruedLiabilitiesPolicyTextBlock_94a7e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_ptnAccruedLiabilitiesPolicyTextBlock_94a7e5" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_b091b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_b091b0" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_bd7cb9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_bd7cb9" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_c60b2e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_c60b2e" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f4d705" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_1246ef" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f4d705" order="16" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="995461 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_ce661b" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ScheduleOfSalesTableTextBlock" xlink:label="loc_ptnScheduleOfSalesTableTextBlock_620072" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_ce661b" xlink:to="loc_ptnScheduleOfSalesTableTextBlock_620072" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="995462 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_cac6f7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock_17d723" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_cac6f7" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock_17d723" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsTables" xlink:title="995463 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_328acc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_d66435" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_328acc" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_d66435" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesTables" xlink:title="995464 - Disclosure - ACCRUED EXPENSES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_8d7b55" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b531e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_8d7b55" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b531e8" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:title="995465 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_44a392" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock" xlink:label="loc_ptnScheduleOfInventoryPurchaseCommitmentsTableTextBlock_7469bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_44a392" xlink:to="loc_ptnScheduleOfInventoryPurchaseCommitmentsTableTextBlock_7469bc" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyTables" xlink:title="995466 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_83e912" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ScheduleOfEquityDistributionAgreementTableTextBlock" xlink:label="loc_ptnScheduleOfEquityDistributionAgreementTableTextBlock_335f62" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_83e912" xlink:to="loc_ptnScheduleOfEquityDistributionAgreementTableTextBlock_335f62" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock" xlink:label="loc_ptnScheduleOfStockPurchaseWarrantsTableTextBlock_2a75e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_83e912" xlink:to="loc_ptnScheduleOfStockPurchaseWarrantsTableTextBlock_2a75e2" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_402c91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_83e912" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_402c91" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2368cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_83e912" xlink:to="loc_us-gaapScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2368cf" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/OrganizationDetailsNarrative" xlink:title="995467 - Disclosure - ORGANIZATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OrganizationAbstract" xlink:label="loc_ptnOrganizationAbstract_be1e75" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_c17eec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_be1e75" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_c17eec" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_4dd9fb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_be1e75" xlink:to="loc_us-gaapNetIncomeLoss_4dd9fb" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SalesBasedMilestonePayments" xlink:label="loc_ptnSalesBasedMilestonePayments_93033a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_be1e75" xlink:to="loc_ptnSalesBasedMilestonePayments_93033a" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_55b4ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_be1e75" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_55b4ae" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_9b3f57" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnOrganizationAbstract_be1e75" xlink:to="loc_us-gaapLiabilitiesCurrent_9b3f57" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="995468 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_a69be7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_a38271" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_a69be7" xlink:to="loc_us-gaapStatementTable_a38271" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_7d8f8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a38271" xlink:to="loc_us-gaapStatementLineItems_7d8f8a" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis_771169" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a38271" xlink:to="loc_srtProductOrServiceAxis_771169" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_04b64d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis_771169" xlink:to="loc_srtProductsAndServicesDomain_04b64d" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_886cc2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain_04b64d" xlink:to="loc_us-gaapProductMember_886cc2" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_RevenuesGross" xlink:label="loc_ptnRevenuesGross_133982" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7d8f8a" xlink:to="loc_ptnRevenuesGross_133982" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ProductSalesAllowancesAndAccruals" xlink:label="loc_ptnProductSalesAllowancesAndAccruals_0743d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7d8f8a" xlink:to="loc_ptnProductSalesAllowancesAndAccruals_0743d7" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_3fe8c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_7d8f8a" xlink:to="loc_us-gaapRevenues_3fe8c7" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995469 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_6d6003" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_edc32c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_6d6003" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_edc32c" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock_4be35d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_6d6003" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock_4be35d" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_2094c0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_6d6003" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_2094c0" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:title="995470 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AssetPurchaseAgreementAbstract" xlink:label="loc_ptnAssetPurchaseAgreementAbstract_a7e9d4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForPurchaseOfOtherAssets1" xlink:label="loc_us-gaapPaymentsForPurchaseOfOtherAssets1_b2274d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_a7e9d4" xlink:to="loc_us-gaapPaymentsForPurchaseOfOtherAssets1_b2274d" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivablePurchase" xlink:label="loc_us-gaapAccountsReceivablePurchase_6a26fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_a7e9d4" xlink:to="loc_us-gaapAccountsReceivablePurchase_6a26fc" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PaymentsToSalesBasedMilestonePayments" xlink:label="loc_ptnPaymentsToSalesBasedMilestonePayments_2f9933" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_a7e9d4" xlink:to="loc_ptnPaymentsToSalesBasedMilestonePayments_2f9933" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalDeferredPurchasePrice" xlink:label="loc_us-gaapSupplementalDeferredPurchasePrice_ad0707" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAssetPurchaseAgreementAbstract_a7e9d4" xlink:to="loc_us-gaapSupplementalDeferredPurchasePrice_ad0707" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:title="995471 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AgreementWithFosunAbstract" xlink:label="loc_ptnAgreementWithFosunAbstract_0ed2d6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_f9a1c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_0ed2d6" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits_f9a1c2" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaapPaymentsForRestructuring_2c6943" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_0ed2d6" xlink:to="loc_us-gaapPaymentsForRestructuring_2c6943" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_UpfrontPaymentOfLess" xlink:label="loc_ptnUpfrontPaymentOfLess_f54933" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithFosunAbstract_0ed2d6" xlink:to="loc_ptnUpfrontPaymentOfLess_f54933" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:title="995472 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AgreementWithKwangdongAbstract" xlink:label="loc_ptnAgreementWithKwangdongAbstract_f2dcfc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_9f66af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_f2dcfc" xlink:to="loc_us-gaapOfficersCompensation_9f66af" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaapPaymentsForRestructuring_8eba7a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_f2dcfc" xlink:to="loc_us-gaapPaymentsForRestructuring_8eba7a" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_taxexpenses" xlink:label="loc_ptntaxexpenses_db9f77" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_f2dcfc" xlink:to="loc_ptntaxexpenses_db9f77" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireReceivables" xlink:label="loc_us-gaapPaymentsToAcquireReceivables_8e0c80" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnAgreementWithKwangdongAbstract_f2dcfc" xlink:to="loc_us-gaapPaymentsToAcquireReceivables_8e0c80" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="995473 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_c7777b" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PrepaidClinicalStudyCosts" xlink:label="loc_ptnPrepaidClinicalStudyCosts_d4d563" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_c7777b" xlink:to="loc_ptnPrepaidClinicalStudyCosts_d4d563" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PrepaidInsurancePremiums" xlink:label="loc_ptnPrepaidInsurancePremiums_af902a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_c7777b" xlink:to="loc_ptnPrepaidInsurancePremiums_af902a" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent_808794" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_c7777b" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent_808794" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_3030e3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract_c7777b" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_3030e3" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsDetails" xlink:title="995474 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_77a8b6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_59cbbb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_77a8b6" xlink:to="loc_us-gaapStatementTable_59cbbb" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_6cc43e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_59cbbb" xlink:to="loc_us-gaapStatementLineItems_6cc43e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_28e6b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_59cbbb" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_28e6b7" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_906585" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis_28e6b7" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_906585" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_6304f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_906585" xlink:to="loc_us-gaapFairValueInputsLevel1Member_6304f2" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_83b162" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_906585" xlink:to="loc_us-gaapFairValueInputsLevel2Member_83b162" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_f749b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_906585" xlink:to="loc_us-gaapFairValueInputsLevel3Member_f749b9" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_380405" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_6cc43e" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_380405" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesDetails" xlink:title="995475 - Disclosure - ACCRUED EXPENSES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract_984c27" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AccruedClinicalRegulatoryCosts" xlink:label="loc_ptnAccruedClinicalRegulatoryCosts_ee7f1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_984c27" xlink:to="loc_ptnAccruedClinicalRegulatoryCosts_ee7f1a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OtherAccruedResearchRelatedExpenses" xlink:label="loc_ptnOtherAccruedResearchRelatedExpenses_49a687" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_984c27" xlink:to="loc_ptnOtherAccruedResearchRelatedExpenses_49a687" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent_664bc0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_984c27" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent_664bc0" order="3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AccruedPersonalCost" xlink:label="loc_ptnAccruedPersonalCost_b8bd38" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_984c27" xlink:to="loc_ptnAccruedPersonalCost_b8bd38" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AccruedSellingExpenses" xlink:label="loc_ptnAccruedSellingExpenses_4fe17b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_984c27" xlink:to="loc_ptnAccruedSellingExpenses_4fe17b" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent_ed7cde" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_984c27" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent_ed7cde" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_8750e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract_984c27" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_8750e4" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:title="995476 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_952172" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_71f993" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_952172" xlink:to="loc_us-gaapStatementTable_71f993" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_fe64ca" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_71f993" xlink:to="loc_us-gaapStatementLineItems_fe64ca" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_0cbe29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_71f993" xlink:to="loc_us-gaapPlanNameAxis_0cbe29" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_de1b26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_0cbe29" xlink:to="loc_us-gaapPlanNameDomain_de1b26" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_CurrentMember" xlink:label="loc_ptnCurrentMember_5b7790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_de1b26" xlink:to="loc_ptnCurrentMember_5b7790" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OneToThreeYearsMember" xlink:label="loc_ptnOneToThreeYearsMember_cf8557" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_de1b26" xlink:to="loc_ptnOneToThreeYearsMember_cf8557" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_FourToFiveYearsMember" xlink:label="loc_ptnFourToFiveYearsMember_1142e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_de1b26" xlink:to="loc_ptnFourToFiveYearsMember_1142e1" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="loc_us-gaapAdvancesOnInventoryPurchases_7dc2d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fe64ca" xlink:to="loc_us-gaapAdvancesOnInventoryPurchases_7dc2d9" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995477 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_54e9f2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent_3446d2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_54e9f2" xlink:to="loc_us-gaapOtherLiabilitiesCurrent_3446d2" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt_976fac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_54e9f2" xlink:to="loc_us-gaapOtherLongTermDebt_976fac" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:title="995478 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_b894e4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_4af12c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_b894e4" xlink:to="loc_us-gaapStatementTable_4af12c" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_1dc69e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_4af12c" xlink:to="loc_us-gaapStatementLineItems_1dc69e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_5b537e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_4af12c" xlink:to="loc_us-gaapPlanNameAxis_5b537e" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_2c01c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_5b537e" xlink:to="loc_us-gaapPlanNameDomain_2c01c6" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_CumulativeFromInceptionMember" xlink:label="loc_ptnCumulativeFromInceptionMember_316567" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_2c01c6" xlink:to="loc_ptnCumulativeFromInceptionMember_316567" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityGrossProceedsShares" xlink:label="loc_ptnEquityGrossProceedsShares_eb1c19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1dc69e" xlink:to="loc_ptnEquityGrossProceedsShares_eb1c19" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity_1863a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1dc69e" xlink:to="loc_us-gaapProceedsFromOtherEquity_1863a0" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityFeesShares" xlink:label="loc_ptnEquityFeesShares_57834c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1dc69e" xlink:to="loc_ptnEquityFeesShares_57834c" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived_ad675c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1dc69e" xlink:to="loc_us-gaapProceedsFromFeesReceived_ad675c" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityExpensesShares" xlink:label="loc_ptnEquityExpensesShares_67c6a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1dc69e" xlink:to="loc_ptnEquityExpensesShares_67c6a7" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityExpensesProceeds" xlink:label="loc_ptnEquityExpensesProceeds_fd366e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1dc69e" xlink:to="loc_ptnEquityExpensesProceeds_fd366e" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityNetProceedsShares" xlink:label="loc_ptnEquityNetProceedsShares_c9606c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1dc69e" xlink:to="loc_ptnEquityNetProceedsShares_c9606c" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityNetProceedsProceeds" xlink:label="loc_ptnEquityNetProceedsProceeds_5b297e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_1dc69e" xlink:to="loc_ptnEquityNetProceedsProceeds_5b297e" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:title="995479 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_80e899" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_600822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_80e899" xlink:to="loc_us-gaapStatementTable_600822" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_5c2373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_600822" xlink:to="loc_us-gaapStatementLineItems_5c2373" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_6de68a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_600822" xlink:to="loc_us-gaapPlanNameAxis_6de68a" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_917f7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_6de68a" xlink:to="loc_us-gaapPlanNameDomain_917f7b" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" xlink:label="loc_ptnDecemberToZeroTwoFourSeriesDWarrantsMember_b4b2da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_917f7b" xlink:to="loc_ptnDecemberToZeroTwoFourSeriesDWarrantsMember_b4b2da" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="loc_ptnMayTwoThousandTwentyTwoWarrantsMember_93237d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_917f7b" xlink:to="loc_ptnMayTwoThousandTwentyTwoWarrantsMember_93237d" order="12" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:label="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_553678" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_917f7b" xlink:to="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember_553678" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:label="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember_57c593" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_917f7b" xlink:to="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember_57c593" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember_6d3e99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_917f7b" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember_6d3e99" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_15e65f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_917f7b" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember_15e65f" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:label="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember_c268d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_917f7b" xlink:to="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember_c268d4" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" xlink:label="loc_ptnDecemberTwoThousandTwentyFourSerisCWarrantsMember_136cfb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_917f7b" xlink:to="loc_ptnDecemberTwoThousandTwentyFourSerisCWarrantsMember_136cfb" order="18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember" xlink:label="loc_ptnFebruaryTwoZeroTwoFiveSeriesEWarrantsMember_375610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_917f7b" xlink:to="loc_ptnFebruaryTwoZeroTwoFiveSeriesEWarrantsMember_375610" order="19" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock_8abfb3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5c2373" xlink:to="loc_ptnSharesOfCommonStock_8abfb3" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ExercisePricePerShareWarrantsOutstanding" xlink:label="loc_ptnExercisePricePerShareWarrantsOutstanding_4621b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5c2373" xlink:to="loc_ptnExercisePricePerShareWarrantsOutstanding_4621b1" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_LatestTerminationDate" xlink:label="loc_ptnLatestTerminationDate_a559c8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_5c2373" xlink:to="loc_ptnLatestTerminationDate_a559c8" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:title="995480 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_de4790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance_de4790" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_87280c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73_87280c" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_0fb43f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance_0fb43f" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_3b42ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance_3b42ff" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_25b78b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01_25b78b" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_d38415" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance_d38415" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_2f7757" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A_2f7757" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_62ed1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance_62ed1e" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_1ae9ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance_1ae9ba" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ba2d29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ba2d29" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_282b4b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_282b4b" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2717f3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2717f3" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_13c94e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_13c94e" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_286ca9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance_286ca9" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice" xlink:label="loc_ptnshareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_4920c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnshareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice_4920c1" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_672c14" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice_672c14" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_956678" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_956678" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c333ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c333ec" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_59f935" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_59f935" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_575856" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_575856" order="20" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue" xlink:label="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_d21c50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue_d21c50" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue" xlink:label="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_1b7bdd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue_1b7bdd" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable" xlink:label="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_a63198" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_d94e85" xlink:to="loc_ptnShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable_a63198" order="23" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:title="995481 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e72845" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_4648fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e72845" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_4648fe" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_892ddb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e72845" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_892ddb" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_ea096e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e72845" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_ea096e" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_RestrictedStockVestedInPeriod" xlink:label="loc_ptnRestrictedStockVestedInPeriod_e38ff0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e72845" xlink:to="loc_ptnRestrictedStockVestedInPeriod_e38ff0" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_add7db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e72845" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_add7db" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_c37115" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_e72845" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_c37115" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:title="995482 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract" xlink:label="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_a54300" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_988fdc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptnStockholdersEquityAndRedeemableConvertiblePreferredStockAbstract_a54300" xlink:to="loc_us-gaapStatementTable_988fdc" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f49e71" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_988fdc" xlink:to="loc_us-gaapStatementLineItems_f49e71" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_885c6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_988fdc" xlink:to="loc_us-gaapAwardTypeAxis_885c6a" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2f802" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_885c6a" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2f802" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_673aed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_988fdc" xlink:to="loc_us-gaapStatementClassOfStockAxis_673aed" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_f5282f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_673aed" xlink:to="loc_us-gaapClassOfStockDomain_f5282f" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_3d7183" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_988fdc" xlink:to="loc_us-gaapPlanNameAxis_3d7183" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_cad4fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_3d7183" xlink:to="loc_us-gaapPlanNameDomain_cad4fe" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_674e25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_988fdc" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_674e25" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_531334" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_674e25" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_531334" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_93c77d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_988fdc" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_93c77d" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_b8d4c9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_93c77d" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_b8d4c9" order="80" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:label="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember_080d2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2f802" xlink:to="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember_080d2c" order="81" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConvertibleSeriesAPreferredStocksMember" xlink:label="loc_ptnConvertibleSeriesAPreferredStocksMember_96d138" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_f5282f" xlink:to="loc_ptnConvertibleSeriesAPreferredStocksMember_96d138" order="82" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember_824681" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_cad4fe" xlink:to="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember_824681" order="83" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_437b63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_531334" xlink:to="loc_us-gaapPrivatePlacementMember_437b63" order="84" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PrivateWarrantSharesMember" xlink:label="loc_ptnPrivateWarrantSharesMember_525253" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_531334" xlink:to="loc_ptnPrivateWarrantSharesMember_525253" order="85" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwoThousandTwentyFiveSalesAgreementMember" xlink:label="loc_ptnTwoThousandTwentyFiveSalesAgreementMember_14f677" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_531334" xlink:to="loc_ptnTwoThousandTwentyFiveSalesAgreementMember_14f677" order="86" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockWarrantsMember" xlink:label="loc_ptnStockWarrantsMember_cbc26b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_b8d4c9" xlink:to="loc_ptnStockWarrantsMember_cbc26b" order="87" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock_db74bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnSharesOfCommonStock_db74bb" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PurchaseOfWarrantShares" xlink:label="loc_ptnPurchaseOfWarrantShares_a9c515" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnPurchaseOfWarrantShares_a9c515" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityIssuanceCostsPercentage" xlink:label="loc_ptnEquityIssuanceCostsPercentage_39a261" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnEquityIssuanceCostsPercentage_39a261" order="3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OfferingExpensesAmount" xlink:label="loc_ptnOfferingExpensesAmount_1237f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnOfferingExpensesAmount_1237f8" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:label="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_971b8b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits_971b8b" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:label="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits_a34419" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits_a34419" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_000c66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits_000c66" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_28237f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU_28237f" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:label="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares_c40edf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares_c40edf" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense_cdd785" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapStockOptionPlanExpense_cdd785" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGranted_0a742f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGranted_0a742f" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_29cf3d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_29cf3d" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmoun_221294" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmoun_221294" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_a9230f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapCostsAndExpenses_a9230f" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c0a773" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c0a773" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_66006c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapSharesIssuedPricePerShare_66006c" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantIssuanceShares" xlink:label="loc_ptnWarrantIssuanceShares_ffcbe8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnWarrantIssuanceShares_ffcbe8" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantIssuance" xlink:label="loc_ptnWarrantIssuance_ec9091" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnWarrantIssuance_ec9091" order="18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:label="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA_7de932" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA_7de932" order="19" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="loc_ptnDescriptionOfSecuritiesPurchaseAgreement_12a3ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnDescriptionOfSecuritiesPurchaseAgreement_12a3ef" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_983a01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_983a01" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AggregateValue" xlink:label="loc_ptnAggregateValue_60d8cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnAggregateValue_60d8cf" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_4d106c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_4d106c" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:label="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare_edc853" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare_edc853" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAvailableForDistributions" xlink:label="loc_us-gaapCashAvailableForDistributions_d70981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapCashAvailableForDistributions_d70981" order="25" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DistributableValueOfDividendPerShare" xlink:label="loc_ptnDistributableValueOfDividendPerShare_d154ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnDistributableValueOfDividendPerShare_d154ec" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DividendAdditionalPerShare" xlink:label="loc_ptnDividendAdditionalPerShare_962c44" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnDividendAdditionalPerShare_962c44" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_1d2c93" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapSaleOfStockPricePerShare_1d2c93" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_f90d13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_f90d13" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_d9601b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_d9601b" order="30" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantsToPurchaseShares" xlink:label="loc_ptnWarrantsToPurchaseShares_8796bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnWarrantsToPurchaseShares_8796bf" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_84fe29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapProceedsFromWarrantExercises_84fe29" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:label="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants_875c73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants_875c73" order="33" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ExercisingHolderReleasedShares" xlink:label="loc_ptnExercisingHolderReleasedShares_b6ee95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_ptnExercisingHolderReleasedShares_b6ee95" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_a415bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_a415bf" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaapPaymentsForCommissions_90a265" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapPaymentsForCommissions_90a265" order="36" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_4db6dd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f49e71" xlink:to="loc_us-gaapOtherExpenses_4db6dd" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:title="995483 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_b43495" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f2f86d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_b43495" xlink:to="loc_us-gaapStatementTable_f2f86d" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_930145" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f2f86d" xlink:to="loc_us-gaapStatementLineItems_930145" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_9e3ca3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f2f86d" xlink:to="loc_us-gaapSubsequentEventTypeAxis_9e3ca3" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_c0a443" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_9e3ca3" xlink:to="loc_us-gaapSubsequentEventTypeDomain_c0a443" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_b455d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f2f86d" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_b455d8" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_fe7d52" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_b455d8" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_fe7d52" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis_ce4f3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f2f86d" xlink:to="loc_us-gaapStatementClassOfStockAxis_ce4f3c" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_e1ef8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis_ce4f3c" xlink:to="loc_us-gaapClassOfStockDomain_e1ef8f" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_d20d03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_c0a443" xlink:to="loc_us-gaapSubsequentEventMember_d20d03" order="41" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwoThousandTwentyFiveSalesAgreementMember" xlink:label="loc_ptnTwoThousandTwentyFiveSalesAgreementMember_ca93f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_fe7d52" xlink:to="loc_ptnTwoThousandTwentyFiveSalesAgreementMember_ca93f0" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesFWarrantsMember" xlink:label="loc_ptnSeriesFWarrantsMember_1c68dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_e1ef8f" xlink:to="loc_ptnSeriesFWarrantsMember_1c68dc" order="43" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesGWarrantsMember" xlink:label="loc_ptnSeriesGWarrantsMember_e74744" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain_e1ef8f" xlink:to="loc_ptnSeriesGWarrantsMember_e74744" order="44" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityIssuanceCostsPercentage" xlink:label="loc_ptnEquityIssuanceCostsPercentage_0ad841" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_930145" xlink:to="loc_ptnEquityIssuanceCostsPercentage_0ad841" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_c53a9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_930145" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_c53a9a" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_745e39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_930145" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_745e39" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DescriptionOfPublicOffering" xlink:label="loc_ptnDescriptionOfPublicOffering_dbed0b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_930145" xlink:to="loc_ptnDescriptionOfPublicOffering_dbed0b" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8f9f68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_930145" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8f9f68" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_1e8790" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_930145" xlink:to="loc_us-gaapLegalFees_1e8790" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_a033ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_930145" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_a033ac" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ptn-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 05/13/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://ptn.com/role/Cover" xlink:href="ptn-20250331.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:href="ptn-20250331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ptn-20250331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="ptn-20250331.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:href="ptn-20250331.xsd#ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ptn-20250331.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ORGANIZATION" xlink:href="ptn-20250331.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/BasisOfPresentation" xlink:href="ptn-20250331.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/NewAccountingPronouncements" xlink:href="ptn-20250331.xsd#NewAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreement" xlink:href="ptn-20250331.xsd#AssetPurchaseAgreement" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:href="ptn-20250331.xsd#ManufacturingSupplyAgreementsForVyleesi" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosun" xlink:href="ptn-20250331.xsd#AgreementWithFosun" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdong" xlink:href="ptn-20250331.xsd#AgreementWithKwangdong" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="ptn-20250331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurements" xlink:href="ptn-20250331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpenses" xlink:href="ptn-20250331.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingencies" xlink:href="ptn-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiency" xlink:href="ptn-20250331.xsd#StockholdersDeficiency" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEvents" xlink:href="ptn-20250331.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="ptn-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsTables" xlink:href="ptn-20250331.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesTables" xlink:href="ptn-20250331.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:href="ptn-20250331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyTables" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyTables" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/OrganizationDetailsNarrative" xlink:href="ptn-20250331.xsd#OrganizationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="ptn-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:href="ptn-20250331.xsd#AssetPurchaseAgreementDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:href="ptn-20250331.xsd#AgreementWithFosunDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:href="ptn-20250331.xsd#AgreementWithKwangdongDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="ptn-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/FairValueMeasurementsDetails" xlink:href="ptn-20250331.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/AccruedExpensesDetails" xlink:href="ptn-20250331.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:href="ptn-20250331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="ptn-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:href="ptn-20250331.xsd#StockholdersDeficiencyDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:href="ptn-20250331.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheets" xlink:title="110200 - Statement - Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrentAbstract" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaapOtherReceivablesNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherReceivablesNetCurrent" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsCurrent" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsNoncurrent" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableCurrent" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesCurrent" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaapOtherLongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLongTermDebt" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockValue" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockValue" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" order="28" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="110201 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesAConvertiblePreferredStocksMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnSeriesAConvertiblePreferredStocksMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:title="124100 - Statement - Consolidated Statements of Operations (unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited" xlink:title="148600 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesAConvertiblePreferredStockMember" xlink:label="loc_ptnSeriesAConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ptnSeriesAConvertiblePreferredStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ContingentlyRedeemableWarrantsMember" xlink:label="loc_ptnContingentlyRedeemableWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_ptnContingentlyRedeemableWarrantsMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsShares" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmount" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SaleOfCommonStockNetOfCostsShares" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SaleOfCommonStockNetOfCostsAmount" xlink:label="loc_ptnSaleOfCommonStockNetOfCostsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSaleOfCommonStockNetOfCostsAmount" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrant" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrant" order="9" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" xlink:label="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ReclassificationOfContingentlyRedeemableWarrants" xlink:label="loc_ptnReclassificationOfContingentlyRedeemableWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnReclassificationOfContingentlyRedeemableWarrants" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesReleasedFromAbeyanceShares" xlink:label="loc_ptnSharesReleasedFromAbeyanceShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesReleasedFromAbeyanceShares" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesReleasedFromAbeyanceAmount" xlink:label="loc_ptnSharesReleasedFromAbeyanceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesReleasedFromAbeyanceAmount" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantExercisesShares" xlink:label="loc_ptnWarrantExercisesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantExercisesShares" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantExercisesAmount" xlink:label="loc_ptnWarrantExercisesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantExercisesAmount" order="18" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="170000 - Statement - Consolidated Statements of Cash Flows (unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ORGANIZATION" xlink:title="995446 - Disclosure - ORGANIZATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/BasisOfPresentation" xlink:title="995447 - Disclosure - BASIS OF PRESENTATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="995448 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/NewAccountingPronouncements" xlink:title="995449 - Disclosure - New Accounting Pronouncements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreement" xlink:title="995450 - Disclosure - ASSET PURCHASE AGREEMENT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi" xlink:title="995451 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosun" xlink:title="995452 - Disclosure - AGREEMENT WITH FOSUN" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdong" xlink:title="995453 - Disclosure - AGREEMENT WITH KWANGDONG" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="995454 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurements" xlink:title="995455 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpenses" xlink:title="995456 - Disclosure - ACCRUED EXPENSES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingencies" xlink:title="995457 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiency" xlink:title="995458 - Disclosure - STOCKHOLDERS DEFICIENCY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEvents" xlink:title="995459 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="995460 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="995461 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="995462 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsTables" xlink:title="995463 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesTables" xlink:title="995464 - Disclosure - ACCRUED EXPENSES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesTables" xlink:title="995465 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyTables" xlink:title="995466 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/OrganizationDetailsNarrative" xlink:title="995467 - Disclosure - ORGANIZATION (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="995468 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_RevenuesGross" xlink:label="loc_ptnRevenuesGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnRevenuesGross" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ProductSalesAllowancesAndAccruals" xlink:label="loc_ptnProductSalesAllowancesAndAccruals" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnProductSalesAllowancesAndAccruals" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="995469 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative" xlink:title="995470 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithFosunDetailsNarrative" xlink:title="995471 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AgreementWithKwangdongDetailsNarrative" xlink:title="995472 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="995473 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/FairValueMeasurementsDetails" xlink:title="995474 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/AccruedExpensesDetails" xlink:title="995475 - Disclosure - ACCRUED EXPENSES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetails" xlink:title="995476 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_CurrentMember" xlink:label="loc_ptnCurrentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnCurrentMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OneToThreeYearsMember" xlink:label="loc_ptnOneToThreeYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnOneToThreeYearsMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_FourToFiveYearsMember" xlink:label="loc_ptnFourToFiveYearsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnFourToFiveYearsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="loc_us-gaapAdvancesOnInventoryPurchases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdvancesOnInventoryPurchases" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="995477 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails" xlink:title="995478 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_CumulativeFromInceptionMember" xlink:label="loc_ptnCumulativeFromInceptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnCumulativeFromInceptionMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityGrossProceedsShares" xlink:label="loc_ptnEquityGrossProceedsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityGrossProceedsShares" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="loc_us-gaapProceedsFromOtherEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromOtherEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityFeesShares" xlink:label="loc_ptnEquityFeesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityFeesShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityExpensesShares" xlink:label="loc_ptnEquityExpensesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityExpensesShares" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityExpensesProceeds" xlink:label="loc_ptnEquityExpensesProceeds" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityExpensesProceeds" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityNetProceedsShares" xlink:label="loc_ptnEquityNetProceedsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityNetProceedsShares" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityNetProceedsProceeds" xlink:label="loc_ptnEquityNetProceedsProceeds" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityNetProceedsProceeds" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails1" xlink:title="995479 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DecemberToZeroTwoFourSeriesDWarrantsMember" xlink:label="loc_ptnDecemberToZeroTwoFourSeriesDWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnDecemberToZeroTwoFourSeriesDWarrantsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_MayTwoThousandTwentyTwoWarrantsMember" xlink:label="loc_ptnMayTwoThousandTwentyTwoWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnMayTwoThousandTwentyTwoWarrantsMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" xlink:label="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnOctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember" order="13" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember" xlink:label="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnOctoberTwoZeroTwoThreePlacementAgentWarrantsMember" order="14" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPrivateWarrantsMember" order="15" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" xlink:label="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnJanuaryTwoZeroTwoFourPlacementAgentWarrantsMember" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember" xlink:label="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnJuneTwoThousandTwentyFourSerisBWarrantsMember" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember" xlink:label="loc_ptnDecemberTwoThousandTwentyFourSerisCWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnDecemberTwoThousandTwentyFourSerisCWarrantsMember" order="18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember" xlink:label="loc_ptnFebruaryTwoZeroTwoFiveSeriesEWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnFebruaryTwoZeroTwoFiveSeriesEWarrantsMember" order="19" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesOfCommonStock" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ExercisePricePerShareWarrantsOutstanding" xlink:label="loc_ptnExercisePricePerShareWarrantsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnExercisePricePerShareWarrantsOutstanding" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_LatestTerminationDate" xlink:label="loc_ptnLatestTerminationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnLatestTerminationDate" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails2" xlink:title="995480 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetails3" xlink:title="995481 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/StockholdersDeficiencyDetailsNarrative" xlink:title="995482 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="100" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwentyTwentyThreeEquityDistributionAgreementMember" xlink:label="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ptnTwentyTwentyThreeEquityDistributionAgreementMember" order="81" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ConvertibleSeriesAPreferredStocksMember" xlink:label="loc_ptnConvertibleSeriesAPreferredStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnConvertibleSeriesAPreferredStocksMember" order="82" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_ptnTwoThousandTwentyFourPlacementAgentWarrantsMember" order="83" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" order="84" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PrivateWarrantSharesMember" xlink:label="loc_ptnPrivateWarrantSharesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ptnPrivateWarrantSharesMember" order="85" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwoThousandTwentyFiveSalesAgreementMember" xlink:label="loc_ptnTwoThousandTwentyFiveSalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ptnTwoThousandTwentyFiveSalesAgreementMember" order="86" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockWarrantsMember" xlink:label="loc_ptnStockWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_ptnStockWarrantsMember" order="87" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SharesOfCommonStock" xlink:label="loc_ptnSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnSharesOfCommonStock" order="1" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PurchaseOfWarrantShares" xlink:label="loc_ptnPurchaseOfWarrantShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnPurchaseOfWarrantShares" order="2" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityIssuanceCostsPercentage" xlink:label="loc_ptnEquityIssuanceCostsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityIssuanceCostsPercentage" order="3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_OfferingExpensesAmount" xlink:label="loc_ptnOfferingExpensesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnOfferingExpensesAmount" order="4" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" xlink:label="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnStockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits" order="5" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_NumberOfOutstandingSharesOfRestrictedStockUnits" xlink:label="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnNumberOfOutstandingSharesOfRestrictedStockUnits" order="6" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits" order="7" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" xlink:label="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU" order="8" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares" xlink:label="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnStockIssuedDuringPeriodValueRestrictedStockUnitshares" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense" order="10" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_UnvestedPerformanceBasedStockOptionsGranted" xlink:label="loc_ptnUnvestedPerformanceBasedStockOptionsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnUnvestedPerformanceBasedStockOptionsGranted" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="12" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun" xlink:label="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmoun" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWithholdingTaxesRelatedToRestrictedStockUnitsAmoun" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpenses" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" order="16" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantIssuanceShares" xlink:label="loc_ptnWarrantIssuanceShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantIssuanceShares" order="17" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantIssuance" xlink:label="loc_ptnWarrantIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantIssuance" order="18" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_PurchaseOfWarrantOfCommonStockSeriesA" xlink:label="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnPurchaseOfWarrantOfCommonStockSeriesA" order="19" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DescriptionOfSecuritiesPurchaseAgreement" xlink:label="loc_ptnDescriptionOfSecuritiesPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnDescriptionOfSecuritiesPurchaseAgreement" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" order="21" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_AggregateValue" xlink:label="loc_ptnAggregateValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnAggregateValue" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare" xlink:label="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleLiquidationPreferencePerShare" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAvailableForDistributions" xlink:label="loc_us-gaapCashAvailableForDistributions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAvailableForDistributions" order="25" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DistributableValueOfDividendPerShare" xlink:label="loc_ptnDistributableValueOfDividendPerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnDistributableValueOfDividendPerShare" order="26" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DividendAdditionalPerShare" xlink:label="loc_ptnDividendAdditionalPerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnDividendAdditionalPerShare" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" order="30" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_WarrantsToPurchaseShares" xlink:label="loc_ptnWarrantsToPurchaseShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnWarrantsToPurchaseShares" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" order="32" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DescriptionOfExistingHolderPurchaseOfWarrants" xlink:label="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnDescriptionOfExistingHolderPurchaseOfWarrants" order="33" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_ExercisingHolderReleasedShares" xlink:label="loc_ptnExercisingHolderReleasedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnExercisingHolderReleasedShares" order="34" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="35" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaapPaymentsForCommissions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForCommissions" order="36" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses" order="37" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ptn.com/role/SubsequentEventsDetailsNarrative" xlink:title="995483 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_TwoThousandTwentyFiveSalesAgreementMember" xlink:label="loc_ptnTwoThousandTwentyFiveSalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_ptnTwoThousandTwentyFiveSalesAgreementMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesFWarrantsMember" xlink:label="loc_ptnSeriesFWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnSeriesFWarrantsMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_SeriesGWarrantsMember" xlink:label="loc_ptnSeriesGWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_ptnSeriesGWarrantsMember" order="44" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_EquityIssuanceCostsPercentage" xlink:label="loc_ptnEquityIssuanceCostsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnEquityIssuanceCostsPercentage" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="3" />
    <link:loc xlink:type="locator" xlink:href="ptn-20250331.xsd#ptn_DescriptionOfPublicOffering" xlink:label="loc_ptnDescriptionOfPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_ptnDescriptionOfPublicOffering" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLegalFees" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" order="7" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ptn_10qimg19.jpg
<TEXT>
begin 644 ptn_10qimg19.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %0 G # 2(  A$! Q$!_\0
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MS%9))"WR8#_,",_+Q5)18)19Z7X@\<>'?#@LUU*\=YK\%K:"UA>>690,EE1
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M_P#"R/"__/X__?EO\*7_ (61X6_Y_&_[\M_A7A=%']HUNR,O[!H]W]Z/=/\
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M>2W4G'I7AM6;'_D*6?\ UW3_ -"%;QQU1O9'!7RFA3@Y7?WH^H@<C-+4</\
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M(X3_ (5?JG_04M_^_;4G_"K]4_Z"T'_?MJ]$^R+_ ,_%S_W^:C[(O_/Q<_\
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MV^98ZJ^Q@Z[K5#M8="/FX/O6+?\ Q:^$NI2SO=:/J;>?;BU95MU5?+$GF[0
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M4)[9'!_"O%A\</A:IC*Z#=J8T,:8T^(;5/51\W .3Q[UH?\ #1'@/_GUU?\
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M/XH@\4:;J-OXB6.P@O)KF:UCEDC!$DS29P 0Y*D*0W''!K*_X7=\._[NO_\
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MCB.VM(V\5['BM)H WVN=_L\C%BKKT\S@J/GY7;Q53_A=_P /?[NO_P#?(_\
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MNC_AHCP'_P ^NK_^ R__ !='U2M_(PY":S^">DVLEHTVM7-ZL 8&.X0[7RJ
M'"N,-\G4YR#C%:-Q\*;"\\.Z+HMYJTTZ:3!-!'(\"DL))$<<'IM$84=3@\DF
MLC_AHCP'_P ^NK_^ R__ !='_#1'@/\ Y]=7_P# 9?\ XNE]4K?R,?*R2;X'
MZ;,LJ_\ "07L2NS.HCC50F22%&#]T9QCC(&*NQ?!W38+N&XM]6>!86MI! L&
MY#)"3ASO9FR02!@C''7 K._X:(\!_P#/KJ__ (#+_P#%T?\ #1'@/_GUU?\
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MKI/^&;/%G'_$^TCC_KK_ /$U+)^SSXUELX+.3Q)I;V]N7:*,^9M0M@L1\O?
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M?8S3VTT*^6#(JY =6&>>F.,FN\_X9M\6?]!S2?\ R+_\32_\,W>+O^@]I/\
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MAD_\E8O_ (FC_A<_Q*_Z&3_R5B_^)K7^SZOD/V4C[#HKX\_X7/\ $K_H9/\
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M'F-D<GRR2$7)R#D=*V9-0U^;5?"JR_;K>XE42W[6UNYM=N.4?*Y5F)&-VW:
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M3:#I+1B-M-0QJS,$+$J"PP2!G%.31;%-4M]0BLU26W\UD"D8W28#M]3M_4T
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MKZ+W2?\ //\ \>HW2?\ //\ \>H^MU_YOR#VDNY\Z?\ #,UQ_P!#DG_@&?\
MXJC_ (9FN/\ H<D_\ S_ /%5]%[I/^>?_CU&Z3_GG_X]1];K_P WY![27<^;
M_P#AFV?_ *'!/_ /_P"RH_X9MG_Z'!/_  #_ /LJ^A=SY_U?ZTFYO^>?ZU7U
MNM_-^0>TEW/GO_AFV?\ Z'!/_ /_ .RH_P"&;9_^AP3_ , __LJ^A-S?\\_U
MHW-_SS_6CZS6_F_(/:2[GSW_ ,,VS_\ 0X)_X!__ &5'_#-L_P#T."?^ ?\
M]E7T)N;_ )Y_K1N;_GG^M'UFM_-^0>TEW/GV/]FUO,7SO%V8\_,$M,$CV):O
M=O#>D1^&_#UGH6DV\,5G9IY:!G8L>Y8G'))))^M7-S?\\_UJ>!GPW[OO_>K"
MM6J5E:H[DRDWN2^=??\ /.#_ +Z;_"CSK[_GG!_WTW^%&Z3_ )Y_^/4;I/\
MGG_X]7+8@/.OO^><'_?3?X4>=??\\X/^^F_PHW2?\\__ !ZC=)_SS_\ 'J+
M'G7W_/.#_OIO\*/.OO\ GG!_WTW^%&Z3_GG_ ./4;I/^>?\ X]18!K3WRJ6\
MN#_OIO\ "HOMEY_SR@_[Z/\ A4LC/Y9_=_\ CU5=S?\ //\ 6J211-]MO/\
MGE!_WT?\*/MMY_SR@_[Z/^%0[F_YY_K1N;_GG^M'*@)OMMY_SR@_[Z/^%'VV
M\_YY0?\ ?1_PJ'<W_//]:-S?\\_UHY4!+]LO/^>4'_?1_P *9NFFEC,Y3:C
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MA103(JJ25 /!)Z<US%GXS\(ZAJ31_954I#%?"X>W4KO9&)7(R?,18SGTX&:
M.=M_C99:C-';:;X<U"6602*7X*Q/&%$H([^6[A6Z="?:K,GQ.N[+2=$GN--A
MN9[K2;74[K$WEE_.=8]D"X.]@23@GICUK4A\:>%9I)ENM)\B*TF9_/>U#1Y+
M2?.I"\L?+)('/-2MXV\&C4+6VNA%"R2)%9-);'>)"2I4)MW1[2N#TQD4@*<'
MQ>\,SR,GV34(V6-[@AXT'[E4W&0?-SQT4?,?2EU+XI6=EX-M?%<>CWZV4LJK
M*+J,Q&-')5'#8*G+[!C/1\]JOZKXF\+:7>K:M8K<7$5RL)6*S+%#T8H0OS%
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M4T4>'^.OCM)X?\3W6A^']'@OFLG\JXN+J1@ID'55"\\=,D]:Y?\ X:.\4?\
M0O:3_P!]R_XTOQ"^"_BJ7QC?ZMX9LTU*POYFN-BRJDD#-RRD,1D9S@@UR'_"
MF_B7_P!"O)_X$1?_ !5>O1IX=TTY-7\V="4+'7?\-'>*/^A=TG_ON7_&C_AH
M[Q1_T+ND_P#?<O\ C7(_\*;^)?\ T*\G_@1%_P#%4?\ "F_B7_T*\G_@1%_\
M571[+#>7W_\ !*M Z[_AH[Q1_P!"]I/_ 'W+_C75^ OCA/XF\4V^@ZWIEKIL
MEZ=EM<0%G4R=0C G(SV/K7DW_"F_B7_T*\G_ ($1?_%5V7PY^#_BJQ\:V&N>
M)+$Z?9Z=*+A8UD222:0?=&%) &>23Z5SUZ6'5.3BU?R9,E"Q].):W:'(N(3_
M -LS_P#%4_[/>?\ /:'_ +]G_P"*H74%;[MK<'_@(_QIWV[_ *=+C_OD?XUX
MNIRC?L]Y_P ]H?\ OV?_ (JC[/>?\]H?^_9_^*IWV[_ITN/^^1_C1]N_Z=+C
M_OD?XT:@-^SWG_/:'_OV?_BJ/L]Y_P ]H?\ OV?_ (JG?;O^G2X_[Y'^-'V[
M_ITN/^^1_C1J W[/>?\ /:'_ +]G_P"*H^SWG_/:'_OV?_BJ=]N_Z=+C_OD?
MXT?;O^G2X_[Y'^-&H$'V&Z_Y^(O^_9_^*I/L-U_S\1?]^S_\54G]I)_SZW'_
M 'R/\:/[17_GUG_[Y'^-.[&1_8;K_GXB_P"_9_\ BJ/L-U_S\1?]^S_\54G]
MHK_SZS_]\C_&C^T5_P"?6?\ [Y'^-%V!']ANO^?B+_OV?_BJ/L-U_P _$7_?
ML_\ Q52?VBO_ #ZS_P#?(_QH_M%?^?6?_OD?XT78#/L-U_S\1?\ ?L__ !5.
M2UO$!Q/"<_\ 3,__ !5._M)?^?6X_P"^1_C2KJ ;[MK<'_@(_P :-1!]GO/^
M>T/_ '[/_P 51]GO/^>T/_?L_P#Q5.^W?].EQ_WR/\:/MW_3I<?]\C_&EJ W
M[/>?\]H?^_9_^*H^SWG_ #VA_P"_9_\ BJ=]N_Z=+C_OD?XT?;O^G2X_[Y'^
M-&H#?L]Y_P ]H?\ OV?_ (JC[/>?\]H?^_9_^*IWV[_ITN/^^1_C1]N_Z=+C
M_OD?XT:@,:WO&4KY\/\ W[/_ ,54?V&Z_P"?B+_OV?\ XJIC?X&3:7&/]T?X
MTW^TE_Y];C_OD?XT]0(OL-U_S\1?]^S_ /%4?8;K_GXB_P"_9_\ BJD_M%?^
M?6?_ +Y'^-']HK_SZS_]\C_&B[&1_8;K_GXB_P"_9_\ BJ/L-U_S\1?]^S_\
M54G]HK_SZS_]\C_&C^T5_P"?6?\ [Y'^-%V!']ANO^?B+_OV?_BJA99K>6,3
M;'1V"ATXP?0BK7]HK_SZS_\ ?(_QJO)(]S)$BQ-'$K!B7QDD=!BC4 URWCN]
M!U"SFF%M%/;2Q/,<8C#*06.>PSFO-9O!6AQR3:E:>,K&W8"47!=D,32YCD5V
M^<8947!YY5@>,"O0_$UG'J'A/6=/DN([9+JRFA::3[D09""Q]AG)KPZW^%NF
M:M>.N@>-M.N);RWN+B>*%/-CFR%BCEX;C;@JWJ"OI0([/6/#^AR^&+"\OO%T
M$=NVI2WCW$38@N99<ED0(V1C!(P21@D]ZK6O@O2-65=/\/\ C"$M!+%<7*P0
MAF9DD8[R<Y#$G!/MS5R^^&,^J:%]GFU"VCO)-7GUAGBA811/);O$%C&<C&Y6
MSW()[UAR_"F:UOTAO_&4$0OW98K=RT9GD\N7[HW#<P+JW']R@#HK7X8?8RLI
MUI8A'C_4VWEJ0&5MS?-]X[<%NXQZ5AIX4M;#QMX5GTG4M+OM,(BECC-Q&F]U
M5$,L8W$L3L+93.2<'UJEX<T&[L9O'5EXJUZ.P\Z)4N-4>]0O%'YC8!4L0J,A
M!);:?GV]@:;:_#V2RB7POI'BO0=0U-4L6DMIQY4L2VTQF41!"2BLK#L<=>]
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M_"CR[K^Y%_WT?\*5P&^='_ST7\Z/.C_YZ+^=.\NZ_N1?]]'_  H\NZ_N1?\
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MT7\Z/.C_ .>B_G3O+NO[D7_?1_PH\NZ_N1?]]'_"BX$4DT7EG]XOYU6\R/\
MYZ"KC0W3*5V1#_@1_P *B^R77I%_WT?\*I,H@\R/_GH*/,C_ .>@J?['=?\
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M9;>3T?8  H !!- %N#P%=6_AOP=IO]K6EU=>'KPW37=S"S/(IW_(G.5X?'_
M16*OPAEMM'&EVWB"&>VGM;.SO8[N.1_/B@>1V13NS&KEP"!T ..M;2_\+&D*
MV/DLEL7$_GD(' ,Y7R^O4)^\STP0/:J=HWQ,MX=+AC%P\9\I+JXNXUDE+"-
MV57^$MYGS#!^Z<T ;_@GP>WA&ZU1FUK[5;7DA>. !@J$RR2%SDGYCY@7C PB
M\9KL_-B_YZ"N'-QXFD\.:)->V^JMJ$>J)YXMU53) '.6D1<80KSMY/3.:YZ6
M3Q=;V]U;S:;XBN+J:S=9FCF)1[KS1MDB96^1%4DD#;D #!(- 'K/G1?\]%H\
MZ/\ YZ+^=<5X?@\26NN:D9&O+R![5"DVJ9B'G *-JA68;3AF.%!!XYJ3Q9%X
MWN/"1ATBWMTU$R[I!9W;(WEKR C,HY) !Z<9YYI@=CYL7_/1:/.B_P">BUY;
M>-XLM9)UFTOQ!=W$B70N!;3'R96,@-N(2&'E@+U("\ @Y)%;WAFT\06OB3-Y
M+J5Y:/8QB:>_7RPLJJ@'EJ'(.XARV5!![G-(#M/.C_YZ+^='G1_\]%_.GT4P
M&>='_P ]%_.CSH_^>B_G3Z* &>='_P ]%_.GPR1M( K@GT%%/C^^* ,O7H=*
MN/#>IV^N,JZ5);2+=EV*J(MIWY(Z#&:YB30? NK:A>6<5PCFZTR&&XM+:Z,<
M<EH2QB)12!@_/@CJ">U=;J5C#JFE7>FW&Y8;J)H7*]0&&#BN.7X:Z1'%*MMJ
M%_!+("@E#(S(GS@(,KC 20H/0 =Z1/-$FFL/!.N2ZS:272&;40EM?1QW#1L4
MC#QA,?PIQ(., \GO5F+0?!LUKK&CQQPR0ZF(C>1M*2) 8PD05L] L8"A3QBL
M^^^&NF7%E=PVM[-#+<1E=[QHWS9DP3QD@>:W&<<"@_#'06GL9Y;BYEDLYA.H
M=5\MFW%C\@  Y/&.G:@.:([4/!_@*UCN$U)B)+XBWN)I;MS+*TCJX+MG.28D
MP3QA<=*LQ^"?!MGX;NO#*QB#2YY$,\'VHC>=BHJMSG!55&.^,U'JGP]TO5=2
MN[^6\N(Y;B7SL".-PC?+G[RG>/D& V0O.,9JO!\+]"M+B2:UN9HY'FBF\P[7
ME4H, !R,X(_+)Q0'-$2W\%_#G4S/':0Q2A&V2K'=,#&Q$AP1G(/^D/\ ]]#V
MJUH_@?P+I,PETRW6*5(I8?FN6R$.5DX)]SS3+?X?Z;9:IIUU:W4@CM+C[0\;
M*N9B(U558@#(W(C\YY7BGW7P]T2Z>XF:6X$\S%O-&TLN2[;>1RN9#E3P<#-
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MCK3/[>\1?]!?4/3_ %SUT%KXTMVNU-W9^3%ARQC?.T^7(%V#'RDE^3[9J/\
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M%_Z!-K_WZ%;G]G6__33_ +^-_C1_9UO_ --/^_C?XT>UEW#ZO3[&'_8>B_\
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M$U8Q45+1'D5<#AZDW4E'5^;/)O\ A3,?_0?;_OS_ /7H_P"%,Q_]!]O^_/\
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MO^_/_P!>O6CUI,5?UZM_-^"'_95'^7\3R;_A3,?_ $'V_P"_/_UZ/^%,Q_\
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MYJERW3: V<CCH*9=:#X)TV:QO+[5KEX]0D:WLI-_F1 SEP55E7 #O*Q!8]2
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MR9%D7+]B,UY;8_!UH;V*6_U:.YMU8%HD0H7'IGG%>KQO<QHJ);PA% 50)&X
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M9F_A^T@_ZG=\_P![;G'7&[C/2D;5--2Z6U:^@^T,JLL2R L5+;0<#MNXSZT
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MH-KN2Q WL%8[%!90<X()'%(#'O/!/C2*U%OH_B#:K3+(S7%Y,S)MD<J5)S_
M8U(/!V_C7IY^\<=*\]OOBIX3TV[U6TNIM06?2[^+3IHQ%DO))T9.?F0<[F[;
M31?_ !3\,Z;IEEJEQ#JGV'4'D6TG$:[;A4!+.H+@D<<#&YN, YH ]!HKF=4\
M8>']&\56OA[4;R>"ZN;62\$A!\J-$!)WM_"Q"N0.X1O2JR_$/P*ULEQ_PDL*
MQ.KN'<NH 7<#G(X^X^ >NTXSBF!U]%<;#\0/"=QK$5A%JZL)U BDWG+R%V7R
M]F-P8;">1C%;7A[6M.\3Z#!K>ER7)M)RZIYRM&V58J<@^X- &Q13/+']]_\
MOHT>6/[[_P#?1H ?13/+']]_^^C1Y8_OO_WT: 'T4SRQ_??_ +Z-'EC^^_\
MWT: 'T4SRQ_??_OHT>5_MO\ ]]&@"&;_ %GX5'7BWC3XA:Y#XCNM.TFZ:TM[
M5_*W 99R.I)-<S_PL#Q?_P!!R;]/\*].G@:LHJ5TKGS=;-J5*HZ?*W;3H?1]
M%?.'_"P/%_\ T')OT_PI1\0/& (/]MS?B!_A6OU&KW1C_:M'^5_@?1U%<=\.
M]<F\5:/+)J#2+=VS^7(R.0K@C(..U=S_ &9#_P ]I_\ OX:\RK%TIN$MT?1X
M>M"M2C4ALR.'_6CZ&K-1C380<B:X'_;0T_\ L]/^?BX_[^&LFS<6BD_L]/\
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MQ\K_ &I/^^C1Y7^W)_WT: 'T4SRO]N3_ +Z-'E<??D_[Z- #Z*9Y/&=TF/\
M>-'EC^^__?1H ?13/+']]_\ OHT>5_M2?]]&@!]/C^^*A\L?WW_[Z-/ACQ(#
MN<X]6S0 HSD8ZUP>G^&O =W%]CT.Z6&;3=2>^>6TN-DRW+M(&+M_$"7D7!R.
MPZ5UPU:R# [Y/^_3_P"%>;77P]TF?S=FM7($T_VB5'@E*NV^4XR""HQ+P 0
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M 'W_ ._;?X4?VE9_WW_[]M_A19 7OM=[_=@_-JD2XOG!^6 8_P!ZLW^TK/\
MOO\ ]^V_PJ:'5+-0V7?_ +]-_A0T@+_G7W_3O_X]1YU]_P!._P#X]57^U;+^
M_)_WZ?\ PH_M6R_OR?\ ?I_\*FR$6O.OO^G?_P >H\Z^_P"G?_QZJO\ :ME_
M?D_[]/\ X4?VK9?WY/\ OT_^%%D!:\Z^_P"G?_QZCSK[_IW_ /'JJ_VK9?WY
M/^_3_P"%']JV7]^3_OT_^%%D!8::^52VV#_QZHOM=[_=@_-JADU2R,9&^3_O
MTW^%5_[2L_[[_P#?MO\ "J211>^UWO\ =@_-J/M=[_=@_-JH_P!I6?\ ??\
M[]M_A1_:5G_??_OVW^%%D!>^UWO]V#\VH^UWO]V#\VJC_:5G_??_ +]M_A1_
M:5G_ 'W_ ._;?X460%[[7>_W8/S:F,TT\T;3,NU&RJ(.,^IS53^TK/\ OO\
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MG_/M/_WR/\:/[13_ )]I_P#OD?XT791']BO/^?B+_O@_XT?8KS_GXB_[X/\
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M1C/]JVN/,\G/G#[_ /=^M8K6?A6'7+SS+R&/41+'J$YDD 95SA.3P$)7I_\
M6K-O='\*V&UKC5YG;Y+0K'(COY3$!8B ,A>GS=?>F!T]KKVF76G/J7VI8;-9
M6A\Z9@JLRL5..?4&H8?$6GS65[=K,S0V<_V9W5=V^3@80#);D@#U-9XT_P .
M7FFQ20ZD+=X1YWG><HDB5BQPRMD#_6$<CO45YIGAG3;&QLIKQX'FN$6TD63,
MBN6!4KV(!4<D$4 ;7]N:6JMYMY%;NB"1XYV\MXU)QEE/(Y(_.I3K6D*-S:K:
M@;!)GS1]T]#^-<V;7PS<:FZS>(/M%P%%ZRM-'@?,JF3(&.3&JD9P/04^Z\*^
M'?LYMI]5,4,C"[$;S1X+ $>9R.1M./2@#=F\0:+;S+!)J5OYK3+!L5]Q#MT!
MQTZ5J<UQ=IH.CV]W)<3:Y'YT$QN85CFC"V\>\,.,=#QDGCTQ713:YH]O-;PS
M:E:I)<R+'"GF@EV8$J!CU .* -')HR:SKK7-)LXH)9K^$K<3+;Q>6X<N[,%
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MP%R 6^;#+N! SG';%/?0?"/]OSPO;Z>-7NR+J2/=B5\$_/MW9 R6Z<')SWI
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M-*G8&["7+EO)M0ZJK$'. 0R'<#TR>212 TSX#O(]5CGM]<>*12&AC-U,<!!
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M\.OL9/$5FRR7;6*$7*X:X7[T(_VQ@Y7K0!S2#Q,UEJ'VZ6_COEDC:,0)(R.
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M6L2M\OF#_MHW^->5-.,G"6Z/IJ-:-6G&<=FKCZ*=]CC_ +TO_?QO\:/L<?\
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MBHQ5DB7S;S^]#_WR?\:/-O/[T/\ WR?\:6BIL,3S;S^]#_WR?\:/-O/[T/\
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)*93X_OB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ptn_10qimg20.jpg
<TEXT>
begin 644 ptn_10qimg20.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !< G # 2(  A$! Q$!_\0
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M;\)Z]JFB63:?J4-A-H^K?VC9:A?:'?1-=NT3QS">"[N3<.?GXD:09P !A1D
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M@2))$C9"5+!4W%U5=X).!@[OAG4-2U3P[;ZAJ0L?/GWNK:?-Y]N\>X^6Z/\
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M+J(/NWG: ,_+_%GCL_$WA_7=88?V;KEI:PO;26MS9:CIQO;2Y5R,EHQ+&<@
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MUVEG#>W+6-C<82&0969HP':),8)+GY0R[B-RYV]1\<Z/#J5QH>GW!GUD1O\
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MS5BA<J[N0ZNI# $@!D]:K:!\0[R/3]4U?QEY5I;G4Y++3['3]-N;BZ557?\
MO%C,C.VW).U%"[3GV=)\.]1U.[TZ\\0>(H)[NQU">X5[&P:V6:VFYEM9 TTF
MY68(<Y'" 8SDU0NOAKXNOM/N[.[\8:7<PW>IRZC+;2:/*+:99$*F&:-;L&5
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MSY)M9_-BC23RW:6/9NB"MD-O"[=K$X"DC@-!\$W'B;P[KGARZD^T:?=>1/\
MVAJ6@ZC;R?:8G5HXY(]1GD>XA 7E050 D Y8XWK[X0WUQI1L=/UK1-(B;2;O
M33#8:#Y$"-<2([R)&DXV@", *2QR22QZ4 =M;^-O#=UH=[KD&H.UG8R^3,3;
M2K('XPHC*[V+;EV[5._<NW.16-/\6?A_#);0OKC-=W4,EQ'91VD\ET4C?9)F
M!4,BLI#94J&&USC"L12U#X9S:MH?BK2]4U6TN8M:OH-0A#:=N2WDB2(!9$:1
MA,A,*Y7Y<@L.X(@L?AGJ>GZMI=YINL:)IT5CI]W9FSL=!^SVY>X8,71$G&P
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MF+%:S"*;<%C8!N5V@,P8Y!*@!CVUW\.?!M]<V4UUI<K26< M0RWDZF>+=O\
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MO[WG&2GW2-CQ=\0]4\'ZGJ%M-X?T^2"WCM[BWEEU*2-[B%W*3/L6W?'E'#,
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MSDYP2Q)KG;/X3^![.WNH(].O9(KFT2QD6;5KR8>2C;HU7?*=FP\H5P4_A(H
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M?<V\,S0";B58/):+#*-YE5B6'R8.:TO!_CN;Q,=6;4M/M-(ETW!EM!=2/=0
M@G]_#)#&T1P 01O1@<JS 9K1L_ ?A>PU6'4K+39+>>.)(0JW<PB<(NQ&>+?L
M=PO D92X]:LZ%X1T/PX9VTQ+QWG18V:]U"XO&"+G:BF=W**-Q^5<#GI0!YAK
MGQ:\0OX/U&^TOP];64EYH4VM:+=MJ!D#PH0&,J>5^[E"NC!!O4YQO&*Z[3=%
MUS3?A?J4,.O3V.KWML\T4M]JDE_%82M& -D\R!RF0&^8':6..,"IE^%?@=-)
MU#2X](G2TOXV@DA2_N0L<3/O:*+$G[B-FY*1[5/&00*Z)M!TM_#)\-W%N]UI
M9@^S-%<SR3-)'C&UG=B[<=R230!Y=I/C%O!^BZZVI6?B6#5K&.SA&@:K<R7Y
M$DKE%D@N5$KSQ.[X+8=UV$;!A4&_;_$+Q%JNGV<>C^"W?79()KJ?3M1NI-/V
MQ1R>7F,S0!W+G!3?'&,<L4X!WH/A_P"%5TO4-/DT^YNHM154N'O+^XN92JG*
M*DLDC/&%/S*$8!3R,'FDNOA_X8NK*SMIK2]#6>_R[F+5+J.Z(?[X>X602R!L
M#(=B#M&>@P <1?\ Q \21ZYXCL]8\-B32;+6].TV$V.JM!- 9O)8/(5525_>
M#(5FR?DP5R]:Y^*5U_:<30^&3=Z+=W5YI]E=6]\IN)KFV5RR-"ZJJ*QBD"MY
MC=!N"YXU[[X:^#=4NKBYN;"[C-U)!+*EOJ5U;QO)"%$3^7'(J[E"+SC/RC/2
MK,?P_P#"L.L7NI0Z7+%<WIE>39>SK&LDB[9)8XP^R*1AP9$"N<GGDT 8G@WX
MD:GXHU/0[?4/"W]CV^N:4^J6<@OQ<2 (T899%" +GS 5(9LCJ%/ O";4%^-G
MV5M4NY;"70VF%BS 0QR+.J[U  )8@]6)]L"KVC_#WPKH5]I%YIEG>12Z/:O9
MV6_4;F58H7.63:\A##./O XVKC&T8T'\,Z3-XPC\6-'=?VM# ;19!>3"+RB<
ME3"'\L\\Y*YR >PH \^\%W6J'XL:E#J&L7SB4WK1B2ZFFM-119U"&W5OW<+0
M#,;JN"20?F'S5M>,_B)=>&;W4[?2]"BUC^Q+%-2U3?>_9WB@=F \H>6PD?$;
ML58H, 8))P.ATWP;X<TGQ!/KECI[)?2^9R]S+)'#YC;I/*C9BD6]@"VQ5W'D
MYJ/7/ _AGQ%K$.K:OI[RWD<7D%XKF6$31;MWE2K&RB9,C.R0,O7CDT <?\)Y
MO$'B)]1\9Z]<3PS2W5U9I:V^J2W%HZ),54^0\:K$R! H9,%P26&3@<Q-XN\?
MZE/X?U)X5B=/&%UI<>GV&H;8KR-$N%"S,T2D*C1@Y!;(R=A(5:]>\,^%=)\(
MV,UAH<=U%;SS-<.L][/=?O&.6(,KL5R<D@8!))ZFLMOAOX3;48[[[%>QS1:B
MVJQK'JETD:739W2+&L@09W-D ;3N.1R: .3O/C'=VVD67D^#[J_UJ6XO8;C3
M[$W%T(Q:R^5(8WBMW+DDKMWI&IS\S+W]:AD\Z&.;8Z;E#;77#+D=".QKC5^&
M?@V"U2W6SO4"7<UZLBZI=B422_ZW]YYN_8_5DSL)Y(KMHXTAC6.- B( JJHP
M !T H GHHHH \$^'/A?2M-\5WFHIX'\,:;86VMZC%:ZQ"5BO5D\\QQP[1&FU
M"&90 [YP!M%=EX7\6:[=7?B6'69=/N6T7?LCTZSDB-V SE9(V>5]R[5$9 '$
MB2#. *GTGPW\)+/Q5)'H.@^$;;Q!I\@5ELK6U2ZMG920"$&]"5W'L2,]JZ*P
M\,^'M+U!+W3/#^FV-Q'#]F2:WM(XW6+=N\L,H!"[B3MZ9YH \A\:ZEXHUWX7
M6^K:I>:#>17=SI.I:7#I\L]LRLUW'F.;+.)4 =!YF ,Y/E@A:;KGQ3\=:5>>
M(M%A_L:_U?P^SSS1VVFSM]HMQ##+NP;@+"%\Q@9&D8L5 2-CD5ZD_@#P+)#>
M12>"M!>.]F%Q=(VFPD7$@)(=QM^9@6;DY/)]:IZQX#^%[->:WKW@CPPQ :>Z
MO;S3;<X &6=W9>P'))H Y&Z^(GCB'5]6E:QT.'2=*\06>DF$>=+/<17'D_-O
MRBQLHEW?=<'.W V[FOZ?XN\;:C\06LH(;/\ L6"ZNENE71[IC%#%D(4O#*()
M7=@,HBDID@C*DUT5QX)^&]GH]U=3^%?#5MIAVW=Q(]A;I"?+!*RN2NWY03AC
MT!-86F_#&VC\7Q>(I_\ A'+A4NFOHKVTT%(-2E8DLOF7:RD./FP=L:[AQP,@
M@$OPW\:>*_&$4]YKVBPZ?87-O'>:?(C0JS(S,&0JEQ*S;<+^\819)(V*16'\
M1M7U:V\46'BK3_#^J7-GX4NT>7489+?[*L#*4O RF82DA'4\1M@Q?6O4]/T'
M0]&GO)M'T6QTZ6^D\ZZ>UMDB:X?GYG*@;FY/)R>:R/\ A'_ MC9'PI_8>A6M
MGJSO(=+^RPI'>.H#.WE8Q(0 I)P<8&: ,2/Q)XFU?7-3DT6^\/VNDV%XVGO%
M>PRM<%S"'297$@4AF=,1;1N7)\P$X%CX4WVNZO\ "C0-4\1:C%J-_>VZW!EC
MA:+AN0&R[98<\C Z848K9L? _@O3=2M-1TWPCHUE>649BMI[?3XHY($.<JC!
M05'S-P/[Q]:GT_POX9TB:.;2?#NFV+QF0H]K9QQ,ID(,F"H&-Q5=WK@9Z4 >
M8_$[2X&\3ZCXADM;;7[73M*0:A9?:3;:CI<)=R;FSD/R_,OF!T)7>(P-Q^Z;
MUU\1/$MK#K#1MI3+I_B2QTR/?:2*9;2Y$)&1YO$H$WWNAV_<&>/0=2\,^']9
MO;>^U;P_IFHW5NXD@GNK..5XF'(968$J1V(JMJ?@7P3K6I-J6L>#=$U&^=0K
M75WI\,TK = 6922!@=Z /,O%VL^(/$GPJ\77][=:1%X?NM,U*.&S@::"_@E@
MW *SA]LN=CEU"IMZ?.,D]7X%\0>(Y?$D_A?Q NFL(-'LM1MS8QR+Y2R&1#&[
M.Q\PCRQ\X5,Y^Z*W(_"_@/7)M2U&/P[H%_+>[K2_N%LX)6G*, T4K8.[:R %
M6S@J/2KUCX9\-Z/<_P!IZ9X?TK3[R.W6V^TV]I'$X@4#$>X '8 !A<X&!Z4
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M0J;3Q\_6O1? FO>*-9T:\G\6:?%8W<#AH_(\H&>%HPZOY<5Q/LY+ 9D.X '
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M%PI1A]H9W)&XD&&/9@<L#FLO4O&WB?1T\6W6D^'?#ZW]MXFL]+9FDD03Q2K
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MC2Z\-ZEJ6L>)M.CA::U2\DM)$N;CP^'E99_-4VT:0[!C"R^:5PS,745]$44
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M5;[Q\T&I6EK>FY\-K8V\LNF%'Q%*J_*X 4 [IG,;^8""@P*Y72?&FGZ]XO\
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ptn_10qimg18.jpg
<TEXT>
begin 644 ptn_10qimg18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1"  T .D# 2(  A$! Q$!_\0
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MQ8US35+Q;>#.G4Q_7N/?ZUT>TCRQI2V:7R?<W4U:-.>S7W'K3<QM7DGP%_Y
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M]'V<E[VFODC1UN:GRO<Z"BBBN,YPHHHH **** "BBBI ****H HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PALATIN TECHNOLOGIES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000911216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,479,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4078884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">4B Cedar Brook Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Cranbury<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">495&#8209;2200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTN1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,520,062<span></span>
</td>
<td class="nump">$ 9,527,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">OtherReceivablesCurrent</a></td>
<td class="nump">271,037<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">442,178<span></span>
</td>
<td class="nump">242,272<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,233,277<span></span>
</td>
<td class="nump">9,769,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">182,437<span></span>
</td>
<td class="nump">388,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases</a></td>
<td class="nump">255,863<span></span>
</td>
<td class="nump">527,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">56,916<span></span>
</td>
<td class="nump">56,916<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,728,493<span></span>
</td>
<td class="nump">10,742,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,770,567<span></span>
</td>
<td class="nump">4,101,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">506,460<span></span>
</td>
<td class="nump">4,185,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term operating lease liabilities</a></td>
<td class="nump">194,972<span></span>
</td>
<td class="nump">380,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Short-term finance lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,576,350<span></span>
</td>
<td class="nump">944,150<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,048,349<span></span>
</td>
<td class="nump">9,657,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">67,248<span></span>
</td>
<td class="nump">163,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,032,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,115,597<span></span>
</td>
<td class="nump">10,853,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficiency:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock of $0.01 par value - authorized 300,000,000 shares: issued and outstanding 28,557,246 shares as of March 31, 2025 and 17,926,640 shares as of June 30, 2024</a></td>
<td class="nump">285,572<span></span>
</td>
<td class="nump">179,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">450,171,385<span></span>
</td>
<td class="nump">441,475,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(456,844,101)<span></span>
</td>
<td class="num">(441,766,550)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficiency</a></td>
<td class="num">(6,387,104)<span></span>
</td>
<td class="num">(111,497)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficiency</a></td>
<td class="nump">3,728,493<span></span>
</td>
<td class="nump">10,742,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember', window );">Series A Convertible Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficiency:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Convertible: authorized 4,030 shares as of March 31, 2025: issued and outstanding 4,030 shares as of March 31, 2025 and June 30, 2024</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">28,557,246<span></span>
</td>
<td class="nump">17,926,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">28,557,246<span></span>
</td>
<td class="nump">17,926,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember', window );">Series A Convertible Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_SeriesAConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenue, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,140,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionCosts', window );">Cost of products sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">97,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,755,158<span></span>
</td>
<td class="nump">7,159,686<span></span>
</td>
<td class="nump">12,928,391<span></span>
</td>
<td class="nump">17,728,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,474,019<span></span>
</td>
<td class="nump">2,033,410<span></span>
</td>
<td class="nump">5,176,794<span></span>
</td>
<td class="nump">8,266,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_GainLossOnSaleOfVylessi', window );">Loss (Gain) on sale of Vyleesi</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,202<span></span>
</td>
<td class="num">(2,500,000)<span></span>
</td>
<td class="num">(7,798,280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_GainLossOnPurchaseCommitment', window );">Gain on purchase commitment</a></td>
<td class="num">(416,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(416,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,813,177<span></span>
</td>
<td class="nump">9,218,298<span></span>
</td>
<td class="nump">15,189,185<span></span>
</td>
<td class="nump">18,294,140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(4,813,177)<span></span>
</td>
<td class="num">(9,218,298)<span></span>
</td>
<td class="num">(15,189,185)<span></span>
</td>
<td class="num">(14,154,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">31,452<span></span>
</td>
<td class="nump">139,273<span></span>
</td>
<td class="nump">139,072<span></span>
</td>
<td class="nump">272,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction (loss) gain</a></td>
<td class="num">(27,900)<span></span>
</td>
<td class="nump">215,600<span></span>
</td>
<td class="num">(15,900)<span></span>
</td>
<td class="nump">68,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,795)<span></span>
</td>
<td class="num">(1,254)<span></span>
</td>
<td class="num">(11,538)<span></span>
</td>
<td class="num">(13,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Offering expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(696,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantsGainLossOnWarrantsNet', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">429,029<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,962,562<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">1,757<span></span>
</td>
<td class="nump">782,648<span></span>
</td>
<td class="nump">111,634<span></span>
</td>
<td class="num">(7,331,633)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (4,811,420)<span></span>
</td>
<td class="num">$ (8,435,650)<span></span>
</td>
<td class="num">$ (15,077,551)<span></span>
</td>
<td class="num">$ (21,485,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net loss per common share</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (1.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share</a></td>
<td class="nump">26,344,584<span></span>
</td>
<td class="nump">15,792,421<span></span>
</td>
<td class="nump">22,245,153<span></span>
</td>
<td class="nump">14,013,848<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_GainLossOnPurchaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_GainLossOnPurchaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_GainLossOnSaleOfVylessi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_GainLossOnSaleOfVylessi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantsGainLossOnWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantsGainLossOnWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized production cost incurred during period for oil- and gas-producing activities. Includes cost incurred to operate and maintain well and related equipment and facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 932<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(a)(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479664/932-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Contingently Redeemable Warrants</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">11,656,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2023</a></td>
<td class="num">$ (1,979,871)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 116,567<span></span>
</td>
<td class="nump">$ 409,933,959<span></span>
</td>
<td class="num">$ (412,030,437)<span></span>
</td>
<td class="nump">$ 263,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation, amount</a></td>
<td class="nump">1,330,502<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 984<span></span>
</td>
<td class="nump">1,329,518<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares', window );">Withholding taxes related to restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount', window );">Withholding taxes related to restricted stock units, amount</a></td>
<td class="num">(56,401)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (255)<span></span>
</td>
<td class="num">(56,146)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsShares', window );">Sale of common stock, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,048,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsAmount', window );">Sale of common stock, net of costs, amount</a></td>
<td class="nump">9,693,882<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 20,485<span></span>
</td>
<td class="nump">9,673,397<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrant', window );">Conversion of liability classified warrants</a></td>
<td class="nump">11,423,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,423,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares', window );">Conversion of liability classified warrants upon warrant exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,358,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount', window );">Conversion of liability classified warrants upon warrant exercise, amount</a></td>
<td class="nump">2,389,903<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 23,585<span></span>
</td>
<td class="nump">2,366,318<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ReclassificationOfContingentlyRedeemableWarrants', window );">Reclassification of contingently redeemable warrants</a></td>
<td class="nump">263,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">263,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(263,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,485,683)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,485,683)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">16,136,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2024</a></td>
<td class="nump">1,578,935<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 161,366<span></span>
</td>
<td class="nump">434,933,649<span></span>
</td>
<td class="num">(433,516,120)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">14,305,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2023</a></td>
<td class="num">(11,384,426)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 143,051<span></span>
</td>
<td class="nump">413,552,953<span></span>
</td>
<td class="num">(425,080,470)<span></span>
</td>
<td class="nump">423,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsShares', window );">Sale of common stock, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,831,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsAmount', window );">Sale of common stock, net of costs, amount</a></td>
<td class="nump">9,162,513<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 18,315<span></span>
</td>
<td class="nump">9,144,198<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrant', window );">Conversion of liability classified warrants</a></td>
<td class="nump">11,423,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,423,203<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ReclassificationOfContingentlyRedeemableWarrants', window );">Reclassification of contingently redeemable warrants</a></td>
<td class="nump">423,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">423,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(423,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,435,650)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,435,650)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">390,195<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">390,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">16,136,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2024</a></td>
<td class="nump">1,578,935<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 161,366<span></span>
</td>
<td class="nump">434,933,649<span></span>
</td>
<td class="num">(433,516,120)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">17,926,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2024</a></td>
<td class="num">(111,497)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 179,266<span></span>
</td>
<td class="nump">441,475,747<span></span>
</td>
<td class="num">(441,766,550)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation, amount</a></td>
<td class="nump">1,045,669<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
<td class="nump">1,043,340<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares', window );">Withholding taxes related to restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount', window );">Withholding taxes related to restricted stock units, amount</a></td>
<td class="num">(99,482)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (547)<span></span>
</td>
<td class="num">(98,935)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsShares', window );">Sale of common stock, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,101,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsAmount', window );">Sale of common stock, net of costs, amount</a></td>
<td class="nump">4,457,520<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 51,014<span></span>
</td>
<td class="nump">4,406,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,077,551)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,077,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesReleasedFromAbeyanceShares', window );">Shares released from abeyance, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesReleasedFromAbeyanceAmount', window );">Shares released from abeyance, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 14,433<span></span>
</td>
<td class="num">(14,433)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantExercisesShares', window );">Warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,907,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantExercisesAmount', window );">Warrant exercises, amount</a></td>
<td class="nump">3,398,237<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39,077<span></span>
</td>
<td class="nump">3,359,160<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">28,557,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2025</a></td>
<td class="num">(6,387,104)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 285,572<span></span>
</td>
<td class="nump">450,171,385<span></span>
</td>
<td class="num">(456,844,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">23,455,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2024</a></td>
<td class="num">(6,381,109)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 234,558<span></span>
</td>
<td class="nump">445,416,974<span></span>
</td>
<td class="num">(452,032,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsShares', window );">Sale of common stock, net of costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,101,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SaleOfCommonStockNetOfCostsAmount', window );">Sale of common stock, net of costs, amount</a></td>
<td class="nump">4,457,520<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 51,014<span></span>
</td>
<td class="nump">4,406,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,811,420)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,811,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">347,691<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">347,691<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantExercisesAmount', window );">Warrant exercises, amount</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="nump">28,557,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Mar. 31, 2025</a></td>
<td class="num">$ (6,387,104)<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 285,572<span></span>
</td>
<td class="nump">$ 450,171,385<span></span>
</td>
<td class="num">$ (456,844,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ConversionOfLiabilityClassifiedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ConversionOfLiabilityClassifiedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ReclassificationOfContingentlyRedeemableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ReclassificationOfContingentlyRedeemableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SaleOfCommonStockNetOfCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SaleOfCommonStockNetOfCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SaleOfCommonStockNetOfCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SaleOfCommonStockNetOfCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesReleasedFromAbeyanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesReleasedFromAbeyanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesReleasedFromAbeyanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesReleasedFromAbeyanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantExercisesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantExercisesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (15,077,551)<span></span>
</td>
<td class="num">$ (21,485,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">205,924<span></span>
</td>
<td class="nump">257,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Decrease in right-of-use asset</a></td>
<td class="nump">271,458<span></span>
</td>
<td class="nump">260,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency transaction loss (gain)</a></td>
<td class="nump">15,900<span></span>
</td>
<td class="num">(68,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,045,669<span></span>
</td>
<td class="nump">1,330,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ChangeInFairValueOfLiabilityClassifiedWarrants', window );">Change in fair value of liability classified warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,962,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain on sale of Vyleesi</a></td>
<td class="num">(2,500,000)<span></span>
</td>
<td class="num">(7,798,280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_GainLossOnPurchaseCommitment', window );">Gain on purchase commitment</a></td>
<td class="num">(416,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,915,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(271,037)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(199,906)<span></span>
</td>
<td class="nump">1,206,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,154,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,668,638<span></span>
</td>
<td class="num">(860,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(3,678,586)<span></span>
</td>
<td class="num">(4,171,297)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(282,104)<span></span>
</td>
<td class="num">(264,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,118,897)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(17,217,595)<span></span>
</td>
<td class="num">(24,988,985)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturity of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,992,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ProceedsFromSaleOfOtherAssets', window );">Proceeds from sale of Vyleesi</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,615)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">12,455,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of withholding taxes related to restricted stock units</a></td>
<td class="num">(99,482)<span></span>
</td>
<td class="num">(56,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock and warrants, net</a></td>
<td class="nump">4,457,520<span></span>
</td>
<td class="nump">14,693,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligations</a></td>
<td class="num">(46,014)<span></span>
</td>
<td class="num">(79,265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">3,398,237<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,710,261<span></span>
</td>
<td class="nump">14,558,216<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(7,007,334)<span></span>
</td>
<td class="nump">2,024,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, beginning of period</a></td>
<td class="nump">9,527,396<span></span>
</td>
<td class="nump">7,989,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, end of period</a></td>
<td class="nump">2,520,062<span></span>
</td>
<td class="nump">10,014,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">11,538<span></span>
</td>
<td class="nump">13,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrants', window );">Conversion of liability classified warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,423,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise', window );">Conversion of liability classified warrants upon warrant exercise</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,389,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ChangeInFairValueOfLiabilityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ChangeInFairValueOfLiabilityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ConversionOfLiabilityClassifiedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ConversionOfLiabilityClassifiedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_GainLossOnPurchaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_GainLossOnPurchaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ProceedsFromSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ProceedsFromSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arragements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arragement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arragement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non Rule 10b5-1 Arragement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non Rule 10b5-1 Arragement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OrganizationAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(1) ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Nature of Business </em>- Palatin Technologies, Inc. (&#8220;Palatin&#8221; or the &#8220;Company&#8221;) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company&#8217;s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Melanocortin Receptor System.</em> The melanocortin receptor system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company&#8217;s prior commercial product, Vyleesi&#174;, was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in June 2019 for the treatment of hypoactive sexual desire disorder (&#8220;HSDD&#8221;) in premenopausal women. As disclosed in Note 5, this product was acquired by Cosette Pharmaceuticals, Inc. (&#8220;Cosette&#8221;) on December 19, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our new product development activities focus primarily on use of bremelanotide, or other MC4r agonists, with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, with topline results announced in March 2025, in which co-administration of bremelanotide and tirzepatide demonstrated an increased weight loss over tirzepatide alone.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is also developing, dependent on resources for development activities, MC1r agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1r agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Business Risks and Liquidity &#8211; </em>The Company has incurred operating losses and negative cash flows from operations since inception and will need additional funding to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit as of March 31, 2025 of $456,844,101 and a net loss for the three and nine months ended March 31, 2025 of $4,811,420 and $15,077,551, respectively. The Company anticipates incurring significant expenses in the future as a result of spending on its development programs and will require substantial additional financing or revenues to continue to fund its planned activities. To achieve sustained profitability, if ever, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals, and successfully manufacture and market such technologies and proposed products. The time required to reach sustained profitability is highly uncertain, and the Company may never be able to achieve profitability on a sustained basis, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of March 31, 2025, the Company&#8217;s cash and cash equivalents were $2,520,602 and current liabilities were $10,048,349. Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the Company&#8217;s MC1r and MC4r programs, and development of other portfolio products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company follows the provisions of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 205-40, <em>Presentation of Financial Statements &#8212; Going Concern</em>, which requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company&#8217;s ability to meet its obligations for the next year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Based on our available cash and cash equivalents as of March 31, 2025, management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. The Company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm the Company&#8217;s business, results of operations, and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company could be forced to make additional reductions in certain expenditures. This could include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If the Company is unable to raise capital when needed or enter into a strategic transaction, then the Company could be required to cease operations, which could cause its stockholders to lose all or part of their investment. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Assuming no additional funding and based on its current operating and development plans, the Company expects that existing cash and cash equivalents as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the second half of calendar year 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company may receive contingent, sales-based milestone payments of up to $159,000,000 on sales of Vyleesi by Cosette and its licensees.<em> </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Concentrations &#8211;</em> Concentrations in the Company&#8217;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company&#8217;s cash and cash equivalents are primarily invested in one investment account sponsored by a large financial institution.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OrganizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OrganizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_BasisOfPresentationAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(2) BASIS OF PRESENTATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three and nine months ended March 31, 2025, may not necessarily be indicative of the results of operations expected for the full fiscal year.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2024, filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), which includes consolidated financial statements as of June 30, 2024 and 2023 and for the fiscal years then ended.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Principles of Consolidation</em> &#8211; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Cash, Cash Equivalents</em> &#8211; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $2,097,618 and $9,089,113 in a money market account at March 31, 2025 and June 30, 2024, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Fair Value of Financial Instruments</em> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Credit Risk</em> &#8211; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Impairment of Long-Lived Assets</em> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Leases</em> - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#8217;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#8217;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition (Prior to the sale of Vyleesi)</em> &#8211; The Company recognized product revenues in accordance with FASB ASC Topic 606, <em>Revenue from Contracts with Customers</em>. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligations were satisfied by transferring control of the product to a customer. Per the Company&#8217;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Gross product sales offset by product sales allowances for the three and nine months ended March 31, 2025 and 2024 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended March 31</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Nine Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,875,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Product sales allowances and accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,735,063</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,140,090</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition &#8212;</em>&#8211; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company determines if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the non-refundable, upfront license fees will be recognized over time, the Company assesses the appropriate method of measuring proportional performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Research and Development Costs</em> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Accrued Expenses &#8211;</em> Third parties perform a significant portion of the Company&#8217;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock-Based Compensation &#8211; </em>The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Income Taxes</em> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Net Loss per Common Share </em>&#8211;<em> </em>Basic and diluted loss per common share (&#8220;EPS&#8221;) are calculated in accordance with the provisions of FASB ASC Topic 260, <em>Earnings per Share</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the three months ended March 31, 2025 and 2024, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three and nine months ended March 31, 2025 and 2024 were 17,749,116 and 8,520,332, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of March 31, 2025 and 2024 due to a provision in the restricted stock unit agreements to delay delivery.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Translation of foreign currencies </em>&#8211; Transactions denominated in currencies other than the Company&#8217;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>New Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(4)</strong> <strong>New Accounting Pronouncements</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, Segment Reporting (Topic 280) &#8211; Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of the adoption on the consolidated financial statements and accompanying footnotes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AssetPurchaseAgreementAbstract', window );"><strong>ASSET PURCHASE AGREEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AssetPurchaseAgreementTextBlock', window );">ASSET PURCHASE AGREEMENT</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(5) ASSET PURCHASE AGREEMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On December 19, 2023, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Cosette pursuant to which Cosette acquired from the Company worldwide rights to Vyleesi&#174;.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Under the terms of the Purchase Agreement, the Company sold certain assets (the &#8220;Purchased Assets&#8221;) to Cosette, comprising the exclusive right to market and sell Vyleesi for treatment of hypoactive sexual desire disorder in women, and contracts relating to manufacturing and distribution of Vyleesi. The Purchased Assets include applicable intellectual property pertaining to the marketing and sale of Vyleesi, including patents, patent applications, trademarks and copyrights. In addition, Cosette acquired records pertaining to the historical sales and distribution of Vyleesi, as well as quality control and pharmacovigilance records and other records. The Company will receive up to $171,000,000, consisting of an upfront purchase price of $9,500,000, $2,500,000 payable upon the settlement of certain purchase commitments, which was received November 1, 2024, and sales-based milestone payments of up to $159,000,000. As of March 31, 2025, none of the sales-based milestones have been achieved. The closing of the transaction took place simultaneously with the signing of the Purchase Agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The parties have also entered into a transition service agreement pursuant to which the Company provided certain transition services to Cosette through May 31, 2024, and the Company was reimbursed for the costs of the transition services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company is also eligible to receive regulatory approval milestones associated with previous licensing of Vyleesi to Kwangdong for the Republic of Korea (&#8220;Korea&#8221;) (see Note 8).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AssetPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AssetPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AssetPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AssetPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ManufacturingSupplyAgreementsForVyleesiabstract', window );"><strong>MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ManufacturingSupplyAgreementsTextBlock', window );">MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(6) MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has transferred to Cosette its right, title and interest in contracts and agreements to manufacture Vyleesi, including manufacturing contracts with Catalent Belgium S.A. (&#8220;Catalent&#8221;), a subsidiary of Catalent Pharma Solutions, Inc., to manufacture drug product and prefilled syringes and assemble prefilled syringes into an auto-injector device; Ypsomed AG (&#8220;Ypsomed&#8221;), to manufacture the auto-injector device (the &#8220;Ypsomed Agreement&#8221;); and Lonza Ltd. (&#8220;Lonza&#8221;), to manufacture the active pharmaceutical ingredient peptide (the &#8220;Lonza Agreement&#8221;).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ManufacturingSupplyAgreementsForVyleesiabstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ManufacturingSupplyAgreementsForVyleesiabstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ManufacturingSupplyAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ManufacturingSupplyAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH FOSUN<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithFosunAbstract', window );"><strong>AGREEMENT WITH FOSUN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithFosunTextBlock', window );">AGREEMENT WITH FOSUN</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun&#8221;) for exclusive rights to commercialize Vyleesi in China (the &#8220;Fosun License Agreement&#8221;). Under the terms of the Fosun License Agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. In July 2024, Fosun, Cosette and Palatin entered into a termination agreement, effective as of May 20, 2024, terminating the Fosun License Agreement and ancillary agreements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithFosunAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithFosunAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithFosunTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithFosunTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH KWANGDONG<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithKwangdongAbstract', window );"><strong>AGREEMENT WITH KWANGDONG</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithKwangdongTextBlock', window );">AGREEMENT WITH KWANGDONG</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(8) AGREEMENT WITH KWANGDONG</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On November 21, 2017, the Company entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. (&#8220;Kwangdong&#8221;) for exclusive rights to commercialize Vyleesi in Korea (the &#8220;Kwangdong License Agreement&#8221;). Under the terms of the Kwangdong License Agreement, the Company received $417,500 in December 2017, consisting of an upfront payment of $500,000, less $82,500, which was withheld in accordance with tax withholding requirements in Korea and recorded as an expense during the year ended June 30, 2018. The Company has assigned the Kwangdong License Agreement to Cosette, provided that the Company retains the right to receive a $3,000,000 milestone payment based on the first commercial sale in Korea which has not occurred as of March 31, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithKwangdongAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithKwangdongAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithKwangdongTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithKwangdongTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(9) PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Prepaid expenses<strong> </strong>and other current assets consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,118</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,926</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Insurance premiums</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95,327</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,097</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">301,733</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,249</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">442,178</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">242,272</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(10) FAIR VALUE MEASUREMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The fair value of cash equivalents is classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&#8217;s own assumptions used to measure assets and liabilities at fair value. A financial asset&#8217;s or liability&#8217;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table provides the assets carried at fair value:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carrying Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Quoted prices in </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>active markets</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(Level 1)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Other quoted/observable inputs (Level 2)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Significant unobservable inputs</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(Level 3)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">March 31, 2025:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,097,618</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,097,618</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 30, 2024:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(11) ACCRUED EXPENSES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Accrued expenses<strong> </strong>consist of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">378,592</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,509,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other research related expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,509</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Professional Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,040</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">284,215</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,771,694</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Selling expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">351,485</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,319</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">201,883</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">506,460</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,185,046</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(12) COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Inventory Purchases </em>- The Company had certain supply agreements with manufacturers and suppliers, including the manufacturing agreement with Catalent entered into in September 2020 (the &#8220;Catalent Agreement&#8221;), Ypsomed Agreement, and Lonza Agreement, all of which have been transferred to Cosette. As a result of the sale of Vyleesi to Cosette, the Company is still required to make certain payments for the manufacture and supply of Vyleesi.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The following table summarizes the contractual obligations under the Catalent Agreement and Ypsomed Agreement as of March 31, 2025:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Current</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>1 - 3 Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>4 - 5 Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inventory purchase commitments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,101,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,101,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of March 31, 2025, the Company has $1,576,350 accrued within other current liabilities in the consolidated balance sheet related to estimated losses for firm commitment contractual obligations under these agreements. As of June 30, 2024, $944,150 and $1,032,300 was accrued within other current and long-term liabilities, respectively. Losses on these firm commitment contractual obligations are recognized based upon the terms of the respective agreement and similar factors considered for the write-down of inventory, including expected sales requirements as determined by internal sales forecasts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The commitment contractual obligation amounts above are denominated in Swiss Francs and Euros and have been translated using period end exchange rates. The Company may experience a negative impact on future earnings and equity solely as a result of future foreign currency exchange rate fluctuations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Contingencies</em> - The Company accounts for litigation losses in accordance with ASC 450-20, <em>Loss Contingencies</em>. In addition, the Company is subject to other contingencies, such as product liability, arising in the ordinary course of business. Loss contingency provisions are recorded for probable losses when management is able to reasonably estimate the loss. Any outcome upon settlement that deviates from the Company&#8217;s best estimate may result in additional expense or in a reduction in expense in a future accounting period. The Company records legal expenses associated with such contingencies as incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. The Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS DEFICIENCY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(13) STOCKHOLDERS&#8217; DEFICIENCY</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Series A Convertible Preferred Stock</em> &#8211; As of March 31, 2025, 4,030 shares of Series A Convertible Preferred Stock were outstanding. Each share of Series A Convertible Preferred Stock is convertible at any time, at the option of the holder, into the number of shares of common stock equal to $100 divided by the Series A Conversion Price. As of March 31, 2025, the Series A Conversion Price was $60.33, and each share of Series A Convertible Preferred Stock is convertible into approximately 1.66 shares of common stock. The Series A Conversion Price is subject to adjustment, under certain circumstances, upon the sale or issuance of common stock for consideration per share less than either (i) the Series A Conversion Price in effect on the date of such sale or issuance, or (ii) the market price of the common stock as of the date of such sale or issuance. The Series A Conversion Price is also subject to adjustment upon the occurrence of a merger, reorganization, consolidation, reclassification, stock dividend or stock split which will result in an increase or decrease in the number of shares of common stock outstanding. Shares of Series A Convertible Preferred Stock have a preference in liquidation, including certain merger transactions, of $100 per share, or $403,000 in the aggregate as of March 31, 2025. Additionally, the Company may not pay a dividend or make any distribution to holders of any class of stock unless the Company first pays a special dividend or distribution of $100 per share to holders of the Series A Convertible Preferred Stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Financing Transactions &#8211; </em>On February 10, 2025, the Company entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the &#8220; February 2025 RD Offering&#8221;) at a purchase price of $1.00 per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company also agreed to issue to the same investor in a concurrent private placement warrants to purchase up to an aggregate of 4,688,000 shares of common stock (the &#8220;February 2025 Private Placement&#8221; and, together with the February 2025 RD Offering, the &#8220;February 2025 Offering&#8221;). The warrants issued in the concurrent February 2025 Private Placement will have an exercise price of $1.00 per share, will be exercisable 181 days after their issuance and will expire approximately five and a half years from the date of issuance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The gross proceeds from the February 2025 Offering totaled $4,687,786, with net proceeds after deducting the placement agent fees and offering expenses amounting to $4,309,641.&#160;The Company intends to use the net proceeds from the Offering for general corporate purposes.&#160; The Company paid the placement agents a cash fee equal to 7.0% of the aggregate gross proceeds of the February 2025 Offering. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 29, 2024, the Company entered into a securities purchase agreement (the &#8220;January 2024 Purchase Agreement&#8221;) to sell in a registered direct offering (the &#8220;January 2024 RD Offering&#8221;), an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#8220;January 2024 Private Warrants&#8221;) to purchase up to 1,831,503 shares of the Company&#8217;s common stock (the &#8220;January 2024 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;Private Offering&#8221; and together with the January 2024 RD Offering, the &#8220;January 2024 Offering&#8221;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The January 2024 Private Warrants are exercisable on the six-month anniversary of the issuance date for a period of four years from the issuance date, at an exercise price equal to $5.46 per January 2024 Private Warrant Share. The January 2024 Private Warrants are exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the January 2024 Private Warrant Shares issuable upon exercise of the January 2024 Private Warrants to or by the holder of such January 2024 Private Warrants is not in effect, on a cashless basis. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company paid the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds of the January 2024 Offering and for certain expenses and legal fees in connection with the January 2024 Offering. In addition, the Company also issued to the placement agent or its designees warrants (the &#8220;2024 Placement Agent Warrants&#8221;) to purchase up to 91,575 shares of the Company&#8217;s common stock (the &#8220;January 2024 Placement Agent Warrant Shares&#8221;) as part of the compensation payable to the placement agent. The January 2024 Placement Agent Warrants have substantially the same terms as the January 2024 Private Warrants, except that the January 2024 Placement Agent Warrants have an exercise price of $6.825 per share.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On March 14, 2024, the Company filed a registration statement on Form S-1 to register the January 2024 Private Warrants and the January 2024 Placement Agent Warrants, which registration statement was declared effective on March 28, 2024 and a prospectus was filed on the same date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The gross proceeds from the January 2024 Offering totaled $10,000,006, with net proceeds from the January 2024 Offering, after deducting the placement agent fees and offering expenses, amounting to $9,224,056. The Company intends to use the net proceeds received from the January 2024 Offering for general working capital purposes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On October 20, 2023, the Company entered into a securities purchase agreement (the &#8220;October 2023 Purchase Agreement&#8221;) with a certain institutional investor, to sell in a registered direct offering (the &#8220;October 2023 RD Offering&#8221;), an aggregate of (i) 1,325,000 shares of common stock (the &#8220;October 2023 Shares&#8221;), of the Company and (ii) pre-funded warrants (the &#8220;October 2023 Pre-Funded Warrants&#8221;) to purchase up to 1,033,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Pre-Funded Warrant Shares&#8221;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#8220;October 2023 Private Warrants&#8221;) to purchase up to 2,358,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;October 2023 Private Offering&#8221; and together with the October 2023 RD Offering, the &#8220;October 2023 Offering&#8221;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The October 2023 Private Warrants are exercisable on the six-month anniversary of issuance for a period of five and one-half years from the issuance date, at an exercise price equal to $2.12 per October 2023 Private Warrant Share. The October 2023 Private Warrants will be exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the October 2023 Private Warrant Shares issuable upon exercise of the October 2023 Private Warrants to or by the holder of such October 2023 Private Warrants is not in effect, on a cashless basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The October 2023 Pre-Funded Warrants had an exercise price of $0.0001 per October 2023 Pre-Funded Warrant Share, were exercisable upon issuance, and during the three months ended December 31, 2023, the institutional investor exercised the outstanding October 2023 Pre-Funded Warrants to purchase 1,033,491 shares of the Company&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The net proceeds from the October 2023 Offering, after deducting the placement agent fees and offering expenses, were $4,573,948.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The placement agent warrants were issued to non-employees in exchange for services related to the offering are accounted for in accordance with ASC 718 which requires the fair value of the warrants to be recognized as an offering expense. The placement agent warrants contain certain contingent cash settlement features that are not probable of occurring and not within the control of the Company, therefore the placement agent warrants are classified out of permanent equity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On January 24, 2024, the Company and warrant holders amended the terms of warrants related to the October 2023 financings. As a result, all liability classified warrants were reclassified to additional paid-in capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 11, 2025, the Company entered into a sales agreement (the &#8220;2025 Sales Agreement&#8221;) with A.G.P./Alliance Global Partners (&#8220;A.G.P.&#8221;), pursuant to which the Company may, from time to time, sell shares of the Company&#8217;s common stock at market prices by methods deemed to be an &#8220;at-the-market offering&#8221; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended(the &#8220;Securities Act&#8221;). The 2025 Sales Agreement and related prospectus is limited to sales of up to an aggregate maximum of $6.0 million of shares of the Company&#8217;s common stock. The Company pays A.G.P. 3.0% of the gross proceeds as a commission.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the three months ended March 31, 2025, a total of 413,400 shares of common stock were sold through A.G.P. under the 2025 Sales Agreement for net proceeds of $271,037 after payment of commission fees of $7,837 and other related expenses of $164,054.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the three months ended March 31, 2025, the equity distribution agreement (the &#8220;2023 Equity Distribution Agreement&#8221;) that the Company entered into with Canaccord Genuity LLC (&#8220;Canaccord&#8221;) on April 12, 2023, was terminated.&#160; The 2023 Equity Distribution Agreement and related prospectus was limited to sales, from time to time in an &#8220;at-the-market offering&#8221; (as defined in Rule 415 promulgated under the Securities Act), of up to an aggregate maximum $50.0 million of shares of the Company&#8217;s common stock. The Company paid Canaccord 3.0% of the gross proceeds as a commission.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Proceeds raised under the 2023 Equity Distribution Agreement are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Nine Months Ended&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31, 2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Cumulative from</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>inception</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Gross proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">547,803</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,744,542</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Fees</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16,434</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,336</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(126,800</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">531,369</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,565,406</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">No proceeds were raised under the 2023 Equity Distribution Agreement during the three and nine months ended March 31, 2025.&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock Warrants</em> &#8211; On December 13, 2024, the Company entered into a letter agreement (the &#8220;December 2024 Inducement Letter&#8221;) with a holder (the &#8220;December 2024 Exercising Holder&#8221;) of outstanding common stock purchase warrants that the Company issued on June 24, 2024, with an initial exercise price of $1.88, and October 24, 2023, with an initial exercise price of $2.12 (the &#8220;December 2024 Existing Warrants&#8221;). To induce the exercise of a portion of the December 2024 Existing Warrants by the December 2024 Exercising Holder, the Company agreed to adjust the exercise price of such portion of the December 2024 Existing Warrants to $0.875. Pursuant to the December 2024 Inducement Letter, the December 2024 Exercising Holder agreed to exercise, for cash, the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company&#8217;s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock (the &#8220;Series C Warrants&#8221;) and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock (the &#8220;Series D Warrants&#8221; and together with the Series C Warrants, the &#8220;December 2024 Inducement Warrants,&#8221; and the shares issuable upon exercise of the December 2024 Inducement Warrants, the &#8220;December 2024 Inducement Warrant Shares&#8221;). The Company received aggregate gross proceeds of $3,419,219 from the exercise of the December 2024 Existing Warrants by the December 2024 Exercising Holder (the &#8220;December 2024 Warrant Inducement&#8221;). The incremental value of the December 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">On June 20, 2024, the Company entered into a letter agreement (the &#8220;June 2024 Inducement Letter&#8221;) with a holder (the &#8220;June 2024 Exercising Holder&#8221;) of outstanding common stock purchase warrants that the Company issued on November 2, 2022, and October 24, 2023 (the &#8220;June 2024 Existing Warrants&#8221;). Pursuant to the June 2024 Inducement Letter, the June 2024 Exercising Holder agreed to exercise, for cash, June 2024 Existing Warrants to purchase, in the aggregate, 3,233,277 shares of common stock in exchange for the Company&#8217;s agreement to (i) lower the exercise price to $1.88 per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#8220;June 2024 Series A Warrants&#8221;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#8220;June 2024 Series B Warrants&#8221; and together with the June 2024 Series A Warrants, the &#8220;June 2024 Inducement Warrants&#8221;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the &#8220;Warrant Inducement&#8221;). As part of the agreement, 1,443,277 shares of common stock were held in abeyance on behalf of the June 2024 Exercising Holder. During the three months ended March 31, 2025, at the request of the June 2024 Exercising Holder, 1,443,277 shares were released from abeyance. The incremental value of the June 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As of March 31, 2025, the Company had outstanding warrants for shares of common stock as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares of Common</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise Price per</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Latest Expiration</strong></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Date</strong></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">May 2022 Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66,666</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">May 11, 2026</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2022 Placement Agent Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,909</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">October 31, 2027</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2023 Placement Agent Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,925</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">October 20, 2028</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Private Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,831,503</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.46</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">February 1, 2028</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Placement Agent Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">91,575</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.83</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">February 1, 2028</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 2024 Series B Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,885,632</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">June24,2029*</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series C Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,907,679</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 17, 2029</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series D Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,953,839</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">**</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 2025 Series E Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,688,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">August 12, 2030</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="11" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance and the balance expire on June 24, 2029.</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="4" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">** 1,953,839 shares expire on the five year anniversary following stockholder approval of the warrant issuance.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5" style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock Options &#8211;</em> For the three and nine months ended March 31, 2025, the Company recorded stock-based compensation related to stock options of $176,410 and $531,817, respectively. For the three and nine months ended March 31, 2024, the Company recorded stock-based compensation related to stock options of $205,176 and $615,716, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A summary of stock option activity is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average Remaining</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Term in </strong><strong>Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Aggregate Intrinsic</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,263,440</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.2</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,338</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.50</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,249,102</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6.12</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7.5</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">937,894</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10.77</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5.9</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected to vest at March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,311,208</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.6</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Stock options granted to the Company&#8217;s executive officers and employees generally vest over a 48-month period, while stock options granted to its non-employee directors vest over a 12-month period. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the outstanding options in the table above are 418,945 and 88,911 unvested performance-based stock options granted to executive officers and other employees, respectively, which were granted in June 2020, 2021, 2022 and 2023. Grants in June 2021, 2022, 2023 and 2024 were 95,167, 60,566, 238,838 and 264,945, respectively. The performance-based stock options vest on annual performance criteria through the fiscal years ending June 30, 2028 relating to advancement of MC1r programs, including initiation of clinical trials and licensing of Vyleesi in additional countries or regions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Restricted Stock Units &#8211; </em>For the three and nine months ended March 31, 2025, the Company recorded stock-based compensation related to restricted stock units of $171,281 and $513,852 respectively. For the three and nine months ended March 31, 2024, the Company recorded stock-based compensation related to restricted stock units of $185,019 and $555,057, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A summary of restricted stock unit activity is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,374,980</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Vested </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(232,941</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Expirations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,726</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,139,313</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in outstanding restricted stock units in the table above are 279,700 vested shares that have not been issued as of March 31, 2025, due to a provision in the restricted stock unit agreements to delay delivery.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Time-based restricted stock units granted to the Company&#8217;s executive officers, other employees, and non-employee directors generally vest over 48 months, 48 months, and 12 months, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the outstanding restricted stock units in the table above are 274,549 and 59,842 unvested performance-based restricted stock units granted to executive officers and other employees, respectively, which were granted in June 2021, 2022, 2023, and 2024. Grants in June 2021, 2022, 2023 and 2024 were 22,343, 40,707, 152,432 and 184,443 restricted stock units, respectively. The performance-based restricted stock units vest on annual performance criteria through the fiscal years ending June 30, 2026 relating to advancement of MC1r programs, including initiation of clinical trials, and licensing of Vyleesi in additional countries or regions</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In connection with the vesting of restricted share units during the nine months ended March 31, 2025, the Company withheld 54,691 shares, with an aggregate value of $99,482, in satisfaction of minimum tax withholding obligations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>(14) SUBSEQUENT EVENTS</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Sales Under 2025 Sales Agreement</em> &#8211; As disclosed in Note 13 above, the Company entered into the 2025 Sales Agreement. During the period from April 1, 2025 through and until May 14, 2025, the Company has sold 10,598,496 shares for gross proceeds of $2,296,532 under the at-the-market offering&#8221; pursuant to the 2025 Sales Agreement and related prospectus.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>May 2025 Public Offering</em> &#8211; On May 8, 2025, the Company completed a public offering with participation from institutional and accredited investors of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the &#8220;Series F Warrants&#8220;), Series G warrants to purchase up to 7,324,119 shares of common stock (the &#8220;Series G Warrants&#8220;), and Series H warrants to purchase up to 7,324,119 shares of common stock (the &#8220;Series H Warrants&#8220;), at a combined public offering price of $0.15 per share of common stock and accompanying warrants (the &#8220;Offering&#8220;). The Offering was made pursuant to the Company&#8217;s registration statement on Form S-1 (Registration No. 333-286280) previously filed with the SEC and declared effective on May 6, 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Series F Warrants have an exercise price of $0.30 per share, are immediately exercisable and expire on the five-year anniversary of the original issuance date, subject to the certain terms as defined in such warrant. The Series G Warrants have an exercise price of $0.15 per share, are immediately exercisable and expire on the earlier of (i) the 24-month anniversary of the original issuance date or (ii) the expiration of the FDA Exercise Period (as such term is defined in the Series G Warrant). The Series H Warrants will be issuable to the holder upon their exercise of the Series G Warrants, will have an exercise price of $0.225 per share, will be immediately exercisable upon issuance and will expire on the 24-month anniversary of its issuance date.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A.G.P. acted as lead placement agent and Laidlaw &amp; Company (UK) Ltd., as co-placement agent in the Offering. The Company paid the placement agents a cash fee equal to 7.0% of the gross proceeds raised in the Offering and reimbursed the placement agents for out-of-pocket expenses, including the reasonable fees of legal counsel, in an amount equal to $85,000.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company received aggregate net proceeds from the Offering of $931,715. The Company intends to use the net proceeds from the Offering primarily for working capital and general corporate purposes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>NYSE American Delisting</em> &#8211; On May 7, 2025, the Company announced that it has received a notice from the NYSE American LLC (&#8220;NYSE American&#8221;) stating that the NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company&#8217;s common stock. NYSE American commenced delisting proceedings in connection with the foregoing determination, and trading in the Company&#8217;s common stock was suspended on May 7, 2025. Since May 8, 2025 the Company&#8217;s common stock has traded on the Pink Market of the OTC Markets Group under the trading symbol &#8220;PTNT&#8221;. The Company has a right to a review of NYSE Regulation&#8217;s determination to delist the Company&#8217;s common stock by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. The Company is currently assessing the viability of such an appeal.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Principles of Consolidation</em> &#8211; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Cash, Cash Equivalents</em> &#8211; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $2,097,618 and $9,089,113 in a money market account at March 31, 2025 and June 30, 2024, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Fair Value of Financial Instruments</em> &#8211; The Company&#8217;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Credit Risk</em> &#8211; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Impairment of Long-Lived Assets</em> &#8211; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Leases</em> - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#8217;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#8217;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock', window );">Revenue Recognition (Prior to the sale of Vyleesi)</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition (Prior to the sale of Vyleesi)</em> &#8211; The Company recognized product revenues in accordance with FASB ASC Topic 606, <em>Revenue from Contracts with Customers</em>. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligations were satisfied by transferring control of the product to a customer. Per the Company&#8217;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Gross product sales offset by product sales allowances for the three and nine months ended March 31, 2025 and 2024 are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended March 31</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Nine Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,875,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Product sales allowances and accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,735,063</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,140,090</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Revenue Recognition &#8212;</em>&#8211; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company determines if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the non-refundable, upfront license fees will be recognized over time, the Company assesses the appropriate method of measuring proportional performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Research and Development Costs</em> &#8211; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AccruedLiabilitiesPolicyTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Accrued Expenses &#8211;</em> Third parties perform a significant portion of the Company&#8217;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Stock-Based Compensation &#8211; </em>The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#8217;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Income Taxes</em> &#8211; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Net Loss per Common Share </em>&#8211;<em> </em>Basic and diluted loss per common share (&#8220;EPS&#8221;) are calculated in accordance with the provisions of FASB ASC Topic 260, <em>Earnings per Share</em>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For the three months ended March 31, 2025 and 2024, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three and nine months ended March 31, 2025 and 2024 were 17,749,116 and 8,520,332, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of March 31, 2025 and 2024 due to a provision in the restricted stock unit agreements to delay delivery.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of foreign currencies</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Translation of foreign currencies </em>&#8211; Transactions denominated in currencies other than the Company&#8217;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AccruedLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AccruedLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfSalesTableTextBlock', window );">Schedule of sales</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended March 31</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Nine Months Ended March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Gross product sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,875,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Product sales allowances and accruals</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,735,063</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,140,090</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfSalesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfSalesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,118</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23,926</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Insurance premiums</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95,327</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,097</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">301,733</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,249</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">442,178</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">242,272</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value asset measurement</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Carrying Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Quoted prices in </strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>active markets</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(Level 1)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Other quoted/observable inputs (Level 2)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Significant unobservable inputs</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(Level 3)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">March 31, 2025:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,097,618</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,097,618</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 30, 2024:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Cash equivalents - Money market funds</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9,089,113</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schdule of Accrued Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2025</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Clinical / regulatory costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">378,592</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,509,797</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other research related expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,509</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">65,972</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Professional Services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,040</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">284,215</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Personnel costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,771,694</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Selling expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">351,485</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,319</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">201,883</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">506,460</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,185,046</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock', window );">Schedule of inventory purchase commitments</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Current</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>1 - 3 Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>4 - 5 Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Inventory purchase commitments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,101,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,101,800</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfEquityDistributionAgreementTableTextBlock', window );">Equity Distribution Agreement</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Nine Months Ended&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>March 31, 2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Cumulative from</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>inception</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Proceeds</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Gross proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">547,803</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,744,542</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Fees</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16,434</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(52,336</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Expenses</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(126,800</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Net proceeds</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,027</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">531,369</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">721,061</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,565,406</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock', window );">Outstanding Stock Purchase Warrants</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Shares of Common</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise Price per</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Latest Expiration</strong></p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Stock</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Date</strong></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">May 2022 Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">66,666</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">May 11, 2026</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2022 Placement Agent Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,909</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">October 31, 2027</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">October 2023 Placement Agent Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,925</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">October 20, 2028</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Private Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,831,503</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.46</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">February 1, 2028</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">January 2024 Placement Agent Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">91,575</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.83</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">February 1, 2028</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">June 2024 Series B Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,885,632</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">June24,2029*</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series C Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,907,679</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">December 17, 2029</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">December 2024 Series D Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,953,839</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">**</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">February 2025 Series E Warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,688,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;">August 12, 2030</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="11" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance and the balance expire on June 24, 2029.</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="4" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">** 1,953,839 shares expire on the five year anniversary following stockholder approval of the warrant issuance.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="5" style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Option activity</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average Remaining</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Term in </strong><strong>Years</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Aggregate Intrinsic</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,263,440</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.11</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.2</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,338</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4.50</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding - March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,249,102</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6.12</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7.5</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Exercisable at March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">937,894</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10.77</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5.9</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Expected to vest at March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,311,208</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.80</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.6</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Stock Units</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,374,980</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Vested </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(232,941</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt">Expirations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,726</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Outstanding at March 31, 2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,139,313</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfEquityDistributionAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfEquityDistributionAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OrganizationAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (456,844,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (456,844,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (441,766,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,811,420)<span></span>
</td>
<td class="num">$ (8,435,650)<span></span>
</td>
<td class="num">(15,077,551)<span></span>
</td>
<td class="num">$ (21,485,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SalesBasedMilestonePayments', window );">Sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,520,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">$ 10,048,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,048,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,657,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OrganizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OrganizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,140,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_RevenuesGross', window );">Gross product sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,875,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ProductSalesAllowancesAndAccruals', window );">Product sales allowances and accruals</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,735,063)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,140,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ProductSalesAllowancesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ProductSalesAllowancesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_RevenuesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_RevenuesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential number of common shares excluded from diluted EPS</a></td>
<td class="nump">17,749,116<span></span>
</td>
<td class="nump">8,520,332<span></span>
</td>
<td class="nump">17,749,116<span></span>
</td>
<td class="nump">8,520,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock', window );">Weighted average vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,700<span></span>
</td>
<td class="nump">279,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents - Money market funds</a></td>
<td class="nump">$ 2,097,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,097,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,089,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AssetPurchaseAgreementAbstract', window );"><strong>ASSET PURCHASE AGREEMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfOtherAssets1', window );">Payable the settlement of certain purchase commitments</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivablePurchase', window );">Acounts receiveble</a></td>
<td class="nump">171,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PaymentsToSalesBasedMilestonePayments', window );">Sales-based milestone payments</a></td>
<td class="nump">159,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Upfront purchase price amount</a></td>
<td class="nump">$ 9,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AssetPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AssetPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PaymentsToSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PaymentsToSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivablePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase from purchase of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivablePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfOtherAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid to purchase other assets as part of operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPurchaseOfOtherAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalDeferredPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalDeferredPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH FOSUN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 06, 2017</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithFosunAbstract', window );"><strong>AGREEMENT WITH FOSUN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits', window );">Company License Agreement Recievables</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Upfront Payments</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UpfrontPaymentOfLess', window );">Upfront payment of less</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithFosunAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithFosunAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UpfrontPaymentOfLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UpfrontPaymentOfLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for current or future transactions, initial payment of the cost of an acquisition or for the right to enter into a contract or agreement, (c) the increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable, or (d) some combination of (a), (b), and (c).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AGREEMENT WITH KWANGDONG (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 06, 2017</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AgreementWithKwangdongAbstract', window );"><strong>AGREEMENT WITH KWANGDONG</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Recievable under company agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Upfront payments</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_taxexpenses', window );">Tax Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireReceivables', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AgreementWithKwangdongAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AgreementWithKwangdongAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_taxexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_taxexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of all receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PrepaidClinicalStudyCosts', window );">Clinical / regulatory costs</a></td>
<td class="nump">$ 45,118<span></span>
</td>
<td class="nump">$ 23,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PrepaidInsurancePremiums', window );">Insurance premiums</a></td>
<td class="nump">95,327<span></span>
</td>
<td class="nump">71,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">301,733<span></span>
</td>
<td class="nump">147,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 442,178<span></span>
</td>
<td class="nump">$ 242,272<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PrepaidClinicalStudyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PrepaidClinicalStudyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PrepaidInsurancePremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PrepaidInsurancePremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents - Money market funds</a></td>
<td class="nump">$ 2,097,618<span></span>
</td>
<td class="nump">$ 9,089,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents - Money market funds</a></td>
<td class="nump">2,097,618<span></span>
</td>
<td class="nump">9,089,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents - Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents - Money market funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AccruedClinicalRegulatoryCosts', window );">Clinical / regulatory costs</a></td>
<td class="nump">$ 378,592<span></span>
</td>
<td class="nump">$ 1,509,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OtherAccruedResearchRelatedExpenses', window );">Other research related expenses</a></td>
<td class="nump">40,509<span></span>
</td>
<td class="nump">65,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">55,040<span></span>
</td>
<td class="nump">284,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AccruedPersonalCost', window );">Personal cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,771,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AccruedSellingExpenses', window );">Selling expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">351,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">32,319<span></span>
</td>
<td class="nump">201,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 506,460<span></span>
</td>
<td class="nump">$ 4,185,046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AccruedClinicalRegulatoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AccruedClinicalRegulatoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AccruedPersonalCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AccruedPersonalCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AccruedSellingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AccruedSellingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OtherAccruedResearchRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OtherAccruedResearchRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">$ 2,101,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_CurrentMember', window );">Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">2,101,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_OneToThreeYearsMember', window );">1 - 3 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_FourToFiveYearsMember', window );">4 - 5 Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Inventory purchase commitments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_CurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_CurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_OneToThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_OneToThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_FourToFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_FourToFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 1,576,350<span></span>
</td>
<td class="nump">$ 944,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,032,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityGrossProceedsShares', window );">Equity Gross proceeds, Shares | shares</a></td>
<td class="nump">217,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Equity Gross proceeds, Proceeds</a></td>
<td class="nump">$ 547,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Equity Fees, Proceeds</a></td>
<td class="num">(16,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityExpensesProceeds', window );">Equity Expenses, Proceeds</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsShares', window );">Equity Net proceeds, Shares | shares</a></td>
<td class="nump">217,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsProceeds', window );">Equity Net proceeds, Proceeds</a></td>
<td class="nump">$ 531,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_CumulativeFromInceptionMember', window );">Cumulative From Inception</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityGrossProceedsShares', window );">Equity Gross proceeds, Shares | shares</a></td>
<td class="nump">721,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Equity Gross proceeds, Proceeds</a></td>
<td class="nump">$ 1,744,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Equity Fees, Proceeds</a></td>
<td class="num">(52,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityExpensesProceeds', window );">Equity Expenses, Proceeds</a></td>
<td class="nump">$ 126,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsShares', window );">Equity Net proceeds, Shares | shares</a></td>
<td class="nump">721,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityNetProceedsProceeds', window );">Equity Net proceeds, Proceeds</a></td>
<td class="nump">$ 1,565,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityExpensesProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityExpensesProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityGrossProceedsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityGrossProceedsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityNetProceedsProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityNetProceedsProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityNetProceedsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityNetProceedsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_CumulativeFromInceptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_CumulativeFromInceptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details 1)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_DecemberToZeroTwoFourSeriesDWarrantsMember', window );">December 2024 Series D Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">1,953,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 0.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_MayTwoThousandTwentyTwoWarrantsMember', window );">May 2022 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">66,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 12.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">May 11, 2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember', window );">October 2022 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">90,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 6.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">October 31, 2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember', window );">October 2023 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">117,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 2.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">October 20, 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember', window );">January 2024 Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">1,831,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">February 1, 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember', window );">January 2024 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">91,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 6.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">February 1, 2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember', window );">June 2024 Seris B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">1,885,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">June24,2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember', window );">December 2024 Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">3,907,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 0.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">December 17, 2029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember', window );">February 2025 Series E Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock | shares</a></td>
<td class="nump">4,688,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisePricePerShareWarrantsOutstanding', window );">Exercise Price per Share | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_LatestTerminationDate', window );">Latest Termination Date</a></td>
<td class="text">August 12, 2030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ExercisePricePerShareWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ExercisePricePerShareWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_LatestTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_LatestTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_DecemberToZeroTwoFourSeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_DecemberToZeroTwoFourSeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_MayTwoThousandTwentyTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_MayTwoThousandTwentyTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details 2)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance', window );">Number of Options Outstanding, Beginning | shares</a></td>
<td class="nump">2,263,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01', window );">Number of Options Expired | shares</a></td>
<td class="num">(14,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance', window );">Number of Options Outstanding, Ending | shares</a></td>
<td class="nump">2,249,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A', window );">Number of Options Exercisable | shares</a></td>
<td class="nump">937,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance', window );">Number of Options Expected to vest | shares</a></td>
<td class="nump">1,311,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 6.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">4.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">6.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable</a></td>
<td class="nump">10.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice', window );">Weighted Average Exercise Price Options Expected to vest</a></td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Term in Years Options outstanding at beginning of year</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Term in Years Options outstanding at end of year</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Term in Years Options exercisable at end of year</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Term in Years Options Expected to vest</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Options Expected to vest | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Options Expected to outstanding | $</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable', window );">Aggregate Intrinsic Value Options Exercisable | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details 3) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract', window );"><strong>STOCKHOLDERS DEFICIENCY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">1,374,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">264,945<span></span>
</td>
<td class="nump">238,838<span></span>
</td>
<td class="nump">60,566<span></span>
</td>
<td class="nump">95,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_RestrictedStockVestedInPeriod', window );">Vested</a></td>
<td class="num">(232,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Expirations</a></td>
<td class="num">(2,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber', window );">Outstanding at ending of year</a></td>
<td class="nump">1,139,313<span></span>
</td>
<td class="nump">1,374,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_RestrictedStockVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_RestrictedStockVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS DEFICIENCY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th"><div>Dec. 13, 2024</div></th>
<th class="th"><div>Apr. 12, 2023</div></th>
<th class="th"><div>Jun. 20, 2024</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th"><div>Oct. 20, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityIssuanceCostsPercentage', window );">Cash fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_OfferingExpensesAmount', window );">Offering expenses</a></td>
<td class="nump">$ 4,309,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits', window );">Stock-based compensation related to restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,281<span></span>
</td>
<td class="nump">$ 185,019<span></span>
</td>
<td class="nump">$ 513,852<span></span>
</td>
<td class="nump">$ 555,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_NumberOfOutstandingSharesOfRestrictedStockUnits', window );">Number of outstanding shares of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits', window );">Unvested performance-based stock options granted estricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,549<span></span>
</td>
<td class="nump">59,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU', window );">Restricted stock units number of shares outstanding granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,443<span></span>
</td>
<td class="nump">152,432<span></span>
</td>
<td class="nump">40,707<span></span>
</td>
<td class="nump">22,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares', window );">Withholding taxes related to restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock-based compensation to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,410<span></span>
</td>
<td class="nump">205,176<span></span>
</td>
<td class="nump">$ 531,817<span></span>
</td>
<td class="nump">$ 615,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_UnvestedPerformanceBasedStockOptionsGranted', window );">Unvested performance-based stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,945<span></span>
</td>
<td class="nump">88,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of shares outstanding granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,945<span></span>
</td>
<td class="nump">238,838<span></span>
</td>
<td class="nump">60,566<span></span>
</td>
<td class="nump">95,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun', window );">Withholding taxes related to restricted stock units, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,573,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,224,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantIssuanceShares', window );">Warrant issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,624,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantIssuance', window );">Warrant issuance year five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,953,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_DescriptionOfSecuritiesPurchaseAgreement', window );">Description of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2025 Sales Agreement and related prospectus is limited to sales of up to an aggregate maximum of $6.0 million of shares of the Company&#8217;s common stock. The Company pays A.G.P. 3.0% of the gross proceeds as a commission<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">an aggregate of (i) 1,325,000 shares of common stock (the &#8220;October 2023 Shares&#8221;), of the Company and (ii) pre-funded warrants (the &#8220;October 2023 Pre-Funded Warrants&#8221;) to purchase up to 1,033,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Pre-Funded Warrant Shares&#8221;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#8220;October 2023 Private Warrants&#8221;) to purchase up to 2,358,491 shares of the Company&#8217;s common stock (the &#8220;October 2023 Private Warrant Shares&#8221;) in a concurrent private placement (the &#8220;October 2023 Private Offering&#8221; and together with the October 2023 RD Offering, the &#8220;October 2023 Offering&#8221;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_DistributableValueOfDividendPerShare', window );">Distributable value of dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock share purchased</a></td>
<td class="nump">4,688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,831,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from Offering</a></td>
<td class="nump">$ 4,687,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds from exercise of Existing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,398,237<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,457,520<span></span>
</td>
<td class="nump">14,693,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 696,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ptn_StockWarrantsMember', window );">Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PurchaseOfWarrantOfCommonStockSeriesA', window );">Purchase of warrant of common stock series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,907,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,849,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_WarrantsToPurchaseShares', window );">Warrants to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,953,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,233,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds from exercise of Existing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,419,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,078,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_DescriptionOfExistingHolderPurchaseOfWarrants', window );">Description of existing holder purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company agreed to adjust the exercise price of such portion of the December 2024 Existing Warrants to $0.875. Pursuant to the December 2024 Inducement Letter, the December 2024 Exercising Holder agreed to exercise, for cash, the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company&#8217;s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock (the &#8220;Series C Warrants&#8221;) and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock (the &#8220;Series D Warrants&#8221; and together with the Series C Warrants, the &#8220;December 2024 Inducement Warrants,&#8221; and the shares issuable upon exercise of the December 2024 Inducement Warrants, the &#8220;December 2024 Inducement Warrant Shares&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) lower the exercise price to $1.88 per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#8220;June 2024 Series A Warrants&#8221;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#8220;June 2024 Series B Warrants&#8221; and together with the June 2024 Series A Warrants, the &#8220;June 2024 Inducement Warrants&#8221;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the &#8220;Warrant Inducement&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_ExercisingHolderReleasedShares', window );">Exercising holder released shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,443,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock share purchased</a></td>
<td class="nump">4,688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptn_PrivateWarrantSharesMember', window );">Private Warrant Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock share purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,831,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptn_TwoThousandTwentyFiveSalesAgreementMember', window );">2025 Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock share purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Payment of commission fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 164,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember', window );">2024 Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_SharesOfCommonStock', window );">Shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ptn_ConvertibleSeriesAPreferredStocksMember', window );">Convertible Series A Preferred Stocks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock were outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_AggregateValue', window );">Aggregate value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare', window );">Convertible shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAvailableForDistributions', window );">Distributable value of dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_DividendAdditionalPerShare', window );">Distributable value of dividend additional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ptn_TwentyTwentyThreeEquityDistributionAgreementMember', window );">2023 Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_PurchaseOfWarrantShares', window );">Purchase of warrant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,033,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_AggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_AggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_DescriptionOfExistingHolderPurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_DescriptionOfExistingHolderPurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_DescriptionOfSecuritiesPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_DescriptionOfSecuritiesPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_DistributableValueOfDividendPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_DistributableValueOfDividendPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_DividendAdditionalPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_DividendAdditionalPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityIssuanceCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityIssuanceCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ExercisingHolderReleasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ExercisingHolderReleasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_NumberOfOutstandingSharesOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_NumberOfOutstandingSharesOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_OfferingExpensesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_OfferingExpensesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PurchaseOfWarrantOfCommonStockSeriesA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PurchaseOfWarrantOfCommonStockSeriesA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_PurchaseOfWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_PurchaseOfWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_SharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_SharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UnvestedPerformanceBasedStockOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UnvestedPerformanceBasedStockOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantIssuanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantIssuanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WarrantsToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WarrantsToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAvailableForDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash eligible for distribution to members or limited partners of limited liability company (LLC) or limited partnership (LP), subject to reserves to be maintained as defined in operating or partnership agreement, or in a credit facility agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAvailableForDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ptn_StockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ptn_StockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptn_PrivateWarrantSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptn_PrivateWarrantSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptn_TwoThousandTwentyFiveSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptn_TwoThousandTwentyFiveSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_ConvertibleSeriesAPreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_ConvertibleSeriesAPreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ptn_TwentyTwentyThreeEquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ptn_TwentyTwentyThreeEquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 08, 2025</div></th>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th"><div>May 14, 2025</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Oct. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityIssuanceCostsPercentage', window );">Cash fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,831,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,457,520<span></span>
</td>
<td class="nump">$ 14,693,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,687,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ptn_TwoThousandTwentyFiveSalesAgreementMember', window );">2025 Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_EquityIssuanceCostsPercentage', window );">Cash fee, percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptn_DescriptionOfPublicOffering', window );">May 2025 Public Offering, Description</a></td>
<td class="text">public offering with participation from institutional and accredited investors of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the &#8220;Series F Warrants&#8220;), Series G warrants to purchase up to 7,324,119 shares of common stock (the &#8220;Series G Warrants&#8220;), and Series H warrants to purchase up to 7,324,119 shares of common stock (the &#8220;Series H Warrants&#8220;), at a combined public offering price of $0.15 per share of common stock and accompanying warrants (the &#8220;Offering&#8220;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from Offering</a></td>
<td class="nump">$ 931,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series F Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series G Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2025 Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,598,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,296,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_DescriptionOfPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_DescriptionOfPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptn_EquityIssuanceCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptn_EquityIssuanceCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ptn_TwoThousandTwentyFiveSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ptn_TwoThousandTwentyFiveSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesFWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_SeriesFWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ptn_SeriesGWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ptn_SeriesGWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  R(KEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    (  R(KEI4E ^*\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    (  R(KEK ^1^KS 4  +X>   8
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M'F5?-XSZ3.@;U/45Y_)TH'^@V+(>_ =02P,$%     @ #(BN6MJ(K03E!0
M[!@  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6RMF6V/HS80Q[^*E9[Z
M("4;VQ@;MME(=ZFJMNKI5I=>^Z+J"R]Q-N@ Y[#9O>VGKTTX2+ AN2HO=@-D
M9OB/&?OG(8MG67Y4.R$T^)QGA;J;[+3>W\[G*MF)G*L;N1>%^68KRYQK<UH^
MSM6^%'Q3.^79'$-(YSE/B\ER45^[+Y<+6>DL+<1]"525Y[Q\>2,R^7PW09,O
M%]ZGCSMM+\R7BSU_%&NA/^SO2W,V;Z-LTEP4*I4%*,7V;O(:W:YP;!UJBS]3
M\:R.CH%-Y4'*C_;DU\W=!%I%(A.)MB&X^7@2*Y%E-I+1\:D).FGO:1V/C[]$
M_[E.WB3SP)58R>RO=*-W=Y-H C9BRZM,OY?/OX@FH=#&2V2FZO_@N;&%$Y!4
M2LN\<38*\K0X?/+/S4 <.2 RX( ;!WRI0] X!'6B!V5U6C]QS9>+4CZ#TEJ;
M:/:@'IO:VV23%O8QKG5IODV-GUZN9*%DEFZX%AOPAF>\2 18VW *S,"']4_@
M^U<_+.;:W,HZS),F[)M#6#P0]BTO;T" I@!#''K<5^/NOU6%<8>U.SEUGYL$
MVRQQFR6NXP5#659E*0H-N%(FL5M?/H< Q!_ 3J9;M>>)N)N8V:)$^20FRV^_
M013^Z,ON2L%.<@W:7(.QZ,L55SO BPU([('X5*5//#/)*U_6AU"T#F5G_-,2
MAW8%P(OYTW%"KET<8A;$M+4[T4I:K614ZSN]$^5[D0BC\2$3JGE./J6'0.&Q
M4H9@P'I"73/HEQBV$L-1B?>EV/-T \1GLW(JH>JAE5:WF9['5>43'3IJ",&(
M13W1KADF&#/L5TY;Y714^1]2\^P"D=2Y>X"# +/^T+IV,:,QI9%?)FMELC,#
M;)A4ZI=Z8&VY[@TE]!04PEL'S%&!(DR<.G#-@B@**/)KC5JMT:C6FG(SN9U5
M2C0C:E9)JY_KM'@$F3!$\0YRY#[B,(QHT)/MFMEIA@=DQZWL^/PT&ZF V+TK
MC1'M:3MG=2(-P0Y \((R'1;7N)\\2H8C$O?'SF.((#,3B0YI/((DNH@?6<H?
MTBS5J?!#I ES)8I<*]IITATST2BFEJ^31%:&&V#/7^SJ[$T8.V/.&(,A[<]'
MCR%!$,4X'G@V'>[0..^,S+(2W0+ME1FXM0LIH;"OTK4C* HA&:J@#G1HG'3K
MG2SU3(LR[R\7QT7EU>XB#<4D9GU$>^R""(9D@"*H R :)^"1]&U:U!O$RX2[
M6'/&VP-("A$9D-R1#XVC[]T)G\_I=,&&0D:#T%'K(2 A*!S88:".@&@<@:>D
M/B?70T (2120N*_7M8RIR2P:P GJ,(C&.?B[+![_7S&[@*,,D_Z&R&.&:,"B
MH5KN0(@N(6'6RC\GUV6>4Q2NB=F6X@ .5 7NP(@O >,9A=@'/83",.ZOP%[+
M* S8T2;D5&F'1SR.Q[66R<>=S#:B5-_9)CI-4E$D+_Y&ZZJ,O%:TT\R/^LIQ
M1JYDGLL"*#L 0&[!*W@#D0%F"4S350FS.>25-NMG^J\AE*F)*3S\ ;7C1L\M
M2)6R\*J;BDHK;0[L9,+1- S9%!/:6)H-DHUO^NIDUS;6M1MBTQC3*27PU-3T
MT&*@AVX>A(MD')F[]L'BL4,L'MQ5X8[<^ RY-YO4OLLQ56Y;K%E:F)YUGYJJ
M]\KUL#F$B*$@"ON*/:8$$18RP@9$=R#'XR WVXTJK[+Z?<FATKUM"G9I/",A
MC8C=]?3E^FP)8I2&0VS!';WQ.+T/JX@:F*%>Z2Z49S2(3+=-^L(]E@@A$@^-
M<@=P?$GO>K3VU:7^55EXVEIOV^ Q'&\;<,=U/,[UM2BM]-=@)8LGT^.F9A<-
M[DNQ%8;T&U OFPK\_5;D#Z+\QYO%Z V^>K&\4K33X>AV#3BZ(B9&=R!?G?F5
MHIUFWFT[\/BVPU<(M\=H(%,8P+&E?I 49SUKC_,PB)TW?*2_U1FW.0S-_.A5
MM/T=P&AY3 ME=H=;XP1OF)EGY>'5^N%$RWW]=OI!:BWS^G GN"D1:V"^WTJI
MOYS8%][M#QS+_P!02P,$%     @ #(BN6A91/N7S @  H H  !@   !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6RUEEUOVC 4AO^*E4W3)G7D@WQ !Y%:IJF;
M5 D5;;N8=F&2 ['JQ)GM0+=?/SM)4U("@6KC NSDO*^?<X+C,]DR?B\2 (D>
M4IJ)J9%(F5^:IH@22+$8L!PR=6?%>(JEFO*U*7(.."Y%*34=R_+-%)/,""?E
MM3D/)ZR0E&0PYT@4:8KY[VN@;#LU;./QPAU9)U)?,,-)CM>P /DUGW,U,QN7
MF*20"<(RQ&$U-:[LRYE="LJ(;P2V8F>,="I+QN[UY',\-2Q-!!0BJ2VP^MG
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M0KH$_K,KA:/^^FR^%#F.8&JHPU< WX 1OGEE^]:'KC?C/S)KE6+<E&+\'UY
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MAS6S*>7'NJFR3?NM;H/L[(NLJ745IG5V:879!%MY(')S*CB8 6WZC&R"Q9;
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MR2@SS_4RN-"&N0,%\1FM;7*13QPN#D>B"!V=USH75#?F0:Q!A2;-+,%E0.B
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M9PVM"R3?@Y^E@2@X,"T.<*L.+O\%W)_PQ9I0>?C+2)0_YZ<D;="7]_I6^4G
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MQ65%)S\Z#J#[K+3?,,'P7V+Q+U!+ P04    "  ,B*Y:-IWE.& %  "(#
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MBMBXJIPC-I\D-IT)F?7![_3(;J#=&56^259CNGF20*,=64?+&D)KL=]0+.2
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M?.!*#[DU2[U549@ _;[F7.T=DV#8T[-?4$L#!!0    (  R(KEJ>G#50W0,
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M@OKG:>* [+9%YVBQLQ-Z*S3-NS5+6K H30#=;X30!\<D&%;V[#=02P,$%
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ML[9-2T)PP;]K!<,@;I.2-H1"=*%OHZ2(]<2$5O+LN>6/G5'+MH,X5_&*S;&
MFFF)%@^5)!7O")D"2ZM4AMC6=)>D;.$%/F'5-O6=#%9];&?D)C+;$OM"_56
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M,!#^*R<V3:W$"N&E2;L$*<G:#FEY49-NVD<'+@'5V,PV3??O9T/"4HGFRX2
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M%IJZNUGF-$Y1F@#ZOA%"'S<F03^@D[]02P,$%     @ #(BN6OH02"), @
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M\_P$PN>?C-7H8*(MA%K;N5V35-:E:8;;[FGW:7#53,3[X\UW!>A=0\F27*Q
M%#(,_5<ULWJS,;*R\_%"&IBV[7(#GS="X0%XOY+2[#:HH/M@&O\+4$L#!!0
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M09!#+!0#EH\-#"'/%9&4\:/FM)J2"KB_WK'?:._2RQ)S&-+\D20BZUN?+91
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M3-1-!+@N4/,+QN1S1Q]V]=TF_@=02P,$%     @ #(BN6F+?ME?> @  H @
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M7^[&+#)F>LEO,S].PM0;V=O#1-TR-W32.(W;NB>P00L;#,+^4 4(HB>!BKS
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MMW7=QDA43:(*%"]MG<VYTE5KIYGNJR!,@MY?<:[V@2G=IE/'?P!02P,$%
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M@>)%2[TX$&R3M[$?F1 LR7?7E"PH5S?(ZTO&Q.N!FJ#ZQ\;X?U!+ P04
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M0\0A7?1U?H_>W+Q%-\A&8DTYB.)B\.26^7 S3^YE^6C*06[(:S:D5].MV-
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M*D!>7U(J7CMJ@O:/BN0_4$L#!!0    (  R(KEJPEO>K?Q4  +P5 0 9
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M0-Q'[_0Z'?2N:O)4Z7ZBN 'MUN1T.QJ.)_I([J87=!PZ5'.@F@O5/*CF0[4
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M>O/E1KZ1GM9EN5[67[Z2=$[R:@'Z^^?UNMQ_4W7POL[_K#?__C]02P,$%
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MB@'"N7* @-820&DFE&9!:3:4YD!I+I3F06D^BM;\Q[1]Y8$JKSRX/$#4@.8
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MU?MFJH4\79=O%GE.\SR-RX]+%LP8+S80W\_3--\N% %V;_UY^!=02P,$%
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M-DVDVS)^+4B]_QJZ_Y+[\1=02P,$%     @ #(BN6K@VQ-RI 0  +AL  !H
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M!(6L"0I9$Q2R)BAD3?Z3K.]:K_[Z-T^[QK4JFZ,_Z_ZES3\!4$L! A0#%
M  @ #(BN6D;'34B5    S0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  ,B*Y:5)0/BO(    K @  $0
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M=#(N>&UL4$L! A0#%     @ #(BN6A91/N7S @  H H  !@
M ("!0A0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (  R(
MKEJG4-S>808  / :   8              " @6L7  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    "  ,B*Y:Y.8,^BD+  ! 50  &
M        @($"'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ #(BN6@U'UR_^!P  0"$  !@              ("!82D  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  R(KEJ":M@520(  *<&   8
M              " @94Q  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    "  ,B*Y:+NJP#P\)  !*%0  &               @($4-   >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ #(BN6F?7!^@"!
M9@D  !@              ("!63T  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    (  R(KEK\,@4?/@H  #$:   9              " @9%!
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ #(BN6J2Y
M$AJD P  5P@  !D              ("!!DP  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    "  ,B*Y:-IWE.& %  "(#   &0
M    @('A3P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M  R(KEK1O0UO* ,  &H'   9              " @7A5  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ #(BN6F15COMM P  ?P<  !D
M             ("!UU@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    "  ,B*Y:PIGS''X#  "_!P  &0              @(%[7   >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  R(KEI/GI;0>P(
M +,%   9              " @3!@  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ #(BN6IZ<-5#= P  1@D  !D              ("!
MXF(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  ,B*Y:
M-+$X 9X"  "^!0  &0              @('V9@  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    (  R(KEI+'B[\W 0  .@*   9
M      " @<MI  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ #(BN6MC6:&)/$0  )3X  !D              ("!WFX  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  ,B*Y:,7\&[#H$   7"@
M&0              @(%D@   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    (  R(KEJ@=X@1-@L  '4B   9              " @=6$  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ #(BN6G@ASNI[
M @  I04  !D              ("!0I   'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    "  ,B*Y:,+2%%94"  "*!0  &0
M@('TD@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  R(
MKEJ"//0:I (  /H%   9              " @<"5  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ #(BN6ET7XKVI @  K 4  !D
M         ("!FY@  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    "  ,B*Y:^A!((DP"   V!0  &0              @(%[FP  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (  R(KEK7\;?W/P4  #P-
M   9              " @?Z=  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ #(BN6GINDWJ" P  Y X  !D              ("!=*,
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  ,B*Y:BJ.6
MV/\"  !E"@  &0              @($MIP  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    (  R(KEH:+XN'6P,  #P,   9
M  " @6.J  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M#(BN6G>#VU"7 @  6 8  !D              ("!]:T  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    "  ,B*Y:+RH=NY$"   I!P  &0
M            @('#L   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    (  R(KEIT/85GN@(  /0'   9              " @8NS  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ #(BN6BE@CZVO @
M$0<  !D              ("!?+8  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    "  ,B*Y:53#@5Y$"  #G"   &0              @(%B
MN0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  R(KEIB
MW[97W@(  * (   9              " @2J\  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ #(BN6C/VD(Q= @  [ 8  !D
M     ("!/[\  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M"  ,B*Y:\W'CI4@"  "U!0  &0              @('3P0  >&PO=V]R:W-H
M965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (  R(KEHJOI_F%0,  )(*   9
M              " @5+$  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L!
M A0#%     @ #(BN6J]$"3^_!   Y!@  !D              ("!GL<  'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  ,B*Y:PC"8ZR8$
M   ($0  &0              @(&4S   >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;%!+ 0(4 Q0    (  R(KEJSDSQ<; ,  +00   9              "
M@?'0  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ #(BN
M6K"6]ZM_%0  O!4! !D              ("!E-0  'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    "  ,B*Y:ASBLX84'   !2   &0
M        @(%*Z@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   (  R(KEH'1_-(+@,  ! 3   -              "  0;R  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ #(BN6I>*NQS     $P(   L
M ( !7_4  %]R96QS+RYR96QS4$L! A0#%     @ #(BN6KY<?7(9!   31X
M  \              ( !2/8  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M  R(KEJX-L3<J0$  "X;   :              "  8[Z  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  R(KEI3V2LIL@$  %,;   3
M              "  6_\  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     U
- #4 :@X  %+^      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>116</ContextCount>
  <ElementCount>259</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>33</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>110200 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>110201 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>124100 - Statement - Consolidated Statements of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>148600 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>170000 - Statement - Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995446 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ORGANIZATION</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995447 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995448 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995449 - Disclosure - New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/NewAccountingPronouncements</Role>
      <ShortName>New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995450 - Disclosure - ASSET PURCHASE AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AssetPurchaseAgreement</Role>
      <ShortName>ASSET PURCHASE AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995451 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi</Role>
      <ShortName>MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995452 - Disclosure - AGREEMENT WITH FOSUN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithFosun</Role>
      <ShortName>AGREEMENT WITH FOSUN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995453 - Disclosure - AGREEMENT WITH KWANGDONG</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithKwangdong</Role>
      <ShortName>AGREEMENT WITH KWANGDONG</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995454 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995455 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995456 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995457 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995458 - Disclosure - STOCKHOLDERS DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiency</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995459 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995460 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://ptn.com/role/NewAccountingPronouncements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995461 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995462 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995463 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995464 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/AccruedExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995465 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995466 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyTables</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiency</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995467 - Disclosure - ORGANIZATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/OrganizationDetailsNarrative</Role>
      <ShortName>ORGANIZATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/ORGANIZATION</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995468 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995469 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995470 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative</Role>
      <ShortName>ASSET PURCHASE AGREEMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AssetPurchaseAgreement</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995471 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithFosunDetailsNarrative</Role>
      <ShortName>AGREEMENT WITH FOSUN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AgreementWithFosun</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995472 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AgreementWithKwangdongDetailsNarrative</Role>
      <ShortName>AGREEMENT WITH KWANGDONG (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AgreementWithKwangdong</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995473 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995474 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995475 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/AccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/AccruedExpensesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995476 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995477 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995478 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995479 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails1</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995480 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails2</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995481 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetails3</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995482 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/StockholdersDeficiencyDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS DEFICIENCY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/StockholdersDeficiencyTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ptn_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995483 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ptn.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ptn.com/role/SubsequentEvents</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ptn-20250331.xsd</File>
    <File>ptn-20250331_cal.xml</File>
    <File>ptn-20250331_def.xml</File>
    <File>ptn-20250331_lab.xml</File>
    <File>ptn-20250331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ptn_10q.htm">ptn_10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ptn_10qimg18.jpg</File>
    <File>ptn_10qimg19.jpg</File>
    <File>ptn_10qimg20.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="416">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>67
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ptn_10q.htm": {
   "nsprefix": "ptn",
   "nsuri": "http://ptn.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "ptn-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ptn-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptn-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ptn-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptn-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ptn_10q.htm"
     ]
    }
   },
   "keyStandard": 176,
   "keyCustom": 83,
   "axisStandard": 9,
   "axisCustom": 0,
   "memberStandard": 9,
   "memberCustom": 24,
   "hidden": {
    "total": 28,
    "http://xbrl.sec.gov/ecd/2024": 4,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://ptn.com/20250331": 4,
    "http://fasb.org/us-gaap/2024": 15
   },
   "contextCount": 116,
   "entityCount": 1,
   "segmentCount": 33,
   "elementCount": 351,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 416,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://ptn.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://ptn.com/role/ConsolidatedBalanceSheets",
     "longName": "110200 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:OtherReceivablesNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "110201 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited",
     "longName": "124100 - Statement - Consolidated Statements of Operations (unaudited)",
     "shortName": "Consolidated Statements of Operations (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:ProductionCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
     "longName": "148600 - Statement - Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)",
     "shortName": "Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "170000 - Statement - Consolidated Statements of Cash Flows (unaudited)",
     "shortName": "Consolidated Statements of Cash Flows (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://ptn.com/role/ORGANIZATION",
     "longName": "995446 - Disclosure - ORGANIZATION",
     "shortName": "ORGANIZATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://ptn.com/role/BasisOfPresentation",
     "longName": "995447 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995448 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://ptn.com/role/NewAccountingPronouncements",
     "longName": "995449 - Disclosure - New Accounting Pronouncements",
     "shortName": "New Accounting Pronouncements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://ptn.com/role/AssetPurchaseAgreement",
     "longName": "995450 - Disclosure - ASSET PURCHASE AGREEMENT",
     "shortName": "ASSET PURCHASE AGREEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:AssetPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:AssetPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi",
     "longName": "995451 - Disclosure - MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI",
     "shortName": "MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:ManufacturingSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:ManufacturingSupplyAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://ptn.com/role/AgreementWithFosun",
     "longName": "995452 - Disclosure - AGREEMENT WITH FOSUN",
     "shortName": "AGREEMENT WITH FOSUN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:AgreementWithFosunTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:AgreementWithFosunTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://ptn.com/role/AgreementWithKwangdong",
     "longName": "995453 - Disclosure - AGREEMENT WITH KWANGDONG",
     "shortName": "AGREEMENT WITH KWANGDONG",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:AgreementWithKwangdongTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:AgreementWithKwangdongTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "995454 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://ptn.com/role/FairValueMeasurements",
     "longName": "995455 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://ptn.com/role/AccruedExpenses",
     "longName": "995456 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://ptn.com/role/CommitmentsAndContingencies",
     "longName": "995457 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://ptn.com/role/StockholdersDeficiency",
     "longName": "995458 - Disclosure - STOCKHOLDERS DEFICIENCY",
     "shortName": "STOCKHOLDERS DEFICIENCY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://ptn.com/role/SubsequentEvents",
     "longName": "995459 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995460 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "995461 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:ScheduleOfSalesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:ScheduleOfSalesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "995462 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://ptn.com/role/FairValueMeasurementsTables",
     "longName": "995463 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://ptn.com/role/AccruedExpensesTables",
     "longName": "995464 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://ptn.com/role/CommitmentsAndContingenciesTables",
     "longName": "995465 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://ptn.com/role/StockholdersDeficiencyTables",
     "longName": "995466 - Disclosure - STOCKHOLDERS DEFICIENCY (Tables)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://ptn.com/role/OrganizationDetailsNarrative",
     "longName": "995467 - Disclosure - ORGANIZATION (Details Narrative)",
     "shortName": "ORGANIZATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:SalesBasedMilestonePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "995468 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2025-01-01to2025-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-01to2025-03-31_us-gaap_ProductMember",
      "name": "ptn:RevenuesGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfSalesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "995469 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative",
     "longName": "995470 - Disclosure - ASSET PURCHASE AGREEMENT (Details Narrative)",
     "shortName": "ASSET PURCHASE AGREEMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:PaymentsForPurchaseOfOtherAssets1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://ptn.com/role/AgreementWithFosunDetailsNarrative",
     "longName": "995471 - Disclosure - AGREEMENT WITH FOSUN (Details Narrative)",
     "shortName": "AGREEMENT WITH FOSUN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2017-09-01to2017-09-06",
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithFosunTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2017-09-01to2017-09-06",
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithFosunTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative",
     "longName": "995472 - Disclosure - AGREEMENT WITH KWANGDONG (Details Narrative)",
     "shortName": "AGREEMENT WITH KWANGDONG (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2017-11-01to2017-11-21",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithKwangdongTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2017-11-01to2017-11-21",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ptn:AgreementWithKwangdongTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "995473 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ptn:PrepaidClinicalStudyCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ptn:PrepaidClinicalStudyCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://ptn.com/role/FairValueMeasurementsDetails",
     "longName": "995474 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://ptn.com/role/AccruedExpensesDetails",
     "longName": "995475 - Disclosure - ACCRUED EXPENSES (Details)",
     "shortName": "ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ptn:AccruedClinicalRegulatoryCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ptn:AccruedClinicalRegulatoryCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://ptn.com/role/CommitmentsAndContingenciesDetails",
     "longName": "995476 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:AdvancesOnInventoryPurchases",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:AdvancesOnInventoryPurchases",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "995477 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails",
     "longName": "995478 - Disclosure - STOCKHOLDERS DEFICIENCY (Details)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:EquityGrossProceedsShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:EquityGrossProceedsShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfEquityDistributionAgreementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails1",
     "longName": "995479 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 1)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember",
      "name": "ptn:SharesOfCommonStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember",
      "name": "ptn:SharesOfCommonStock",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails2",
     "longName": "995480 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 2)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetails3",
     "longName": "995481 - Disclosure - STOCKHOLDERS DEFICIENCY (Details 3)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-01to2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
     "longName": "995482 - Disclosure - STOCKHOLDERS DEFICIENCY (Details Narrative)",
     "shortName": "STOCKHOLDERS DEFICIENCY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ptn:EquityIssuanceCostsPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-02-01to2025-02-10",
      "name": "ptn:OfferingExpensesAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://ptn.com/role/SubsequentEventsDetailsNarrative",
     "longName": "995483 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "ptn:EquityIssuanceCostsPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-08_us-gaap_SubsequentEventMember",
      "name": "ptn:EquityIssuanceCostsPercentage",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ptn_10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://ptn.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ACCRUED EXPENSES",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r471"
     ]
    },
    "us-gaap_AccountsReceivablePurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivablePurchase",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acounts receiveble",
        "documentation": "Amount of increase from purchase of accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ptn_AccruedClinicalRegulatoryCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AccruedClinicalRegulatoryCosts",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Clinical / regulatory costs",
        "label": "[Clinical / regulatory costs]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails",
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "verboseLabel": "Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ptn_AccruedLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AccruedLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AccruedPersonalCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AccruedPersonalCost",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personal cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ptn_AccruedSellingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AccruedSellingExpenses",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r471",
      "r599"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r511",
      "r512",
      "r513",
      "r514",
      "r556",
      "r601"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r214"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvancesOnInventoryPurchases",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory purchase commitments",
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "ptn_AggregateValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AggregateValue",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate value"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithFosunAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AgreementWithFosunAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "AGREEMENT WITH FOSUN"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithFosunTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AgreementWithFosunTextBlock",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosun"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "AGREEMENT WITH FOSUN",
        "label": "[AGREEMENT WITH FOSUN]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithKwangdongAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AgreementWithKwangdongAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "AGREEMENT WITH KWANGDONG"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AgreementWithKwangdongTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AgreementWithKwangdongTextBlock",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdong"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "AGREEMENT WITH KWANGDONG",
        "label": "[AGREEMENT WITH KWANGDONG]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential number of common shares excluded from diluted EPS",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ptn_AssetPurchaseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AssetPurchaseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSET PURCHASE AGREEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_AssetPurchaseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "AssetPurchaseAgreementTextBlock",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSET PURCHASE AGREEMENT",
        "label": "[ASSET PURCHASE AGREEMENT]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "[Assets]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r82",
      "r99",
      "r121",
      "r152",
      "r156",
      "r162",
      "r163",
      "r169",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r269",
      "r273",
      "r302",
      "r342",
      "r409",
      "r458",
      "r459",
      "r471",
      "r487",
      "r527",
      "r528",
      "r563"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r103",
      "r121",
      "r169",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r269",
      "r273",
      "r302",
      "r471",
      "r527",
      "r528",
      "r563"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "ptn_BasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "BasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://ptn.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIS OF PRESENTATION",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "[Cash and Cash Equivalents, at Carrying Value]",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r97",
      "r452"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashAvailableForDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAvailableForDistributions",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributable value of dividend",
        "documentation": "Amount of cash eligible for distribution to members or limited partners of limited liability company (LLC) or limited partnership (LP), subject to reserves to be maintained as defined in operating or partnership agreement, or in a credit facility agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r59",
      "r118"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r59"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails",
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents - Money market funds",
        "verboseLabel": "Cash equivalents - Money market funds",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r568"
     ]
    },
    "ptn_ChangeInFairValueOfLiabilityClassifiedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ChangeInFairValueOfLiabilityClassifiedWarrants",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of liability classified warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r100",
      "r101",
      "r102",
      "r121",
      "r143",
      "r144",
      "r146",
      "r148",
      "r154",
      "r155",
      "r169",
      "r179",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r191",
      "r192",
      "r195",
      "r198",
      "r204",
      "r302",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r397",
      "r419",
      "r437",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r496",
      "r509",
      "r515"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price per share",
        "verboseLabel": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r177",
      "r178",
      "r448",
      "r523",
      "r524"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r511",
      "r512",
      "r514",
      "r556",
      "r598",
      "r601"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r397"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r43",
      "r397",
      "r415",
      "r601",
      "r602"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock of $0.01 par value - authorized 300,000,000 shares: issued and outstanding 28,557,246 shares as of March 31, 2025 and 17,926,640 shares as of June 30, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r344",
      "r471"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r85"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r453"
     ]
    },
    "ptn_ContingentlyRedeemableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ContingentlyRedeemableWarrantsMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingently Redeemable Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConversionOfLiabilityClassifiedWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ConversionOfLiabilityClassifiedWarrant",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of liability classified warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConversionOfLiabilityClassifiedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ConversionOfLiabilityClassifiedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of liability classified warrants",
        "label": "[Conversion of liability classified warrants]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of liability classified warrants upon warrant exercise"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of liability classified warrants upon warrant exercise, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of liability classified warrants upon warrant exercise, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ConvertibleSeriesAPreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ConvertibleSeriesAPreferredStocksMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Series A Preferred Stocks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees and expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_CumulativeFromInceptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "CumulativeFromInceptionMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative From Inception"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_CurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "CurrentMember",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleLiquidationPreferencePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleLiquidationPreferencePerShare",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible shares",
        "documentation": "Per share excess of preference in liquidation over convertible debt instrument's if-converted par or stated value of share."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "ptn_DecemberToZeroTwoFourSeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "DecemberToZeroTwoFourSeriesDWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2024 Series D Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "DecemberTwoThousandTwentyFourSerisCWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "December 2024 Series C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25"
     ]
    },
    "ptn_DescriptionOfExistingHolderPurchaseOfWarrants": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "DescriptionOfExistingHolderPurchaseOfWarrants",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of existing holder purchase of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_DescriptionOfPublicOffering": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "DescriptionOfPublicOffering",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2025 Public Offering, Description"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_DescriptionOfSecuritiesPurchaseAgreement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "DescriptionOfSecuritiesPurchaseAgreement",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of securities purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_DistributableValueOfDividendPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "DistributableValueOfDividendPerShare",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Distributable value of dividend",
        "label": "[Distributable value of dividend]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_DividendAdditionalPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "DividendAdditionalPerShare",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Distributable value of dividend additional"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted net loss per common share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r143",
      "r146",
      "r147",
      "r148",
      "r151",
      "r264",
      "r267",
      "r285",
      "r286",
      "r339",
      "r352",
      "r455"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r150"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r92",
      "r107",
      "r108",
      "r109",
      "r122",
      "r123",
      "r124",
      "r128",
      "r135",
      "r137",
      "r139",
      "r153",
      "r170",
      "r173",
      "r175",
      "r206",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r265",
      "r266",
      "r267",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r284",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r325",
      "r351",
      "r360",
      "r361",
      "r362",
      "r378",
      "r437"
     ]
    },
    "ptn_EquityExpensesProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "EquityExpensesProceeds",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity Expenses, Proceeds",
        "label": "[Equity Expenses, Proceeds]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityExpensesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "EquityExpensesShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Expenses, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityFeesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "EquityFeesShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Fees, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityGrossProceedsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "EquityGrossProceedsShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Gross proceeds, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityIssuanceCostsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "EquityIssuanceCostsPercentage",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fee, percentage",
        "verboseLabel": "Cash fee, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityNetProceedsProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "EquityNetProceedsProceeds",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Net proceeds, Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_EquityNetProceedsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "EquityNetProceedsShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Net proceeds, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ExercisePricePerShareWarrantsOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ExercisePricePerShareWarrantsOutstanding",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ExercisingHolderReleasedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ExercisingHolderReleasedShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercising holder released shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value asset measurement",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r557",
      "r558",
      "r559"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value By Fair Value Hierarchy Level Axis",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r295",
      "r296",
      "r297",
      "r331",
      "r332",
      "r333",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r338",
      "r468",
      "r470"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r207",
      "r212",
      "r288",
      "r296",
      "r331",
      "r463",
      "r464",
      "r465",
      "r468"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r207",
      "r212",
      "r288",
      "r289",
      "r296",
      "r332",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r468"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r288",
      "r289",
      "r290",
      "r291",
      "r296",
      "r333",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://ptn.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r295",
      "r296",
      "r297",
      "r331",
      "r332",
      "r333",
      "r460",
      "r461",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "FebruaryTwoZeroTwoFiveSeriesEWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February 2025 Series E Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term finance lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of finance lease obligations",
        "label": "[Finance Lease, Principal Payments]",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r322"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency transaction (loss) gain",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r434"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign currency transaction loss (gain)",
        "label": "[Unrealized Gain (Loss), Foreign Currency Transaction, before Tax]",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r417",
      "r485",
      "r561",
      "r562",
      "r600"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation of foreign currencies",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ptn_FourToFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "FourToFiveYearsMember",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "4 - 5 Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_GainLossOnPurchaseCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "GainLossOnPurchaseCommitment",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 6.0
      },
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on purchase commitment",
        "label": "[Gain on purchase commitment]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of Vyleesi",
        "label": "[Gain (Loss) on Disposition of Other Assets]",
        "documentation": "Amount of gain (loss) on sale or disposal of other assets."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "ptn_GainLossOnSaleOfVylessi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "GainLossOnSaleOfVylessi",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (Gain) on sale of Vyleesi",
        "label": "[Loss (Gain) on sale of Vyleesi]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r65"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r371"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "[Increase (Decrease) in Accounts Receivable]",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosunDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company License Agreement Recievables",
        "documentation": "The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for current or future transactions, initial payment of the cost of an acquisition or for the right to enter into a contract or agreement, (c) the increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable, or (d) some combination of (a), (b), and (c)."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "[Increase (Decrease) in Inventories]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r507"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of increase (decrease) in current liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "[Increase (Decrease) in Other Receivables]",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "[Increase (Decrease) in Prepaid Expense and Other Assets]",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arragements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "[Interest Expense, Operating and Nonoperating]",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r156",
      "r159",
      "r160",
      "r163",
      "r315",
      "r458",
      "r459"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r116",
      "r117"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment income",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ]
    },
    "ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "JanuaryTwoZeroTwoFourPrivateWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 Private Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "JuneTwoThousandTwentyFourSerisBWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 2024 Seris B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_LatestTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "LatestTerminationDate",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latest Termination Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "[Liabilities]",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r121",
      "r169",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r270",
      "r273",
      "r274",
      "r302",
      "r396",
      "r456",
      "r487",
      "r527",
      "r563",
      "r564"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' deficiency",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r76",
      "r346",
      "r471",
      "r510",
      "r521",
      "r560"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' DEFICIENCY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "verboseLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r96",
      "r121",
      "r169",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r270",
      "r273",
      "r274",
      "r302",
      "r471",
      "r527",
      "r563",
      "r564"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ManufacturingSupplyAgreementsForVyleesiabstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ManufacturingSupplyAgreementsForVyleesiabstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ManufacturingSupplyAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ManufacturingSupplyAgreementsTextBlock",
     "presentation": [
      "http://ptn.com/role/ManufacturingSupplyAgreementsForVyleesi"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI",
        "label": "[MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_MayTwoThousandTwentyTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "MayTwoThousandTwentyTwoWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2022 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r62"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r62",
      "r77",
      "r94",
      "r104",
      "r105",
      "r109",
      "r121",
      "r127",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r138",
      "r139",
      "r145",
      "r169",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r264",
      "r267",
      "r286",
      "r302",
      "r350",
      "r418",
      "r435",
      "r436",
      "r485",
      "r527"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://ptn.com/role/NewAccountingPronouncements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "New Accounting Pronouncements",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r93",
      "r125",
      "r126",
      "r129",
      "r130",
      "r140",
      "r141",
      "r167",
      "r171",
      "r172",
      "r262",
      "r263",
      "r265",
      "r267",
      "r280",
      "r283",
      "r324",
      "r326",
      "r327",
      "r335",
      "r336",
      "r337",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule 10b5-1 Arragement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule 10b5-1 Arragement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ptn_NumberOfOutstandingSharesOfRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "NumberOfOutstandingSharesOfRestrictedStockUnits",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of outstanding shares of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2022 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "OctoberTwoZeroTwoThreePlacementAgentWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2023 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_OfferingExpensesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "OfferingExpensesAmount",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Offering expenses",
        "label": "[Offering expenses]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recievable under company agreement",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "ptn_OneToThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "OneToThreeYearsMember",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "1 - 3 Years [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r457",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets - operating leases",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in right-of-use asset",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "ptn_OrganizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "OrganizationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://ptn.com/role/ORGANIZATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ORGANIZATION",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r73",
      "r368",
      "r369"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "[Other Accrued Liabilities, Current]",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ptn_OtherAccruedResearchRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "OtherAccruedResearchRelatedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other research related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Offering expenses",
        "label": "[Other Expenses]",
        "verboseLabel": "Other related expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "verboseLabel": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r471"
     ]
    },
    "us-gaap_OtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term liabilities",
        "verboseLabel": "Other long-term liabilities",
        "documentation": "Amount of long-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r75",
      "r567"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "[Other Nonoperating Income (Expense)]",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSE)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r522"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherReceivablesCurrent",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForCommissions",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of commission fees",
        "documentation": "The amount of cash paid for commissions during the current period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForPurchaseOfOtherAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForPurchaseOfOtherAssets1",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payable the settlement of certain purchase commitments",
        "documentation": "Amount of cash paid to purchase other assets as part of operating activities."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosunDetailsNarrative",
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payments",
        "verboseLabel": "Upfront payments",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r506"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of withholding taxes related to restricted stock units",
        "label": "[Payment, Tax Withholding, Share-Based Payment Arrangement]",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_PaymentsToAcquireReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireReceivables",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payment receivable",
        "documentation": "The cash outflow for the purchase of all receivables."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ptn_PaymentsToSalesBasedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "PaymentsToSalesBasedMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sales-based milestone payments",
        "label": "[Sales-based milestone payments]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r191"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r397"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r191"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "verboseLabel": "Convertible preferred stock were outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r397",
      "r415",
      "r601",
      "r602"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible: authorized 4,030 shares as of March 31, 2025: issued and outstanding 4,030 shares as of March 31, 2025 and June 30, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r343",
      "r471"
     ]
    },
    "ptn_PrepaidClinicalStudyCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "PrepaidClinicalStudyCosts",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical / regulatory costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "verboseLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_PrepaidInsurancePremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "PrepaidInsurancePremiums",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance premiums"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_PrivateWarrantSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "PrivateWarrantSharesMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Warrant Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity Fees, Proceeds",
        "label": "[Proceeds from Fees Received]",
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from Offering",
        "verboseLabel": "Gross proceeds from Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock and warrants, net",
        "verboseLabel": "Net proceeds",
        "terseLabel": "Net proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Gross proceeds, Proceeds",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ProceedsFromSaleOfOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ProceedsFromSaleOfOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of Vyleesi"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Gross proceeds from exercise of Existing Warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Revenue [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service Axis"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r334",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r451",
      "r462",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r525",
      "r526",
      "r529",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ]
    },
    "ptn_ProductSalesAllowancesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ProductSalesAllowancesAndAccruals",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product sales allowances and accruals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductionCosts",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of products sold",
        "documentation": "Amount of capitalized production cost incurred during period for oil- and gas-producing activities. Includes cost incurred to operate and maintain well and related equipment and facility."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "auth_ref": [
      "r164",
      "r334",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r451",
      "r462",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r525",
      "r526",
      "r529",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r104",
      "r105",
      "r114",
      "r121",
      "r127",
      "r135",
      "r138",
      "r139",
      "r169",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r264",
      "r267",
      "r268",
      "r271",
      "r272",
      "r286",
      "r302",
      "r340",
      "r349",
      "r377",
      "r418",
      "r435",
      "r436",
      "r466",
      "r467",
      "r486",
      "r503",
      "r527"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r323",
      "r341",
      "r348",
      "r471"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r86",
      "r89",
      "r347"
     ]
    },
    "ptn_PurchaseOfWarrantOfCommonStockSeriesA": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "PurchaseOfWarrantOfCommonStockSeriesA",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of warrant of common stock series A"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_PurchaseOfWarrantShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "PurchaseOfWarrantShares",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of warrant shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ReclassificationOfContingentlyRedeemableWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ReclassificationOfContingentlyRedeemableWarrants",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of contingently redeemable warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r449",
      "r458",
      "r565"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "ptn_RestrictedStockVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "RestrictedStockVestedInPeriod",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r68",
      "r345",
      "r363",
      "r367",
      "r376",
      "r398",
      "r471"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r122",
      "r123",
      "r124",
      "r128",
      "r135",
      "r137",
      "r139",
      "r170",
      "r173",
      "r175",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r265",
      "r266",
      "r267",
      "r275",
      "r277",
      "r278",
      "r281",
      "r284",
      "r316",
      "r317",
      "r360",
      "r362",
      "r378",
      "r601"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r450",
      "r454"
     ]
    },
    "ptn_RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition (Prior to the sale of Vyleesi)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product revenue, net",
        "verboseLabel": "Net sales",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r110",
      "r121",
      "r152",
      "r157",
      "r158",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r169",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r302",
      "r340",
      "r458",
      "r527"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_RevenuesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "RevenuesGross",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross product sales"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arragement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arragement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "ptn_SaleOfCommonStockNetOfCostsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "SaleOfCommonStockNetOfCostsAmount",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock, net of costs, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SaleOfCommonStockNetOfCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "SaleOfCommonStockNetOfCostsShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock, net of costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SalesBasedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "SalesBasedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/OrganizationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales-based milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://ptn.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schdule of Accrued Expenses",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfEquityDistributionAgreementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ScheduleOfEquityDistributionAgreementTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfInventoryPurchaseCommitmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ScheduleOfInventoryPurchaseCommitmentsTableTextBlock",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventory purchase commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://ptn.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses and other current assets",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfSalesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ScheduleOfSalesTableTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r69"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ScheduleOfStockPurchaseWarrantsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ScheduleOfStockPurchaseWarrantsTableTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Stock Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ptn_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SeriesAConvertiblePreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "SeriesAConvertiblePreferredStocksMember",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Convertible Preferred Stocks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SeriesFWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "SeriesFWarrantsMember",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series F Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SeriesGWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "SeriesGWarrantsMember",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series G Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "[Share-Based Payment Arrangement, Noncash Expense]",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options outstanding at beginning of year",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of year",
        "label": "[Outstanding at beginning of year]",
        "periodEndLabel": "Outstanding at ending of year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expirations",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations]",
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures]",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails3",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted",
        "verboseLabel": "Number of shares outstanding granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock units number of shares outstanding granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Exercied",
        "label": "[Number of Options Exercied]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedNumberEndingBalance73",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Outstanding, Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Outstanding, Ending"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Outstanding, Beginning"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Outstanding, Ending"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Options Expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndForfeitedOutstandingNumberEndingBalance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Forfeited",
        "label": "[Number of Options Forfeited]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Options Expected to outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value Options Expected to vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r218",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options exercisable at end of year",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options outstanding at end of year",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Term in Years Options Expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "SharesOfCommonStock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares of Common Stock",
        "verboseLabel": "Shares of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SharesReleasedFromAbeyanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "SharesReleasedFromAbeyanceAmount",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares released from abeyance, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_SharesReleasedFromAbeyanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "SharesReleasedFromAbeyanceShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares released from abeyance, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r119"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Class Of Stock Axis",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r100",
      "r101",
      "r102",
      "r121",
      "r143",
      "r144",
      "r146",
      "r148",
      "r154",
      "r155",
      "r169",
      "r179",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r191",
      "r192",
      "r195",
      "r198",
      "r204",
      "r302",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r397",
      "r419",
      "r437",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r496",
      "r509",
      "r515"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r43",
      "r46",
      "r47",
      "r92",
      "r107",
      "r108",
      "r109",
      "r122",
      "r123",
      "r124",
      "r128",
      "r135",
      "r137",
      "r139",
      "r153",
      "r170",
      "r173",
      "r175",
      "r206",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r265",
      "r266",
      "r267",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r284",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r316",
      "r317",
      "r325",
      "r351",
      "r360",
      "r361",
      "r362",
      "r378",
      "r437"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
      "http://ptn.com/role/FairValueMeasurementsDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative",
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r153",
      "r317",
      "r334",
      "r370",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r437",
      "r480"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Changes in Stockholders Deficiency Equity (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://ptn.com/role/CommitmentsAndContingenciesDetails",
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited",
      "http://ptn.com/role/FairValueMeasurementsDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails",
      "http://ptn.com/role/StockholdersDeficiencyDetails1",
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative",
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r153",
      "r168",
      "r317",
      "r334",
      "r370",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r437",
      "r480"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock share purchased",
        "verboseLabel": "Common stock share sold",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r43",
      "r68"
     ]
    },
    "ptn_StockIssuedDuringPeriodValueRestrictedStockUnitshares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockUnitshares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Withholding taxes related to restricted stock units, shares",
        "label": "[Withholding taxes related to restricted stock units, shares]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation, amount",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r42",
      "r43",
      "r68"
     ]
    },
    "ptn_StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation related to restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionPlanExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionPlanExpense",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation to stock options",
        "documentation": "Amount of noncash expense for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ptn_StockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "StockWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets",
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' deficiency",
        "label": "[Equity, Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r64",
      "r399",
      "r415",
      "r438",
      "r439",
      "r471",
      "r487",
      "r510",
      "r521",
      "r560",
      "r601"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' deficiency:"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "StockholdersEquityAndRedeemableConvertiblePreferredStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS DEFICIENCY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiency"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS DEFICIENCY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r120",
      "r190",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r206",
      "r282",
      "r440",
      "r441",
      "r447"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r329"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r329"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r329"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://ptn.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r330"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalDeferredPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalDeferredPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AssetPurchaseAgreementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront purchase price amount",
        "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ptn.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ptn_TwentyTwentyThreeEquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "TwentyTwentyThreeEquityDistributionAgreementMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Equity Distribution Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_TwoThousandTwentyFiveSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "TwoThousandTwentyFiveSalesAgreementMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative",
      "http://ptn.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025 Sales Agreement [Member]",
        "verboseLabel": "2025 Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "TwoThousandTwentyFourPlacementAgentWarrantsMember",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Placement Agent Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UnvestedPerformanceBasedStockOptionsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "UnvestedPerformanceBasedStockOptionsGranted",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested performance-based stock options granted"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested performance-based stock options granted estricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_UpfrontPaymentOfLess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "UpfrontPaymentOfLess",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/AgreementWithFosunDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront payment of less"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r83",
      "r84",
      "r87",
      "r88"
     ]
    },
    "ptn_WarrantExercisesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "WarrantExercisesAmount",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WarrantExercisesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "WarrantExercisesShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WarrantIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "WarrantIssuance",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issuance year five"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WarrantIssuanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "WarrantIssuanceShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issuance"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WarrantsGainLossOnWarrantsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "WarrantsGainLossOnWarrantsNet",
     "crdr": "credit",
     "calculation": {
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WarrantsToPurchaseShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "WarrantsToPurchaseShares",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r148"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesRestrictedStock",
     "presentation": [
      "http://ptn.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average vested restricted stock units",
        "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmoun": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "WithholdingTaxesRelatedToRestrictedStockUnitsAmoun",
     "crdr": "credit",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding taxes related to restricted stock units, value"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WithholdingTaxesRelatedToRestrictedStockUnitsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "WithholdingTaxesRelatedToRestrictedStockUnitsAmount",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding taxes related to restricted stock units, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_WithholdingTaxesRelatedToRestrictedStockUnitsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "WithholdingTaxesRelatedToRestrictedStockUnitsShares",
     "presentation": [
      "http://ptn.com/role/ConsolidatedStatementsOfChangesInStockholdersDeficiencyEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding taxes related to restricted stock units, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://ptn.com/role/StockholdersDeficiencyDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ptn_taxexpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ptn.com/20250331",
     "localname": "taxexpenses",
     "crdr": "debit",
     "presentation": [
      "http://ptn.com/role/AgreementWithKwangdongDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Expense"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(a)(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>68
<FILENAME>0001654954-25-005610-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-25-005610-xbrl.zip
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M26?KV1X2(39=8>!92,1-2?!4#(4(7KX=%(^T8^T\UC_6K[WQ@A8Z'%4X#K<
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ML8=.X*-[(OR'K,[@]82PEV<DPP,*016@/*TW%$+%I9'G&86P"=-+\9)B8T>
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M"LG;B,EG"8?#.((1&G3N]MF5PN&%=&U-M"XO4/-A$/<('XRF(%RY?IH.'?V
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M4J:N:FPE?5CI"&SGA#$+MY(\_:-7U439DM*TD##L#D [=).M\G ^ 78<(OT
M2 !MXA+H+,C7UH0(>8%4YV_?"4+,C@&X.<DV$5B"BCHP)2M+"V_0FPO4!Q8(
M8.+3HP^+8AD=5$J!7>_)^8:[>"X.-_TK#KU/MDVR?9W7@@X,519*\1OW=^ Q
MVCI><D#OW3]BUTE<.:DPP)?9]>_;GD;<[BLB85J5I6[!I?ELN1Z^'-8+POR%
M!9Z[A%]-(]X$DA!Z&@R4V'P!?S&9KX?S._?9=8#O<(82WN)(U=1!^=+"$/TW
M:$Z3CYB.D^C%\D1:9Y?71M=L$8B&][.NF[Q3+>M"8M;0@0VA$(2/_8SU9DZ4
MR\?@V0X=/YDL.%T6U-6)(PEQ"%N*SO_SS_\2?T\?*Q2-\/C1<VT2ZLG;:4LW
MH1%W%:2JETN-YUZ$TX"X'R2<MI32.BB<*P#1[1&\<9^!)(<JO 1<W%HZ<"(E
M".&FP5/T'1]<]SO:X:$1]B7)BEWRDS(&0\4F=&"CNE2$F@:O-V3$;SX[!AY(
MPG9X[V,+ZFBB?)$81-N*3'#:4B6ZE,99Y32\IB8O#:%*T8%W%J<$>T&(8;D0
M\MTDK/(ZD<(0@3"QGV%>FXED^RT.ZRD4TTCO!>1$W1LK_3#OB,2/$/P1([C=
M9]P)9-ZSN"Z]9S&[G73_,>L.ID;W*_IS<GK)XO22!<78?@TO610&3#&G.SW9
M)K6"5NGCF%*H?N>BC$N8IY%=Y2@2QPEZF)B88WE HD%JCBAA7$/T:/$RPRFU
M,#NUL+)A=4HM3*%+/K6PJF3UI]3">W.GP\L/IU=L.*_8Z/EZRK',A<V]8J/J
MY8C3*S;45VR.^4F)W*95E J34?P(7'$B"X2_62\DIGO78*#R*1MCX]D8WS5X
MRIE>ZNA)Y6.D%U6O=JD$R@ST1*4-GDZF7_HLK])24:U46D)/5-I@ZK53YD!N
MYD!5&2E.X77[A->=3N:54E7A9+ZE8")A-&,QR$;'V$61#+7R<YZ2.NB5U$%1
MB,L]6%A>#_""*G)%-&(CA[I6<LU3S/;QQ&P+HV&RG^,_'BT(_OK_4$L#!!0
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M1\O\]Y]@C+G"@/+@/X[SOUS@]D#H 8>T3%E'LY_&TY\FH\DL)WH(O>0KC!"
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M.?XN"E]1E+S?890)5C/$B'HEKBZ\WPE5DXQ%YU;0#+V\!XCIZ7PM)\[9W+5
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M#)[-U[0-&DN L@9,;W2MI[GS4&G=VG1*[\2&P)@NF&M'D:P1DOLG;09D[9P
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M6$-I:E5NC14GVG6H5()"C96]*'>7:&F#+[03Z%JQDR]W=]>;SU@\U]<@CXW
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M&3"G1XI\AJ+*99T0QICSF-@=WW8\T78_)1*A#G!5XL_QCPY[F\#.:G'Z9'L
M4;M L1/YU#-RZST@9Q_Y"?Y6ABI_H\3IO#JK'H%KVY5,YE3YV XP'4^1Z3##
M;HBKDE=HA3JV\G; :R:3,&O)B">UG.@@#4([^-UX)F8#"XLI1^,ETG49J.#3
M;(59EMGA-4_HP-3&5Q2A@4N8Y3621#4%JP1Z5 $?5K;@RW]E5P[3[0KI\G.+
MEK4,E[@XE0T>O+((%V22_1B3JT9R*E): 3)VG>D3VG5)K(7$O$P_CYT)M*%8
M1S?4?(5$B/LX"!\MF1=HFQPN>PJ=NO;_L?==>GW$.HZ"1I=+U\;T2>UQW2W*
M<+>6V-.YU<R#)E-"]-D'V8;;1SS8\:YQ&#^OWZ"_(V4(+\.HF%-,>)4BY]'H
MZE8!7W)IRQA2S31&=MRXJ$.MF>89*6%E.SPQT5W_S7=1H#\6M82'6B>WWD4*
MAJ=$5'G2 IQS5YOMU1!IVAYT;U/7_0C?8G):=E7;T7U(^9J8SI'6#FDMSK-!
MHH9X_)JA6[NN3]05W$D%24RL2WR:X!Z$1D3)O'3C+9J8OGY0Q=A2\P"8MV?Z
MIO.0(5KIHE-(KO&>LP%RZ9I30)L^ZD4CSV3VBW8HA=YJR^[.^:'UJ2\M>1:F
M:51AU!QGKM2-6LRYE(M9+,YRNK#A5-86;_T$5KP:(5RYP]IT2<:[*'00<N-+
M/*W9O>)5@+4NUN'[[<YWLM050A>,,K].3UC+3I5=88K,3.\@.#8:KGXD['H=
MVC".L:YDC0$RKB#C'"Y$('X,,SW=%"3"(=4:-""$6HD>J-&Q$*^IZQJ_C%-#
M*(@GB$EL;J:]#%VR'20]!95%,G$=,#)Z]C)^X3EG5EVOJ0)66;THB_+"EO7F
M&[:X2;1U/PFJF^_GLP_^&NY<%-6"#WCKO"6_@9MZU4YQK^N;F)DO%ZTF<]/1
M1D? ;KBX1YD8/M/6#K?WAXB207(9LI60]^(>[1!]U27:<IH8-&4S5(*=IS.4
M4K/S^!)-1B;C5MOB% 2N%B0H2KD;+S@T6YW"9+7*3*S ZF2U6EB0^[ CZMK;
M-)3DFY3I\P][<4?J=1/X?AQ++J%$Q!I/-E*X)<'B4K)2T-N1YYAT,;?!6//G
MI$5(TXA#QD.RFYI9]/3T+WMC52)@79N.X-8B<U."L);#E)#FC_0L>6E%"OFA
M?^RQ4&S>\'\>WZ7U-H74>JLI2@!7:RER2--W'9YGA>M!"60M/T/.!"B7924Z
M"_V15LT1T!H3)G'-'"XAN\1;C;?0AOU  6*C&!FK3J"IM(@[7YQ!2V(/.B(W
M7F&$/DZX;*XQPJ?3E'M*!C+/+<4C8K;W?+X=FRYRI "OMI[9PY'+-N5&CA2$
M7Q0%H4:G4Q $(,N"\ MGI.=P<K8RGD"Q&9Y $'ZQH.Y,S^4D%NYX-=(U(PT:
MO 5:ZZI*:+F#7LT@&NORQ*JD$VH)6^$J.@YW9O).#>DP0R,/ZG*8)2CJQ5V6
M81[.7=9\82.]]&^D-G 9([[0;R!EVFVU74U-N\*5058%XS-\!]1X9DSY1?T)
M*#1I9&E;D!!FX3CN2E="& 7-W4-/ADS@<;37Y!H]P1W)PB3H?^'O^KPC-5!%
MV<K_F'J<(5J8?%#9 *LZ^90,7)IR?&N,L9HM1W@)V+.2.Z(_*M2J^(MK_!/^
M9?8K_!^24?1?_B]02P,$%     @ #(BN6GBXP(\F.P  $#,# !0   !P=&XM
M,C R-3 S,S%?<')E+GAM;.U]Z7/C.);G]XW8_T%;^V%[(C8K>8E'Q_1,*'UD
M><MI>7Q43?<7!$B"-J=ETD52SO3\]0N0HD2)( @>$D!W]\1D.9T B-][.-Y[
M>,>__ON/E]7L#25I&$=_^4G]6?EIAB(O]L/HZ2\_K=-/,/7"\*=9FL'(AZLX
M0G_YZ1VE/_W[O_W/__&O_^O3I__\<G<].X^]]0N*LME9@F"&_-GW,'N>D7_Z
M!M,,)9\^;5K_5GSGSS/M9_UGQ=[^_@M,<:\XROO@?U2W_W*.QYO%P<PC(^==
ME?EG5?^L*=I\V^@^#K+O,$$SF'C/88:\;)W U<Q':?@4S?#$9P6@/\\6_\>;
MG3_#Y 6^)N@%1@34;/&6_;P=ZRQ^?4_"I^=L]B?O7V;D,[.K3S<7#[,OZS2,
M4)K.[N/5FDPE_;^SJ\C[>;98K69WI$<ZNT,I2MZ0OQEN%49__S/YP\7X9IC0
M4?KG'VGXEY^>L^SUSY\_?__^_>?O^L]Q\H3Q*.KG__QV?>\]XWE]"B-"< _]
M5/8BH]#ZJ8[C?,[_M6Q::_G#35;E-_3/Y71P\S3\<YI_[CKV<N)R=)LUMB!_
M^U0V^T1^]4G5/NGJSS]2_R=,C=FLH$<2K] ="F;DOX]W5]MOOF;1SU[\\IG\
M_O-9C)<DGF+>XSE!P5]^PO_^B;!#T8LQ__=>F^S]%:_,-'QY76%HG[M_+TKC
M5>B3U?L%K@CI[Y\1RM+6.;3T.]:\;O%RC[)GE(4>7/6=)'60$6=\G^$_R<&0
M+H/E*TKR198^1G#MXUWJ=Y@VYTA'FOO9,XR>4'H5W6>Q]_?G>.7C<^P<!:$7
MXK/R_>*/=9B]#X75[R/'0@S3Y\M5_'TPLYH'ZC[S_+Q)D??S4_SV&7E^ >$J
M2D-,JH<$DB-^D22$C/G7]Z=,!DEIHV <!OF! #)R,.U##B3[\N[KXN;J;XN'
MJ^5-"V%I30=^'=^V(6;-;8)OJRC+MU++)!@]!L[E?OWR I/W97"/K^H0+W88
M90O/B]=1ADE_BY<47OYMIW"W00;.^ 9]KXR=Q!'^T:,MN-HT.7H.G-LB35%V
MN\92$+Z#%T\)RD=OF1:[T\ 9?8/1.H!$(,.8[]>OKZOW[2?2RSCY[7V%L)C6
M,L6.HPRE8CGT[UB,O8S3==OV:.XPYDQ^_8Z/(3^.GKK,IM9IX(SP$? *0__B
MQRN*4I0N(G^)!8CD;)T042)?2FW;H,L0 V=["</D-[A:HV\(INN$:Y<R^PSE
MI^<E:[2%WL9(>NO!5_[+2YCEJ##I\;U-3B,L8;0?LQP]A]X&5-&G[?1G=AI\
M/[DI^F.-,5^\<2R>IN8GN25'O2U'OC7Y/OH W=5(\]\?Z@2G'M?<NP]TC!.0
M:ZH</<<]#;EFQ>QSO).1:V[<_8]R2O+M'8ZN0W6;Y E&X7_G2L(YRF"X2F]@
M0C3V-]2FZW!T/<DYM/GX* ?1P5BGG#\OW8<->A2=I2.";H.,KA]TG2WW $?1
M'X;,MG60$]RT?+NSQTC'N&OY)LO3==S;EF]>[$['NV_Y9L<_P-%GRKN9>HQT
M%&F!\X;CZ7O,^:E#)JB>8H;:D!EJIYBA/F2&^BEFR"VG=!ID9,V_LTS%U[UY
MEJ\5:_LU_L5>!_0C0Y&_>TTA4^9X2LW"C+13BO^ILT^[M_M/L[SE[!8^H=E5
M%,3)2V'HSZ=43FH5>WOS6)&GX_C@J9;ZU.*CL'AJP3_LGEKP7T#^W86;9@GT
MMG;G%731*A\?X#8'33X??4X7^&#.WN_04TB^&64W\ 71IT9ON3_#*BL7B3>+
M$[R$,1O*$6'B[3&P_KJ^:?'Y-7^R_>0]AZLM[X,D?FFBU(8N<<MTJ^3#GSH=
MA<\PF@2NKO!:_O$K>F>1N-:4B\:J,!HW0#LID<O=_8!'I--VOP47234!)*4!
M.2DE%_CK/IG!Y0H^T4EYT(2+EKH 6E*AG)28&R7L,DP]N/HK@LE%Y!-/KX;#
MO[$U%XD- 21N RC@I+U_@:M5Z<3&.F</&G+1>"[LE*7"$D'>9[1:8>WN%4;,
M6VR_'1=Q37'$I8 20-N+%Y0\83WY:Q)_SYXYB-S0@8O:EC!J,V&*D,V*0^P.
MO<8),5,0OZXU\^AHZL%%>%N<I,8$*D1@NT5)&/O,:[&A*1>M'8$B'!6:@.5]
M&:Y0<H;G\!0GS-/DH"&?VB%.MZ/B$K*("_&GX/<E_EW#V<%HSD=K$3I>*T:!
M%"<")S>]*XWYJ"U2_6O )^)RC%]>XL)7^_X9PTN7ZRP/D@FC!O60IQ\?!T0H
MC?RHA2S\_UC#)$/)ZKVXQ-D+O]:8C^PB%,D6?&*,20F,TI!0AX?8]=9\U!:A
M4K8A%"2EW*Q?W)T-OTE$*5OQD5><4EE')("L5Y$7)YBU.5WR@)4SXNZ2X!/.
M9QKZ6SKR$5^<CLF%6P _'N"/*Q\#S+V/R-S:UWQC%SX>B%,W6[ *H/["]S&5
MTLU_KL,(J2S*4YOS45V$XMF*41S%S_"/R^0A_AYQT+O:F.^A1IP2VHA/'*WS
MTVZ9W";Q6UB$5K<1O-:#C^KBGAS92,61_C;&2L+J;^%KV^U*;\]'=A%Z:3O*
MT[ZKD<DD"#:3>;\%'V%%J)LT)"<E)<F)L+I]CB.F]%UOQ4=2$:ID$Z*3DO4>
M>>L$\U;5W ?BBT0G:[T5'UE%Z(Q-B$Y*UDVH^OW[BQNOZ#0]:,)'4!%:(A6+
MD$5Z\</+DS(T.W_16_+15H02R$(F1 O/$)EI^(;.808W[W!L]9O>@X_DXG0^
M-M(:Z?_U<PT'UEC^?@SOT+8$-H7'J*HJF"RS3[-M<H_<8737>;;I/=MT'[B"
M IBZ.3/6Z:<G"%\W63I665K^9K>>-K\ VZDM@\LPPI,)\7T7%W8\AGOIICM/
M;V JIF;5E-T3P\O#]3B Y.W W+8,HU4_KZW#<?=)'QKO[R0VN.VKJR*8-\2N
M<(5_I#V]'4+8M@5. *$-)>/1/H79W*A#V9H@A+/D; 73=!GDCU:+'R$/9PZ[
M -_T CB?,(,:$55,12*X5)W7>?P"0YHA;-.XWA;H@6OJLAUNC;2FLHB!:AAO
M:B$I^!=8M$U"E"[PS8VEEBS$"^@6-T98&O'S&:3?4(.VBWMS=@::HEJZ+@=7
M&.3=9T</?!6#GXB]4\2PMDLV^^V 81NV+PEW&!<(=;,T0-G%>HCC0QE8S,F.
M@^9@;@6&W:H[RLR5)D2[J!$A%PQ,G\G_D_R);W"%)YC>(3S#T,-*"_F'1>3O
M_Z+2DG$7#1D66-Y\KCC39/8XR'?A+R(619X)X YY",^+I#ZY05FS[6'3J;D/
M"#2DN=8TV<D!:Q='(X)7^WD<RC0.>T=.,],X.F-Q "FJ/TWN=<&W"]41?DER
M7HX 0J@8LNG%?2[%+9)=2,]K*5I>%T1HG&4^Q2S.X"IO*6H7QJ]8)GZ_79'<
M0)%/SO170@U\7K"V7W,O8!J& 2>[[SB [0**A-QQ19KLZ.D:P13E">J7P2,^
M),BZ9%QSK&Y "5S?,:?),SYDNV D88))<7+<Q)'')9,<-@>NBHR@9C.8").8
MB';12^*NL+:["_B^XEF3OK2V$"K!3-.ZKJY#Z(:K, OSQ%_5O#%%'OUV+9UW
M!(#<N:+6WDRGP>[.("L15X+9RFUN:>X#H(TL.'W6-<&J!&P).2Z+#)+I+7PG
MFF6[Z$]M#TQ=-^S:=3P-)K5 JL1S"6(02>Y77TE,'M&[ .2X4)NH9-B.JA("
M)EZ6+^?YWFZS8O8#IJU8ACM-GG%"JT23B6!<X>6 .K*-U0OXB@9=V9X\.9G&
M!:P2H29,!>MR)C9T -!R_6#*5F$&IDH@FQQR8!?Y#QBN#_V)6IX8<"J1;=/2
MUAK.<BX+2%M7H-N^YT]U&W*CJ\37B3LTX^CI 24OY\AM/2XK38$)?<><J(3?
MC$:P8U7EG. Z&\$<*M":Z)LT#4?%.6=:IV$?:Q7#=&,;6F#73 #3X"L'K$KT
MGZ#7Z8J#6)["G_D:?=@86);M!Q/U^V'AJ00/"G'[V26J:6'*84M@!4$@B_=B
M9^><)C"5P$,AIB;?SYW\X>H6AOY5= 9?PPS2(M5*DPR] W!\W0V":3*G#5,E
MBE$$C^Y(AOH(^1<PB;#(F2X\;_VR7I'@GB+9/N/^:>\+ LVP](ERK@.\2N2D
M',)#%Z$!G]Z>:DST-F+ J81<3DL6;'N@Z_]^"7S'F+L3934WN$K@YU#&BP_)
MO,U)^8RRT-M=G=7X3)4_/G/VI[W1_N6#QFNJ"E(,02)HSWA-0[4,33;C) ^-
M&PYE*KB)QVNZEH%\V=Y@]BG,YD8=RL>*US3TN2Z=XW 7!C4BJKAD33!>4S4=
MRY'-&-5(:[J*W8QJ&&_$Q6N:BJ8A29Y(&.3=9T</?(*]U_8GA^6O99*O03\W
MU=RB)$^IS&L^;.H/%,_6-'F?4\H+A\.BV I1;-SG_F2+?-B+=?8<)^%_[P3]
M-CX>]@.6YWF^O.[;'?C7"$UP2.C.2-I]$W)T)D&.MG39(C@YV 6?V"#.6BYZ
MGKW'Z 0,%&A^S4 ^.;8UXA(;QUF;X56:KCNQJN@ D&N9AB32RF V'6 2&Z/9
ML:9%$Z9*+X!,S8(?94_1@.T".F410=KV57,?X-F&.I=-/1L@>AS $AN029L@
MUP9KZ0CFCNG9\GKN=.8:#=MA6*80:_P6'%90-ZYY^%\?([CVPVPW6&F2UPR5
MG3)Q-]XL#F:[$6=_6I=C"C',DR(1+V@[NW9;?$,'X.J:IM7>?$_UG/V&HC7B
MR(]TV!) 4_>0),=@&VD;WJL;$(E5F,MIM;,"^#K4=$GDAD9J,FF_A2!6V=VZ
M$&]RA'#LA\8NP/5<7Q9#83>NM&,2J\S>)K&_]@@%S^*4%61^T! @1[4#25XZ
M>IU538#$:JMWF'X8.TEF=8X7VBK.LWML%@_K_&)T U"%EB))O''/>X4'GE@E
M]AZM5J2(,HKPCE_AF2[\ES *"3R2?;N5A7S]@:FJ 9RRC- 1YR ]E_JT]16&
MT76<ILOH'J[0,OCM?872-*0_934T!KIBV+HD-U(W-G" VNFKG,Y+3J&S1.B)
MZ!?]_=9:^'6[QF< 3!$QD(39"SU :P]?O0> ,%!-2;36 9QC(-OIK"=FW_A"
M8P=A$1!M7YNR1-(,:9=_:%INI%M$!3W(RN7@Z*XQ<.:6:TJ2*6 83RF@)IOE
M* \^O(FC>!]<F0VR7='CZ@\4 ]G*I)G?#:=@-Y&KZ VE^4U23).989'2&)@2
M5?SH2'HJ^U@8!><XNHP3%#Y%122^]Y[7C8:Y,EM*"%]0@-L\P!_-/.PP"-:.
M#4V6S-%C\+8/=L%ID_)23GA!MFJ2!PV!8ZD:DL2S>YQ]2<=7298T.<&7D(5#
MZ*TV X9FN\$'XBL=7263D@S:Z.\PP6=%ENXTL?(W]/L2]V%VP4HWFD-)I)Q!
M7.1&*D.BI4:0?:568*J*A20QLHZV&]OA5C(R34N)P2N21RO=:P:\.?3KF54F
MI)+0X4PV@U,9&%VZB)Z'JW7&<D)JZ !4'9FR%&/HQ=@V8((3-?V.2-YSY"_>
M\&GRM*D$O0PVL^S@E-1Q(*!HT%8DR:K1B[%] =?R0 EW73K+2_^F5U$U<+K(
M8T!TL"*$NM&KR;#-+EY-FX_-PFA6_=QL][U9\4'13D^56-=^&9@XN@-#17-]
MA ++)XQ'-C77@Y*\L'4C,OW9DXYNX@')CA',;4E.UP8*L[E1AR)/0'*QO,[B
ME]<X(L<:9U RK1O0K;D");'-]F(4$Y7@G(<'<VN+3Z8V!W/5=AW9SCLFU>ER
M*!.<@,JR0P*5RSA>!*$LJ5S9]*U99#HB%%Q9MA+YTLBV3=M:4^#8MF9-D$NM
M@ 2GFFQ(']?&(&8WH 6!*XNK>P]F\8$3G(OR,'M<&\?H[8'ES)$L%8)[L*H%
MU; $E=0;"1^VQ%Z*Y[=ZOT,^0B]$SBDMX:S[B*<G4%&@&Y)$>7>\C3KA$YR6
MDB^H<3_>3U/F]5(MT@3$E1H.7="F =F%[70S"[]BJ2,FMI\DDRJA-4M[JN7R
MLW57LR4Q"7?F9C.<75C09'E:K-+S=8+/DMMB6OGJS?_\ E/DDQ,)16G.I1:F
M=QL,GTXNDCC'1ONJZ(E7;)A2P\SS]" C<9TQ%K #VW E>=L=B>D\< >%0M&]
M)\+LF1Q+>!H/\ =*[U">S/@AOD-IEH1>ME%+'Z,P*U8DS>)%/ VZ#P1<$[J>
M;,;*-BX.Q#HH)FHX"Q<OI [A""PL!@+(49 J;XZQ<5AX@'7\"*@BZJ=B<+A!
M&?E[RMYSK=V CTS7E[@88Q-[^)$-2N71E1FLW=/:#>BZ9P93DU0Z(1M4,[U)
M=7_#(C.FS3+8%0HDJ2'#($3^1E-M5-XY^@*D>^Y<MI<8#K9TA#>H9/H WJ2/
MKW'I=7CQ R5>F"+6H39T5&#XT \D\=\<GY\<P(^0?;;_W%A'YM!1@8^EJOD_
M%*L/@ ^+4**R^@YYFXEX.07)2<\R$M)9VW448'ISSY+$D;,+*WL#%1RPU,O;
M%MI0#Z:FL#&15$*(NEG?\/YUXQ0)M+PM_/]:%]%PZ4/<\/Z5WPSNH3WA#OVQ
M#M,P0_<H>0L]5!@@\$J.GZ)\E)9*:<?^,E"0[MN21(YW76<G(\ZP4O1TU2<7
M)+ N3*K,^I>8% L7O1>%9QAJ:$LOX%FJ(4N*E$Z*#R^P8<7E.[*"J82V] (N
M@JX]11V4%]BP6"96A%DI@K'-H-2VP+5<SYS:TU4[G&'5W[F(S3184ML"5[,<
M?XHV23:<2DS01)[?D:-XSM2LCRP@E9B=/F^U%Y'(D.:!K^^&'01UD\)$F-D,
MI^( .P9+Q<?TP/3Y<A5_;\Y&;"E*I[@=/. L'U&BP)PMRD[Q.+5> .F:K0N*
MP,,**9G0;1*_A9CE7]X?L61S%6T3%"V\+'PK2ENV@NP^%K ,!WJRE>%E\:A)
MJ^\+7'3-H#@(,[;Q9=<&8!H@2Q*Y?0#-J3RDP.SK$R6958;H[I$7KM">\>DA
M'FW?'^-K0-.1%TB26FCLM794@HEUR3I'F$5>6# H\K'VD&3A?[?X7C$Z 1O9
M2B")^'Y4OE%7"@]EQ*:FWD*[)D:1.Q*5O@PPZD6:HJPZW_9,*AU' H&"7$\2
M>\;IET9O<HE-B-V>8NTQ2A!<L0NG=1D%^([B(-E\*SH+F;T@[[S$II;[K+/_
M+MUIU54\RY3-#->9]RW@.F?F'DM0I;MIY#DVKJ)+&";Y8Q'3O:#!*:/3&& .
MYU#"K!"\7.X/>)"OV^ ]>I@Q/D\.EM\_#'V2T0FHEHVTZ?*Q \+.N;NGE$S?
MTQS3D,U*VVD[<L'KGJE;FML52Z4)$1O/4?'?BARZ\0[@*K/&.08^KFS%D>WM
MO?.^[@%8>/+NPQDO/(^\YZ5814'A&SOU$D]OH!M:8$MR9/=@$">C&< K+G0?
MX!0@5]4.).,:;^\+ D=37$E,-\=;&HVPNWOU2;PP;A/T"D/_?(.CS!D;^5PR
M7[_Q@&_.]8]_MG0BQ82SF=>1DU(*$?Y0V.V@J70#ON;:OB2VG>,M$1IB<1G0
MCRB6W,+WOC+)IBM0T-R'DEB%CR^0'**N>!Y.[=&2"C)9X_EO#"$=CXEZ;Z#.
MYZ8LV?2.NC::@/?.RR[C\MA_ =F:RWIIK/M# !,ICD1U;(\ENK:@%^SLV2!K
M%R\@6<]3H6$(8%J6$GSXHZ$-O>!\\/R.%F-XH0%H&XXNB3_36#SO ;^W]ZGH
M.@\-6(L*;>,X+S+& L9<F[N2N"B-[KS( UQP7E@\90\A/R6!..2E!:O,WV"V
M3O 5M@R^P>3O*".R\3WRR.^8AT;GH<#<]PQ3$@EA  NI2Z(_-88EI:6^31U.
MINV9$?=A=@&..D=S2>*'1^,<-VK!V6>QOEI&I7I_K,,$X5GCJRE[OUW!*,,+
MC41&O#:\.Y;+DWL,X,]M TIR1(^^2[N3H9+6=FHV(W[JC7'' ]OW RA)8,+8
M"Z<'&2I9=S^$B'@91C#RQA$1&6,!#YE0DV09C2XB\@ O%XZ@JH[E&;G-K/<
M?U2R[EW&25<_P[XC ML.-%E\( 8PE'D5]29*N4SX[9+27$Q5L8M$ZI)T 'N)
MZOBT#FI7 #W719(\H8^^:+C1EZM#D!VR0(AR(^EM$F*PKR252K'D&3[JK&[
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MIG>=; M_@6F8+H,J<-I.M@YW\I?%_=7];'DYN[V[N+^X>1AU2U,FQ=[9C [
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MV<5_WE[<W%_<SQ8WY[/EPR\7=[.SQ[L[LJURY4F(+74?Y7Z.X!)JJR&FPR!
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MQ=[/8X=1VK[ESD6E<-W>'8=!?9N)[ED[N]_(W4<%[EQ7D22N$CQL:[F3!U!
MV$YE!'$U[]I:W@%F:*/0+2PDQM$PH.[T>P]H46:O(A('$"?O9:;"RL2ZZ;C\
M(P'+,!U7$E^(?HQ@:,,]Z"!LL]*C$)OW:2TW04,LXI =.J6@1%M'3L]WNI9]
M64P'TSI+0G>=;XEM"M%.VY)[(*#K\\ 4;9 :DRN,3=J=*H/B*]HLBF3ZY7%1
M5BCL:&%L'P)HT)JC?Q &=Z&'V%"-RIRIC\8YDN+E.%UX6?B&Z=5=F.X[-C 4
MS:O7@?HPBV9\0HF-$3D XAX"V54F+ZA3K56>_^8Q"K.AZVS4KP)--^UZWN0/
MO@*/0\+#4)?35<2K%!<[1QD,5^D-.92)#PQ-T*SENJE6R)O]:3/$;#O&:(+F
MP*IY+E*1)<@><T>($B&_='I8>-[Z9;V">($4LCU#'6WO"SS50DBTTM9&=^K6
MZ@!NS.CW4]=4R0I7I>LX903@[C4#AN\[@>CXVUX\I>/827+=V)?A(WWL N_Y
MJW@N2'P+\4]9'*%;^+Z7>O- F&_N !P=CRTZXU,W1G$B$BLNT<-_%]D9OEC>
M\5F1OZ,PK'@\W<%\[AK":U'WVF7=\.VDBZD=GA5[^N8)O)GG];; <?5@+CH0
MOA>#&6!V\;4?+A',1GRD"9X#*D)NQ=*/X#X'3<=%HAQ[RHBR7(MA:)U[[0#4
M;<T2;:G@IRQ="Z1#V@9>"8J\VD[KNJS+SL&5;5M@^79@BY9>V!1F<Z,.I90T
ME5%9DB99A1WX;SM6X+^0I /^VLN6R3U*WD(/+7Z$-$;@IK26P+)4U90D'(.+
M#6U MDPX.0O(6^%F1NEY_(+52R8?ZLV!8KAF/??\B9G11N F=C#P'(,GG3Q@
M\PE^0R\N2IH/J;UFP+9-SQ/],,)%7>HQ10=3,F+$%ZM-I'#Z-:';&';QXT43
MH.JZ8XLF;/MA7E-<Z2C&?P+<<"[7DQ>K5?P=1MZ>QQ"=R*W=@&(9NB]:(^E!
M>'YD8A_MR@7"LJ@6+8 >(-N;&BN:0.RL-1]5*60^2U!2]7;6#H<]6LBF)YJ^
MB9DLJ(X'GI(?KM:$EO?$?3FW8US\\%9KO"XN\>(G#VCK8OTL@\-@T,4+ <5
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MN(YB4$[::7EZ0WRF0TD4PC'N33;*72+:8[J*;/Z%_.'"%/W;_P=02P,$%
M  @ #(BN6G_9G(%+_   XB(-  L   !P=&Y?,3!Q+FAT;>Q][7?:2-+O]_M7
M]/7L/)N<(QP)\>ID? ^Q<89]'/#:9&9GO\QII,9H(R1&$DG8O_Y6MR00"(,
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MEE<J=J_:X/ 7SZ6F?%>NBGBNE*W_K#DDS,)B\$OL#$7DFK#)^>2+,*V+QKG
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MYA&ZQ1Y&-+1I$_^KET3/7X]S>+(FURG$P8*9F_Z-RE-EB-Y0RC3?5]7J9?"
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MNNSDN 4?I8=%HX3:@/JF-6\G,FZ8?YKY)9@_8V*;8 V[@3< W=(W&,32%L<
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MF4:(G%$^4P?D$QX34 "1XZA@><FDO1ZPO'Z)!BROHV?YL?"&;0EFETF^C4;
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M\9P:+;2L COY@8A= K2_$4I-EU%"PW.ZM# +=9.S(0- BQF:!P-OXX2'PT(
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M]__(I-MA<82L7@N(N#TU-+"U7&?.E)'+*^B$N MQ+X*XDQ]PZ/=-5=\F_D[
MBH73$(@N_#DP \+H?EK/Q"7$+]CB6]_4&J G)(L6AP9M,#'(-]9(=0JZ@^D/
M.&V,:9$7)OF\HD;(JY#7(LCK*"A1*D4*!&IAW+U?5\A9!=[;JP31P(N!]6^T
MPR0<7_%X[%<N'"VHL#L$NR0H9.3ZWZ8O6VW.=)2Y[\R8S*>L3(C!*L,C.#WC
M("B8E6=?G<?9'.8.L]<=/QJ+/>;.9S/38'X3A["W@OHQ?!<)J OVR3=F)P3=
M!-8^V_M.]B,M_H?]>=/";@;UE; 'P0BAA>)IC7@XD @+0F@DH9&.G'%84_/&
M=HGG$?0PP2#X&IFS62S+U"T]U^RIT#$HA2Y++6C#$)%^]!M,F+@&K+A9>^_[
M&%G!,E8ZD=DC(]IRQ,26[=&";\Q" 1WF,0<#J(C)8K;L4N&2'W/J5( 7@L4"
MIP?F[D+,-J$>"7N&YRX\\-V&7][2SV_A),**1U;EJBKY%M$$TU?-QWX&K(=<
M%FX(AYYG8K$:W&NNE"EM(N'1%HPSO/!]CG[Y-+;*N0/*R05U_.P0WR?":L8%
M%.)5,(1*$BJ)=Y7D%W-=6D";1@H3,RJ"M'1KQ:460*ASW*B_0K,K6)_"=ZGM
MP,P3>-FZRO&K/!K.?\D,TP]HVY!/]P\5!:3:IE^,*R5[!"K(6X2:CUW @N)[
M8+J@ZM\Q4'5%;2WTEW_3P%8!JH86?D8+@IE.J@6CVS-:C6VY8&Q9]IR5J32L
M(/':KP@)O_I#QM>EDZEO(5%;$%M+6U"'HR"%/#L#(IN>[B*+1=@$W?8>/=RW
M&S65-5BQ9Q,X09K403.CKF)XR+5-=@'#**$["T063/_2]R^WA=ON[>:6P,IC
M$S8AL',=(*5/(G4[/X$,Z 4ZA 5/7WA!2')_D-T4I[:C/SWFU;895M@49S:M
M\ V[PQ V'72#IH1XR]K>]/5WMQWV==@9)" XK>09.-%65CS,'7"I!<'JX3ZH
MPVG:M&<,0#/'L!T&G[ <*:+,H'\BEF.;)GN*UB3']'Z*UOA<+HU>.VY=5]WO
M%/-PWU*:39^/]!(TY""UY,/"KC$XSTV-G2]@Y9H-IWO#?0G9FVP+R.Y-#&<W
MT*ML=BM^;B)^ ^>^>%NDXK^9]C'W*>0BW6:8I@_XBPV<%4S:P^F!@!M^FC.L
MP_3+2,],L&A&-BT33VOVXN^T?&W\&[QN'6+3%ILV[YLV6,K&E-92#P_WU"UI
MN316)7 S.J 'V84?TZ(SPV.BMVH\R"L&A/0)Z>-=^C:N_4(?OO#;"_D2\I6!
M?.G?F&\\-/$UVN=#9[N?87FV%'BS-3@*N..Y21W9P7%(VK2C><6&D$HAE;Q+
M)3W:L0:M89RF,64QG""6SW"Z=#?OTL)H4X<LA=#UYGJ87;XAF=(R3([>F+,3
MJG^=%CW.PT!X*H18"+$0XA.$V!=<Q/H'?26F,;%MYOEQ_)9$MK,(.M7[@HIG
M-/Q]R^;Y8H)/+NV.2YSFI8HT+Q&,+X+Q#PS'<R/A[U3-+0T,0F^@L;9@VFSN
M+0-JZ??]ZRF--5)>7D-M.6C$7/F&-3;Q=.JK2Z8FYYYM3*=SYFLWV>50<''C
MJ]'P%GWMULS60.,Z80-5$9\KC!MAW*3F-Z!> .(%]\XVB[L);Z[]V+M(CJ<O
MW*'J<&G,#(UY TMI0SY9UF,D[F:E(WC%CY!<(;F\2RX5NDBJ"Q4P=B%=F6''
MH_X\DP6A8A:\2A-T80CJY\..0_.*6;]4PT'ZG*7@+MMNPD?+@+$@]&$NY%3(
MJ9#3='98AVCVLP5'#3_NPZ:'1!J:\PV;\V4LNVG P=;U<[D=FNP>D48_ZH0*
MN2$V4"&80C!/V4!7\A>YE [B0-Q58!\-PPYE4UBQ0@B%$&:=#D[^FM-L!X<8
MT]'<<?W\!2:/,\?X1O]D6+3H:I"8Y1]5)P2;WD2C]4]F> %_XQ4?0C*%9!9,
M,J.IUFS_,XWPKTP26;@)K<F :&2_;;';!IKF29U"\+5(4A.>VG.6*6F,@RH.
MO*)%R*F04][E=#,=V@\I86:MGU'$[FPBA9$(GDK(]>O5NQX>CUD4)F$)!BRJ
MQ-],E^7EI"#K.NI;6D^+ING/<Y/651([KI!D(<DG2+*KV3-VU 29](*BB=\)
M*^D7UC\B+KW*-]Q)4!<EV)?';)_UB&G"UV@J,KP!] *(*ZM)3+/)8$%AH;,M
M][5K]SN+,'WJBV4LF[*&]1<<>_X\"5S(Z+OMF#JOX!-B+\2>=['W"XW ;FNP
M_9LY><=$)S1%DH5I4]%#)OX>AHL^!\F28K,54B>D[O2H3M^$I06)L.O:FL$"
MD?P(".:.HL]$ CW#X$ZVXPJ/L!!,(9BIYTQ,9]@O!3XVY]2:]>.(?"L7^&@A
M$E8!=X2\"7D3\I:6O&%K@9Z)/6.E-C16O,0-\W.E575<6BC#H7LC_93%];+J
MO; [SFA>T]PA&Q7R(N5T)>1AQQB/U^H+3ED/=Q=]L^FK_-%@>PW3\,,_KUX3
MI$VQ0K[A-:UM^66Z'^>N:^#*EZ^T))_O$>NY#B9FY5<\Q2ZMFP5O=9@C:VP:
M-+B1;N74[?7=<(D4U -91,8@K)*A&_98"*Z(7ZB0:#O;"R3R*BQ"30DU52PU
M9=*.O*9?%HA)V](ZC]P!.X0ZQ=VMGBQ6D8A34 AQW$KYK)O"\9T4%$OPQS/6
MY,(W@QG(GTU[1'-WPDUZN2.YT?Y#?H@_W=->C.R_S"EC,064K?Y]N4'37)OL
M[@T$1@<-^S+<KV"3K$R;,.W:OP\;!Q=>K(*Y9L]-W>\ZXO<-\5WNX:X/?&'=
MG#Q"$[7!"-+!WJ$=NH(8ED@/H*6AX/A_6ID=+LW4HM84+5OJ4.5G&GXI97?W
MBB[1 *84Y)*OVJTL"]<YM,3HZ#]@S[" 5+IL/\\KMG+ZJ%]*CDY]3AM=3^D$
M UHDZDODO]^@;S#&= '+4'-JW3%3+BC2]PA/HCO_U6''*3H+8KKDN]_!Y>4&
M6X'%QII+V2[Q&U0%Y9Y]!CKL49<FZH;^';8M7#Y=;K9Q7_:8NK&G8;&V: ^J
MI^[-JO44/$QFK"9>4"R*\<C$WR5Z<Q,TF*(W,Y8N!736*9V_TL90R!X!7$-R
MV6@VA]\U6-A\1CU)NW#+@HG']+8'46O4QY!F.-I\2GO<L"I_-+.5K9*]C!''
MH&7JX!F6E.=$W\),: T(P5K)L>)[%NV5HQDSYA+S1[E,2W1/35DM>49S360T
M[X%'EMM'I''EC-6A9Y# 'GZ^"$>%L^C,Q(LKD&U:+O("=!PP0;E8]KI\Z#P.
M46_9P!*%GU/5H8!NN^OU._V;7N<>]?IW@\?/G6%OT(_TNUP9"(4GY^;)(S$]
MC0@]68-NY3*P(.Z6)^]5!\;+"+'3)5^"E?&7:Z_9)B7"+Q?MBX0V;[:2%(K%
M/2"]#UKPYM?^X'[PJ==]DD $;I;,NTRLL#A=(MWEGY8]3[=TNR[FL@Z4W1%L
M/;!IL$V/&1 ?L<FNN)\FA+#.OKZ$%IPZ;\!* AL8%OB6BV/M]XE!RXZ#NB%7
M8&%^=W JY]HM X:&DDYUT\6*+=4E6WP%ULZZS$=N*Q8DSG;%YR@VVP\-J^/"
MDL$;.FYD>YX]W79VB,(DYRW"+Y2N*E+J?=N3SX&6:=^RJZQ8_="YO>WU/T5I
M_?Y\=$BI\/8/6CQ(E5\9;C5>X9;089&5)]RG2>?IJ3M\VDFBX*#S<XYB&$C%
M>/S:.VO^2Q=$SWOIKRJ'-\RC2SW4+AR[KGB@QQE#01"=*_E[/\+:5]IVQ](K
M0 [;N?I)TP@9CS,7S*6%X:N!&QQD]&CT!WJ3](TV*J)^DM>GWY:1MUN'V^?S
MMY< N FZO28GRV6B*S1^7%FV=<?:+]+&KCJ\U-#_K#;;]0O6P/&7B[E;><9X
M=D4I2__MKFCZ2, 8,6AK6OJ'CJ6O?Q!Y\H)E.\($'NF52,<=C.GQHB*K%56Y
M8*VKL/?+A?'#N[+F4]WV=*(94PQ+FUN&_YTO3[<7*/C89:[;JE2ORI+<J'YX
MM[X,'ODL$!9#6"-[A-4J<J.BRL<BK T(:TIJN\$=P@[2Q&/V3]Z:>!"$"V@$
M6#0R":\:^-7,ABQDJKDI4XP+CRLF](D7&+*9J.2F(LEJDSMQ.=.1<P!<ZT3
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M)NO^R E\2RTXL3")0<B$>\H#QJC!^(M+V*$IDSNW>EUJ-53N).=,1\X!<['
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MB2+5FPU)K>_WH/ 0Q"Q0RP]J8Y50#D'MJ351:C5)*0AFN3;MMY6LXG:_X$;
M4I6CV#5E3HI?EN1:2U)K_%TTG>G(.6 M=J^9D[J6&O6FU&@5/$=6E+ 2,4=B
M9,'B@AE[%]?WMO4LKMTXV'_W%$A9>M6R3;-O-*5JC;]RDF<Z<@ZPVU,C)2GL
M3DW(;*A2LU7PN[?<,J5\'ZZYU-S<:FKA#_.%;'O9%+KU#H%_MV24_V4<#^XO
M 5%^(+J]4,I>B)ZJ]R59K4JJ+-RUJ;IKQ8; N;3% C4BSK:,/+J*4I?J[?U9
M)SP(FH J-U!58[$>^Z!Z>FV65AU. PDJ=?( 5>$EYON,7+;EGN/(Y\1B'FW,
MB^L;>SHU/%K6W.^$2-6^83T32X-= +WIVQY!2O4M#P042#T'0@L6<Z>,A'$C
MP"9&%BPNG''SY-G:UXEMZL1QPP)S.AD;8-M8VD*4=SHGA)[IR.?$8A[O=./=
MY\?$<0@=$W03LL?H;R^YZ-1:[.IF^76FV1ZP,W">/.P1_3=LSLD#<9XFV"&I
M^)D?V*O<J ^OU[^[N)8OY7A$)YIA!WVC<T!,SRKO$9Y[$]L!:NGHQ076MW7#
MCBS0GT)G^:;3%Q9?5! 5+;-_XPMSV1>N@O\BPW5IJ1EZ4K;GGNO!#S2N2B<N
M((8R F$7)F*:]G=1/O"LE,^9CGQ.+.;1R-W,UR<.]=MUT(UML>%&)I DD2Z.
M)20>KXO_G'G6G_Y4.I&)K+_0_4RF(^*<H+=KDJR^J+*I(H;=]3-VM E2%0G1
MZ5V]I,!?)$LCEO&VC2P]]M9"DH21XA]SBR!59I_4>! UGG5:&G>O6QK<1H'
MS+E\X;0E%5\46.-DY!P N:7];3) !D$!9PK( APYZ0T?\#K!>;,> X'_W9(<
M-F,!\9'5Y7325.4$1\U#391Z+.8LMK#]]LD)BZJVI'J=9I?$RR/N-3Q>7E3,
M]W'(H@Z*5-KN$VA*[6I#:FS1.>N+$J93SCM5+)TJ HR]=M/1+:9;=:DNZA;R
M,G(.,-NU6^RUAHX.D6RV$_6NX]K,>:4JX+IN4%IA$^P#0Z\8%M+PS/"PR0EF
M2RTML3RH%3L>@!L]Z\;G11:ZN5:7):6I2&JKSIW@G.G(.2 N9A\>@KA3BQ36
M%*G6K$O-&G^]/@IP(NUHVGPZ-]EUF1^.X7&"V^"%9Y4A\F:'D,5.EH_$PX9%
M]"YV+#B4NA%6WOJ<S$##(WJY^LM%A:KZAM2JL6XII^60'-*$YJT )F_ K,4"
M!XX$YFD;0028L",T&PVI?FI]PB. R;5Q'DU>=7>&XXDM@$M)BUT+1X,JNW_-
M#6^1J<IO@%W?!(6_OR:T4/@EAF'L&CXA#--2\(H")O^I2=99*_>\S?D7*A,P
MSWZ!E;T*2]/M^<@DQ[%N7]?"?<.E<T*N[:HQV['T7/3XM2HUJRV0G,-SOE51
MGJ!$8-Q5A#8Y&$^O0-"L51-YV'E (]/][[R1K2_H?VD/TL@@=X/^L/+4^W<7
M-ADZ"F(?W'4^]^[_N$*;XZ#/G<=/O?X5BNIOV8 _1/BH$:"X\WYM)KF,-YP0
MA#7-GLZPM:"7W9;MT7W$@8\!1O#4L\,<^XY'[UR]"7$)Q0>S-)@?R>].9+!3
M!GS $IHO\UM A&",3^&8(]L!2#.HP+*N9(8%AHK8@ &Z9/EG@#Y(Z SK]-Z?
M ?=# (*MAL!%5+HGL]'$6<UGMPEQL4/OC$PP+R+F'!IV_S6L]/JWW?Z0$>7]
M-CK4$PT98<H,/Y/*R"'X:P6/X1U7")O?\<*%YQ*X-(.WD>GU!XPF#I7ZGX:#
M&P 48P) Y88J$<#"AW<87D0?S%2TUM#QG[GK&>/%(?"(?-LD8R]#N-@FC JV
M+>T*F,Q6S%)^/KB>8UO/UP^=^\ZPUP>PW?S:']P//O6Z3Q+J]6] EH-'$N."
MUS52Z_AI/G(-W<#.HCSK^D G%>HA[.'GY>1TPYV9>'$%FMPT+'+!# /-M6EP
M6D2'/RTU-Y7<H%PI/  D@C=?%Y]2;^86GNM@.^AO#]!N&1JY>?L.)KIO>R[Y
M4LT[923W<X0@L2!Q<5<L2/Q:M_7E5?[I.8[#C74%DT;>1L\03AT$?0;B3%S4
MM70P8\(PYRWVRCF*<*G8W0?SE5]N"VV2+KRJ><.+^MMW FGK]9)0)07E=4WP
M^FQX+>3Z?'C-K5PGO K(IAK;8_>W;O]+]XF3Z]:-Z]#7.VF>TQVW(+H@NB!Z
MF8G.=<!:6(3/UN>:AQSRC5AS(L%W.$M R232)\5XGK82B^=Y](FYT3GD#E;M
M!Y$I\#_/SKCW&0<<$UB)8266L;\3*[4(5FH"*V>&E5C:_3ZL-(5>.5>LQ)+.
M=V)%C6!EJUXY(/]74FJR)+<+7H\JD@M6<@B_=I),.4W],QU9L+CT(PL6EW[D
M<V(QCSZ9B^O!0_>1!GM_0MU_/73[3]S<# A0EI[0@L6E)[1@<>D)+5C,G?7P
M.L4?;VR7)8;._)L=E\:-Z#S0CF>0IN&"BQ4("^[6X#'*$W$;= 8C9P^SZI8^
M8?MA)BZ22C5R#C#;T@(I$<S$'51Y1LX!9EM:2NV'68K75^VFU%!%Y=HC[,Q'
MXA*6[T-S^'7RC9CVC":L<X+=4DM-K)Q5R(R.I=^N6-'],2.62XXS/ ^J:U6O
M2TJ]Q9T8G>G(.2!P2\S;H0C<:Y,F1V 3T->6&BW^ND6<Z<@Y('!+)-T1"-QM
MKAY03JTJM:LM26WO+\9]5D H-02W!.@="L$435FER>I+UA7^M& !W*9/@!+#
M>I;0,[$(+;!'S5JL3PW+<#U:?.D;X038I1:I6!QCP)=//E= L#IK/,G)Q*4]
M3FJ2K+2Y$ZTS'3D'*,:ZZIP Q11MW:HDJZI44_@+N#W3D7. 8NQJZ30HIF7T
MPJ&_V9":[?W]",X*$&6&HAJ[?CH!BBD:ORU:R1K^%:[<(VS?>]MUT9M/V+#>
M(MH>&_OU@G^# 8AK<(+M4DO5\K9MYEE7E!&4)0/K"3@Q&%,^N*XAX@?*/W(.
M4*L>"[7T;-A5*YEJ78*W"?3Q,7):Z'NY>5%;54^ 7UIV:U6JR[(DRP<<H0K:
M,ZND(*H="Z(4+<XF''S ZFQE"Z(">$XI_:G9.)L[V@2S9B33J>'Q%PL@&L@%
MXE/?+CX/ 0-OEOS+VJU:4QJ)U+!H9UAP-.X 8^,D,.85V+H3@>>PK9\C:G?I
MT.:IL$W+F!4Z]$S0N .,K9/ N-<H+I$.Y=H;&^TA:_LMGZQG1'P/NBLV AY%
M+W8U-P@9%]Q\')GW=4@%II:B2DKSQ(;,PH@Y-^S68G=YR;";8C!#6ZHJ+:G:
MWA\Z+K KL!O%;BP_+3%V4POYK4M*JPW_U@5X!7@/ F\LZRT9>-,,%J9:E]5N
M+ 1X12U'OF]URK;<<QQ9L+CT(PL6EW[D<V)Q 9QY++1R# ^%#CW6P_WU27>F
M-OF.&YU:+*E^:93W+,V>$LK*C'UYJ\"XE)QZXEZGV)B,I=DGQ606P9HI.>L$
M)HN-R5CB_0&83,GWML)D6DXX <IB@S*6BI\4E.GYU"*@K$E*O2;)]?RC,H2C
M3)R_SH/0@L6E)[1@<>D)+5A\KHZRB^O!\-?N(^KU;P:?N^A-T/CD+0_T$L \
M!T(+%I>>T(+%I2>T8#%W%L3KY*'VK&_$95D.R& ^'Q[HQC- TXADBQ5)6W'!
M=[SU2>99I*HBU>JBB 0G(^< NEC.15+0I1BYKJAMJ=I4!>KX&#E[U-5CV1('
MH"ZUF'- G=P4NHZ3D7- 72S/(2GJ4@P6KS9I=7/^:M_RZ-;:,$KO; =F92%M
M[CC$TA;(<[#E!FQ^8]JN^Q8]8\/B!-#%%Z4=E\3U6-I%P)V;@#G#%6_").J/
M!$2&#/&/W"*_JDVI+2I3\0RQ'0B+Q1">BK T"T<K=:EQ"++. 1/%1^,NA1<+
M'TP!CEF$< F%QS7$=B L%@QX*L)2-%L;+:E1Y^^$7@A7JD<<.&6$M4<XP7/Q
M)6F7LHZ%,(9<R*W'2;.]/XI6J&$NP1/KFY,$/&FZ0Z5J_8 V$ (\/(%GRR5.
M(O"DYM54I+IZ0/=0@1Z>T+/E-F8_>M(L9:%*S=H!;1>SCJI_'4?C8#PF#K_E
MX@J,_9>AWX@7T/(FQ#FM\)MHV%&DD7, 6;S2U5Z0Y545^:Q876J0Q2M2)0'9
M;@-0@*Q((^=@*C;B)1;VHBQ-?V"[(;65 X(GRMFOXV:"K6>"# N-L>&@;]B<
MLW9OW['C8,M#IH%'AFEX!F\VY%DE.^^0HK7N-[_[7'-75;_#3XZ.O"Q1N6\!
M6WY@6S\-MBDZ*VO5MB0GB&<2"!8(CB*X<3*"<S&8!6S/$+:[S.[F:;A-TP27
MX*@IU1O[C?!7+8SRJHT_Z)$HR&!";P)O[EL)7B#:Z7&Y*\1NS]BAMF];]GH)
MHORN\>NB%8@ \6$@CK>Q.1S$*5KHS595:M1$5Q !XX-@W-Q^(7<PC-,+;%"D
MAKH_+D; ^ QAO,-B;VZ_\SL,QUE4-FQ*JDHAO3^J5A0V+-G(YU3MXDQ'%BPN
M_<B"Q:4?^9Q8S*-7[^*ZWQVB^\'3$P\4>M&X5L%TU>WYR"3'V65_.\Q2C@V7
MEJD<BUSJ$^^5&G8H4JUZ>,EOM7QUZ,N"K5B\TGYL9=%XHR75U+K4.**<O, 6
MM]B*Y68GPE86V==RLRG5Z_LS* 2X"@.N6%KV?G!EX2ZJPH[8 LW5.MQ?="JX
MA+]('$/.@]""Q:4GM&!QZ0DM6'R^_J*/V#4TA"T=Z88Y]XA.@[T0+0Z(9L0!
M8VTZ!?/.G6"'LTHL);6>8Y58NMBQ#.O9?2#.$^7"K<^FU)U+#^SM;M2<[O7O
M(@:U?*D<'A0CSFG<(BU6MN40I)WB:DJ M 2ELP32"H.T6)3J@4@[VO&4 &D-
MH=-*A+18*.DA2#O%"[47:<IKZ#3AB!+GF_,@M&!QZ0DM6%QZ0@L6GZ\CZG<V
M#:(C#._'SP2!M34B#JT.$G5"N<B>>ZZ'+9T6G)N[\ 7#HD_,YC0T'8U*[,]Z
M;7%(TXI_V8AOQ1)I0FAT?&3T&3 &X\"6]RWOP0H5Z;K&XH8][6?0D-1:3:JW
M#L^O445^S9GC.Y9@DP:^CW;(;<6W4I>:[:I4JYX8F2/P?8;XCD7%IH3OX]R
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MQ\A"115[Y!Q45*S,(S<J*J&W0FBD(HV< Z)CA1VY0W0F#A.UUI0:[0..LN<
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M2&JK+J MH'VHP^78BO!YN07K#:E5J]&<^]/070['X#DC]=C:\FGY!&FU\"8
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M6$6_E2P7!IMYJ<VTG5%1 &9[$2K0EQGZ6GFC+POOT@J)[9;45O=7'A9@Y-&
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MX2(J]L@YJ,/U- 9?@KJA  F_$+?0*#4H&[M R8$S2)7:<E-J-/G+ZC[3D7/
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MWG&%L/D=+UQX+D'$?? V,KW^@-'$H0+]TW!P X!B3 "H4)<]8;4Q,+R(/IA
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M @^)!_V+ CVU]!]!>!_@<S] B$J I0;_)FZ$:XN!#0T&KFVE=P(_PN8\MR^
MTL#&@/,"'4O&#Y)SFXOJA_?"5S/FY#RK+WP/CD$*CPCM^=T#1P38B1%>S>,B
MIMB/0A<!,/$.<M,IX8/.8CI%%('# HKH>W^@K( E/$ " 2DEN'5O,_X ]Q3>
M CE.X[Q (<4/$BUN\\+#C(2",^(=^ZEZ)K>PO "S &RR?=.QD.6.&0Q)V"@
MPQX HN:(/GP'1)_D2/1%/'%]7POLFG3-0A:=5((-N16!HK>5[#8X4)W"%'^+
MD9[("BE6Y$8:NNB],)J.B4J@4$U]"?:."*#HK'6V*R_^P<#WU0,&/<3S(P$&
MU#(2H<V[1V$9SBZ-D.YCWWJ7.J C!14\2""PFP-</55]'?GAO2P]+I^&\P2\
MQ/X/^)\I 1[U_?%\I<$,80WP-0O;W/$M)&7/!QW*\@ "I@!$ 3Q:QB,!G0"Z
M8A),XC&2!\F7<C;FI?9CF][)]DVL X9()ZF$)@$"KI<@\0'$86;5<$@H:>$W
M?Y[G^'":S4)6_Q4 *US'\-2-L"I#W,LF.N%Y-I 0E165:K;:=K?9M)V2UE5,
ME^!J)*/4,N4X$HPQ ;)PX+')&&D4UOA]Q&G4&T[!KG0N$I #0;S\"A.6&H5@
MX\ZZ*VLU[2Y%!!3;#M$N%]UG(9-]^0XV41O,:=FU3L=NM8JW:!,U%T25_8<\
M04>6A)T:$J&0&S'$U.'$[]A C?D:WOTH)=,/"O52=L,[CE%TH)HB 6&IB96
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MF$UW["7';A0A#_VGZZ=B<WFZ[5HQ3Y>WAM('D!058H2PNG1WA18:7[.WCWG
M36P%$SF;7;O1+#81.X0+#4">)_*(7NY@&)N"O_@=A%T25=PI@+X_HXV!Y"\B
M,H)'TQ!U6VN:1HBKDL2&T0_C95/BU83$I,]2/YB%)]9NM' NB3@C[\SK;&2
MM20C$*S"C&+L&S::K!.V2A(NGAUU.(A)P(7CR'QZ(,N%:4!7>0V,;NA&<-&?
M0OA?9L#K77_25J[2YX_#(3'CG-VO=WVLW[H!36P E*%UT*S9%DKXI@<NOZ+,
M"<>2?OVC]27$^8Y#I,\!B?U*U99D/D;&H< 5*3-*_'$IT"@R;3)K$A5N0REZ
MXR0$Q<AGR2A$_G\:;:B\,4M%=%(TO3A.Q?#0^G7L^6)&9H]!N_.0>RD]0HHO
M4S=.F'X:2Z5'S2>ED,,5)&)D8D&8T*I 08V8R?614=EDJ  Q'9D1O"\WXF;W
M&*M[9*T$6*UM/"A/F/<$%P77JB_2.'1BD,8*>"M:#1Z1*9Z6G-^N%\G+6H3H
MQD%,!(@#*, 8K?FTU!\ 1M"-,5K_-><LWA8&5@$W'(O@U*J(FRKBYJU$W#PJ
M=F;+FP<R*%F=JR7/EPA$^:3"'$!2M-P[U_,),^>K!676JQS702Z*'!N$1U3U
MT+YK:NQ8GR5A61692)@F:Q,)=*]P)1&L$O:9DPEFK-8"-IVZDB&CR$QJ+BQ)
M:M(EAD>#J1KV2^F#X$.Q^BF;O)$W^][$2U@EYD%Q$#SOQ.AZ9=,"\9>AZ"?2
M[PZR,EG2I2%#65Q 8+!&<(VX BVDE"PT)*<!NQ+(Q&-Y:"^E*QR$<<(S\/)!
M+/&'%GI>2^^J+RW#MG;+H72O=\_"OQ*.HI"L2K#.LYQ@H<0EI<C'8D &AR$<
M!EYGR18*(E?>!,NK[@N\DP$?\<3]D1O)V",,)BT-?)3P#(Q,Y@M/G8"Z0)_L
MW@P8*"E)7TR<9@:M"+5.&,TW[TBI0WE 0S&-_"/D]$G03^*[#S8OCB74> #'
M":=JJSD(!@0"3X"'(ZU/Y#E!(9ZP<U;ETA8U3.U.XIP!BHF0M(3C Z ;QHAR
M&O '%OP1Q*R+EEU>&JBK8YA36NC]6 1DIT<Z$[$/&-77<-[@=(M!^56:)J0!
MMX,VX$QY?/'A@8O>;=QGC,V_QZ&/CAQ\#P,/T.I#V\QBQ#U<U9V(R7G--[2<
M>+"?3@@*=8#!T*((J#HA'X2Q 3)@+B!DV=KA>  /R;0J=1I\1\:8F9ME12"[
M//C9@$6"&O@A'DG3AI%BI0V$  !>PAN1BDZ 1@M<*5P_QP9(W$8]1.XK",N0
M$0?4,7,$7M+JDCE]"@ ):#&#LXAZZ-HDMF$8-!9S(TWSZ6^ Q1'C'9UZ'ZVY
M(W2)2$64;,!R=;YIS#8=5(8!&QW1693"V/5'I2$*K;VV6R"10N\K.>H()F_A
M^( >P3'$!WSQ$U"H =D"U)<?M'*:3O'0Y[MSG'8NU?,:!R2IY)L:;EN]Q9W6
MD5VKU?#?HB$1EDQ[Q2W)6"PS+LF5?@7?&R#< .- K<>2*LU^P07NC P_0:($
M'.G_Y0C*F=^\H%S"RXB5Z>E-^_\&"@!GR20^DBX+=J%&Z'H^-$1X#^-T4H8U
M)6K2^R9181G27!+B+]!JF 1'-(*BR%02)XS@<XA.>2#O AI%8H^:@7D,!RPA
MJF0\1]E_+ JB"&7@FVOY& MLL!_<,P@GQ(>U3<54)EXX[+_HW/R$_I:+D6E?
M[ 7#Z\Q?F%DP+S$  QC4<T/\MQ[(7_]@?>I=GUU;%Y^MRZO3:ZSTM=<1_84L
M/!  TR$I,T^2FSR*E@BCH8NQ'N1(-0RB@$ PR!0)L'1D(.L>8$ (OTL!L %-
M3WH]&T8)-EUM_Z8(V2^]WJ6V@NLZ1]XDAV+,0;)8$XP]Q' HHC=290"Z\AD>
M@[,]^-]#LL)'* KY#R33/("J2QJ-TAI(Y)1153/CC\(PP80?%1B+FD=.UNTC
M"2'L$5R;24>WE*8R6F=\(!AL)86_3$.W5U:-$?-(S_71TXY7S]^_EV12M@.1
M0F,D5"2 \>P'T_X="/0JN]$#J\FN%ZE=N:Q5W(Q%N0[YA" 26]N_U;1(?OM"
M!VK="74=Y5.R+"K/FX,8? PSB-$5EEFT*Y1FH(C'F9+F$DKJX$JLW: P:/4!
MZ9)#J0A% K# 4U:E.2)%+P@P.OU*H%,1)3:%GO_0=TC2.H,+1;TW:K:,+P:=
M01B83J3B&D$Z4YA4=S2<>.+%L>E:NS[5KC4[;^^)5]DK 5]N130C!JQ+"B%A
M, ._F/5DVLS&G"O/R/XK>- WRO!+<OKZ@\:H^0*B0..#=?W]&[S\+Q0&KL^^
MG)]]/CONG=]8O>/CB^_G-V?G7ZS+BZ]GQV>GUSN4K]DJMAHT<S3IIAY>C6!&
M#FTM-+"K*=L,:RHJ;'4U8X]BY(:O-IYQCVH]\'X<@H1R$-X'1*Y4^HQVMX"\
MX/LL>:BL1#TDV6\R>Y@I+6F3GR*PV8YVD 2T"F&KWV-Q,3J%(28HHKT"$/K.
M9C"]Y"+<L "K;7"K@!$^A (@6O6(X6BY=%[P!!FNA5H$1]BB/6XJ)5&*HB=;
MOA1HD .B,7*BH=30MV<-@9G4*7<@S3MSWTEF3&XK^5FD5;)L;3I<$Q_2IK=A
M&BD[*K_$F0-HZD=Q.TDYQHE$-S;Z#CTX ^T(0CNO/K-=1(_2?E;%"+K71WAQ
M [9%U62-?>1QYWBNP4316?HAQ Q1='C0)\"=OAO\D#XEU$MDG"B[9 QKBLSZ
M<-&3,1BS?1+SSZ4EW>=8)#>0&@4K$H>\*G,Q4M41P\5!Z=W2=M+;#H.L'77L
MME,L_;HX'KU>:Q:JCCYA]<]N"UCK'MF.4RR:1*8!O"'QH(*/E:D,*-%,Z@#N
M=$:RSP6R[R 9* 32?@;-F,[9J(-QEEDZF1Z\ C* ^[!H(_EP0F,O17XZJ]2-
M2HV]RE!KY+.."I3$SF2JJ?M [DFRYLC*8+F VF*BWD!"O(51 "Q"/G(",OT"
MZ](V#FUR\"(#*MD2(F?1/C3R.8V!ZQV C#@!"%'%,]AZ8QS&+L)T0?G+.04P
MA>R8#/#XURN 9%XLI;[E(;;<%<'ZOPZU!.A\DE_" '+48VB@)9Z)$%WN\QX
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MJ-S"^Q!+>'V0G#Y!$96+ 9"6/F>:0VMN*,<+9)>^[0".>A7 405P5 $<.QS
M(<,T2F0!M^UT&ZUW"][=LK1P5N3@,\P[64D68-Y"U;/G\"FR*"E.PV&$4H&,
M9+$;N#^=!:V&IU) BAL?6I<BISD6+-A2H% O<%'LLG&QAY">'_7L::CYZ)UX
M4"8#8(^^[A,2#K137]I^S='0G4?+I;  -BRPI39;_DU$!A\5%\R/$1D=IF)6
M229):69C7#Q';DX>:4(X8:B298X(90:)QP*]M^A^A>W=N2 3HDT)92AR+$M&
MOT>ZY>6LT)K+VBC4;2DK%Y!W&M!%J\>Q&AEV-W-]D*-D=S(C#0I3_03)VA1\
M$K,H3C74R$+ YB6"'[(%XB6C4(TEUW\GEP#<9Z-F#8%=[[76KP.?"CJ&!-4,
M1+E_$!L+.?I*?A@)07UY.,B </]@B@748KQO O^LZ'3F+1^,L8A*'V2Q6")O
MGR]=00[#""$;U6+3\=IHF4C2*& _G2XRIFWG1M>#_<.K+Q$V\)CFSB@<C= P
MTW^8^7[F\I)'%6M0R>Y-[@44JSK9/VUQLRM8(CJY!O37@[$8IFAQH*)5)"L_
M/SQAL>)CK-P7HV1CBM#Z6\\;3>^WT^O>T.:&> #OYJAHF7+&1W;TEX]W(B*?
MK#SI?I@ -R[3U."2?6R[_#_OVAL6YPIB\PTAUS?&J=,<3N7EY!<[_>JZUWC=
MYTA!2V_;WH7K7MU24<'7*O!5WS9\(4=:"$B7O9.3L_,OYCX_5K3DM=YUL[KK
M-W/7%5Z_G;O>6;Q^20&!-:&_;!&L)92-1@QE!DCD%P6 M5F\VO[6JT.O#KTZ
M].K0M\M$/J)M]S8*TV!X ,<11C_]:3 08C3*.>=GF'@2KF&5)GLNM9CNPL&5
MS%PNT)2OY\_S(&\6VI9*261%_ZBSVTNZ.]?;)=%>,9WKJIV=?Y/I8[])Z_XW
M,>F+*%^8Z@\!O[GQ>&%-JH-"+:H=O,@*A H@U'D<"#4-$&I6(%2!D%-_- #-
M^G4J 'K+  0TJ/4X$&H8(/0(&K1Z?<6NW>VT;*=5K*_XTK?Z**EN1/]L3ZIC
M"\7E/%<W)0-@LA(<\VYAR!*3UDOJ*^LSNJV AUT3#^4]DK^^IV^Q%PQ[\@YW
M4,0L-=J]/.&M /J% /KH^0#]L@)O!= 50&N ;M=::X'G%Y2_*WA^@_#\?CZ%
M;CC/A^A-JP,4M_H_[P[>_=RT.XV676LOUPL6POEC]+ /K\6:>RYVTH8[ \8-
M6"ZV5??%TZYCF5J\;+KUR#6-0O$OI32_ IF\49'\/8+$0C>,A9"X6\)T!8G[
M XGM0O^L98"X0U)P!8C[ XB-1J$*\$)(W+@QNVD[S9I=.RHV:M]%L"S-DM]*
MG87EL8,;S/1^7.W7>;3.+/3RZBK EA5IH83F^D>JHJ#;R&"M(F_ 182P:A?L
MR\=2/EBN4U4ZS>=I<YU%3D-5&<19:=E<F>;2T:C<)35QQK1*S$,.Z86Y-4BX
M0(J7M=\UJA91K6:J8D6;D(VAY\^;%5WF(H]J(;;.-<^7VL*,0@";2(Q )>0:
MF^D4%ATDZM@H,S3+VE;?>OD4<)E^K=*K=7E%_<7 #:@0*_[0%X$8>8E1@(T'
M??IF9:VKW(:3DB7W89>Z&[&\%EB$9Y28RI>,@D'#8%[]F'QJLU%F6):#5+.5
MOTV%ZW1*/U=3 \3 ZEK8=-*:AE[ -5'A6WTTNDQIJ,I9Z2+F6,AJ^45ZOL^]
MI+."?&KJ.7A IX))U=,(ZWOI%@DC6=20V\B'U$@R#/"2LOWN7=[UE;A-?6[D
M .Q* '0'1J5#;F4@:YQI\"Z6)3(J%F!I6RYVB37[5"U;62"A;Q221P2.8M<_
MM*YT92:?2^)14;(QMEE3Y6$3ZF6F5SA;@U'".O?\Q$^<?(W?9;O":G\\ZG#_
M,K#);'C )8.C\(%*$"!M*KE4;H6*Y\Q5)31)"U5YB3CTL=9 B-1$#$/N)(QU
M"66^ML+ N=2,L#(,X)4\:E)E#5DZ0U75R)=7Y%ID4<G]2Y^Z<9]\Z;+ /5>P
MATN/"R>AVM>6G$4)^5"E^4#&4  EW"C81Z I+>T6:]:*UQT);])/HSBK4HB%
M+"FCE#H"PZ-^J/KJ8.59[J<R"'W9(H8:(-Q&(FM@3Z<KHCN/XB(BS8U48>A\
M&8A8XO[,0MQLF5ST,.%BA0"OZ4 5Y9R[5%V'<:98MJ?JB<L^>@H8Y@Y$_;JY
MJ#E#'$&XE\1FK1D"R^Q)51K"RY6@QN+=J@XK;!M0#GOKZ)?VCO&<&*<XA_-D
MW8>0OS1J((#$*(_$5 +%HOIEBVC\]0S!6#!XLS5W\ &V1!RZ$;4RRO.6 D4R
M9[^25'C!K%0Z^#\IW#R2/UDVN%Z^S[Y \N@%=R'@S4XV "ITJ;Z26-,+AL9M
MGS+NO9KFM%<F[IM0>XSTKE@KD\G@(NIC$ WJZT0U9X9<XU@5G]45O,VN,(D<
MG@K/YSI9:)B,9*<!"V!/1 &7G55-=V*QBW"3B^/O<4'OKUFWB->GS,L]6*>*
MRTCP8%BYT;T:$  D[Z,RN[I D"5U#R7YS%8X*P>F6>[)W:9(V\D 3O-:R:BQ
M-7HF^ D@7XH@92&+\%K&,*4BG!5SY\D,YBPU5UWWC*M9$TOT==^X'+],<AV+
MLJ'OP^@'51SV!15GDMP24<%0!3*2>\IC*%213130<>S>DK IQY)'JXJ+:V%$
MUI*-K7^GPUON]JQ[<.C^3D9GIX(6JUMLZ"JQ>NSLX*G35T)](J@+%XB@62M=
M^?R![.\149LG;CM"%Z:.B:I6HZ:;?9'K&U$RKQMS_ZY;#QOS<1>!2""HP8_Z
M@I5$3+/)>G)R*OXTOY%O5?UUR]5?&U7UUZKZ:U7]=8>KOYHU7LNEG\ZLU'P-
MXJ#XA'P'N0H091KR@JSU($F?J98EV,0W?C52]'4"LML!;<LR]Z5%9R(7I@##
M8G%LBL5D[LFZ,B*;PV&S_E#8!(*LX,C(T0)V[Z(%X39R ]GL0(  $#X(*<G
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MFRDF=$_%/73<&092@<R%(&]PAUB:*ZU)2KS1 T%D$G#0%(5>J= MP9X+71@
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MR,O(L(JT_A*4%P[$I!MG#DJGX7RTRNUB<VVMG5JA"(L>GD:_'@-/BB_2)$Z
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M*0[&S50 '>9HLEL]+ RI"XP4BW3@Q<3"]Q\E)^?&+I&2[<>(0H5Z1T\4A9J
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M .L;L^-39,=J_VO6#5=?44X<:"[L^+[]UJT5S*WAAH]3D#"X@Q.*,"\(:UZ
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M-6:SXHVSF?>RXB2\\O<4P".K]<<KP]X2U/_E<56%FX5&*(^K*HRUR0Z<!I%
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M8SR26X)M3@#O)ND$Q./?^=IY)U;8!RADD^CA2T8USXF7:QPU"G;AM!^+_Z1
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MCVAH!+3KV(UZTW:<(X6=*)$3'DG%(0EO!1E%:*YK01+W9PL4*#9J ,0!] V
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M'</M^AZ\# ?ZWOO <E)35HQ:^=;1V/3>DZ\+'3RD7OI\TK/465LLRUOO43'
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M?A8A"&D<9E.D"EJ1'-C:#5[!SQJ=W=$KYC+BK[J+25O>H50O2%4',Y&9)&X
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M5>^$H?*4>!P,H+9>G!@*)<6,E!1Y!JP38 HD0%,78.2Y2,DBT+423,5D]#%
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MP6T&GMY9D,^'=@GWR*Q =RIZ0:F4"/#F7_#!H$^#E6-S.]'MQ">R6S0[C6R
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MT++18=D E OBJ$]C!+4C+5G5I<*B?%\,JR\D?Z\AVY>6.@?(\:JE6"[*U!3
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M'C*W7<0S=NY!;6'4)BLS_:@V%VFGU),DOY)G9&2K*8KH H:5FX>5J<V-^OA
M'G9:.@X9$Q$R.X\[& *_N-([-,$OK$ZROE7HWU.37'R^.'F')-C>+30_1$ZL
M@FD_6G6@EL-#36500.2X1N[V4!2?N [Y6!M2O\I%CY-8BXP]<TYZMB*S&I*9
MFXS\<LOEPYU^[N");ZWP0GCAS=(MM??3Q\/,TNR95G--7J05-&'<I0,.F\^T
M>GWB2BJ#GO&WF_\0(V5P9+J5ED(S0/6T1WL8R^(!;8Q/E#3^['ZM-@E<+.]
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M-H*GH'Y#+-0);[;D4X(^T@%>K>7+'2AJ9]UO('8@-DQOJ\++R\$F?.E%_O6
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M%=>L]O2F8858T5#>&\_JN]<%U[1L_:[K&S<TR. _BI_E52M^4+I20UVZB6
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M_N1+-0Q+ V^<VERK^Z5,_Q3ZCE512 S\ W.]@@<.A!$$OZZ;&*[;B@26P%Y
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MVR?WB<#1E2B>DN3&CPQ"1H9K.C3J'7P_+["%/8WCB:)RHIWGI4+<F@^0N>P
M:Q0]'<\(I3-9MCK3P40<R,%* @<J!3I*:2@3,0XLX\X"2^ 9Z,5E_>[(] EH
MER.^Z-'8A$.$POO1TKR8R))P/R0'^7"J*E%CEM[G,M?!)4_STJCYL6:'BN]:
MW$\D2*I-K<[OB0[^'@+QO[Q9JSB,+K4,V?'JHZ,?O.I@N+OPH.ZF^*7TA65K
MOY*'&RTFI_TU"[]0/W-,NYE38CY -:%LVZQYC< YU'GGN03["X]<C9HB+%U>
M<S*@2)!MX"5$^1"@C3W*_3^#1=-Q0*,XU3&SM6)61*?T5R?_M8Y8_FLQ'YHR
M;L2!;ARF  ."=^S?0T$$]H_+5B<P,DQ]%[#)/#(>^U,]8*[_M2(F[S(".GD:
ME<K:"&R1U/) ^G[(_M0_)0N,[*K]NQK H*<1."M5S&K^UW![]S"0'2(1[R1.
M!6^'?RY0@##B0%=QH)_.]W_[^647@$%K>0H?.%2XG*Q<M_M81^U?H>>FS.!
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MVX =\)FJ/#1!"_FM8W_-^XVFBM_0T*:=V]P[GURM]Y%A8VXO5-69%J@7AFG
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MXPZ/A>)T.V]+VK6X=O4'AU<]QE%DM@XM%Z=YR/4ABD&7:T AK?>3#^NI#P_
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M-HAB+6QZ@H 4OTEPLCQ8>$D9L:H/M@R8Q_[F**698!R>L_\-O_P@9L*6PVN
M0^:[5"K;>_:L#5/N=T9R&!0,>B]];A=O0LF*3L"X6W65Q9%.S.MQ647'RPE]
M5>YOY!Z&F B!.H6ZWKH7??727G*U_N! 13X](!@+?N=7VRNFOA<>O":";)H8
MF9O9+&OG2"^MQH0SWVJ(N[72===M,V(<8\T%2@6ML#,JK]X_;#4[I">9U_D5
MRI9M5"[]<*ZUL\UV#V[+]:1NHW.&MU%:M;1\'S;'-+86RGVY06?!W;^[].[R
M6ZNXR"KM MLD[.V/&($(.6IS69Y&+;*'M4.,-$=#DTFGPCI^IS]* 0 M+GL
M/4%J0&3[Q1B6[V03NZ4/\$"$2O>D:5O]QZ7.F8-L?6]T=&;$PTZ*L@R#50@A
MS5AD)R=!)A[3A5X!'N\+\).52!^9^8+PJRD<D&L43RI;-73X.$59/DT>.F93
M_)1%H>S%07@QH!D9#'[]";R/"LZ:[3#-V>3_(7&78N25P;*K;>?;MSQ#D[Z"
M0F+<FY:G/8QCN\RJ:I>\DFH\Z^QO=VC"-,+B7]R>/][3G4SROLK+U+32 \?8
M+D5 ..UMDC[3F-A[G)!Y7O*WV=O]F-O%CEI46B69JJ[-G11<:K?O+.U,9F7P
M)?4 /%>6I .NE$2,ND':S[2 P<=NG(D]R()/G_(HGD0YJ^(-T3X#:ZVAV6U&
M@^(UX,4IFEA[]Z%XH?>;\!#Y^A2PK47*<OG7K2BSFNFR?%DL ?9,;DK*05R^
M;DAK$B(!K=&0AB B1S-QO48J-U=Y(3X(_WMF/%I7)*]K*.BG[BADKQ;2&8FP
MV".%#->CF2/,\1H0[@C:ST8Q7P.&2UA0V)+7@(Z;;Q?:P?6O[AY"EE[I(U7?
M>[(+),"N =@%XMO0?YK&-X' 6PE /3J0;_(OVHRO>Y>08UK9?BOE3<H++A9&
MT<@B=P'D$V@(Y)BMYQKP@0ARH#KC)80 P0N 5-/6J4RES[U34Q[7:$R^BI'-
M!+XWE 68QX"SG*:R@E56X1/(K\\42H_A6@OIW34!UX Y'K1MRJ@A-$$53;\&
M0&]*C'3G6W;UUO:0)4:D)<SV&I C%WFY"@EWJTO.\/F'8,:OL[2C6>#E*;JD
M<9V#;HZNH,Z!*]+_.9+Z)O W";%_Z.9XUZ-2.$![T2C>OXZLL/Z?#B!Q2EUR
MCOB$NDI#L<;^$M _.B"_ND079[)7F6E'VPXWMVL?9%Q*0C8F(3<^")=&7P5M
MHWP8_C/ WU6^0X^V05>'H,[(';)K0)KF->#&*-T/P&E;Z :<\X\7;<[7 ! 1
M!%:.!DXE;9;M&B!6?G/[--("-:)_?I)V8Y?D-/[EO2DD$AUXGYL:[JV<=CL.
M2:O3->#-[R9J%"U9<W/?,V*T^!OU[NP\$(&++I+Y[GNG'J$\7_Y+37IF#[11
M 3K[=5- [E5#QK*Z?EOWGZ/X__\!YB[:HWQ]OH_V\+?#$$-TH9KV$;J'+OK@
M^<:0#[&6#I%GTH@Q2$4"RMOV]R GF)P_%B!#[?I_#/?^.^!YH IUE+?Y;]='
M_@+\T__GN 3&6[L;D[Q[[W*75K#EF*$(8E&"O!CZ'?_\0YFS9Z\^D4@3_S#2
MIV1Z3Y&A<,]Q4;@11Z$\T="&]'2T_8C&B*M7PCBU3:B$+ZE%B\91/D_+K;=S
MP?>S#KD)-V]MA*3+>2>EHKW[F@8=%]LP4MZ<+GU9U!P< Q<VJ2M+?) (KKUO
M0E]Z2ME30E"-T,ZVFHJHPPFOV ZQ>[K+P1)*>F2<]- H0H\ZO(9U\5M)%J:P
MJ'';!4T3Q8^&IH/W1'-564]7YE]-^ZUK.FK>9S0QQ@XCEKHCNE59XG<<KJD.
M1H,?]O I=JF.3N'](#.3Z(A#IZCV9)*= 9TFA+%87KIWJLV+6>$>/O>3(+=T
M0U(P<WW[ ^[D,%NU(<<[>QJ.R">)DU</H0>?B?#.3$,7^J3,8_L2=L/;G#"W
MYB&.OL_9](. QFQ/)N,?TH'&Y]RMQ$UM!HZ\5ZIOU8=YJ%&Y*4VV=2Z2I<F.
M5]3O<'W,BN!QH+)S5GG);NS _K9UYLUJ,E K:WG@]FZG':VF6X%>1-M@B-**
MBN<X)ZF/L0$9^XN,A]CQLS[>C1^R9Y&B,;W,^TW1<#3TXQ/L6G*677'L<C;<
M7U])W'E<6"A,X[PG3GMRDA9\(B]V#9"[!@3T9#\OWG:+UT:LX]$;V(?,^_NJ
MCT6</"A9P@OW5*2*SRIBT.FY.SO_R=HF1 10:]'-_O:.B2C$?['FBN3EV,X<
MBICIH"K8+D\;)I:1M\5?]EG_D;2"0F>7%2.N&G?]92UVXHEGY'TWGW%=OL%:
M8T"EB>;9_.-#N;!OMF[L0I3;LU$46IP!);RZ; HC.R<!UG(?87TNE5>_'.MN
ML;_]]6S5!-^UTZU0&Q0(-1\S+Z^=,( >92A0K?>Y!\8KT]^)/U>([3UK7E5W
MY2_(UK:4*Y#WQMQ<?4@NW!(6]%#%[_EJ%,YDH>A$@VNIEJR(M4C^ (VIKSE>
M>#O!DHGY&$,N :T/->?LI"9?'A5-"#XF9\+ 477YR1X=8]>WH4H5X-UQB%GD
M3GCI])?FZJ!'08]47BG8%T7!Z(5P$$F3C7?AI[V#VFZV>_35,6O(&B5-S*_:
ME+/?KE9\W]Y2BFW7 P:1)>I:@R,>J9BZU(IGZ40%"_ULOT_H105H#6XYFZPC
M2,B:VW*9^0'5;C[4BL%DVR4JI@#:M,=XKI<#FSU6'9X6132:DS6X/+,\$-:L
M3OS1\&&.28SR([53I]C^ZI2G=:ZF'MCA5M$J3]^[N4<R\]SAC=2T]S2^$8#E
M]Y,L+\(G^ET=9CKX<JL.WR-F =S5Q,2:94L<P_8$S]>32MR>.@_=*XY\U)CW
MJ >_3Z0_MO2=@2U^#;TS+9=[<5THX&@[\M9V#Y/B9N): U=SM1QVS"QW/*A"
MT-7H):#=X$/S%B&3VN"G9?U?X6;"B/6JZB!A">M33QDMOE@,@.6S#9?A+\J^
MXBQ,4XJ2 -)__R%0B&QE=.WBRZKS-&6B(GZ*3N=';Q8M=53SR>W2M?VN@/5J
M3W=>3Q[20MWQ1P+$'2$KX^4D)WPY!58NB6+A[@4P'N:LY*<B_04U 8JQ'Q9K
M&T%PEF ^70[4Y5OKI,"Q97)RHJ):0JH'SB(T6/[4&SC?ON%-I3[8+]JI&);/
M;BW@->.W."SRDQ4\.T]*<U+N6A["?V'3_]RT0OY=R_?WS)HR0P=8L>,;HDX#
M1CI>;_=W4@H3U*.V^/>E#>DR36(&? ]I?(O.4X-Q_+O(OGG9I7<]^E']U,DB
M4;3!5?W9 ,:=M287,D8A%LOF[;$(2PP^6!!2 ,+7?I:H6S@Z_\-2MSR>D4*$
MCA K>@J+C\W-K@U_,$>^BJ@^,YR"Z:'I98Z%L-N%2WX\2GB_L-4Y344;[Y,C
MW--Z@EN>H#GKTY.? &>AS:.[?N"/8M21X)IQ*KA492A*5,@T7*!PM#OTIX*_
M7Z;@ZLJYPNT8A&M;-&P&]M(<7UFSURS8L)EP[5R[=+L\-$87I\TI,X\_R6*;
M[8&]^AY)?5K)(.QKKO%!0L!:4WPGB$B#;UR[K9V9.L%6SF&G$KH7NZGRU.<A
MPNQ,GTHTKFV!!*-6.U?<31/;LP>?4,33^1M>6RN*C$B::K/J ^,M%8 TMH'_
M$'W$MY/LCF4(7AMQ!UV"!:,*=V +H^5"=,_&7K6HC['F<_,.,-96N-'3$V.*
MAC+/8\MEBW:'@H"'/9=%-4M/5D^+\.SHW-ZNH^1 .P4:.F]^M([VYE<S9VAB
MA&VL4S@@#L0?3+4U46HK6]5YE[5+X>KXN=$?)6_@SV^()(Y7:PMK:Q39!-BW
MW,5="1=44> "G&+6[KSL2B4;.[9T!N_(V&:$O\3=F>>-,6>RP:'L5@-)\@XH
M=RV2C1Y;%^E6?K2U>;<;,[B\ _(RC)M^C$\>W;-Z2LG;O.5U\_GL=]1[]Y%K
MP) D<CNV$A&R['FE9\,P"/?LF[9-G5@)6DBZA9D0*XIOW2CA\Y5/TX?5C:\2
MCXUB-\?=SG:U+*"HW,:=*%J6+O]-B!]/E-.PF:^P_G/0^4]H"MU[R-$(Y/DZ
MTP$TR,8Y15^^88*Q(DE69K7.O45F'/2&>_EC-S;!5[I**S 50HPW&M:NY5'H
M*4?"M6+?BWJ/4;\AC:8:Y$?YD>P^QC[[SL4^*W"60!L;6UN.RE?A-NN'7TE#
M-/SIPW6PAWHU@^YTO+=#E395C+SR,8$<#2NNWRC?<E</%Q/XV40ZM3[\Z[BV
MTKK N&IY4H+&H?J,QT^6]O+N.F@Y$TUFTL7 2'P@4MZYZYZ6Y6ONX299L> F
M]V@T)A+27X'(8[(ER/ZH IJ.I[&@;A/>W(!C^1CR$XSFVU@XUP 2+6^UZL/@
M\@1CF$@W&L]O&?V1*(^[^Z!_2NE*^_GP6XIQ3<&'UT=A<HTU0S/]9<$1:EC"
MCCCW(I*=%$7X+"1[%8??$NL2:@1IG*4M<H*U2O\%0G96XRBQ2SMD21K)"N;8
MOHR^N:[+%E+.W?0'9)%_!7+OW^<>'^Y":\FOCB&M<<UV*6@?] <C_X1%N*\.
MM:K_^VJN2'W)KN3O2[[?EP0&T49S;DC_D4U96X X<OZ^NDRG.W6&)E9-D0A%
M^\?GT1M7!G_\*SV5*Y&!_KYT'+$]^D=6_1FE_N^3?X#(0W6AZ>Z;?PNAOMY8
M]N3H8=3?L05-[T(W$VXLC2Q=@(S]Z8BF&_=?77Q+9!?8(R_BG.%H_&.%2G3+
M>U]D*<TUH +2&FO ^3\[EU?+^%\3?7/Q+Z?^\I0<XW]&\],'TEC)-71L-E0;
M?AM8$'YO[(EN-"&"Z.:J_*\$O=\*K+&/_?]G(.CICQBO :E^D<_0QK-"_G(?
M:(SFR=E__!"*NO\'KM=ETHT0M^?CL+^=_'A>"J9QDB(5-M1]*R&6.JZ#VR!A
M25>^G"(GHYT9 -/JLUDGJGETS);LVFD]8(*0L,:N4J=ZVWBJO>UFK%8?S\,4
MR16MN;IUFU+AT>*7$H6I^%UY+ 5YD.L<U:3B[;:@(_Z4&M$(!SU#AQRD5, \
M>WB>KJ;.G>QVY0^\V+QR:\6X3,^"3%N6=FE,5(@5(Y<)<JN>XKE-K,3+K(<O
M/OZ"6;RUC!D;J..?\HV8(B)N NK7J^7&CZ?=IXNBJ;N4B%\5&7T>9_HXXJWX
M^>4UP%GZ=0F/VR%,_(<NAY"$S0M=F+6B:#M_9BQQS89H^> 2]Z![[J,&1):U
M)691TB*8_4"8*XA,XW,I(27ME 6.J*/'Z3=<+XG]CLH!5]6OSB.&F59E7<PG
M 5QVVO$O"$X)7@<+J]  <&G"X.4DRR4?*RXQ;;QDK=TAMML.UL(OC*)SM,%E
M>:X]&"^\5C&.[M_2&ON%8I ^)8M9/%DI[R6L>*?6\YY=3.U\_/&YQM%97A^<
MD-82Q3G,*VIUOA*Z\SU>,[#0/=8Q&_%1P1XK04$*MU.VBQ=#3@/!:)RK-T\-
MNO\T):ZCT,5)VYTZ8$32MK2]V&EP1D7V/.(\IVT_3:E\0EVC^L!$6:_'B6RA
MW_5!6EV\3#:,?.'ACX+/JZG/U3V+@ ]ZOFV-S+19DTW%P(RM+;]TOX7,*>3/
M.?G'#K)%C;,CT47#(FVDAC^XH52;B/:D^=EL/6_8%!;[V[76B-KSJ5%?$@6$
MVI36@^#,+CBNGV638>R [V>.LSM";N-<N!)*_D*ME2J5".4\"6^Q+,[0IQQ\
ME&*CQ)KL93]"8OB,/B5C?3GT].JLXR20AEL+VTB<6.LJK:C+.1J:)_,UA!*Y
M,/A-'STCD*5UE*4/[8NP"ZF^X#W8NI.K,8\[L6PM8[! 3V):'3MR"L#TQ< >
MOE4C<LO9;AF*8PF=G4Q0UZ-K$)!W=<+CZ<Z!=">ON7E!FB6-2EHI;2H<LN;<
M_"AW<BK+RQLC=H6 0Z$XT3.DN_U6:\WT[P$K13:<2';+N]/G[/$=[2AW7!HL
M(7W.$H6TAJ$W]T7S4S*\WE0'RP5QVQ^D/>$HYEC19&9G%)]111$OFO=S^6P.
M .P0+"T[R]1%BDE:EZJ5JX$KOK?O!O0Q!0[*GD=^(0_#9SA(_(6<AFY\*Z:9
M=TL$$UC$ZLUM%>5*Y[.D/IU0Z0$XQ4>34[QHV%D]'K1.C0>3:\\M: ]D(T+A
M6]8"FHE"(=)U1U(S#*9VT62R3/=J ?C$]P >0RGDR&.M?R48YPXW'T)BK>W$
MZ.@23GI/E2?\>5^"DS'#\\F^V B:"2I(K"3&=D2[+:ZT2M$R+"[PD7!LWDJ9
M8W2W[L;MSX@1Q\FAW$@T<!%[IW\T8G'T'9U)/NEINRVR5\8X)\D=W%IH#WG/
M<:NBJR<NS'?NHXSAFF^C#%XS_6JT]B)EQ<&MDA >=XXL=XM3[I <J#X[>WXN
M3GQZM_!'QQD%B5TG&8*Q?VP(:9)<E/_:BS+^G !_]_WW.SEM3#;T=Y?2)"3%
M0$V/L3CU@E_7["_FV!4_*XYCKOCDHAN:^\D2%O,<WZPVA!>(N34;N):LCKN^
M_2:(^I.<=0:-HQ9Q)X.B# 5(#'?KSHZN;98Q05Z6[F8U=3QU;B(YV_AM"L%B
M(1^J3:(.UCDK\GTY^L?,^&'=:8*XSVJ:9>\2BN-XO#IZE6A-B+T=L\T?H_LP
M2?&.C3>-ZSUJTC 10V[DDW;_,*R>/36C82]JON+2C"Z:9R_S/H:OVCQA$#>^
M<U]M2+S4-QU,47BY%U1GVA$WSU]=_O)INZEK@P6,WZ1%Q.3#>C5E%Z;_?I>$
MY2_S>/BZ)OLZ2:ZS_M,D!^-# &#U("(EE\ B8EP$N,2FL4NB9,34Q+ (M[2=
M[V.3V5JJ-Q=ZQ-0B8N@P6MBUE'9[!F&[W<9&X2^7^HJGY?2[0$IH:-&@O:J*
M<1./XE8:X?M&=:5Z:/PA7,B6^>@'8WBK0%]:0X[;^6TL$T[!3JL&(-XQFUS(
MH\K:1"$ZB^PC@JFXU_@ FK"ER#X64AS>5]7[^FTI;X9H,[E?$U6]+EW@XBXE
MIB%*]D=%70/.AD\+M$ ?D'B9_<QC3R>?*#TQ/"_6?DB@]O;.F<C84Q1PLTHK
M.\79VID^8G1EAY":==V(4575"- ]_Q&Y$0=/<]X_>U7G&9*H_4&D7WN 6HY#
MKFI1FNTK@<J^/8^XTZO!,23A?B=\H83WTFV%6.;N8#68\HB4H> )DU=;MQ+N
M[IU=*VT(%E(@6"7$QF8G?-7AJJ.&0TO@C5<;RYHAG=/6G0&-*H1KMN:Y&4RA
M3EIFD6&.$<061IMA>_^"K(7VN0H_%/\]FZB(1I>GZYJ[&;^@^$!_\BJ'O<CD
M2@ZF[_K'S28ZQ.TE\2F,'"+M_.S+=?K.T-Y"']L7!<_\IVG4/M/=VO_^,\:2
MR'*YHB>'7$\F*FZ>8-D/%,QT$#M9#EW6^FEVYW,?&YC+X(@B T6_Y)LNCG<4
M6V&/2S:K.?=)&,\3_$PV@*C0QR2Y?,F8A?8G@45R4]K^5,O%Z]EK@)GEX2RU
M,U&!I!,],S\KJ7':5QG);E&9(:UW^OA($KOG\M;I6>6%, OP(RD)ZKWPPV_
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MUM1]:9=+.R9/$\E0[OHLF)CFK,T\RPO*6Y_F_>O)-8"571Y>$NQRT3!)\M*
M&%=+E@,9=SC1'D[YZ4--S>/5)8-;+)5V%H=N;.V8+B,/QTI&%^),+8I:5)A?
M8B0;"]*OS*LS OV:'BRVEFIM#3#*\FB%&(QK].ZJZ6Y&]\RS1*7IS@PX>V"C
M</87/ED^ERHQIY'/E<5CTPD&63'9AJ7MX>?.S7V0%JD/GMA$VR( 6@:.@'Z2
MH,LD'W+D8W2((:_0(9;/N4+H[^>/(@K:[*E+Q6J-*<MJY.2BQG(/S=#IL)&R
MC$MX_7M2IQY)57?-P8.T!\P68I;-U%-['-X_G#9#O0YWI2?0/;)R0EI!WR'#
MC\902,Z;WVO#185< \23P)?[T&6EGCS+X:W)BS?5P\PG_3:\_ /TQ#*?POL+
MQC]$Q^ZI3<I,WRMCQ$HV_##X?&2(8_E$"](;"IRF EYAOKL&[+5> P)93@F"
M;[KCO.E.[<'%2,E Z."]YC#Y:AQJ.3(<U[??PLQYMX7G1%\/</)>YA;O9 [.
M&-KW3@L*,LX3R:7J]EXT@M8D]7_1$J(^/- _6X:T)ESBO$1[+YEPXWT1U9,C
MN1I4"?A<,>G*/_T:,,PP]-N//XU'?3<-M3A2)[E:D'H.,G<0U3)\#?A)9/H'
MRG^TV*1"A;+F2PS1?:7\75T)8O 3<GRG##W5\5!D69(TH[O2/]!]M=O@2"Y<
M ^B3)+HL5)0A/RKT+VZA=R!8NI[D"N0CU34 R325Z)/D,JDV&6%$I]$F1"O+
MUP]IM8/O71 L0&"J6\HMD\DJM?$Y0Y,=(UF*;3&G8^G'P-,'GV[PTK\\?HQJ
M'8'\)+%&&Q?H=8[.,%TWCP%#$QEOQ;\WU&"*1<B^ ZZ+$^ JY,/_BPX43ZA@
M_5 B;X_(0U#S!=E[6MJ/P!FU3,C4P[?HJ>8IAP;;-.?JDNRH^V#J$\\U@/'6
M,&CO+ACQ5@1=X;^\-71U_,1;JOJ(LQVBFX&,W!<+0FNY2J&U='.N+DBA^Y&6
MP&/\"C1Z+YK<T*=6T 3JF$L'#=2+R+_UP0HIWX8\0TJ?S(*ZKP%8/R,1TN\A
M%[=F;P"51C+6@:XP=R![PR4IZ!KD^4'P%3XYZ&PX T520@$9;G%"NW%7+%W[
M/ $./@TDO,$!_)=.!HIH 8CZX (]^ZD^"-M/<6M#!>&E7?Z\06$J#/33H/8:
MT!0(5+B!D7"'!G0# \DEGM00TL\&K9[YOX-1]>H/"/J_0?#_FQ)P6HOS"O.F
MJY(TT++@S:-]BJ%[^7\[%,NX,1WX/ZD*_*4J\$]5SIV[?V #_7I*COK #SO[
MJ9PQS.MRKUZN G3:K3ZDOY_L5H_RG](_F^!$LM!QH&@]?D&: X$S)]"O/@RH
MX?2;D3_>1$YR[F9.VUT>/[E).R[7@.YG8ZBKN^>POV.]W8"UDF)[UCYY(57D
M_G25W%W5R'ZDZAF!M"W;W2^LP_YISUR>6QC_.,F72F-4'TO?ANU'H-<07N7-
M+$A $5VA5W,\.AQJ.=.&*"3T[ 2]#_YHNSJ'[&U#PMWU1J5'O/72C'G^"-[$
M[7=>NDDD]>AYS0;^Q74-&)*%WD@##8-1'O+H?48;:7E4UE0"+HUC"3[FIF24
MKQRZ<B33OR24O,F5)5<79#7O'C+>6F=$U54C1JY2[*X!\J"]%4@XW:ANST6E
M6"?PE.ZOE=/VGQ"@&9/YW$4/>@1JI 5JJ/HD%H420(R=%I84C/TR@AC^A![?
M^>U7Y"_1&^AOW-HX=89>\:+?#$?OJN;:UX Q\"4"S0LJ$^PO&O\QTA/U%R.N
M)<C7-AYHCQYJZ\],HLH@L$XT%2C@!9F[949(/1XDBQMT2 V@\IF4./'P#G6=
ME0XN_+7>4#=6I(;G-JM)W8MCE=L#BBIV:5/;Y\B"T(8I:DDX,9!KH&F2SM)A
MO3:._7;DBWO.LQ>ST.!*4FAT1KFUYJO=-'?C:5>BO;"IY"[K)<U8<&F0*%A>
MD[Y*8U7C+NX1H_N;/?_*A?(>D8/1C%2)7Y:GSYTAF!5FD@E2)D24GVZ_P<:Q
M--Y)%:O080FP*3[^:3*VDW0IZS?71]N$F(^.$OCP(9G&8XK1>!F(M>!F!#_P
MDG3CG3:-N6/^N?!5_R/"VHAA?0(,!4<NQ^>3'>UB>"''ABPA10:1;;M^@B-P
M<::6N9C;ZB*K3P"^$IM@]/!/3MGYL_9/1!9&9K$>9%S%;)\:1SM=]1OG7.J*
M;DZ>H>[4E5MWE <MWJH4J"]^BN_N2^/NSQC=W55D*&&]?W$-:-<*O+1*X)*_
MMYW!6Y;?P83R.51P9G%1 .ZN>HYN7G#ZHIK?7^I3,$U&3?=8\RI\(??"]H\M
MQ9@G&*MQ=.1)3+-\Z*V78*Q868+1B=*9A<1LU_3&6.X6V698<M+/'7+0OEWI
M))PLF4Z[O?7BU_3TG/PIW\+SHM)^G1^S4F)GW3!.O=3OM5^?>C%ZY^E7=H5Q
MK-<^GKSXO-I9X$ B2?V.Q0##!;OE[=N5^2G%;,EE\HGBE5%G.?5QCBP;&7>E
M/(N9#)5%P%)X?L[ZD)9HIO_6<3WQ"Q$2AVS+BZA(<"A,H6M&RZW=3,D#0(TC
M-H&EYR4:0;'N.7#'^/,/J6=26&27S4YS%Z']U>7[[Q/-0K(XPT2.<.,[[V"7
MXM1*-[M]Q(O8[ 8<<KGG)DCN/PU$%KC#)>,O9I9E&\Z-\>^*2/&QD@(@SE1+
M^*G(Y FG;K$2N=)2!Z<E;5<B-*K%[D[DN^FXN]AAZ=I8"!]GH6.AW(&SMA:O
M*JC%*'XXWCPF?]QT&%G$;C*Q8+$13'R?=>M1ZW:'OJ6?K*8-?:ADNYX*]QV\
M&KT[&O7)QCE\1B \I @5DYHB(OW!?/,O6N9PN>]U]P>ZF*F8*462[SM)BP2>
M6(E&Q/#OB\PN-$7:$*0Y>#K@Z;"^R$>$W1*.>&["U54DR^9&C%,ONS:RXBGB
MG:X91>%H+T P/P7ZOBE&$=S^8'OY&D LBWU@<V@D&=;QK$YJE**9\CR>%Z<L
MQOZ9%? 7"+^G6$]/WZU5<&]C?,V3+%2F:R;3J%:!\NTZZ+%PF1!%UHX)4#UC
M>F&<$P7<C-]S<'\4_Z.SQ>2]JGV KY3#%BZ?#63YCH7)UP2Y<$87:<Y2E^@8
MB"3+3[;XROUK@)\MN:JVJ"-<6/=Q%W5W#'W0;>X=;(<@+V.FP[<X?,RG_ONG
M%W(S'%ZOPA]7&PMI?Z;VZ@GXK@2X;$G&0/49TXQM1'EK11I[G-IA;6X:C'7E
M '<HB8450L/,YL7Q1=6C8V>_7[JV70.JJ/4K+.D,J@5>+;N<&YX^6!@+6J&U
M?D -!FS-ZGT5$7O$SSTST[E#:D?ZQIB 2<JT9=:5"\3!4^.IZKR_X6<PE@0&
M4^J\X'C)*'?Z\4SWMDE"A!!-1(JKP6G&[!NQ(NE26+;_-UFJ'KHDBY_-S\HZ
M<>F/&3)O2.E-HC6]2;3J;539_J[?-T^U'F1R+ ?U,E((P=9L,"B#;M_!FJW>
M/.J^Z27AWRE]#H).N#?Z-[3.!HK6SY.D.20L4$(IL_W9 :K0.54Y??C8S4SS
MX9C-2)<4$7[H6$[76<>-F.(O7AHNL;AU-<A=F^.97R>T()5[^7-;2HN5'?UO
M?AX(#[8"TH,F@!;&4>XBJ96;!6U8H8<[H%:?1_[*SUYTR8;OZN_$:B^:[BD6
M>S4OB"F5(J&+PJ7#*BG,CU&X<RUY+;DSB)CU7C@_;O:"]MG]W(\,K^1B"K'%
M3>(IC+A'2[21C-K"W#ESB B72M3,)_7;&A+1K]W==/)4C=YXQ2N?E0$8^5AG
M$!>7+6=X!%E,'E_&\17+:<-.2XF3@ER68=1#C$+'^6.64.+BP+7&XMIG12GP
M%V4_5-Q7N!/,*>E-39SU:AA$G&1P*R/]'WA4?SRY)P6^+WMWBYS3E?E'@(VE
MZ\.02)$OS5&$%YNIXU<OES'&&_BRW'P@1&05(Y-P8?Z(^6 VAJCO^DG$QB)A
M@!4AFLG(CPT"\ &YCA$][7ZZ41I>YF+,[YBAA2*-4+>JE7I17#(]44:XD7X;
MY^D'_I',Z9!=#$N-A+GUY"7S)^&^.W.=/.)D2.O]/N6#!UFN<'E0N]++0FFK
MJE,%W DC%2*9&"G9\Z C-AH_0.N^@T8=I,6S;^ VM?:5+*][0\['EYAWF"2^
MVL_Y&Y ?E3.$^:G:2]H4?SJ0OF3ONLJ5[ E@X]'QKR8QMS*X6J%L,1,Q,#BT
M&JS_MIT8>!)&KA9>(*+&;Z;(R&XM%+'$NP5>P&^S[+1W$"=%$\(W >.2$]4?
MZ6Y%K)G[\57UMH2\"51UM1'"[^MF3%[AFW.3;ON! +=%6]SO(RUM82HNHGG!
M4[EJ3NTKZO/.O(GM@SX&XNO#<:6M2>'UU$7L .K AT3,^,-V=FG48OHO(ZRS
M]N,C"RSU&%)LOUL4#:2+:3@QO*!:GGW\$MA8>F=SS)Z66YQV@-1@Q/\-9BB7
M1<NWO_\G%#R0;A,5T)M8'?_6X$D=XOZ9-4A=K*GS!VCY3=<U0 )=]4-!5QXG
MF]!)'S(RES82-6Y%I1$Z21T"NLP%66GU]:%'Z#**!WB%,X="7@-.?OZCM3UI
M4>13K7T.Q4K;$O2!A:S"]K.-T<OH$@)+0S4"_][P&"#]_="6VVDSXZ"$ _//
M+"UN,U77 +L?Z(R!MB 619H(&7:&[J&MTFO4 IYD_+2:O"?7SW;S>[?^E_R1
MARCV@VL 0@E='DJLHZT&7GF EE^S7.$DH9"0D^UIM+=Y%R>0=236_TXXYP0I
M?>2#"RK[>?,KG$-T:,<>@WX*PLY6K@$ETL@GJFC35R"P2%2C)R&OD_34]AGR
M/L14$:7??I"&4.9&UV?>T+TAM+&1_V@U6IQD=NA/%4 $EH*OXJ3/(20]T']
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MG*U"AB ^'9#2M_%]XR7SE[@F )9M> ? 5<.<GRRV=83U/=-(0?[3R(NW& 0
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MFECK1YS_U)KSIS!\?X>0_%#\M<Z9I;FUO?FC43GAGG!#K69]#AU-@T.'U,9
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M8P2E&SU)XPO/ L2$O6]#0Y%\ZAV8+'?DY'?VO(BJNNFX:="Q^^)IJW>9V,*
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MO::3Y'G4)74R=Q"8A#=F=:8IG5MY+UFZ.4@VGHU0NH=.3-;3D&S?:DZ&Z :
M#^7(VH[1R&SGSYYV0 ^WI,,IFO,3D>;W60[O0B5-"$:-!YP^8?PV(?A^!4;:
MH=)$,6Y-Y[.S.2G=\@R]-^0QKE/U8>G#=:P5TM%\UG;0G<HR+7"K],/VG7WR
MOAP4)]3$4.&U98IZ68Y /8=355+L=NP'\^8X:J+Y^0_&[V<LVAT3&1V?&]B\
M+TD28]/4H9BL.,#[^<+<52N6=M1N)\FNPC):/_LIQ%>$%%])L!1V@7 '(11J
M< C"]XDATS?V 9? D)\C&V$'S;!3$Y33_R,0&&'B+T92[ALCQNKE.X?51<Y+
MOZ+7JP*% I)UYM)NJL?5*#%V_!$R]J##$N32]\N>9KG#8MDDM(*TS(]%[@L6
ML]$,H<F,CF.IIQX$)P%0)FR$_H;MK,>@S\7;L8GO8)_/+WT&KFC Q(H_&L#R
MQ:]TESW(16V7L,YZ&I33^VA31ID7RJ_LV/D>+@?[AD[,WP",7R.<1C;"?_@W
M])9^S%IA'CEU=ATNE.)Z5DX5 #.Y?E*N$,+]V(ZV!G@^/'8#*!^[]8TK!0D\
MA(%ROTY_>[9+$_B0W.\@P3_ZA\9ST-]@Z1 AT*VC?,)R9T02EI3\V_T] LYL
M_XXD#D=L&"@JHC] V('(R@E03O"_#.7'I542_-<GH7J,"BK@\F=_E5!H0SA6
M$++4PJ7)YIU*.?0%ZT*!?]#RL]J;'=V\;P"6C^B>8:=%_L/1/TQFVF*(TIV[
M_HZ$.,$?LF\]>IOH_R#(7]4@"K_SL[^P8F&[ 6@_XOFGM7%_E;2"/[4:]JL;
M?%O[X7!L\[96Q#=L9*T(9//_LO^"(%?UH'A<^5_@"4GFIB%J1>K1"HL5=?4R
M,=?'"-$L-5K)5<4;1O=)(DB[*= -5[R,6JB6XM>XL %#^:\?[L3_= J<U]CW
M'Q<K\'I!0AH&XA'*;XQY?!^VGGPQD@,M/L] CLN7= A;^G!SD5Q"1V,'!8>6
M7=R2.:_GX1VM95J1[A-AI>G@U;Q9*%_-&&>(I?ZD!OQ$OK2VZB7U*ZY'#,6"
M>*'R'ZII&_%Z;P!F<L@1;7MQ2U2>P@V]C2:0),.\S[$^JA,Z4_S5SY!%7KP>
MIC[$F"0Q8+0->F3-W&!\8H9Q;_";U7!CP_&>"YD8WH/JX;((^PO'(HY(G<*_
MWJ'CKHLE^#4GRA9W\D/+T57U,V9-B.1ZPN =3>6'V>YO;3B\PPFQ0 WFLKLK
M>]$#6='6MJY&OG)!/3@-SV)>UH1_E47CN%;]L(%]((DTJX+%Y^M(#@$VMNY<
MH43^$F>^6Y0,WV9G-%Y73DQARJ$^72?SC<\U.*P2X'7L*>(LJX6M[UK@OG7I
MH[\_<R7VDGA[J-(5% 5JI/N#M1_34+:*RD:?:QE1G554G. .,RJU<T'+:!)>
M8YSW87;M$)5^.!%BRB$V;GG DB;=MWOD/+1Q5;I"[EXS(\O#TBXO3KZ;>=P\
M%XD@YF( N;7_@),@.;\@<WNRH2*,:!]Z __G3+%]2F2?EZ,'L>E%]GD<5BN8
MW=%M/ZP 'YN8%[N,F;-S5+97I7QVHE?ZA(EFPS%NK]W\-YN_*:.T2R\_ ,HG
M:Y1/+HZIQTAN$%%RFXQD?C'@#6Y"XUZG:!B?Q?9:&6YX35%X[]BKI,#RKGP4
MUAM]84E]J977EGP"7_B*NO[I:' UW5_V[2^%4J@"/1%/AE%_9KD(?O@8=P-P
M_F]64!6B"$8:0;FP@\" WW9P;"4,%[5V4$B3$Y#.1[RK19&\4HRRT'$NA+7]
M/D%F/.EJHZ)FAGV^7H*X'OR89EV+++0MTZ%-I0P3ZPIT@'AC_%PJI]H6:,$\
MQI5V=\=@:>^<:1CVFI2"?1X&2_^X"^BKS^7T&@M 3 /:ZOMB:CXSM^\*]'#F
MVH9Q!LB/=*L"<IPC-]:BK\?'+K%_,.9UG,^Q":<[Y##W#E'W&[L,,WJ'#^O3
MK'F]NBC8/&0)H/8S;GID1A/_$E#R%,CVO6QI44^WN"2W0O?!G*DPO8P=&$?.
MN;OWC?% I(#!1Q*J)F"1@/S="T^T2Z<\Y_CSU1TVVCS,,#X>3&Z73/+&@.O*
M:\S0S>SDE69?%B8EN;I04XN]>.4J[_TOTG)<-BILR9%%JC6\72_5V!"AVIH_
MPE]$QZM!2V\ N!?R-@!<8>S!&P"+I"#>N$&@Q1*V95954P <U]S/K6?2E,Z<
MYX,%(2^5P,M[90^]O0#K\FA;@<(DEZH=8M>;RV7F1 SA71Y;Y8+,9!:!@.XU
MK+G8ILTAC=QL*.WAKWA.Q[J.MAWUUR1L$B.M\M;'X_1TPFKAK:74P8F;^3S>
MG#.L*76QJA\"'V2&6XI6]. &Z,T3Z,V5\5$G^HC?J;L!8!=F!:SL"M%*=]5R
M[[R38/Z&QBX!,$@ALX^P[:'UXC"^?+]"4K11Y\8'G<E27Z=<\=]4%VPYO:I=
MHX@>,;D6BO'-8OF6_8!P@GP!5YRUW(WP*=X<];)C;G.E17,S'>P:?)@.4>F#
M'(.7$#;UH9YV6B[83!VOK0<QB4^&TL,GRN#0Y N$1VGU8AEY]R>28A_)$BUH
M-P@Q9@"_L;"*GR*FT:QP?+#9#!@Q?A$>;$6$R"1/=[9*=RD2#@-=*L!RC<)^
M$TC!0N\ 8UJ<+6AHRTY>SLBQ/%%^7JO>Z)&?C/S=@ >&GHXP\710\XF-\5_]
MW[!@H*U(L)\X+/,#<NPW6\()%C!EU#I$I0VZ\F-6=@;&HQP\/\2 6[\EP'U'
M$(8_$LZ)[<N^_D'GK=LK<&>C'$1J"&D*D >6X:/EM]$#<DK87#@)M_[1!V'%
MAC9_25[Q0 ,]W&9\KX_[MFJ;QGT_O-$<O*?:O.![8I;Z;\OX8%-UA%'Y?7C;
M5N:DIU=V+ZF#P2;SGFQ\F9C/@DZYY1P JI%Y4MR\O70#H"B8KF1D>RJP!(?Q
M7"J'[6FR'OQ6+B-W>*XY,AU_-ACJ&L8/@7]'UDK(A^4;P?YZ%X'_*$ZQ[,X4
MLB: [ W@\HS"X0(F< -8FU#]H^= _W1-6C>&SE\0XRY32Z<'R+S]NO^V^V>G
M!CVEAB@?7.A!9R/WG&X%34<(FHQ@ZO;P]AXC"&%T(-:'>64D;G\!"$^YP:9!
MW'F@614PPN(@9]GGT<D(VXT\+6YX[Z!R\0;@B#V0 ]&^I9MS _A#7<!_D$2_
M$C7]II2+NWK5<J5'? -P+0=7(#S\7ZUG!;PKEY]Q0NA<!H[/Z=6\I0L>:X8+
MB?^C!^4_!/E#KPP6GS3^UGWZW_K-0]C:?P:E^'EA[ 7"T#;+(2;N*/]?^P A
MG'_\U;NJ:=#13M!?RO"74>SN%$."@OU4_QQ8&>&B_WM-I/_1!_]ML!&*Z/Q%
M*VZ \T1LC'U/K#<-BV/'7AGTA]ZB'1B%VK8\FT\&FEN_?R7BFFCP^+]G7!*N
M[7"9Z(Q=$^CS$)>+UQ95Z:4QYTNO9VL<CRCC,,Q'A920\ZW%G[IPF>.*#]'!
MKL"'".;_&6 YU&N"FM9KSPJVS^&D/DX5E<<;0=%LW3O4=]_^FCL$.7EQ)"9.
M&N5!I=@1$@O*T4Q]S<8F%M7WL=^(XB6-B]+^@7*".MM(^E\';Q8Z.B9BVI(]
MWLYA45$=)>(D;A&JKV+(KI?$\Y0E ]>^XK&0+D7I6E#8?7,GPA+2$-G)HP)F
M][AA$L&JV9-EG_L&<V1ZJ_7)_S':2Y&#9*.Y]2N%"P?T3<,Q[3?KPJQ E1/+
MPO3/KW8F]Q];#6Y2O->>AV9G2QFMNLO4E46@F>[)E%68"N6$]2<\))- H?X0
M3H'M0-=D/O(_V$T;5MLC2B&-8][8[A(<V?-]RT^#O]3/(Q#Q\IDS2>>#U0+S
M)['MHHVC4^*C1@_/2?<;EIZW]BO4=*-NW64E>SXD)SOW7]61@9XXTW/$T-JY
M2K_'4J1O*S1NUQ_^H(6]K,#(3H2:O<?K/HH41/ES$9P>YL^8GZ.M(:H<3VRY
MP@K P#'%H]NT>]O\?"TT>@G\W\<^RE9\3.H1JF3%A(->$=.>4W>X-*:%X2MJ
M@2%JGYHP[RZZ2MU#>&Z^^36KO\KFCELN;;QFWUPX<?#=+Z'=7^3Q-P(Q0XD9
M*:)GP6;3"%TCZ"^M2'!)/TY53J3_>9<) *-''7 0D/L<+YN_2IJ,U>4FZ,0?
M>\V:\*)F!GL&/^=->%4>::*_D @=F7[)VJ0PB[D]:?TC?H',LH8:Y:4GHD^D
M@4F!C_WOC>T;5KNKEO_Y DO"\@UN7Q!FA! ;KOU+>)5"*E.RE6-GJ!EA93TT
M_:W$1H[JJ8[67Z'-K'$D=B]14X885ZF.#.!X00NOQ2N^SFD6E&BN&+SXK"%Q
MWX&D/V(/][ M6,]A:P+T7[L7<!0=L(86FV/V9" TW@$CXHD<<TF^?6V:8D[1
M4CWJICNX1-QUKBQRC:#C!C!]L)]2]6GIOLXF!N^<!0HU[#CF2D*?JGO=1^ZE
M3NQ_M2SRZ%^[UH"?IW2Q*BS5Z*+S=V8+JL)?FYN3?1(E8_<2L<!.DJA>/U7I
M>%,-?%(Q'K/8)NH4[[*_3Q/>;]=1.Q%X=]X.8%-#@OIH;&RZN9()W("P XCA
M'ONG ,>[^4LA"M*VYP)J5@U?,&T*1M[DVV5FW1%[NF&3AM?)#S-ECEW-2BV^
M?,]ELLG]0D?45F"N]:M/2B^93#>?O/X/A<HR6=YBQ3\L;F;U.+/Q=X.0Q-+M
MN&DPFPC91<CZT5U7KI3#Z_F(BU+FW5EZT[7*+9=@BL(+<3(O2;*I!VB51V:@
MDM=HOK9&)"^9@OA)EU'4U:N[U82750CNLWL:KQ_I]#:44)RMU8':=8DD\V:U
MS%548N())DM9DF+9Q?0[.VL4TYGLV/#%75!IXE!$L$?W/9D6S1]+?JR. 9MI
M$F=(%JXZ6TX9%ML^[42#M3Q&';/IYLV9TKX<L(GY6??647__G20+7?F\18(!
MD<*3"!VA.7R^7?_MKZ*ZC]S?'7$7PF*N/_%K)ZIJS+NZ>X]$SY(\8RD$#@3O
MHQ;WHZ!$X6E4-;$>^4V7FKO-289F%C<EZV,EJ0Y5!,$^[IU 4RQB30^.78?O
M2;(VL>KL$)K:/NK(S(@=EGQ642GJO(HG$]=#O2%%+1!FS;$K6SK1Q"Z3#:M;
MDZE6A_?9.UOX);66Y:6$3MGC?.]7VR=_M2:X&:EVF5YD<EV4M313=6&CKK.@
M4165UV?W+!";S>KMMZ>,5>@+G<1ZD2I9E]\\[-?V>%IC8ACOIL&)K6FU1Y\I
M%E&PU8K=U\MXL2=",K8#)-!\5]G$[[$[I_F%"C>S+K^"O=>WW]QFFCTO_;W<
MRZ=TB9/"Z4<8J\;?N1::4JI4G.JLOC,O]$O>D2;%]V='6Y[!%2S#?S 6RA%?
MS],Q1-11-)1>%'"W_'4!?X :T"+>.?%'"MD-H(B=A6.,;+72LL$ECU3WX8[B
MHHD]V*J[]?S>YXRJ@7.GZ/<;M0P[^#%;@GK&7IR&XPV6JT"_)\&.-@MJSDEN
MWA^:B!M*/VQ*U-+++1ZGNW-<&%JH @U<CGH%\CT4W31SVM1:#"?+O!E>S?4V
M]E&N-P3TS=M^O9L>^LC29 FO0<;V<$IMLI*1&%RU$C&[V#ECF4@4L<K;;Y2N
MV!'[\5-(-LV[+;1OV5"KB!WJ$*AP(5=CAJ7K$)]79HN1N$AP[6R!--M.W@-*
M+ZY"\(KA+G_CYK=5PH@I49,L-'-BP2]D[>\?E%X04IB>A/(^LV''YCQMN(SV
M6&'%VIS8X_KB8'DQ./(IA-E@<9JAF3U_3Q0 7>)^9+ (U6^,E*OAAI/'](<M
M9/9*T0CKD58S1+4] ZS4KY.I7/@U/36CH#XJ,V7.:C,R9"YZZ[UN'"6'WYN@
M7%K9V8EI(Z?3H._%-\"H<CF#]?UY_9A(! 8;;Z )9IF6Y//Y'R^>HN*XWQVB
M%+1/G/@8N;IP\9FI$J-CPF)OM3:0]K%(H%$U[A"MAN!7XCR18'$YCC&N_7?R
MZ+%0KG'!]_I]*T,D-.,7<@\77C.V17BEN'P*B_SA(EBY+\7S7JLQI*LS7P!2
M7^7_"VS"'X67FL3(NQYCC-Y'\FR824)9;*$XJ2',>2^0'K5[<]+SQ>L<K7)3
M?6G:KYV8A%(Z^'@%^N_NP>WD)2!R(CT_S>U7AJ"TL:#9^.(0@_C9?8?*0 ''
M*P7'CMH9>5PBE@VY7*G3A\^]-^ LEZF$004#F=N3=_;5A-4-PP]3&P'DYHAX
MS*\G#SS\9 X.,0.'").:JU)0UHU7?)2.8TD88(M]V-V5LY539 XG* X&_R2X
M 8030<UG4Z5\LPEGFQ.$042Z^/F2H@*ZTHSY'_E9+[7BDV%W+)L/JM+A1+39
MR(, UI"]?&0C#FO :[0;P+KH#> ):$7+N1GNW7R% ^ZL$XH!]AWP>531099L
M1\"MZ^,W@)_8EHB8K!)X6,L%ND:= R]9:AU &<,0$>PPQPV DO42F3ASK1-T
MB@AENH/@G(TQI'T'=+O$Q0<>76+-))6B OYAMQ1 <"*QXK^YB$=P8;Y&RPOO
MVX+7%5^.(FQLQ5$L[,X-X!@12(6 #/R.(0/"I4'PB_F/X,,Z+NOKN\C55$MQ
M*$N()MR;$+G"J(J(^A\.=2:?8B!:SD>>*RP_RKXEP8 @H5O6<H4()0^ESVN:
M$:P@1,5(5T$>Z&J&G8^#6W].-/_$02ZS5=HG'Q9 /R 8:X8&-J^)0QE!) C9
M6!&R%5].>O9A;%S$[MGJ+D)"P^!$PH4(N" P9"\'678V'SQ,N83HJBWPBOKE
M&-P;?$6 +#ZAXLF):$<7+JI[E#[SWKWIR$U+]Z)I#8SHA5P$NIOU;W1D3U/,
M_4;7N.R#>^LBNP"!?KO.K I_<XO>T'3XKP"12L@S)M6W MSV#=ZM9NV;#PL;
MWM]*\/E6 FMB\*T K)>CYVI@U@;/.2+80<W/YA4[L^13=$3(WC0;[<F^0]KU
M+6TN^J!*; "A@T)W P2%8B0%63E_3[8/#S].B+A5Y'M?CYVK6;,VF#5Q5#2M
M+7PDUW9_G:ZY,\ESGS+.8_)UU/L6I2$#C6UK9Z\;0,8;>W@+8DQMN0.SBOW=
M.:PSRF0XO\2&MP83&D2&NJI*5??.S)GSW0"\PHZ*[Q1&S88N8.>UU=8IV*M$
M1\-$CUF;MQI %T@*@D$'5P?8L$-PY_?S@^N/R;\K(81!K^5NJP@4G/&0KNN"
MAYS!![YP3A>BI9-%(&09T>L">UUP#[K?%0W.UVX PI&_RT&,HUW]"T0A>@&]
M"(!?@M9D(;8W@&3)WS4,/&IN $,9B)'5C:S^@!)B[=JK.G0+I@#S/[FMA]"$
M?3G>"4&EG70'UX$Z$Y!U+?9NBR$DI8B>,PXABU\@P,6GBT'(4@C(MB1A:7_#
MA.WA(QHS_:M@0I3X_Q+!&_@'E-BB.WLG[6SW+WQ^0[UK'!50A1+<(_M6[@D7
M6O-<2N4OZ2%:;*S!I>1HSQ>\/9W4AKN['N:I)8LPH@UUN-+L]7,?+<1EQAD1
M.K#A7=B\F%_W5Q1Z65@_Q/JK[&J@"L1<79VV%GFE2I YZ\PJ/\8<*]G\SH^
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M0I<U$JAGTK;RW4"F*4RE9C)U]-?>*FG2\_7(;NT$]Q2:WC(K@8L7"TD,B4F
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M,F3WC,#^WWL3I$&VF.&2^&5W/SSLUA1RQ8GG\_KPA?.JTAK#K$ZYOL!>9V;
M*O1JMN#G.[Q0VT@=3>O#,(T1X]*&P_UZ,J)AS<XRB?XC*LG-?*E4*H"+$1'
M-?&,K]@H7EC\ 'A2T*>M)-44;E ^057CN.!-YK5EQ0'MVI*7W B_1%_U*G=
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M/3Y\?A6\\L<6WS'5-[!%W'&YCT ]3[5YE!X!UUKZ]3^U6M($54AE,SR-,#&
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M2[# TN,,ZXL_->7 05U<[O<>5AE_JC'_I,!08[)AG(GU ME>=CXV' =UQDI
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M%@WI]$6QRI94]1200RYJQK_$+AGA:IV>!ESU)8R;9$SCQ7FD0:>8$.MO:=*
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M),>T%U9R1_YQ<FB+9O&&N?\D0J*=GF,;N0OU;>-4/,@9E"3#:+<1FHBVZ<A
MA+_"X6=!41=(?(# JZU6Q*1^,KT-8G@IA\)G[<G0]=LDT[%1TB7OQ%7&<WI
M-!T5754-WV7N]E6%[00QJ9]J@Z\W)XQG.*6U0/3B-\L@7=>M#&Z"0\822'U9
M80I+]&_30)RV_#[69:6EPAJ!1G!-3#N->,O8E(7KL^N)@HLG74)#Y*O6!7\!
M V&D&VN3Q"EP&-C3S$C-JEK-&8@#!Z8CE<$?TH4OMB[ZB]7=6"TM 81=;JE\
MMLW+WV6G[1^#>-&MN[:W38AKTU;M=*8.-@)]_H)Y(<:F#3(L_9]_ 60G!D4$
M/G]"!_D-ANB38153<=F^5P0[&62C:8.J:R"+'@F>]VE!2S+RT;?BM]+PUD?6
M9;?*1=>=/IH,>->TL\>3VE$^<]/GQ>'Q0[P\H^S84>T!NQ)?+B'_DN_6HU1G
M6J @$;.G[86'-+*( >#W5/P*-<7O'WT94$SR?K>P'45L\GZILFL%SN0V=+G>
M3WVJWY(P@2*<HLX5Y&>/;\-QG#%_L1(Y5!%DD;J%U]/2U05/U>XU"<H+<H=J
MC_K.$^SS,.;$J%P// \U$I?<@4QROS0OVO'WGC9?UVE?@>O[P-745K?/'LTK
MJRNTJ[3),!8975.M6 &> *H1_Z'^P-[4(70K"^$TBLF9/CK/Y%6[>(+WI'^5
MD>9'._(Z"&'TC>S(??%#9S'Q"+JI,O1Q69#X=,'9=UZ]7?J9BMMM!P50!4QB
M3]Y\GB$LWDV]!<".Q&&RV=//)"FJ-?7W&NJ:Z?D=FL[\>7X4\S4@\HV]BJ!(
M"?O!/JO]"8##D' ^F&=AOS=1/]5B&=;SNDN_R"CY?'AZ?B(AE3'!2NA\G=$2
M)\G&DC4JP]XBNHO(K4X%Y[:,.:_FVWB)7"&,)I.JB_?Y1SF+3SUNH48S:HQ1
M(P".5G0L8VY#=,F&?YBVAL7[%K5Q?@0T?%UY2K?SO=R1UFNN"0H([692POI5
M41SG96.D6".%8M5XM5P>F&.L/3E+[=STIS4NWOL9=Q(,2:KHZF"IQZ_M\[N]
M5_HM_KE:":K6A3+/&D7?Y!SPWUK;>*1)J+2P>I)*(:5Q1F [4L$2*-[V7NCM
M,$S005EKMO=)$XXVC>Q/_.*?2&DMO#RT!:JR-;>MJT]@P4?$M:N@H,>>P9""
M_X7 L]A)(T/U]>MK3^URJS355Z\:AA31!;MAY/Z__^UX)&0\1'E,[8;OLFO"
MVC(#4,.6+MZ"<8]XM9&U@>O\(I3,Z"_ [@1*^>_\>B6_NYB_!1>=O49 [[&#
M?-=QL.X\]BV/+'^Z_$"21D-^O'QW<3%KN(B<01EQF8F#V.]%*<;6R[V1$3.'
MXT,RW'R^$:_(_QER*T+_DM;$$%+]3GC*+LQ^R2J:?I[@@]V$U/8A$1'FO3BF
MPL6,DJ?X/Y,N2Q[@[.=EPUP2S'\!.5_B*TLXKJ <TY&2]V$/L,R2Y^MF=']R
M\)%Y4!YOV T55* S:[3$#Q/DO-=8SJ(<OC6);XL66$L:$\8\T']5Y?;<TRM3
M8K!;*EB*)7;ORB&.?>'\@K5PY@5'=TBR5>94"G"38"*&</(BF)NA*>V5$/Q[
MP@J]6S+D0:(:[8<P?B.B8CERL<G/Y<_1D5]:_J7'QW!<(3I<-C-23L'+AY3)
M/T:3_H0TP*?Q&_V[3[!UQT>-BN2L10-[;>;-"S40)74:Q1'!P>XK"F89EJ?!
M(@L]&HVC]=.-)TC(:#:$L<86<JNQKVX?UYY'F*:8$:K3^<U+[[L<U?K6=%U/
M(=_*G(_&.V)C7<UF:ZF2YUJ<D/'U:V5\X)'E$70,=^6!,QV$4BQ#?J.?'FY^
M![%?LHPP7Z:+I'G1QC*U8^F*_]Z#L%O6@*LVV#Z&B<4@4^VRKXJSKM)TS63:
M2@19'R=@NYHTX"!#>D^B-V"W44O 7BN'U_X/,F+N=%JO<)MLP"%LA:<:;5#1
M]ESK/**\GB]B( P0P;.:YP1X7+)+10,APJ.JG?-_ ;N<RY5PZ!9RBV/-CF4M
MNF?+FR]2Q@XG"@KLL%Q/V0G\BG-O$4\?EE?[RS?P_.#W27S%<+D&<8_.G[(Q
M(WI)-6$>K>Z<GM3(U\CAM_;U8;2B#/'>]R$20UO/%@6_PUP%H#,,'/IQ US9
MHJ[7TB,-L&[V4,E3Z*N%\<O*$9/$NF-9[88P\'3U:.U0*/V:';S#L*=T+@*@
M0/\"GK44P11Q6-&.=JA";AM:&)XB>^O;?/WT.Q1=WYR[KQ]^NE/0S+$@'GE*
M!1 0QL>QH M^U1F[ZYJ-<B,Z;E])A(V#&4G)HNW:U6+U-MOL"7MP^_$\+]C]
M)C.U';^05<X'2\F:/X.OB!%NRABFJG05.@>I5NCGU,1O6N64 3B20>] __)$
MO\)"?%:!]BM#<\J3.XLOYZJG@8@WPNPEB/<_.PZY?B@!1'\++RB3&I\V<]ZU
M:X"%A7G+&C4>7VUOFFQOF!@S6/!?6.)36!3B6H9Y?PCWS0]! DIH1F 4*!,J
M^&51@KV&\BU$;N9U56W\Q3,!.J&9)R$S#4^#-]+;-'(#\1 0%L0CY_P9A,:T
MJ3-W^=J(KX'?AIPGQBYZ686AY=EG27(I6F"[7J7A S^\*565  4+M#B#Z8>8
MLW.MR0?P=;?7H3"NF:[=A91O9@GC>^0O^T:''EG;EOD?-&%FXVZWTTVF#!9\
M?RI? SO7,-NW 4E"(R\6$@"'8O*)]#%E7-$^FL2K3N3'-,:SJZ[L9":FX]51
M1 B@O531!-L> _154B=# F )5AOL<ND;7VQX@BSWT]?P>3E%ZN#!W_I^/<]O
M3?Q\ 1L"2X6*^[H\U&Z@O-$J58UQY[)*\@GP[@(=Y E#B_O5:MD[:Y5D:AWH
M9 ]V^HK'K\O0.RP*9#!_\\*4ER&ZR@S>I]9=U]@VLCRHT\['[*AY(?[++MSJ
M^D)'TNH5G;DL.KEZ?=K.9I?6=56I]OBKDW2"B1)'C_;LL] C05;+LY0J7H9S
M(I'6-.7MI#XVQS[B%06G6%,/YXH-)QV3U=5XJUQ1;W/#!M1..X8A-W9V/]*)
MWWG7O*#>J7WEJW^BR;S^;V?GO+P@*5;'P\*-F@2;(R5V/ 8R1C):[C$QB:0^
MAC7TI#:-02'K,E\8RDP\=V[M3SZO$L][-CE; 3^FNC%VVAV?8L)'ABMX48*8
MVI_G3!)Z\Q<0RY@#I0<>.BB=7X!G,1'"P2:X@2K6APKA3V.\#">EW3C.C4V6
MU:@V13K1?,T+@C%OR? 4QR@DR/YH2Q4.G@@%D>!+:?%VSC_0YZK$7\B^ZKJM
M"?#QLL(M/';GOX4DRIABQ[][:*&<V<ZY"@?,S,FQ;#@:D(^SI#Z ?%Q64L/X
MRXNL#0^S5KM='<_3;Z%22%JL!5I4N,"WOA=YB*\GMVW2XB5E6\<G5ZJ_D]R;
MAR3Y,)M57@!W^'+&<)CPW7(,"K_)TV;)T1B:H6N)0YD4(,3?9^J<K4A_OU>!
MVSFR'^$8*TGY(_Q_-1OD_B!F[[_\]COYL<0-16Q4]:5=:%/TBX.<=UY.8@Q"
M4;@:4ER4[52-5$@XO A] I8P9YEOU42K]2@R-7RJG*UXH[5V$100MT6;YS5#
M]8J=D?L"Q$KU0S/>."6O 9W+0JE8?6(,@<*(6P.CX1\]AJR(/@]:4SS<;T S
M#[E9L/<_Z)36-R+&V>=;":=9U);A8_!>WSV-Z47]VQL%\HJ-$D*5A4D9/^)U
MW8M?GTGJY8F]O_WD38P7FS8_F;AV%' 3/=;XLG91&4^NH\*+G_EHQ$YE@*]Z
MWP'4&;C\HAFEU+)@<\79RM&\5+[,_]T+<J0BFG?7(%L039K[0 5TW4DB CBA
M)4:60R6:__E'[_4.OKV0]%F9_E-Y(&. 3J?.BPE5\A%E77W^AHJZ\2L:D\N!
M*\C77#4,KZ<2]$XC_/&9####$>S:VE>0:0'&1A>8"]IYP'>+<5F,7P_N?&ZA
MO4@-+#RYE?%.APHI8%HFO-S'2I[M;(K(U]78.2[XWG A:P3;<*(A&W=S"U9J
M5JM"G-$MDZ5A'SD]S#1L<P\4XZ$Y]XR#7IJO&"T5&:B]5#8)^F]L>E54%-X;
M[1 2TMT]A'2C@"!(.B((4@,#*LTPA-0@W=T_ND%*2KJ[NSMG*.D94!A"O/[O
MPWVZ#^?UK&_ML[\=:QTM9:.B.%!$@'D7E[[RV/X\?SY+CD1F#>),#]R"B4=N
M\NIV1"''!HP[L]_W<(E61NP',R<="BP'_L3WSA0)/6^ <=V+*])"94AK:,<C
MEY9]7$H4W;XG"'[2P*6J=QF]K<.BLNMB@,@-R79'TAETM20;:"2!C%445,R,
M^JC7Z?U"NZZ:]<X"GK("T==9"%_OMW/N0B(ZMHT,B,:XW_(I 2 !&A6F/</$
MEE$*KC/F; ./:+3)ZV4I(86E;=6E,Y@[T7BL M/)N'X06X,R<X.5\4-O2FR$
MG/0U4)2?&TW7;V).#L]Y4/H+(&2M*H&\23WB-*ZJ$"#@OK(XL 6Z,Z'>5#P!
M$@>_7_41^%''J)M'!?5\5F*??#Q;N6TUD#3!-*&^#AAC$W^'1S;EA7#&2BO"
MW!N@\0<G^8>UFSL:4%4'R>[NCC?2LWQ=\/U8E9$^M00>IE#+F)W# US86N=B
MC:""H.W=ARU@BXGOFV=11W4KL*:/Y2D44URC61SIY<E,6+?XN/V([3!I5H9E
MM\TW_0-?-W[8O=>&V91.+9WADK_IC6&/4 E5TE]/ \)PGH]4!\ ])]# KTL%
M5?:,4;T<27-#+MB]UOMO:+42*VK7)A3A%['#S#-X!ND^FA9H5IC"[@ EE-'R
MFL1=4'Q]D/Y'VB2V5,Q009-L&E+Y[+[C_$05@99*&_"ER5_^UC'_&R_'T:TT
MB#MNBR9>0%S47,+9-\I3[MG5<Z)!X9R=K$V%N\>?\*L!3S(/2Y\W@FCJ&.QP
M)M@0,A_P_?X_@(+9$VVR8,<"](?,7<R\6?:;D3FC[E4#O _X]E8?*7%QDQL4
M"'E?C.83F]/!*R"HBX%I,J/U]4W[KY#K/&\NNR;:LOEQ21@%L96GOO[3R87\
M:=V!LK(#S.I.EG<>F9+0P/>U4W)3%48-"H1FEJ5WD1U.JU"""HAG@]+Y176T
M$>J_KZ51_ZHUI3_,WL!0UK?R.E$5MD>?KA5[VHNTWDQ1%GUUJXX/9,XA0_CE
M(3"_RG[E44)_$!%]J/TODAWO#O<+^MLW%;%F5\#LJ0,EH226LE.L&4,SZE<7
M>\N\NYR6O)E"'F[:MDW]_8>?4]71AQ-9'A'C5#R](X#4L=!Z3*.%/Y+PH5,:
M(2]%&TS;LM9/WT2P[85;ENRGH-SR]-W.5V*J B?4TM2TDI8P&3F4R 6O5+@*
M6G:P?49;KV'4HKUQ:_7N!E=6AM073]#<1W;.74O9N^),7;<U[@KT.-P=9$R1
M="W82GQH_=O9\O-3<5)U>H#.DVUBS-SZ #CT,7--H;C(7OH9]1S8_AF]=93.
MVR\"*N>A[Y;8O-G+<9\>NHM$;['-_":Q'_XP^[O"RRWKF3MV(?V>=X2N$H-;
M)%"<3Q!NIRNJ9O(<=UD)X8_?C\C@;8.9O%]R.HP2\.Q< '.))),KF/JWJYB2
M3'Q1^FRTERLVON%#-U=-]S[4QQQ)Y W]U1ZGP6DB^*35W:O+U0$2R=\M42\-
M. @0,O/YB-I**_]YI]8(]2[>.BZ18);YLO8M\5N2EXN<^J'3Q\,Z ?$XB&ZS
M_"=DI(_B1\%?G0H7NLLBGS).S\XXXY0+I<;?(#4Y(5%O]NAP4P&6F9X/'*+5
M-1;?>Y$L9FL'1+:5YYFTH7A%S#9\/'^V<2DW!O?STN.R=>%9O4U=P 6W3;U[
M\%^ ^J(D6M!Y\^B,]CKJ%6ZB:*J,@5ZHHB=[&7L4 .G&%K/&'1_>06:!K'HU
M7@/-]/UV-=ZV)10K1E!I(5RYGB>O$M_,\+$HL]L+/=_K\;6DO;0>L@DJ5)6L
MBQ:CZ1_C=-=4'F8.4UF;>)%(3DZ(&Z!E__,O@/CT%\U<&@@MW4JV(F11F_ _
MDA&L-+B,J;QF\A0E81WJ94\&>:.FQJ[>+4O^AZ9MMBL^?G2!\ED&CS79F;A5
ML?Z,]AGV)(6H(3\\ZP60S3WRV+4U=9-&N+VT[O-R-)N>: ^34DE7/>2GK*-*
MC3ZDQV=A@OHT@J>1-\$U\GJ5&%^GAU;)")M<KY@?;2D!@3(C<7/5<_ZQ=)YR
MGJ3VD]W]WB:^UB\_PH,-O$,6WU4U/DXW?A,ED*_#93^]''K.43]U7,L6(#F3
M.?E?9FJQ:^%QG[^$>I(*;2U#:TJR/:'"9R-$3H#@F\!7]'Y$:,\(>56TR("'
M;&CL><:W_E)CB)&QV7H_\W>@^/F7V5$>3QBSF*Y84,!>AJ1_E)ZYG8QAVB/U
M0D&K[,"=5FR,ML/<5H?#3B@/+* L=IS.TDQ!=\,&U+<%B.^[V\CL?@"N;57)
MI[ZWVW>G<NP?BTEF$^N+,?84'>5]<<B+JY^&L$Y%OB?MK 1KM-6?2.LIHYSF
MJYEKD\<F5,2[;IY841(S$^O@@Q#^E$:8BOZENZ4\XFOTR#13KROKZ,=$^J*A
MDR0<@6?XN''/@:X0EH\8_]=UJ/-8VI2/<QI1%\"D":4D.Y;HCM@ O -KX [6
M-(#XZ58^=A3?_SMD/$[1T5"D$%2[>P9Y+YP#<W&A&<RY62..I1ZEB'J]7_E^
M!%3.S_TE(/;>%3P/KQ^BK3,Y:LZEJ TW[VR%.^PP#IUH[FJ$Q//F[5V8?FE_
M^T)0L?V*<!=CL],.>;4IG.7)FY[<!SM8J"YNHIAPY2=@?4U9P>H1BL-.,4(C
MAO%%^)]VGQX$ZR0:6+7$(;7 Z'.D.Z3(:O2_B8!G7$]W/J5;'+P ]"TK\-FO
M"17W_ZOQ; <;1XR6LM6MUG=1@DTN[:*KA!\L<X;3.'IM>P$?]W8^#:*S#).U
M87J/Y!).#D*.%]B3WWG3:\$3G%G.1BMX^QX!$_1[E/EX+QNW^_/PMDU7M=R+
MQ^:,>X1>"^T=VT1[_ 4(^SR_5SZ_C4B# Y.^9@_^!3RMZ?D+L$I:/I6I(DY=
MIHVI^K[9]#E76_S31*?QK=!RD\L@0!6IS0C-=(JNE)<I@&O?&QS<:&?IQ"%W
M=4!&ZJDCQ):AGE/,KLT,_+*T M,K#[8PD,$\1RUJ>DWP-Y._M!@-"EJV?5JR
M ZP]O2S<#*KHLK+N_=CN525"B<$[&6"C\'GA+>^/UK;+=+O^(@E>W*Q"V#VU
M^*.#ISKPD67N83V2:__P_2,=1APTZ\X2^[N(4'XQ;%R_HRE(YO*A:IQ8M]+>
MPZ?UJ3@?3EHMIA99I0VJ;:O'?(UU^6Y;!Y5U+U@<SE!,M2"C^DQ)GLBC$[3>
M0DR>A&^'V*8V@Z=ZV\%^W8N5C)?TPF]TMCI">9+S@!R17P ,&QKR,?F3>N$]
M7\W#D?,U'2+%'6MQL;;77QUD,@?7^A+EK(H^O\UVVRM*;'S5@\-H1HW:[P[[
M50[;J6]J:FEO3;W[":[FDA@;S&,F#LS&?@7$ZOG'Q*PA17+W9P\ORT&4 Z.[
M1%7"+Q6U%Z0'O1BY^YYD9')SO"_"9V]"I*X8\2]K(L@BZ5B!2S[@:033.LSP
M58. 4(=LLNF@)_#+5"C[6ZQQ%;7+J+,$@K[JKV$8)X3T E>'B<#*0?1[&%@J
M_D.;QFZ;PWFBA3$V\;E#&=.[W<31,K?N, 6262?WZ%@9[<XPF+5,U._U#^T)
M8]43IVI'[Y8V)CR%"02=U;0 %A ?M44>C 32G'YU_5]K UOJEH6M'8-2FMUQ
M%.Q'B775CI+ ,C$4S3/SCF>.#VPU&-D3S>7?$.U[#XS1,84]W3R$>\;6,GE*
M];,!967&@!(5E*(9RV7]*)=N]I>OPLF[QB#O:.\A(=?K^W(G,Y\R799#&VNF
M5_2\],A6""_"O2;<QQV&%"(S:H$^+[+EFI=22[J6(Q@!5$7:X:_6![9\Z@7P
M/7T"D-'"9)29\8:#=_L]4"2&^IUS-I>_L0^V0/XRQ!F1*E%;(/=G,7$=NWGQ
MNP;?EF2218)U[XR$'3ABCN[24PDIC]5B9++1A4U+D-*Q*T.7H4?ZN";_4#_"
MEL6P8IZ\KU9T2>:"%GKMY,#I]@GW$-!^]=D$_1.L8'*ER5<*9!B2HLO)ZA]Z
MY&5D-<?$U,KK!3@2*(JX#Z3X]H#><*1-M%M%/,,&/*__#AZMUM98V]@T[\33
M9I-K&?'=Q8'EOPPE0>H?/REJDP5\--#2#0Z23&P$6W9T=[EYGLXWGIYX,^!;
M<8+5(N/\*Y,PTF*$Z3X6CJ!A0SM*).RBNM$[NIW!$F9'(?(?9*+\V:L"9G;?
M"G:"EL17+@T^&_KZ&!>$_H*04T>.^IE!TSQ876RQ>CQ]_R_ N..VU4/>YRSU
MUC OQ1EK%*,^E+D?'Z; LGZ\)+9Y=#>54*/0[E7VP[W5R//4_7*=.P HYG)C
MTH)5A;F[!R\HD*A6;H&WCF2C3<$:0FZQND;%_1N<7I_?[R49L]'#\JFFWRY5
M+0?"F)3G?8A@A>!1!)&3L*;"NJ_4 #I]CQ)HFR3@:%K&%%-D.T(48ZB.%"$^
M\N.?2]-<VFU-G9_0;#+9TK)?3]A_]S/')#@X9I>=-5\'_\E.YV<83J^?,/I=
ML<MWA4@[%_GK.X\B^$WSDL#3)ZD,+.,L@[,1D'/ IS!V]+MAY&'4;YC92[QY
M1-4"."9U?A.8MOQEU>1-[:W-GMW9G,5 .N\H0!H M$J;,>QC966L.B^Z?A'3
M%MK2V*'>EE'0IE4@ 52]ECO#\JQ+ZQER,66YZ!/PDO<OV%@S&>EBKJ]O:<Y\
MC63ZU27$,\'W$21IST7T8XR.V,\\+8&PQD_,?R!#RI>LOZH,;'(D"OV:J>U^
M[555M<^++;729PS0)-0=$<6C/XSR V**=\E^G%P@M@G7UE6_'2^U02'VX 2U
MM"E;CSIU9EUB"A&Y=!I<9K$QTD,=C/?.']WKJ>,3]77N;"([QO4-D!-3SS>:
M,)78%*L8BK[G5B?#/$E.X5W4+?&F85"F4BT/^'F-4E=K_YL0:K<_A^?I,%/Z
MZUW[NZ< STAY+=\"I2+CX=)U"!0\V=/0U.C=%$4FJ3:G<-31]+'@_0\5R^0X
M//@>S$_P!)PRE55ZI/#$2XJIPF2TY-Z@E-G@^G)M@C/UY7'UJ42V:'QV*7/M
MNUTC5'5XS<_K-8,JJ-  ;9*Z4$?AL=%AF,I]G>!QGZK_=;#EWEYV9GXWF3R/
MXZEC07W;OR$U'?)MW9G2T=2MXHY$[*03[Y!GJ8(X-NR,@'T?NVI-I&+ #WA=
M_[V>=NHQD]Q*86UWTIJS99*HQ167V]3KNDOE7_(6T=*RWW)IYAV*:F?=&Q9_
M_WFUNGIDQK7,W4+1QM7JD=W8J\H7@B *\D"):QSQ8/P1[?%X8+C468WAZX85
MSN9XW;;8 +T4//T$C1[FC[3L'[\2FR[)"Q2<W+UL2JD C[L\^98X[L37EOH"
MD:AP&BW[(]'\3_[JBQ>\/ '/Z?V$H9G!1TM@[0"KE@7>AHZ6ECC8.[ZB*)!Q
MB)Y*?$/:BZDE_OQ]B9A:=3M%>BFM5T>7$+B4PUGU\KN,[?NW&K.J7P^>Q\W2
MCX?C"R1(7[5[CD+L'^11&>VU;6%3QPR5,.ZZP((%1XL!W;W1%L$ .3&YZ":C
M'R39 ?8-_D0/;"0MS?':G1019YSO_Y1[IICHM0'(LA(;DN#'7P\"9'Q,TWA[
M,Y=7+@[GSVG'K.,.UITRJ'"!-!L$TZPI^W?5!95F&!.0.'3Y6JV_]ZQ*< 8B
M[R2U5@CS(N":?#_*-U!!=QNXR]I>;K=TUY7F7KPM& OUI'K-%V43&O6C%VLF
MS$PNB.2S)NI?3*D_ INEN)2."U7_EZM?YKTZ'H&9>'=_H\G0=R C6&J_QTP,
M4,N5GOT+J*==OC=YYT_E;QU]<>KBEF?'.W:EN&CCITB:<N@"L<_T[_N#@[2J
MB9 2F/1X!#$X%B5=VPD)IR*-9G= #K?O ]B>CD3MY(^^@&V=S7@;IF\\<,]_
M0COF($5(CW6-N/][A,]6/XQ7B3$G@6UA'0/DDU?,LCE%P%/@/S0ZW)'1>80_
M4>;@E;5M+<FM-Z]=X$N(J2%8&>4+R\2I#7YU)C'>'[C+^ 4/T$6I"M7%M)XK
ML)U F;'1!LBU7/V@9LV ,Y[9MJH=[WW"1)[P_$TT_YU:)P+"-D@$_5/!LG0O
M8\>>.G7M_<)"L-B$4OGG"GN"FC,TMQ[S>L>$A0?&OZR]8-&0B20JB;^W_ETO
MR$Z03B6M-D,7X')9<Z,&>#$)&F)\;$4+])$5A]>C^J#+7RV35,M\EN=4<0LZ
M1E1\V-U@W9V'#,]N-%;0G@,O]7KO<@M@,N&_;MF;X[:06\;NS[B\(R!C;^]I
M-]'[S!( DWVY2)J&OP 2'\XM+E9.B,(Y$\+K3[Y\SIMCOM"AS1)S;DN*\T_]
M+-VBO!Y?H-ZZ,PVQX&.B6)!6T#F<,Y5^2W_T0XK'2-%J0.]U/BG9@)E@1XLO
M[6S#?33\M\E].Y1%[^T"JI9@)^';1+%ZN@GTL[1A?,! MK#S \YW:!KXHM^S
M$XU7Y$7S%Q"RGXDD+-E(FJC"O\B*J<_9LXH<=K \G'$WQ\;8&#7-"5X(GE.2
MT'\>%!*Q:23WR35GU:OV4S;,WJ$ZMA?B15R$_I+;9+W2JN^,@M"NGIYZ'GOJ
M"NJTCG,8)(2S**">K[7<%P'H%00Q695P?U,T36Q:\-K==O^=#[AX<.,NZE5=
MW_H-P:+^RH\59WJ^YPXI?:GQ8$RQET69F4(*8J611'CH>OMM6VOJ7\!HJES&
M+%B4B^*';6\J^V2W\X9S;'-NEL&_V.[KJK-XT2A@,FJ]>$8[=&-=[,H(>IH=
MLI+TQ.RA#/_ Z8(Y&G71!ZU6K?2W'G.B^(S;N'?&/,2]3C7.X)LT4E345D],
M"J?&ZC>%)P]^O3EM+L-\OSMJ@%G#>$ CU9(5,2U8GL^>%$%"?K%;!LY>C<SG
M(:V+"HZ6=4ZZZ&Q%D/6-K7516T?GL6N3O$E1CZ:J<Z\P&V5U*#_=PZB34Q\&
M1#L;_@;\S=:07L&&&OKEMV6]M]C/>U6%!Q-=9C\$= 9\=WY01'7(2EW'7S-%
M5T#W/^1<B%0+VUB9Z1!^\TA4SOT@0/(M2?2=+5:;4VRJ=KB,F>1R W221K @
M%QIMC$QD)FBVS$_A^E))QV],GJ#VJD:N&7T3V6!."V\V07/'U!;,N[5*_F%=
MN[W@5,_5Y-*1;\'!$XI=U]4;'C.%@7^?:.%K-LY8SLQM5@L6JVM2GMNTV 7[
M7HCM"4Z]<P910G/J,=H[WG+>95SS-991![."EL:-T-'PI-@V*<AE3A89G^$3
MQ9 HP*'3H[#YFNV=_.A.C@'L\X,IB"==R$E^((J.8"( G$&*'*^?B&-7NLW@
M-_;CAU95FQXUY>*P\Q3P9!!MV8.(-/G7B4*M]=570B62DWK.F#2!(GHN_Z2K
M7T9:6MIU;4NT+G&+8:CX2S-N]_;V\^2)!!FLX%J2P 3G9WFHZ@?.MHP%@[XC
M1X5%[G.UHB_4;]!>@KWRD_E>_GR 3^JO^'#P33"5:W[!B,[7(%3G>:UGU<I?
M@&U52H?K.- Y5+G'BWP,=*"*XZS"6U'#,(0)W!7RNSN6$R$1;#)@?-=:O'YL
M&.V]]VY2,K$V0'6_UG*=T_%V]\7SVX"/WI$*K!@S+5Z-V<=!M]0VV?33S)?*
M^]R1!+WQD\:X,2$?::SY7P'BGKRN\)% F;56C)>9VS6_WWC+<:4P7&:Z!@RC
M2L](8J Q3MB%4B0&!@\"S)<:?*&Z[5Z2FVYVJ,;_FOHDB&.;#-@K\[^5SV 3
MW&\\5(8#;Y]<MR+C,5J-6J\'1,U!L&\GUV"5UZIHW.L?*2F?>S.Q\\4=T[S8
MZ\\YQ=]@#_^,\<GW5X"&MF+L=N['<]2@T1#-N"(OEC\CC)W(BFF&L>?8IL*B
M+42!EV7#8Z)80_Y]+N5PD#XZQ/4?1/"X<R<*H=P<*%_&@+W#;GH^+6KD. K'
MPN&MZ^CQY'L?94P@DN@B/+.J)JSA?I)73PL I9LSA60QY4@Q)Y1]_^QA1Z@I
M3A /<#[6&/:5Z<\C--4LGY3*.<PJAQ0_7%:7NE77Y_>-,A%*$#VY=64P3XO+
MUG./#_,C64[:=&<1=MU;DPH[\3Z)]DC=;+7=L]W3XT^>8O,$YG[+!&0.]S?K
MOFS*7QL\)UGPW#)?JR883J(I8I_X$+2QZ]B[BN/S>\R>"AX-QJS[%F]!0*6V
M8)K8Z@+J)<:&'R,@^=!_FNUGVOO0&6J:\%V\U)7YJVI.MC2MP;7S;31)!Y32
MJZZAIH&8N)URPG<4>%.YTL']S033=S*8H.K6UK@A )-H_'5&-=3M[I/T:#3\
MO ]E'.^:0";9A=FL,*J.E7E@O_C7B0B0+7-630N[<@BO),$I%KHQEX,AC])T
MTE-'>I[V/%IXOR$J/J12RCN>^!_26QN0=>-Q&RMXEZF(8* X=Z).7= K-G9@
M8D(14,\I1 $+ZM'$"-EPOJT0=!DNWRQ<3TF>("(P5D_*0JU3V>]_V-VGST-Z
MAKG'T\%Y7A*IAZUIDOQNN/SS_<[DK3IU!<<Z4..<_@Q $221O?<QP-KX06-Q
M>Z!)@6VA0\3)QI.GBB?9PV(!_"'T<?(Z8DMBKR:],L?U1_GIUR7ST"ZADRV>
MI<8J:45 ):^J)K UT=WRDZ@F3S0Y#N,Y=T'/E7SMN&4,R6;,-NF#B$(X7M*2
MY^?GCET;]=7%;L)=LPTUZ8XJ0=:P;]6@/QND 4^+BGUD_BUVB*'!@CQWJ19M
ML:\CFL*S B*OFV0\=';!;IZ3?DZ@L3&<G1W@*OT7P%A#!YK]36+1QZ7-REX7
M=ZBALJ R9 ?60%Z6<(IR,I4HTSN-[>V(KH(]S:FDH/]R1IJG&5V4D+;&_WZH
MU^S>.]09K]>D<M.1R#M+1#31C-.KS?G!\FG+?)A0:6KS?JRK&/]!,-C<K#%I
M%<)V)I U$E1AZ44B/ _@UD<SEM +2S0PGC#U^+$\#L>#XEZJT2?M;#(4+%8C
MVY)TBT$O^\:X71MV#UQ[</+I 8=N>5&44%;Q)M2?M'";MOJ/B1OV!@J^DQT2
MDMB.W$;RJ='$15XI1JEL/*104.^C7-; L $,I-TPQSWO;-5 I_MR 1#D[T^<
M,#3+#%!BF@T<J\?*G*U'L86>2AFY"PA)@[QV(SF>-KL29'.>JL&;3SV)>A+_
M:_E=(4L7XJ9(RK#^%C3L-6MAW;D@+$+/>6C_+&>C,'9XWY3TJPY^.C2/MD/Y
MD6S!J:&;S,18TZM J\JV&5;&@-,7@B=>FG+?JMPFJM3YSJ7C<]N9C.JRY';H
MW7^B)_,KQS=-TY*ZV_9)YH.?!-0 J_(CS"6OG-)9BN.>]Y2G(<P#YS47)%M^
M1<[-/4H':>@^[@FZ2%S8%@[DM<1F)26>Z0TI8;?QS+@UHT91FX/MFW;69/62
MAA*C$IJL8HTY*^TN&TE: "^/Y%U:E%]T=5.Q#=)("DI_BF#$JW#EOJ5\LT^K
M(?SAS=7 .48HW'U%K3=4J=L)330 KLZS88W?:?;UT.!IRWNWX/AM_GJ0.=?,
M0N(5RW@V]3:SQ;^V@[45C/@+"#4$+4C>2MYGE372?&CQ'K^/SGA3/L8/ L:@
M0Q7%0SY27XIZ?6O[5SJB*P3D[*I$7AM?7)Y_7A0N:N-XQ'B')H#8'8C#/Y/.
MY@8#F%7_ @;(*-6KX7'31JB59,VZI5]GTE06WQNH7EE?&LF'ZFN:;Q&'6H_>
MBAJ*@ ^1*<O7V5ID85I;T9[N7J6K$)/M9RV9!ZNF=9+"W\LJ/R<(>,7..!+E
M2EUT,6)D/K2UM+;^:(_9U,2M*^XJ=G=B&B5X3W7K,E+1JBSR?'I,8JYR^']1
M_L<)7=M_LJ:UIEL99EII]9508'23ID6,PLBW3[V)V*VCA\FOZ'-),(GEF"*]
MF;/?9$3^%NLGF7K'J5^(T"[L!+-AQM3L1'FB-!Q97&5Z/1T\"W2[-JLF']I3
M^R D);2"/:^9HV6K?P.PC8(7(Z][*M84^[>?_C1<4SW(L/&B;GM9L;KJM.!H
M953@FJI5PT$L$=]!*ETMUF"A]"#Q;7*7X,%H=M,?^AJKP?C)7I\(7W:*:/CE
MM/Q>]1>L4SZ<Z0XZ]^]LT8S_R8;5^B#UOLY&"I=DSK]7S5%F<G?:[)LA'CIN
M 2;X?;HR6(YYY(3 K6_TFN=^\37&GX*H%QJU;KIMX/D>'^4+]G\DHIEJ#?A$
M\0AY<0KF?9@0D[P#5">ILM[<O[IL1%P%$_L/I(_DRU:C5#L#A&H-7?8.BI;E
MR1!Y%%#RX[6NW,LM=;H$,X&,3U2J[9XI_$-C/&]C3A/$?^\FOV+V[_/J4$+R
M+OC8U)AJ$\]M0HR+J[K*A0:+"M_J:R>@OP^,D/-9]CIK?DH.G-!"7K =ZV'\
M=>$&O-KT$#N7HVO&L)4:+I46G7H)E6_\DA_W:$=&5S3T:\Q0TZ%N>00KDY\*
MAMUI.JZD^BMOZC?]T'%&P0*UIME)>%C W)*Z=41WR/K[N/M3P]I)VL*U2BAK
MN5MB\;R-6S3C"+F-JR56P_D+YDS WH6"V.:Z':V9=O!YS>]R1Y%/+?.G6H,S
M,>#Q?0T+>-5&*[!Z\X@Q^V&B\X\]@_Q/BRR+DGV2QF7B5A:"4VBL^3][#5H4
M6IKZC0V9_%HG7.[!30EZ;+[)=?P3OY@L1[@7=584RQ%K$8O-"?C^713  L@G
M_%D8!4!IARO0S35LTVS9/]OQ)[9KHEW;*J*IKB4TJC'0EA]FEE.Q:R2PUL'I
M<L:;A:2%/AA7;T(PJ2S6$(7]!L@]UWSE7L1FP)2!QNJ^[WBCBB760"3[%*#\
M5Q[) [ >_2'QIRQ9"*Q#J72$)G5L:5&X*N>_! *E3D+(<"W7RXK"'ZCI\(9.
M)1&W:;*C)AF*_FO+S*VYYYN?-]O'B?/)VR/EOMID B[9&(_-^);]Z$R.UXH/
M@KUH-J>2R^V<CRZG'<8F/5DML@21'[!FO-)Q7B@8<=BU'0XJLM@9YG+.?GH<
MZEY\4)B6GUVWJV]>$QH0'6_'VQ'D\!G"4TN,IL'BLD@T^_8(0 DF;*GR!C70
MQ5U_<G&++>E3'0A(8AG:S@BTWMN[]+7/K=U1##U=SMSJW(DG%L,J;>OLF(=-
M 1AL/*U.\8'_WLVQBQ..9#$W2*ET>^Z6(S! ^U4SQ&MNVH5F./G*:4S0H1"R
M[=X[M4'2GOF8A[Q@LE<D!X\1./P%U'YL:S,IAK >Q>@,)H2*$!<20E:("Y\]
M2R(82X;0# ?Y,:W^O#'4PQCV&ZQ]6O=TX5HQ^<8[CEM9_>;L5NFYQ0R5$=BI
MG\GVP9PNHO2?\7Y!Z![5%'8VS.B2O#$ UMVF09^1*CBPU%8CAG'8 T"H[:%<
M 72(WA9T35#6-W2RPS/3)V*F0EQ"U)(_C;(>UO>(#C$&QD:I?GI06_P-=:(V
M@E=HHQ[+76T0H 8O=WK+YGO^GC%=E'A&R+<0=WFU%3%?Z,*O/_BO9TL[LM1G
M'=R.G+Y=5><NK7)"PP\/ON0[.FKS\F:._!O,OZ=)6KTO;^4K355NY07'W./X
M4W7X,8Z<E]% ".!;-O-'ZP Q+C1O9*.OJUZR:A?J3W7R)_B:]Z W<96S:1\+
MCR'E$XZ,>0H84QKO!.Z.$4;/M_KX+^"I)(G> #@&'/OGK&V#P2*T$-&*57>6
MRGPI*OM)3<!ZN.>1:-Y=0$M="Q47:^5EQ1"UYNVKP+<72/JEK%?I_94,SOWP
M4NG\@P@BA]/V8,Y'KF2EPUHY'FK#_+9$F3B='T^&!K+5PG#TBM4"+0<*[- N
MPX2!3&!^R^_F$NQIS>VDU^+2"#UY#J9>7SZ,'^ K&\)C2(;/LY;-*>1!4-(?
MLTW_C9=BDH;?QOM^B[)J:"5/3#Q \U'YGH<[;3#LSKB+$&/\C3N;NQ8[%$OL
M90S.@4'>%<_WX>E?&(P#^=4_\S>5[ICCGH"3[<'#P6Y::K<+ A#($6I2 &N&
MU@H8&+@5(#\^N#8=(:^)JAA<OFD&JYBQM<U+\2'J TN"'@D_;F#7AZ\+>[QP
M?YKUU6<7^-OO"1H_8A\-?*1#8Q]5LL^>-C*Y6C!'[PN&J8BUR[&)Q@OZ(/1>
MW!<V<Z&Z WZ/-@JI*9+^I+O<.F_H;C%YSFTW)DI"717<#F5_8O*<_R7_[_@P
M'YFBC;\ NZ-<MKF&^Y&SI?4SZ>O$ >03'(IS $L 5N@4'GXQP(5PMX9*/?_8
M3S3=]NJGSOJV)*,#".@Y.^XX@&LCJ/LVY$L/O\/N18#69XSG\#:U5#R+W1;=
M@F0.TYLXY)K)KI<P=ZK1?WUJ[&''JO&<ROD-DWG=#5BU;9N\QACU<G@;-(_T
MA)6L RU<6,5<9V0*'O5RR[>LH);;^*2F-$UT9K+F'^A#5[2]OFVG0#9S*ESE
MZ26Q=C0S"#3INE[2?^*:G.T^"?#BKHGL<.%<$2YVR3].@F#2/M0W=K3.[XF4
MRA,Z4Q2]?H9_3I$PIO^E6^QS7UZ(SS3Q3U8L-/=0<)&]IQ^W4X,]7>VZ)O,9
M)UA+T+$VS0H:?-\SOR>!-[0%_QUKT?L70+*B50X/[NMB4O!![+=VU3;_V9M2
MQIXX&:_E\-K;>]J-'_3 98.71U(3VA#!.<]M=YHD1_\?6.,=: #[(48;6$T"
M<(G>%:%51SQ9=I)R(A%=+&C,>F,"!658OI8(F$W7'S<E9U"N2Z];W2 G7F*)
MC^GBM%\[#$T?+5E]<_VUW>PH>;T->+DV40N82-;@&N$J^._9AI]/S%<3.%VO
MV;L"QRVR617&K$@GB\>I<-AZF"#C^V92)>!^_>BDF#S.CM$I^X_X7O#3M5XN
M+6JBDCZNV!68M?YZ@ : \@6[#GX:^$%[6>B!Q4XZN.2GK/^U85B5^TGG\[61
MVHUA+E%;6%/+95 (NY@Q'D0-W]<[/B)7/EY_L?2>--*IV,Z/O7XNDUA+: !M
MZJ4H_?!]Z.3@\+SEQ7I@L^O7IQC>WA.>]&C$2VKAI,$&E"#G8(902WJ7^69V
M@)^IZ^2'3E1I__4"X[+./_?(/-'/.Q.BOM;Q2JL;(KPB$,A@>$W5GB3N:XO#
M-;S%BS8/N\A_'$Y^)WW3--=KQ3(8DJS)DR\ZJV)LK=2DNH6/0]S1;-^W(&]5
M8;^%]0/]=.WGVE"*;[E=4Y]<Q0M.L=14J8R^-.>INFR^L5.^=T9ET]6C3L23
M;!F4&I]A1ZU**RM#Z@6]BCE6QZQ,J.O:CYF.5?E'=Z'97[S&G=SMDX;J+',0
M1N1,P*OEY%>LSQ"="EM;VN&33*9L]9AAHU#Y\0PV?K_E<4>+SJ[W5](F-?+9
M-X_\:+I8P0??4HQ-_\S/F77(D:?,T/4?JXQ9A"7]94(^>SC.17QGKO29+\;G
MR4Z6'NQ:&\_6V3=U9W/]]JN;P-Z$2X8>T67W6+?H8>"1P<6#!&+31$_K]0?4
M8XZW+[.68YJ,=.(H_T!/V*L)PJ>O1;D*1G_GD_'_\Z7(Z@XYUHKBM2.#&UH%
MED;TD]_%&U]:.XPU29B)67PZV\DF#-Y!E'#*-U D-Q$=JCO^U%K(V/?" \UW
MH97*:\^$+ ,IU>,=$0(4,[#UAIH*5FBM.2[FI>4\A0]O8>B<45/NDQ"C>NYF
M*KKQ^_H$LO$XKRJFEW3J\]4UC@U_>*;F#NZTI8^-V(VV_F7[3@X<8=\I6YQ!
M>:9=$2J,(B(^+/9/<5AIJ4SH?G=34[TF+9*L?B#$JWI"?_&&5+ED?GAZJ9.N
M)_,F2BJ'\=*?U@YMM-F#*+J4S[<)+2*MV1]T49@"8660[F#U3.&=)R,4B3 ^
MF_X?,:Z@.;_E8)=K@><[5^B\[A\DF]KF>@9NOD2JJ#_Q*VXDK..:]1OFI]<&
M1[C>\09K <1Y8 #*Q)\>2H7IU\+DP)N:F^;@>GH=#?,.(=]G!+\,^)0S[/%-
MKV;HRI,KX=L.J_P%4'1QO$9XZV?UUY+XZRPD34U_-A&7U\;*L!2-1N;G5.8S
M!;:'X6 $9F$/9#OM+V&-%>8$MDMW62.74GM@'Y"8S8B',)V'$55RKNND.A21
MASU9M W7G>Z_H\ZTU,/Q+%:U(PSEYC#U2L1J$&,R2<P-GPN0/W:*9*/ R^>$
M\;ZJ-=J=ZQAAM6EUY=ZH(JK&K'\^3=3<G1@QM1%*F>_"A"++'G"*-H[N?&1R
M.1;<[7X%? KTR4'+CYFJ"PV\/B!'A7T*VC2A?[F0^Q3EUHQ];$[X\_(M,5!C
MB8(6CR,BSN-PC\WSOK/V-5R[K\[VAI%YBWXN"]3ZW[149%U,KV#(N?!H,U2,
MG3DQ.PJ _@N(-./[9_(*K% %EM72GVGOX1;WYKIAZEY;NL8I!8&(E ]/Q'(F
M,^@.]/F57ISZN%3 T[18<2%D'X*&Y"95.=J,86:N_$1VP/701%)%#_BYQB$@
M[.2W(AY&'1PUQ6+2UZ903!/EY5'N:4%=N"F*MT!<:MN#@\/RQ*05=1#H661B
M>P/&RW,M6?M/U'@<RM1/J-VB3[#6[OW192W@N38VYGZ E7/IEW_S<(E6,298
M,UF__I[Z"[!)#J@O.F&\HN$/QT-QW::$;;_5)H=@@I4PM;LYWOW-C&Z?E_NO
M/9=?ZTF\K0N!QF^JX91%.YMWB&,=6M#R=!IJH<Z#"[?-S&S;6/-*3;<5,]RE
MJNI4;DB2/#4^8 \#+UT7%CP?Z5!;5=_!]FLUX;_6_[R99K/I:*V/,\[OW9"6
MPQX/GL:O CAW/<$$(J=IX8767:B9^8Z7'"UA^"D%FH69=$_?AZ\Q;"2V)'R*
MM\87)(6*Z**;(W^YH6%+R8AMLJH_S9&5OYJLDU2H!OE[*H#5Y6G)E'P_L>,O
MSOJ_6J>58JRUP%<#C*IQ_[D+A$&A[?=&11(:(Q[I>XEJFKHM_-JX%HV&>3U=
M)!WWYNOR;(7O1'CI##FU%&BO#A@&XE-NTRT1\?+_EN)J7(351WFA U(-9]W:
M[=<Y 8- ?)VM#3FP&BXCQ"?&(1XA)AR9B?MM #;Y8?3R-J7\JRZN=ICP2V&8
MR-M%![>L=FE-QH.=C>\4\KIA3\D9U+!BS@F&G7_*$<6'/S[IL%N[ZI4E&3=]
M*VPM88=J3=4AH)0V3.U5%#M,-H"YY1$>M_7!D[:UYT1^F^A>EY<-$^M.8NGJ
M(RD#C)U!V*V[0!W\S+R(/ JZGDM,)HB-1#"V6C@N-;24B/+/C_4,XM;;T=M7
M3%3T0LDY 4X19C).5&9P;N ,^W(5Z]FR7NJ4A8U'0C]QH53T%'&=WP.>@@6,
MX!VILVP\K8_$W.]X_.90'SF;0KC?&!3C5%WX.&K\L94/,=:@@0YN^1ZD^8*!
M_ESVF3S5SDDLZ;)2"RHW6CC%]M&25KMTX&/D[3C0RJ-\[Q+?]16KDP5:9(@Q
M>6L[79*%2+,!]:>D00NY8:HQ*:MYR9+E$7 LUFB:((HE<OG!B>%?0!=VDWLF
M(NB658!,+)F:+AYE6_LH;8T@4KU.%0N2+??=]N30L%2H$0EYD' M,[.G8V6>
M*^GH"C]MUANU8=)T(05<;D;M)P-\2KD"C3W\B#!.^^9VC.8A#Y)<8?"M\[FU
MH6U"\>J?$Q$5_:$.Y5SLTNI@P&X!)@>9UPS/^M"%ZOL+Z),I'O:_]B2A?#NW
MUB3M(C=RW_/9WY6U-[Z+U$Z!^2\ JHVV&%A+K2TS,I\LL_UJ-:=9*CCZM(CA
MQW=@ZCL\V>J9KV>XV7>6"JPS,'=HYV<6VCZ6=[]Q/0T3USDGG8OH#9UE1'><
M-8_TW?R?8!3[FV.]"S!ZZG/"QL364";Z_"_?]JKW=)PU\%D;L)"/;(L*''"G
MWG+8SE6!:=5AA)20PMB\+BCRT)-JZM%B_""H?X]?"3? ,TV^ZJMGD+Q^.;S>
ML8#D.D\ABR3;!:+.4C0H^#7<V (XUHOM_)0&2'431V(_BA#B'SJX-T9UQ1?:
ML7)VX"J4K7UN;Q4D\LIBE$E@=MMZT7L&!K.F_4DN(8*,2IY?2 V,M>/.M=-Z
MKB?'U,I;[GRT1 ;(#VTCZ6*3$4,UR$F0]AP8^5+U5[N< /WF0S.=]?9$DK%5
M+,2+3>1\>#SII)TP%-[%BUZ.Z9 HPAP/@^)&C+8GO;YIVG-; ,6'"C_85F>_
M%E-_HF%M&_DI=3/Q-#67!C49EN)9M/+/QQKGG4!2D]G2+M\D4ND__\1;&MG9
M<]59APOT-F6&AO[."_D%]:Z2DJ]X4?@CTFSQA9S%QU:E?Q6(#7XW@__?VH,V
M)E(FC',IN7_M@ZC9AE$TH1.O_I^)J]NW3P?EISE,2Z>V##1?O#*T6T5[QG7X
MYF/"6,A49QVD*J*)")RD&/8(;7 +-1F(!#1=NV@@(:@TW"2ZX"!OIK\  @S>
M4M_)O4E_%TO4U.41;XN,@;.@ZP;M6MQ]&@F'30]O=A,^.!SL%';7U=&DP)[<
M+W.7FD1-[S3946\<^>9[;$UJO)<E3LEIX)0JP)G1?]")'OPST[H1R<1"J2&E
M33I>J?HDZ6W8ZJYMVF%B1C,'Y?GS5SK8XIC1S64?R.XTJ9W!DJ DS,EDP9W^
MS*%X7J@I/[; #BN)L#H!CT=&_R]  RN,8 _V,J?T7PBW$/JVI$ U6\7=$+O3
M#'?@5 N2!M9Q$%V6;ZSB!">?Z&?U=>',_U)!C6-<^Y>^6A<KCI=(95/TNXLR
MM40S07YD_'Q'][(,)Q>M&-'X";7=?U?\%Q#^J[RZQND7QNGT?,\8V6230Q/E
ML%%]C%F_^DB1G?T1 <TCE_>%>B-?")W](C)A88,TS;VWC/..M-$<4#)-0(<(
M'(1Q$3/)^4':U^>80*B\2#=;MUNW32ZCN2KN56H28D/RUT"5$AIG?6,"@<"Q
MG3C^ZN*=OP! /ZS<GK$YS$>1I6-*^*):V.$CP7D&IYUQ&FZUT;ECAOP,?B8&
M.LSZO 6E'2+Y%W 6RPKQ-)D[=__D[6_U+#2)O724GP>W520)\8-&^_RDI06=
M\FN;\%<>C0F0$?)805*A2C)!N8F;]+F;<Y!V.:7U.:#Z:U(1$"H3Y$/D6C1<
MDD?P4X;1)MN)JTG61X@LL_^/+:3=D^(!HET%M5]32*XZBB\Y 4.J2RUX9-8V
ME>M55EXPJ.$RD\OIX">M8.Z1:C6>14>)1K9?89N+N45"$S<N8P?/8([RE01<
M_U43#&-[[$<2*R/VYA^YX&T@B(#N0I9Z;3V:-9KY3OQ/JIK-0KHP;#6F1Q1X
MKH^E"=F(#6GVA*$N>CS$U;EK GT4'8[C&1MD30F46S@6/GT5!5)L4&6:F!-5
ME91;D73(0DK#&_H/CN[T4_/VO*A@[*W.]QJWVT]KJXDLDU\QIPU$LY';)V'H
M^I?3,E6N[U+S/RZ<G;LM9ZZ=I6ZI'TB(WHJ'A')'P&+STO!CZX58@U&/)]HS
M;G]D3]ZB\4IM2/.@KJ*-%LPR;V3J+=O9!*W5=#=J 991-R_U^OW8EIV$A*4V
M\=\M\M;YBR^!QHT.H!XC<@D_N-^]VK/(KQQ58,7@F<!/]U$* =>S;^;5B>P2
MJ#69F+))6HB=Q;]F/P5<;7(-Y8JV_$"9I2$V1?HSM;HJ$*M2/!;$52P-B;=>
M&CMJ2O6' #)15M>AC1?N:*IA<&YH/@1NWS<H\EN(9^UFY'&L;<' >-^!VB9*
MA;8LGY)5+VP4$!MK%LOVKT2SK79TX_VTNS8R6R-I\^$:C;SJDKKUTY?+XG\N
M%U_UQ8\=HUURG#8KG%>,4281?DZ[):?UNE\,TEBX'^V;$Y(846>43>.?E9NM
M@_<7$-%8!55!DP6?%B2-GC5Z+]=VB)MTG6V]'JEBN!+-'E*;8V+_37\X5NDG
MY*/9T8"..7%"6$7W2U]N>IV0]#,-QB'A4;=^-N?C!%\O?%M^KO_('2^S?:3N
MJOV!BNNT*3FN]5*J.FV4C$,44P"*^Y[+19TS.+BT;]65H$3Z7[)N(>WDF1#>
M!"(>:Q/FVLV1-ALG3=)C :O.+7H+NUU\.-,*[-"[YL@+QJD7IZ>_-G$@LR'7
MU?5,6>&I&MG/K1)UU&0"<+C"^(?WV3^Y^T=M4W M"O/,/8B4D+#=F]_S,,4J
M?X@8.G%+8*7T3-)=%0JF5L(C-8^YR[D(]"'[+D]ESTHT<V$91-,<6BWYTU)L
MH-M#BOL=M0=.X+LNE$B0.Z@B^@S4V\9]-MFK)[C,Z"8N7PR'3(QI#CO\RB?U
M1ZK>1#4XA>E,ED(-?MAO.]0UYYX);J@A01&[L,3;]@26[6V+F)B]<V9YV>[(
M#B[D-HN]P1>[JY6:",F5FL&^26 SB;S!;'=*AMC3ZC]CA D6^SU$R6=W85FE
MQVV6;8ZEI>OF1A/MP*;66,LHU9,P UR*GF.!E/A^_Z=.4K[J_:B?"E2M"X;C
MN??:(!.;=!A;NY<%CCS>+8A48A@,&$/EQ7:\1Y*QVM/>@(D]ME@USZL^MEJ'
M HT_)O"0"C/L;<A($XN=[J;B2QWK1T,1?TBGC5J7*AM,B'QUCY1-S08=(B7'
MQ$(]<5RQ GM?AL)TL%2I_^_!#[1M;H/%#[03L=!>::&?M!_+7/67:--'&\SL
M.Q]H8NE=K<N%,[BSG7#U*V)_A_LC\6.%.V3*[<'#D0T_$795NI<@3<J#W7[$
MOE7>I!Z,\?4/"R*13$/B"8BJ+X4J *ZR)0UC^S 7>S%H>]&A6&[7%N-\?,&2
M3:'IRASQZ1G/9#R?H=6MG]JS/FQZ0PHGM.$@N#14RE=W&QF6\V0J#>&MI?\Y
M;FDQX]SDZ]NZ0T7ILPX^K<K9& O^OP##]Z_8GL-/!C-+(I'QY)A@;4Q(IEL>
M*J+7M^2ULU#N%F)\M'O,0,<4]8U\F'C7V:IO6;,4LSTH&SY$T/![^5>ZI'.B
MN)'FERJIW^WK7GEV8=S-@KL30">J$"P"@5SMQME7K.]1I8-I;;_6)F3#(_X"
M$!R9RV.NKC8N=BZ6!3?,*C/#S!'P@V?_M>U\RF893D4?1I0LQ.11R,M)!_H7
MPM_</</[UC9\H<-C<, =H3P"JBQ^)5X.Y, I\0LH#) WUT(W^/&CK7KF_?A>
M?^I"[-3.5GUJRCM;&F)+17)^&)GL2.Z@8KRU,A:GG\.0F2X*_@58[RU+=JHY
M44,]OOK4W>K2[[NU?A@-#'GS+<7Q^ZJ?%Q#9F1L%N&V[1ZI'5+DQM4_R(E7C
M"HJ8)KD__Q,_V$J1-H=)END05SQ?@>F^9V$MR12]9S=MTEW_/T\;1T:?N#JY
M?Q9VES>I&*5HB;7T4O3<#VQ(?:YO]N+V"]GW?U"+^BBBQ>$>0A1NYDQ&FT>,
MX='N+&*2(ZK?!R5MIMR2OU1[IEU&K+P7XPS(#O+^"PCQ$T1K1^1]:$7S-)9
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MG$\#A_S!IYN[WI!=B+?PY>_@_U!+ P04    "  ,B*Y:AU>)0Q,'  !4+
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MLI+)+1Z\$+X=O>J$='%<4C_5?L0RVAW&);5#O-WB@Z89=WK4M!&N?L]%,"&
M,DD&FDA:J(F0Z76)!9>,1I6^$V;..W17D:(:L:>O2+^NK'E:K1,>6#^)=>WN
MA8BVO(7PU7[#CT_2LHW  ]Y&Z9PN'E.SC"ZC*(@?%;CCN2WI9_#"(W\+4;,\
MI\ ++_ <E#[@E.BNB"@<NVJTD!\6+A?+Z^G2OURLUXLYG0?U#HP2/+]''HU?
MQ-_<W&1,W(_]1EFKJM@[0ML#,W@P[:Y]NI#SCM]11>U0Z:'_0Y-,"5):7GA#
M[Q!TNN;__S%W]L0U> Y_;Y0>SD?'E=']ZTG_ E!+ P04    "  ,B*Y:!UKZ
M]4$#   N"0  #0   '!T;E]E>#,R,BYH=&VU5FUOVS80_BLW%RT2P+(EN2Y:
M21'@)$YFH*Y;V]NZ?1EHZ61QHTB-I!IKOWY'.4ZR=,NP(OXB2+R7Y^ZYAZ22
MTE8B34ID>9I8;@6FM96_XFX4A@.R)</]8O*=YUVJK*E06L@T,HLY-(;++4PO
MKR?+.3,6M>>ER7"?:Z/R%HQM!9[UUM//:V_R?G;](8+?&F-YT<9PM?BPCB#P
M:PN65VA X@UH53'92Y/Z$.J\O-7LE^G>=1_F74WFL_<_1X\#8YA/EM<S0O'K
M70P6=]9C@F]EI/FVM#$E-E8KN4VGG[^?G<_6, H'83*\74R&=0KWT(62UC/\
M3XPZY.ZS8!47;?08MV)ZRV5$J+WTE=R8.GZ4ZYG:R(A]U-3'!6IBD6?,<B5!
M%?!1<YGQF@FXXI+1*[TM"O) ?>12/C;:-(Q4814$;^&'P6IP,8 59EUIP6CL
M'[F B8%)KFHGR(>U'"IXY[]Q!-D28<7TADDTWF(GL(5)9ITE]/WPR"7^HR:^
M45^S/JPLUB5*6 _@)RZ$Z<-TAUEC^1>$'VGDI 8T/"?T/ER4'(NO10%,YK>V
M18V:=$0[^6!S>F+"K<$:LU(JH;8<"68FLT$?2M2X:2'K--CV'=E5"[]+=2,P
MWR(ME,QVA']JF"8&1 M+K)4FNB5<*5T1J]XG*)3NO B?JQQ0YC3".=-9":.@
M3W,)QT^7 B<N_-6+MV'HQW=YN^\@/H6B$82<J:H6% (WW)8=GL8_&J[1'67&
M =QK]82= A45C$_RTSO1$+.:6Y=ANLM*)K=X4$[P;O2Z(]+Y<4G]5/L-F=$L
M&9?4#M7MC ^:9MSQ4=.$''[?>3 A@"*)!AH0&6HJR/2[P.)N<)0SYUUVATA>
MC=B7K_;S4](\S=81C[=OS'7I;I&(1MY"\'H_\.<OTK*-P$.^C=(Y75.F9AD)
M/O+C1P W/+<EO?HO>Z1O(6J6Y^1XUO-[+I4^Y"G172A1,'9H9,@/AO/%\G*Z
M],X7Z_5B3J='O0.C!,]O,X_&+^,O;M]D3-P>$E;5<>]ASP\;&9KA5[O=M477
M<M[A_EO@/0.=*SWT?S20*4&TR+->V#LX_9]*CWTFG3QQPYW^O4]ZN)D_JXZZ
M_YGT+U!+ 0(4 Q0    (  R(KEH>8#5#@1(  ,#,   0              "
M 0    !P=&XM,C R-3 S,S$N>'-D4$L! A0#%     @ #(BN6ME1+L,2#P
MSJL  !0              ( !KQ(  '!T;BTR,#(U,#,S,5]C86PN>&UL4$L!
M A0#%     @ #(BN6A.=4QRG&@  BY,! !0              ( !\R$  '!T
M;BTR,#(U,#,S,5]D968N>&UL4$L! A0#%     @ #(BN6J:/R-L83@  BPL$
M !0              ( !S#P  '!T;BTR,#(U,#,S,5]L86(N>&UL4$L! A0#
M%     @ #(BN6GBXP(\F.P  $#,# !0              ( !%HL  '!T;BTR
M,#(U,#,S,5]P<F4N>&UL4$L! A0#%     @ #(BN6G_9G(%+_   XB(-  L
M             ( !;L8  '!T;E\Q,'$N:'1M4$L! A0#%     @ #(BN6I<_
MY5@!#P  S \  !               ( !XL(! '!T;E\Q,'%I;6<Q."YJ<&=0
M2P$"% ,4    "  ,B*Y:#+31K:+*  #MW@  $               @ $1T@$
M<'1N7S$P<6EM9S$Y+FIP9U!+ 0(4 Q0    (  R(KEI?4NAZ-X4  /6%   0
M              "  >&< @!P=&Y?,3!Q:6UG,C N:G!G4$L! A0#%     @
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52P4&      T #0 E P  8#<#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>ptn_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptn="http://ptn.com/20250331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptn-20250331.xsd" xlink:type="simple"/>
    <context id="From2024-07-01to2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-08_us-gaap_SubsequentEventMember_ptn_SeriesFWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesFWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-08</instant>
        </period>
    </context>
    <context id="AsOf2025-05-08_us-gaap_SubsequentEventMember_ptn_SeriesGWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesGWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-08</instant>
        </period>
    </context>
    <context id="From2025-05-01to2025-05-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-08</endDate>
        </period>
    </context>
    <context id="From2025-04-01to2025-05-14_us-gaap_SubsequentEventMember_ptn_TwoThousandTwentyFiveSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptn:TwoThousandTwentyFiveSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-05-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-08_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-08</instant>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_ptn_TwoThousandTwentyFiveSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptn:TwoThousandTwentyFiveSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-29_ptn_PrivateWarrantSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptn:PrivateWarrantSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-29</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-01-29_ptn_PrivateWarrantSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ptn:PrivateWarrantSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-10_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-10</instant>
        </period>
    </context>
    <context id="From2025-02-01to2025-02-10_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-01-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2025-02-10</instant>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:ConvertibleSeriesAPreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-01to2023-04-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-12</endDate>
        </period>
    </context>
    <context id="From2024-12-01to2024-12-13_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-13_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-13</instant>
        </period>
    </context>
    <context id="From2024-06-01to2024-06-20_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-20_ptn_StockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ptn:StockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-20</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-10-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2023-10-20</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="From2023-10-01to2023-10-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-20</endDate>
        </period>
    </context>
    <context id="From2022-07-01to2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2021-07-01to2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2020-07-01to2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2025-02-01to2025-02-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptn:TwentyTwentyThreeEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ptn:TwentyTwentyThreeEquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:TwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:FebruaryTwoZeroTwoFiveSeriesEWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JanuaryTwoZeroTwoFourPrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoZeroTwoThreePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:DecemberToZeroTwoFourSeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:JuneTwoThousandTwentyFourSerisBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:DecemberTwoThousandTwentyFourSerisCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_MayTwoThousandTwentyTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:MayTwoThousandTwentyTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CumulativeFromInceptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_ptn_OneToThreeYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:OneToThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_ptn_CurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:CurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_ptn_FourToFiveYearsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ptn:FourToFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2017-11-01to2017-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-21</endDate>
        </period>
    </context>
    <context id="From2017-09-01to2017-09-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-06</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2024-03-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_ptn_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_ptn_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ptn_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">ptn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-01to2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-01to2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ptn:SeriesAConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000911216</identifier>
        </entity>
        <period>
            <instant>2025-05-14</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2024-07-01to2025-03-31" id="ixv-9337">0000911216</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2024-07-01to2025-03-31" id="ixv-9338">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-07-01to2025-03-31" id="ixv-9339">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-07-01to2025-03-31" id="ixv-9340">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2024-07-01to2025-03-31" id="ixv-9341">2025</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="ixv-9342"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-9343"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-9344"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="ixv-9345"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-9346"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="ixv-9347"
      unitRef="Shares">28557246</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="ixv-9348"
      unitRef="Shares">17926640</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-9349"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-9350"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="ixv-9351"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesOutstanding>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-07-01to2025-03-31" id="ixv-9352">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-07-01to2025-03-31" id="ixv-9353">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-07-01to2025-03-31" id="ixv-9354">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-07-01to2025-03-31" id="ixv-9355">false</ecd:NonRule10b51ArrTrmntdFlag>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="ixv-9356"
      unitRef="Shares">17749116</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="ixv-9357"
      unitRef="Shares">8520332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="ixv-9358"
      unitRef="Shares">279700</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="ixv-9359"
      unitRef="Shares">-14338</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOutstandingNumberEndingBalance01>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-06-20_ptn_StockWarrantsMember"
      decimals="INF"
      id="ixv-9360"
      unitRef="USDPShares">1.88</us-gaap:SharesIssuedPricePerShare>
    <ptn:PurchaseOfWarrantOfCommonStockSeriesA
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      decimals="0"
      id="ixv-9361"
      unitRef="Shares">4849915</ptn:PurchaseOfWarrantOfCommonStockSeriesA>
    <ptn:PurchaseOfWarrantOfCommonStockSeriesA
      contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember"
      decimals="0"
      id="ixv-9362"
      unitRef="Shares">3907679</ptn:PurchaseOfWarrantOfCommonStockSeriesA>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      decimals="0"
      id="ixv-9363"
      unitRef="USD">6078561</us-gaap:ProceedsFromWarrantExercises>
    <ptn:WarrantsToPurchaseShares
      contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember"
      decimals="0"
      id="ixv-9364"
      unitRef="Shares">1953839</ptn:WarrantsToPurchaseShares>
    <dei:DocumentType contextRef="From2024-07-01to2025-03-31" id="ixv-10206">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2024-07-01to2025-03-31" id="ixv-10207">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-07-01to2025-03-31" id="ixv-10208">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-07-01to2025-03-31" id="ixv-10209">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-07-01to2025-03-31" id="ixv-10210">001-15543</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-07-01to2025-03-31" id="ixv-10211">PALATIN TECHNOLOGIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-07-01to2025-03-31" id="ixv-10212">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-07-01to2025-03-31" id="ixv-10213">95-4078884</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-07-01to2025-03-31" id="ixv-10214">4B Cedar Brook Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-07-01to2025-03-31" id="ixv-10215">Cranbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-07-01to2025-03-31" id="ixv-10216">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-07-01to2025-03-31" id="ixv-10217">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-07-01to2025-03-31" id="ixv-10218">609</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-07-01to2025-03-31" id="ixv-10219">495&#x2011;2200</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-07-01to2025-03-31" id="ixv-10220">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-07-01to2025-03-31" id="ixv-149">PTN1</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-07-01to2025-03-31" id="ixv-10221">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2024-07-01to2025-03-31" id="ixv-10222">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-07-01to2025-03-31" id="ixv-10223">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-07-01to2025-03-31" id="ixv-10224">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-07-01to2025-03-31" id="ixv-10225">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-07-01to2025-03-31" id="ixv-10226">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2024-07-01to2025-03-31" id="ixv-10227">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-05-14"
      decimals="INF"
      id="ixv-10228"
      unitRef="Shares">46479861</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2795"
      unitRef="USD">2520062</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2796"
      unitRef="USD">9527396</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2797"
      unitRef="USD">271037</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2798"
      unitRef="USD">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2799"
      unitRef="USD">442178</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2800"
      unitRef="USD">242272</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2801"
      unitRef="USD">3233277</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2802"
      unitRef="USD">9769668</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2803"
      unitRef="USD">182437</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2804"
      unitRef="USD">388361</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2805"
      unitRef="USD">255863</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2806"
      unitRef="USD">527321</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2807"
      unitRef="USD">56916</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2808"
      unitRef="USD">56916</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2809"
      unitRef="USD">3728493</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2810"
      unitRef="USD">10742266</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2813"
      unitRef="USD">7770567</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2814"
      unitRef="USD">4101929</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2815"
      unitRef="USD">506460</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2816"
      unitRef="USD">4185046</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2817"
      unitRef="USD">194972</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2818"
      unitRef="USD">380542</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2819"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2820"
      unitRef="USD">46014</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2821"
      unitRef="USD">1576350</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2822"
      unitRef="USD">944150</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2823"
      unitRef="USD">10048349</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2824"
      unitRef="USD">9657681</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2825"
      unitRef="USD">67248</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2826"
      unitRef="USD">163782</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2827"
      unitRef="USD">0</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2828"
      unitRef="USD">1032300</us-gaap:OtherLongTermDebt>
    <us-gaap:Liabilities
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2829"
      unitRef="USD">10115597</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2830"
      unitRef="USD">10853763</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="fid_348"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_350"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_351"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_362"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_2833"
      unitRef="USD">40</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStocksMember"
      decimals="0"
      id="fid_2834"
      unitRef="USD">40</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="fid_354"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_356"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_359"
      unitRef="Shares">28557246</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_358"
      unitRef="Shares">17926640</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2835"
      unitRef="USD">285572</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2836"
      unitRef="USD">179266</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2837"
      unitRef="USD">450171385</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2838"
      unitRef="USD">441475747</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2839"
      unitRef="USD">-456844101</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2840"
      unitRef="USD">-441766550</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2841"
      unitRef="USD">-6387104</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2842"
      unitRef="USD">-111497</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2843"
      unitRef="USD">3728493</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2844"
      unitRef="USD">10742266</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2914"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2915"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2916"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2917"
      unitRef="USD">4140090</us-gaap:Revenues>
    <us-gaap:ProductionCosts
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2919"
      unitRef="USD">0</us-gaap:ProductionCosts>
    <us-gaap:ProductionCosts
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2920"
      unitRef="USD">0</us-gaap:ProductionCosts>
    <us-gaap:ProductionCosts
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2921"
      unitRef="USD">0</us-gaap:ProductionCosts>
    <us-gaap:ProductionCosts
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2922"
      unitRef="USD">97637</us-gaap:ProductionCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2923"
      unitRef="USD">3755158</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2924"
      unitRef="USD">7159686</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2925"
      unitRef="USD">12928391</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2926"
      unitRef="USD">17728516</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2927"
      unitRef="USD">1474019</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2928"
      unitRef="USD">2033410</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2929"
      unitRef="USD">5176794</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2930"
      unitRef="USD">8266267</us-gaap:SellingGeneralAndAdministrativeExpense>
    <ptn:GainLossOnSaleOfVylessi
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2931"
      unitRef="USD">0</ptn:GainLossOnSaleOfVylessi>
    <ptn:GainLossOnSaleOfVylessi
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2932"
      unitRef="USD">-25202</ptn:GainLossOnSaleOfVylessi>
    <ptn:GainLossOnSaleOfVylessi
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2933"
      unitRef="USD">2500000</ptn:GainLossOnSaleOfVylessi>
    <ptn:GainLossOnSaleOfVylessi
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2934"
      unitRef="USD">7798280</ptn:GainLossOnSaleOfVylessi>
    <ptn:GainLossOnPurchaseCommitment
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2935"
      unitRef="USD">416000</ptn:GainLossOnPurchaseCommitment>
    <ptn:GainLossOnPurchaseCommitment
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2936"
      unitRef="USD">0</ptn:GainLossOnPurchaseCommitment>
    <ptn:GainLossOnPurchaseCommitment
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2937"
      unitRef="USD">416000</ptn:GainLossOnPurchaseCommitment>
    <ptn:GainLossOnPurchaseCommitment
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2938"
      unitRef="USD">0</ptn:GainLossOnPurchaseCommitment>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2939"
      unitRef="USD">4813177</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2940"
      unitRef="USD">9218298</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2941"
      unitRef="USD">15189185</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2942"
      unitRef="USD">18294140</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2943"
      unitRef="USD">-4813177</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2944"
      unitRef="USD">-9218298</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2945"
      unitRef="USD">-15189185</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2946"
      unitRef="USD">-14154050</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2948"
      unitRef="USD">31452</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2949"
      unitRef="USD">139273</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2950"
      unitRef="USD">139072</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2951"
      unitRef="USD">272929</us-gaap:InvestmentIncomeNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2952"
      unitRef="USD">-27900</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2953"
      unitRef="USD">215600</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2954"
      unitRef="USD">-15900</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2955"
      unitRef="USD">68653</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2956"
      unitRef="USD">1795</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2957"
      unitRef="USD">1254</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2958"
      unitRef="USD">11538</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2959"
      unitRef="USD">13741</us-gaap:InterestExpense>
    <us-gaap:OtherExpenses
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2960"
      unitRef="USD">0</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2961"
      unitRef="USD">0</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2962"
      unitRef="USD">0</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2963"
      unitRef="USD">696912</us-gaap:OtherExpenses>
    <ptn:WarrantsGainLossOnWarrantsNet
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2964"
      unitRef="USD">0</ptn:WarrantsGainLossOnWarrantsNet>
    <ptn:WarrantsGainLossOnWarrantsNet
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2965"
      unitRef="USD">429029</ptn:WarrantsGainLossOnWarrantsNet>
    <ptn:WarrantsGainLossOnWarrantsNet
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2966"
      unitRef="USD">0</ptn:WarrantsGainLossOnWarrantsNet>
    <ptn:WarrantsGainLossOnWarrantsNet
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2967"
      unitRef="USD">6962562</ptn:WarrantsGainLossOnWarrantsNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2968"
      unitRef="USD">1757</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2969"
      unitRef="USD">782648</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2970"
      unitRef="USD">111634</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2971"
      unitRef="USD">-7331633</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2972"
      unitRef="USD">-4811420</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2973"
      unitRef="USD">-8435650</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2974"
      unitRef="USD">-15077551</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2975"
      unitRef="USD">-21485683</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-03-31"
      decimals="INF"
      id="fid_2976"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-03-31"
      decimals="INF"
      id="fid_2977"
      unitRef="USDPShares">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-01to2025-03-31"
      decimals="INF"
      id="fid_2978"
      unitRef="USDPShares">-0.68</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-01to2024-03-31"
      decimals="INF"
      id="fid_2979"
      unitRef="USDPShares">-1.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2980"
      unitRef="Shares">26344584</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2981"
      unitRef="Shares">15792421</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2982"
      unitRef="Shares">22245153</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2983"
      unitRef="Shares">14013848</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2984"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2986"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2985"
      unitRef="Shares">23455846</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2987"
      unitRef="USD">234558</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2988"
      unitRef="USD">445416974</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2989"
      unitRef="USD">-452032681</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="fid_2990"
      unitRef="USD">-6381109</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2991"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2992"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2993"
      unitRef="USD">347691</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2994"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2995"
      unitRef="USD">347691</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2025-01-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_2998"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsShares
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2997"
      unitRef="Shares">5101400</ptn:SaleOfCommonStockNetOfCostsShares>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2999"
      unitRef="USD">51014</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3000"
      unitRef="USD">4406506</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3001"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_3002"
      unitRef="USD">4457520</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2025-01-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3003"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3004"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3005"
      unitRef="USD">214</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3006"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_3007"
      unitRef="USD">214</ptn:WarrantExercisesAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3008"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3009"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3010"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3011"
      unitRef="USD">-4811420</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_3012"
      unitRef="USD">-4811420</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3013"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3015"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3014"
      unitRef="Shares">28557246</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3016"
      unitRef="USD">285572</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3017"
      unitRef="USD">450171385</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3018"
      unitRef="USD">-456844101</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_3019"
      unitRef="USD">-6387104</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3020"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3022"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3021"
      unitRef="Shares">17926640</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3023"
      unitRef="USD">179266</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3024"
      unitRef="USD">441475747</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3025"
      unitRef="USD">-441766550</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_3026"
      unitRef="USD">-111497</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3029"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3028"
      unitRef="Shares">232941</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3030"
      unitRef="USD">2329</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3031"
      unitRef="USD">1043340</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3032"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_3033"
      unitRef="USD">1045669</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3036"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3035"
      unitRef="Shares">-54691</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3037"
      unitRef="USD">-547</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3038"
      unitRef="USD">-98935</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3039"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_3040"
      unitRef="USD">-99482</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3043"
      unitRef="USD">0</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SharesReleasedFromAbeyanceShares
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3042"
      unitRef="Shares">1443277</ptn:SharesReleasedFromAbeyanceShares>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3044"
      unitRef="USD">14433</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3045"
      unitRef="USD">-14433</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3046"
      unitRef="USD">0</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SharesReleasedFromAbeyanceAmount
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_3047"
      unitRef="USD">0</ptn:SharesReleasedFromAbeyanceAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3050"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsShares
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3049"
      unitRef="Shares">5101400</ptn:SaleOfCommonStockNetOfCostsShares>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3051"
      unitRef="USD">51014</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3052"
      unitRef="USD">4406506</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3053"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_3054"
      unitRef="USD">4457520</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3057"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesShares
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3056"
      unitRef="Shares">3907679</ptn:WarrantExercisesShares>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3058"
      unitRef="USD">39077</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3059"
      unitRef="USD">3359160</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3060"
      unitRef="USD">0</ptn:WarrantExercisesAmount>
    <ptn:WarrantExercisesAmount
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_3061"
      unitRef="USD">3398237</ptn:WarrantExercisesAmount>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3062"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3063"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3064"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3065"
      unitRef="USD">-15077551</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_3066"
      unitRef="USD">-15077551</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3067"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3069"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3068"
      unitRef="Shares">28557246</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3070"
      unitRef="USD">285572</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3071"
      unitRef="USD">450171385</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3072"
      unitRef="USD">-456844101</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_3073"
      unitRef="USD">-6387104</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3076"
      unitRef="USD">423100</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3074"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3077"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3075"
      unitRef="Shares">14305137</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3078"
      unitRef="USD">143051</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3079"
      unitRef="USD">413552953</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3080"
      unitRef="USD">-425080470</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="fid_3081"
      unitRef="USD">-11384426</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3082"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3083"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3084"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3085"
      unitRef="USD">390195</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3086"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_3087"
      unitRef="USD">390195</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3088"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3089"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3090"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3091"
      unitRef="USD">11423203</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3092"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_3093"
      unitRef="USD">11423203</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3200"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3193"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsShares
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3195"
      unitRef="Shares">1831503</ptn:SaleOfCommonStockNetOfCostsShares>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3196"
      unitRef="USD">18315</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3197"
      unitRef="USD">9144198</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3198"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_3199"
      unitRef="USD">9162513</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3094"
      unitRef="USD">-423100</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3095"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3096"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3097"
      unitRef="USD">423100</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3098"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_3099"
      unitRef="USD">423100</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3100"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3101"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3102"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3103"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3104"
      unitRef="USD">-8435650</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_3105"
      unitRef="USD">-8435650</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3108"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3106"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3109"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3107"
      unitRef="Shares">16136640</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3110"
      unitRef="USD">161366</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3111"
      unitRef="USD">434933649</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3112"
      unitRef="USD">-433516120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_3113"
      unitRef="USD">1578935</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3116"
      unitRef="USD">263400</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3114"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3117"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3115"
      unitRef="Shares">11656714</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3118"
      unitRef="USD">116567</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3119"
      unitRef="USD">409933959</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3120"
      unitRef="USD">-412030437</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="fid_3121"
      unitRef="USD">-1979871</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3124"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3125"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3123"
      unitRef="Shares">98372</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3126"
      unitRef="USD">984</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3127"
      unitRef="USD">1329518</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3128"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_3129"
      unitRef="USD">1330502</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3132"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3133"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3131"
      unitRef="Shares">-25467</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsShares>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3134"
      unitRef="USD">-255</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3135"
      unitRef="USD">-56146</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3136"
      unitRef="USD">0</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_3137"
      unitRef="USD">-56401</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3140"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3141"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsShares
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3139"
      unitRef="Shares">2048530</ptn:SaleOfCommonStockNetOfCostsShares>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3142"
      unitRef="USD">20485</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3143"
      unitRef="USD">9673397</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3144"
      unitRef="USD">0</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:SaleOfCommonStockNetOfCostsAmount
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_3145"
      unitRef="USD">9693882</ptn:SaleOfCommonStockNetOfCostsAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3146"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3147"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3148"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3149"
      unitRef="USD">11423203</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3150"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrant
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_3151"
      unitRef="USD">11423203</ptn:ConversionOfLiabilityClassifiedWarrant>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3154"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3155"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3153"
      unitRef="Shares">2358491</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseShares>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3156"
      unitRef="USD">23585</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3157"
      unitRef="USD">2366318</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3158"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_3159"
      unitRef="USD">2389903</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3160"
      unitRef="USD">-263400</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3161"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3162"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3163"
      unitRef="USD">263400</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3164"
      unitRef="USD">0</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <ptn:ReclassificationOfContingentlyRedeemableWarrants
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_3165"
      unitRef="USD">263400</ptn:ReclassificationOfContingentlyRedeemableWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3166"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3167"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3168"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3169"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3170"
      unitRef="USD">-21485683</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_3171"
      unitRef="USD">-21485683</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_ptn_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="fid_3174"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3172"
      unitRef="Shares">4030</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_ptn_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      id="fid_3175"
      unitRef="USD">40</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3173"
      unitRef="Shares">16136640</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_3176"
      unitRef="USD">161366</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_3177"
      unitRef="USD">434933649</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_3178"
      unitRef="USD">-433516120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_3179"
      unitRef="USD">1578935</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2846"
      unitRef="USD">-15077551</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2847"
      unitRef="USD">-21485683</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2849"
      unitRef="USD">205924</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2850"
      unitRef="USD">257115</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2851"
      unitRef="USD">271458</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2852"
      unitRef="USD">260832</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2853"
      unitRef="USD">-15900</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2854"
      unitRef="USD">68653</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2855"
      unitRef="USD">1045669</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2856"
      unitRef="USD">1330502</us-gaap:ShareBasedCompensation>
    <ptn:ChangeInFairValueOfLiabilityClassifiedWarrants
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2857"
      unitRef="USD">0</ptn:ChangeInFairValueOfLiabilityClassifiedWarrants>
    <ptn:ChangeInFairValueOfLiabilityClassifiedWarrants
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2858"
      unitRef="USD">6962562</ptn:ChangeInFairValueOfLiabilityClassifiedWarrants>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2859"
      unitRef="USD">2500000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2860"
      unitRef="USD">7798280</us-gaap:GainLossOnSaleOfOtherAssets>
    <ptn:GainLossOnPurchaseCommitment
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2861"
      unitRef="USD">416000</ptn:GainLossOnPurchaseCommitment>
    <ptn:GainLossOnPurchaseCommitment
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2862"
      unitRef="USD">0</ptn:GainLossOnPurchaseCommitment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2864"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2865"
      unitRef="USD">-2915760</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2866"
      unitRef="USD">271037</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2867"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2868"
      unitRef="USD">199906</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2869"
      unitRef="USD">-1206564</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2870"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2871"
      unitRef="USD">1154355</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2872"
      unitRef="USD">3668638</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2873"
      unitRef="USD">-860280</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2874"
      unitRef="USD">-3678586</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2875"
      unitRef="USD">-4171297</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2876"
      unitRef="USD">-282104</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2877"
      unitRef="USD">-264875</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2878"
      unitRef="USD">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2879"
      unitRef="USD">-2118897</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2880"
      unitRef="USD">-17217595</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2881"
      unitRef="USD">-24988985</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2883"
      unitRef="USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2884"
      unitRef="USD">2992890</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <ptn:ProceedsFromSaleOfOtherAssets
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2885"
      unitRef="USD">2500000</ptn:ProceedsFromSaleOfOtherAssets>
    <ptn:ProceedsFromSaleOfOtherAssets
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2886"
      unitRef="USD">9500000</ptn:ProceedsFromSaleOfOtherAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2887"
      unitRef="USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2888"
      unitRef="USD">37615</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2889"
      unitRef="USD">2500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2890"
      unitRef="USD">12455275</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2892"
      unitRef="USD">99482</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2893"
      unitRef="USD">56401</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2894"
      unitRef="USD">4457520</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2895"
      unitRef="USD">14693779</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2896"
      unitRef="USD">46014</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2897"
      unitRef="USD">79265</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2898"
      unitRef="USD">3398237</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2899"
      unitRef="USD">103</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2900"
      unitRef="USD">7710261</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2901"
      unitRef="USD">14558216</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2902"
      unitRef="USD">-7007334</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2903"
      unitRef="USD">2024506</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2904"
      unitRef="USD">9527396</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="fid_2905"
      unitRef="USD">7989582</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2906"
      unitRef="USD">2520062</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="fid_2907"
      unitRef="USD">10014088</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2909"
      unitRef="USD">11538</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2910"
      unitRef="USD">13741</us-gaap:InterestPaidNet>
    <ptn:ConversionOfLiabilityClassifiedWarrants
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2912"
      unitRef="USD">11423203</ptn:ConversionOfLiabilityClassifiedWarrants>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_3180"
      unitRef="USD">0</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise>
    <ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_3181"
      unitRef="USD">2389903</ptn:ConversionOfLiabilityClassifiedWarrantsUponWarrantExercise>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1937">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(1) ORGANIZATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Nature of Business &lt;/em&gt;- Palatin Technologies, Inc. (&#x201c;Palatin&#x201d; or the &#x201c;Company&#x201d;) is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company&#x2019;s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Melanocortin Receptor System.&lt;/em&gt; The melanocortin receptor system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company&#x2019;s prior commercial product, Vyleesi&#xae;, was approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in June 2019 for the treatment of hypoactive sexual desire disorder (&#x201c;HSDD&#x201d;) in premenopausal women. As disclosed in Note 5, this product was acquired by Cosette Pharmaceuticals, Inc. (&#x201c;Cosette&#x201d;) on December 19, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Our new product development activities focus primarily on use of bremelanotide, or other MC4r agonists, with tirzepatide, a GLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024, with topline results announced in March 2025, in which co-administration of bremelanotide and tirzepatide demonstrated an increased weight loss over tirzepatide alone.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company is also developing, dependent on resources for development activities, MC1r agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The Company believes that the MC1r agonist peptides in development have broad anti-inflammatory effects and appear to utilize mechanisms engaged by the endogenous melanocortin system in regulation of the immune system and resolution of inflammatory responses. The Company is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Business Risks and Liquidity &#x2013; &lt;/em&gt;The Company has incurred operating losses and negative cash flows from operations since inception and will need additional funding to complete its planned product development efforts. As shown in the accompanying consolidated financial statements, the Company had an accumulated deficit as of March 31, 2025 of $456,844,101 and a net loss for the three and nine months ended March 31, 2025 of $4,811,420 and $15,077,551, respectively. The Company anticipates incurring significant expenses in the future as a result of spending on its development programs and will require substantial additional financing or revenues to continue to fund its planned activities. To achieve sustained profitability, if ever, the Company, alone or with others, must successfully develop and commercialize its technologies and proposed products, conduct successful preclinical studies and clinical trials, obtain required regulatory approvals, and successfully manufacture and market such technologies and proposed products. The time required to reach sustained profitability is highly uncertain, and the Company may never be able to achieve profitability on a sustained basis, if at all.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of March 31, 2025, the Company&#x2019;s cash and cash equivalents were $2,520,602 and current liabilities were $10,048,349. Management intends to utilize existing capital resources for general corporate purposes and working capital, including clinical development of the Company&#x2019;s MC1r and MC4r programs, and development of other portfolio products.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company follows the provisions of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, &lt;em&gt;Presentation of Financial Statements &#x2014; Going Concern&lt;/em&gt;, which requires management to assess the Company&#x2019;s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. While the Company has raised funding in the past, the ability to raise funding in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future funding in their assessment of the Company&#x2019;s ability to meet its obligations for the next year.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Based on our available cash and cash equivalents as of March 31, 2025, management has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern for one year from the date these consolidated financial statements are issued. The Company is evaluating strategies to obtain additional funding for future operations which include but are not limited to obtaining equity financing, issuing debt, or reducing planned expenses. A failure to raise additional funding or to effectively implement cost reductions could harm the Company&#x2019;s business, results of operations, and future prospects. If the Company is not able to secure adequate additional funding in future periods, the Company could be forced to make additional reductions in certain expenditures. This could include liquidating assets and suspending or curtailing planned programs. The Company may also have to delay, reduce the scope of, suspend, or eliminate one or more research and development programs or its commercialization efforts or pursue a strategic transaction. If the Company is unable to raise capital when needed or enter into a strategic transaction, then the Company could be required to cease operations, which could cause its stockholders to lose all or part of their investment. The consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Assuming no additional funding and based on its current operating and development plans, the Company expects that existing cash and cash equivalents as of the date of this filing will be sufficient to fund currently anticipated operating expenses into the second half of calendar year 2025.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company may receive contingent, sales-based milestone payments of up to $159,000,000 on sales of Vyleesi by Cosette and its licensees.&lt;em&gt; &lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Concentrations &#x2013;&lt;/em&gt; Concentrations in the Company&#x2019;s assets and operations subject it to certain related risks. Financial instruments that subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company&#x2019;s cash and cash equivalents are primarily invested in one investment account sponsored by a large financial institution.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_1444"
      unitRef="USD">-456844101</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2317"
      unitRef="USD">-4811420</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_1445"
      unitRef="USD">-15077551</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_1447"
      unitRef="USD">2520602</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_1448"
      unitRef="USD">10048349</us-gaap:LiabilitiesCurrent>
    <ptn:SalesBasedMilestonePayments
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2162"
      unitRef="USD">159000000</ptn:SalesBasedMilestonePayments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1945">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(2) BASIS OF PRESENTATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnote disclosures required to be presented for complete financial statements. In the opinion of management, these consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for fair presentation. The results of operations for the three and nine months ended March 31, 2025, may not necessarily be indicative of the results of operations expected for the full fiscal year.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The accompanying unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended June 30, 2024, filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;), which includes consolidated financial statements as of June 30, 2024 and 2023 and for the fiscal years then ended.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1938">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(3) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Principles of Consolidation&lt;/em&gt; &#x2013; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Cash, Cash Equivalents&lt;/em&gt; &#x2013; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $2,097,618 and $9,089,113 in a money market account at March 31, 2025 and June 30, 2024, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Fair Value of Financial Instruments&lt;/em&gt; &#x2013; The Company&#x2019;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Credit Risk&lt;/em&gt; &#x2013; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Impairment of Long-Lived Assets&lt;/em&gt; &#x2013; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Leases&lt;/em&gt; - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#x2019;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#x2019;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition (Prior to the sale of Vyleesi)&lt;/em&gt; &#x2013; The Company recognized product revenues in accordance with FASB ASC Topic 606, &lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligations were satisfied by transferring control of the product to a customer. Per the Company&#x2019;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Gross product sales offset by product sales allowances for the three and nine months ended March 31, 2025 and 2024 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended March 31&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,875,153&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Product sales allowances and accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,735,063&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,140,090&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition &#x2014;&lt;/em&gt;&#x2013; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company determines if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the non-refundable, upfront license fees will be recognized over time, the Company assesses the appropriate method of measuring proportional performance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Accrued Expenses &#x2013;&lt;/em&gt; Third parties perform a significant portion of the Company&#x2019;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation &#x2013; &lt;/em&gt;The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Net Loss per Common Share &lt;/em&gt;&#x2013;&lt;em&gt; &lt;/em&gt;Basic and diluted loss per common share (&#x201c;EPS&#x201d;) are calculated in accordance with the provisions of FASB ASC Topic 260, &lt;em&gt;Earnings per Share&lt;/em&gt;.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;For the three months ended March 31, 2025 and 2024, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three and nine months ended March 31, 2025 and 2024 were 17,749,116 and 8,520,332, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of March 31, 2025 and 2024 due to a provision in the restricted stock unit agreements to delay delivery.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Translation of foreign currencies &lt;/em&gt;&#x2013; Transactions denominated in currencies other than the Company&#x2019;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1953">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Principles of Consolidation&lt;/em&gt; &#x2013; The consolidated financial statements include the accounts of the Company and its wholly-owned inactive subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-07-01to2025-03-31" id="fid_1954">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1955">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Cash, Cash Equivalents&lt;/em&gt; &#x2013; Cash and cash equivalents include cash on hand, cash in banks, and all highly liquid investments with a purchased maturity of less than three months. Cash equivalents consisted of $2,097,618 and $9,089,113 in a money market account at March 31, 2025 and June 30, 2024, respectively.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_282"
      unitRef="USD">2097618</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2040"
      unitRef="USD">9089113</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2024-07-01to2025-03-31" id="fid_1957">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Fair Value of Financial Instruments&lt;/em&gt; &#x2013; The Company&#x2019;s financial instruments consist primarily of cash equivalents, accounts payable and warrants. Management believes that the carrying values of cash equivalents, accounts payable and warrants are representative of their respective fair values based on the short-term nature of these instruments.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-07-01to2025-03-31" id="fid_1958">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Credit Risk&lt;/em&gt; &#x2013; Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1961">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment consists of office and laboratory equipment, office furniture, and leasehold improvements and includes assets acquired under finance leases. Property and equipment are recorded at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the related assets, generally five years for laboratory and computer equipment, seven years for office furniture and equipment, and the lesser of the term of the lease or the useful life for leasehold improvements. Amortization of assets acquired under finance leases is included in depreciation expense. Maintenance and repairs are expensed as incurred while expenditures that extend the useful life of an asset are capitalized.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1962">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Impairment of Long-Lived Assets&lt;/em&gt; &#x2013; The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1963">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Leases&lt;/em&gt; - At lease inception, the Company determines whether an arrangement is or contains a lease. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, short-term operating lease liabilities, and long-term operating lease liabilities in the consolidated financial statements. Finance leases are included in property and equipment for ROU assets, short-term finance lease liabilities, and long-term finance lease liabilities in the consolidated financial statements. ROU assets represent the Company&#x2019;s right to use leased assets over the term of the lease. Lease liabilities represent the Company&#x2019;s contractual obligation to make lease payments over the lease term. ROU assets and lease liabilities are recognized at the commencement date. The lease liability is measured as the present value of the lease payments over the lease term. The Company uses the rate implicit in the lease if it is determinable. When the rate implicit in the lease is not determinable, the Company uses an estimate based on a hypothetical rate provided by a third party as the Company currently does not have issued debt. Lease terms may include renewal or extension options to the extent they are reasonably certain to be exercised. The assessment of whether renewal or extension options are reasonably certain to be exercised is made at lease commencement. Factors considered in determining whether an option is reasonably certain of exercise include, but are not limited to, the value of any leasehold improvements, the value of renewal rates compared to market rates, and the presence of factors that would cause incremental costs to the Company if the option were not exercised.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented as an operating expense separately from interest expense on the lease liability.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has elected not to recognize an ROU asset and obligation for leases with an initial term of 12 months or less. The expense associated with short-term leases is included in selling, general and administrative expenses in the statements of operations. To the extent a lease arrangement includes both lease and non-lease components, the Company has elected to account for the components as a single lease component.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <ptn:RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock contextRef="From2024-07-01to2025-03-31" id="fid_1989">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition (Prior to the sale of Vyleesi)&lt;/em&gt; &#x2013; The Company recognized product revenues in accordance with FASB ASC Topic 606, &lt;em&gt;Revenue from Contracts with Customers&lt;/em&gt;. The provisions of ASC Topic 606 require the following steps to determine revenue recognition: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In accordance with ASC Topic 606, the Company recognized product revenue when its performance obligations were satisfied by transferring control of the product to a customer. Per the Company&#x2019;s contracts with customers, control of the product was transferred upon the conveyance of title, which occurred when the product was sold to and received by a customer. Trade accounts receivable due to the Company from contracts with its customers were stated separately in the consolidated balance sheet, net of various allowances. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Product revenues consisted of sales of Vyleesi in the United States. The Company sold Vyleesi to specialty pharmacies at the wholesale acquisition cost and payment was made within approximately 30 days.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company recorded product revenues net of allowances for direct and indirect fees, discounts, co-pay assistance programs, estimated chargebacks and rebates. Product sales were also subject to return rights, which were not significant. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Gross product sales offset by product sales allowances for the three and nine months ended March 31, 2025 and 2024 are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended March 31&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,875,153&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Product sales allowances and accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,735,063&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,140,090&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:RevenueRecognitionPriorToTheSaleOfVyleesiFinancialStatementsPolicytExtblock>
    <ptn:ScheduleOfSalesTableTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1971">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Three Months Ended March 31&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Gross product sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8,875,153&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Product sales allowances and accruals&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(4,735,063&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Net sales&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,140,090&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfSalesTableTextBlock>
    <ptn:RevenuesGross
      contextRef="From2025-01-01to2025-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2326"
      unitRef="USD">0</ptn:RevenuesGross>
    <ptn:RevenuesGross
      contextRef="From2024-01-01to2024-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2327"
      unitRef="USD">0</ptn:RevenuesGross>
    <ptn:RevenuesGross
      contextRef="From2024-07-01to2025-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_12"
      unitRef="USD">0</ptn:RevenuesGross>
    <ptn:RevenuesGross
      contextRef="From2023-07-01to2024-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2325"
      unitRef="USD">8875153</ptn:RevenuesGross>
    <ptn:ProductSalesAllowancesAndAccruals
      contextRef="From2025-01-01to2025-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2328"
      unitRef="USD">0</ptn:ProductSalesAllowancesAndAccruals>
    <ptn:ProductSalesAllowancesAndAccruals
      contextRef="From2024-01-01to2024-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2329"
      unitRef="USD">0</ptn:ProductSalesAllowancesAndAccruals>
    <ptn:ProductSalesAllowancesAndAccruals
      contextRef="From2024-07-01to2025-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_605"
      unitRef="USD">0</ptn:ProductSalesAllowancesAndAccruals>
    <ptn:ProductSalesAllowancesAndAccruals
      contextRef="From2023-07-01to2024-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2331"
      unitRef="USD">-4735063</ptn:ProductSalesAllowancesAndAccruals>
    <us-gaap:Revenues
      contextRef="From2025-01-01to2025-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2333"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-01to2024-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2330"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-01to2025-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_264"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-07-01to2024-03-31_us-gaap_ProductMember"
      decimals="0"
      id="fid_2332"
      unitRef="USD">4140090</us-gaap:Revenues>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1964">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Revenue Recognition &#x2014;&lt;/em&gt;&#x2013; For licenses of intellectual property, the Company assesses at contract inception whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license is bundled with other promises in the arrangement into one performance obligation. The Company determines if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the non-refundable, upfront license fees will be recognized over time, the Company assesses the appropriate method of measuring proportional performance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Regulatory milestone payments are excluded from the transaction price due to the inability to estimate the probability of reversal. Revenue relating to achievement of these milestones is recognized in the period in which the milestone is achieved. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Sales-based royalty and milestone payments resulting from customer contracts solely or predominately for the license of intellectual property will only be recognized upon occurrence of the underlying sale or achievement of the sales milestone in the future and such sales-based royalties and milestone payments will be recognized in the same period earned. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company is the principal in the research and development activities based upon its control of such activities, which is considered part of its ordinary activities.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Development milestone payments are generally due 30 business days after the milestone is achieved. Sales milestone payments are generally due 45 business days after the calendar year in which the sales milestone is achieved. Royalty payments are generally due on a quarterly basis 20 business days after being invoiced.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-07-01to2025-03-31" id="fid_1965">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; &#x2013; The costs of research and development activities are charged to expense as incurred, including the cost of equipment for which there is no alternative future use.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ptn:AccruedLiabilitiesPolicyTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1966">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Accrued Expenses &#x2013;&lt;/em&gt; Third parties perform a significant portion of the Company&#x2019;s development activities. The Company reviews the activities performed under all contracts each quarter and accrues expenses and the amount of any reimbursement to be received from its collaborators based upon the estimated amount of work completed considering milestones achieved. Estimating the value or stage of completion of certain services requires judgment based on available information. If the Company does not identify services performed for it but not billed by the service-provider, or if it underestimates or overestimates the value of services performed as of a given date, reported expenses will be understated or overstated.&lt;/p&gt;</ptn:AccruedLiabilitiesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-07-01to2025-03-31" id="fid_1967">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Stock-Based Compensation &#x2013; &lt;/em&gt;The Company charges to expense the fair value of stock options and other equity awards granted to employees and nonemployees for services. Compensation costs for stock-based awards with time-based vesting are determined using the quoted market price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model, and are recognized on a straight-line basis, while awards containing a market condition are valued using multifactor Monte Carlo simulations and are recognized over the derived service period. Compensation costs for awards containing a performance condition are determined using the quoted price of the Company&#x2019;s common stock on the grant date or for stock options, the value determined utilizing the Black-Scholes option pricing model and are recognized based on the probability of achievement of the performance condition over the service period. Forfeitures are recognized as they occur. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1968">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company and its subsidiary file consolidated federal and separate-company state income tax returns. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of assets and liabilities and their respective tax basis and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences or operating loss and tax credit carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The Company has recorded and continues to maintain a full valuation allowance against its deferred tax assets based on the history of losses incurred and lack of experience projecting future product revenue and sales-based royalty and milestone payments.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1969">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Net Loss per Common Share &lt;/em&gt;&#x2013;&lt;em&gt; &lt;/em&gt;Basic and diluted loss per common share (&#x201c;EPS&#x201d;) are calculated in accordance with the provisions of FASB ASC Topic 260, &lt;em&gt;Earnings per Share&lt;/em&gt;.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;For the three months ended March 31, 2025 and 2024, no additional common shares were added to the computation of diluted EPS because to do so would have been anti-dilutive. The potential number of common shares excluded from diluted EPS during the three and nine months ended March 31, 2025 and 2024 were 17,749,116 and 8,520,332, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Included in the weighted average common shares used in computing basic and diluted net loss per common share are 279,700 vested restricted stock units that had not been issued as of March 31, 2025 and 2024 due to a provision in the restricted stock unit agreements to delay delivery.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_287"
      unitRef="Shares">17749116</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_1415"
      unitRef="Shares">8520332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_1416"
      unitRef="Shares">279700</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1970">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Translation of foreign currencies &lt;/em&gt;&#x2013; Transactions denominated in currencies other than the Company&#x2019;s functional currency (US Dollar) are recorded based on exchange rates at the time such transactions arise. Subsequent changes in exchange rates result in transaction gains and losses, which are reflected in the consolidated statements of operations as unrealized (based on the applicable period-end exchange rate) or realized upon settlement of the transactions.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1939">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(4)&lt;/strong&gt; &lt;strong&gt;New Accounting Pronouncements&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, Segment Reporting (Topic 280) &#x2013; Improvements to Reportable Segment Disclosures. This ASU requires that a public entity provide additional segment disclosures on an interim and annual basis. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements, unless impracticable. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently assessing the impact of the adoption on the consolidated financial statements and accompanying footnotes.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <ptn:AssetPurchaseAgreementTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1940">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(5) ASSET PURCHASE AGREEMENT&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On December 19, 2023, the Company entered into an Asset Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with Cosette pursuant to which Cosette acquired from the Company worldwide rights to Vyleesi&#xae;.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Under the terms of the Purchase Agreement, the Company sold certain assets (the &#x201c;Purchased Assets&#x201d;) to Cosette, comprising the exclusive right to market and sell Vyleesi for treatment of hypoactive sexual desire disorder in women, and contracts relating to manufacturing and distribution of Vyleesi. The Purchased Assets include applicable intellectual property pertaining to the marketing and sale of Vyleesi, including patents, patent applications, trademarks and copyrights. In addition, Cosette acquired records pertaining to the historical sales and distribution of Vyleesi, as well as quality control and pharmacovigilance records and other records. The Company will receive up to $171,000,000, consisting of an upfront purchase price of $9,500,000, $2,500,000 payable upon the settlement of certain purchase commitments, which was received November 1, 2024, and sales-based milestone payments of up to $159,000,000. As of March 31, 2025, none of the sales-based milestones have been achieved. The closing of the transaction took place simultaneously with the signing of the Purchase Agreement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Purchase Agreement includes customary representations, warranties and covenants, as well as standard mutual indemnities covering losses arising from any material breach of the Purchase Agreement or inaccuracy of representations and warranties.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The parties have also entered into a transition service agreement pursuant to which the Company provided certain transition services to Cosette through May 31, 2024, and the Company was reimbursed for the costs of the transition services.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company is also eligible to receive regulatory approval milestones associated with previous licensing of Vyleesi to Kwangdong for the Republic of Korea (&#x201c;Korea&#x201d;) (see Note 8).&lt;/p&gt;</ptn:AssetPurchaseAgreementTextBlock>
    <us-gaap:AccountsReceivablePurchase
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_1450"
      unitRef="USD">171000000</us-gaap:AccountsReceivablePurchase>
    <us-gaap:SupplementalDeferredPurchasePrice
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_1452"
      unitRef="USD">9500000</us-gaap:SupplementalDeferredPurchasePrice>
    <us-gaap:PaymentsForPurchaseOfOtherAssets1
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_1449"
      unitRef="USD">2500000</us-gaap:PaymentsForPurchaseOfOtherAssets1>
    <ptn:PaymentsToSalesBasedMilestonePayments
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_1451"
      unitRef="USD">159000000</ptn:PaymentsToSalesBasedMilestonePayments>
    <ptn:ManufacturingSupplyAgreementsTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1988">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(6) MANUFACTURING SUPPLY AGREEMENTS FOR VYLEESI&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company has transferred to Cosette its right, title and interest in contracts and agreements to manufacture Vyleesi, including manufacturing contracts with Catalent Belgium S.A. (&#x201c;Catalent&#x201d;), a subsidiary of Catalent Pharma Solutions, Inc., to manufacture drug product and prefilled syringes and assemble prefilled syringes into an auto-injector device; Ypsomed AG (&#x201c;Ypsomed&#x201d;), to manufacture the auto-injector device (the &#x201c;Ypsomed Agreement&#x201d;); and Lonza Ltd. (&#x201c;Lonza&#x201d;), to manufacture the active pharmaceutical ingredient peptide (the &#x201c;Lonza Agreement&#x201d;).&lt;/p&gt;</ptn:ManufacturingSupplyAgreementsTextBlock>
    <ptn:AgreementWithFosunTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1941">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(7) AGREEMENT WITH FOSUN&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#x201c;Fosun&#x201d;) for exclusive rights to commercialize Vyleesi in China (the &#x201c;Fosun License Agreement&#x201d;). Under the terms of the Fosun License Agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. In July 2024, Fosun, Cosette and Palatin entered into a termination agreement, effective as of May 20, 2024, terminating the Fosun License Agreement and ancillary agreements.&lt;/p&gt;</ptn:AgreementWithFosunTextBlock>
    <us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits
      contextRef="From2017-09-01to2017-09-06"
      decimals="0"
      id="fid_1618"
      unitRef="USD">4500000</us-gaap:IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits>
    <us-gaap:PaymentsForRestructuring
      contextRef="From2017-09-01to2017-09-06"
      decimals="0"
      id="fid_1619"
      unitRef="USD">5000000</us-gaap:PaymentsForRestructuring>
    <ptn:UpfrontPaymentOfLess
      contextRef="From2017-09-01to2017-09-06"
      decimals="0"
      id="fid_1626"
      unitRef="USD">500000</ptn:UpfrontPaymentOfLess>
    <ptn:AgreementWithKwangdongTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1942">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(8) AGREEMENT WITH KWANGDONG&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On November 21, 2017, the Company entered into a license agreement with Kwangdong Pharmaceutical Co., Ltd. (&#x201c;Kwangdong&#x201d;) for exclusive rights to commercialize Vyleesi in Korea (the &#x201c;Kwangdong License Agreement&#x201d;). Under the terms of the Kwangdong License Agreement, the Company received $417,500 in December 2017, consisting of an upfront payment of $500,000, less $82,500, which was withheld in accordance with tax withholding requirements in Korea and recorded as an expense during the year ended June 30, 2018. The Company has assigned the Kwangdong License Agreement to Cosette, provided that the Company retains the right to receive a $3,000,000 milestone payment based on the first commercial sale in Korea which has not occurred as of March 31, 2025.&lt;/p&gt;</ptn:AgreementWithKwangdongTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_631"
      unitRef="USD">417500</us-gaap:OfficersCompensation>
    <us-gaap:PaymentsForRestructuring
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_633"
      unitRef="USD">500000</us-gaap:PaymentsForRestructuring>
    <ptn:taxexpenses
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_634"
      unitRef="USD">82500</ptn:taxexpenses>
    <us-gaap:PaymentsToAcquireReceivables
      contextRef="From2017-11-01to2017-11-21"
      decimals="0"
      id="fid_636"
      unitRef="USD">3000000</us-gaap:PaymentsToAcquireReceivables>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1943">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(9) PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Prepaid expenses&lt;strong&gt; &lt;/strong&gt;and other current assets consist of the following:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;45,118&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,926&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Insurance premiums&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;95,327&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;71,097&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;301,733&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,249&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;442,178&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;242,272&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1972">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;March 31,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;45,118&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;23,926&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Insurance premiums&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;95,327&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;71,097&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;301,733&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,249&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;442,178&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;242,272&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <ptn:PrepaidClinicalStudyCosts
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_637"
      unitRef="USD">45118</ptn:PrepaidClinicalStudyCosts>
    <ptn:PrepaidClinicalStudyCosts
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_575"
      unitRef="USD">23926</ptn:PrepaidClinicalStudyCosts>
    <ptn:PrepaidInsurancePremiums
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_638"
      unitRef="USD">95327</ptn:PrepaidInsurancePremiums>
    <ptn:PrepaidInsurancePremiums
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_577"
      unitRef="USD">71097</ptn:PrepaidInsurancePremiums>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_640"
      unitRef="USD">301733</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_581"
      unitRef="USD">147249</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_641"
      unitRef="USD">442178</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_583"
      unitRef="USD">242272</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1944">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(10) FAIR VALUE MEASUREMENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The fair value of cash equivalents is classified using a hierarchy prioritized based on inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management&#x2019;s own assumptions used to measure assets and liabilities at fair value. A financial asset&#x2019;s or liability&#x2019;s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The following table provides the assets carried at fair value:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Carrying Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Quoted prices in &lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;active markets&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;(Level 1)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Other quoted/observable inputs (Level 2)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Significant unobservable inputs&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;(Level 3)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;March 31, 2025:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,097,618&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,097,618&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;June 30, 2024:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1973">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Carrying Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Quoted prices in &lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;active markets&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;(Level 1)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Other quoted/observable inputs (Level 2)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Significant unobservable inputs&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;(Level 3)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;March 31, 2025:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,097,618&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,097,618&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;June 30, 2024:&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Cash equivalents - Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;9,089,113&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_1460"
      unitRef="USD">2097618</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="fid_1471"
      unitRef="USD">2097618</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="fid_1461"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="fid_1466"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2042"
      unitRef="USD">9089113</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="fid_2041"
      unitRef="USD">9089113</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      id="fid_2043"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="fid_2044"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1948">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(11) ACCRUED EXPENSES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Accrued expenses&lt;strong&gt; &lt;/strong&gt;consist of the following:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;378,592&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,509,797&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;40,509&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,972&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Professional Services&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;55,040&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;284,215&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,771,694&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Selling expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;351,485&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;32,319&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;201,883&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;506,460&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,185,046&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1981">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;March 31, &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;June 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2025&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Clinical / regulatory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;378,592&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,509,797&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other research related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;40,509&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;65,972&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Professional Services&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;55,040&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;284,215&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,771,694&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Selling expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;351,485&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;32,319&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;201,883&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;506,460&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,185,046&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <ptn:AccruedClinicalRegulatoryCosts
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_661"
      unitRef="USD">378592</ptn:AccruedClinicalRegulatoryCosts>
    <ptn:AccruedClinicalRegulatoryCosts
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_660"
      unitRef="USD">1509797</ptn:AccruedClinicalRegulatoryCosts>
    <ptn:OtherAccruedResearchRelatedExpenses
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_663"
      unitRef="USD">40509</ptn:OtherAccruedResearchRelatedExpenses>
    <ptn:OtherAccruedResearchRelatedExpenses
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_662"
      unitRef="USD">65972</ptn:OtherAccruedResearchRelatedExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_665"
      unitRef="USD">55040</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_664"
      unitRef="USD">284215</us-gaap:AccruedProfessionalFeesCurrent>
    <ptn:AccruedPersonalCost
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_667"
      unitRef="USD">0</ptn:AccruedPersonalCost>
    <ptn:AccruedPersonalCost
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_666"
      unitRef="USD">1771694</ptn:AccruedPersonalCost>
    <ptn:AccruedSellingExpenses
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_669"
      unitRef="USD">0</ptn:AccruedSellingExpenses>
    <ptn:AccruedSellingExpenses
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_668"
      unitRef="USD">351485</ptn:AccruedSellingExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_671"
      unitRef="USD">32319</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_670"
      unitRef="USD">201883</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_673"
      unitRef="USD">506460</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_672"
      unitRef="USD">4185046</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1949">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(12) COMMITMENTS AND CONTINGENCIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Inventory Purchases &lt;/em&gt;- The Company had certain supply agreements with manufacturers and suppliers, including the manufacturing agreement with Catalent entered into in September 2020 (the &#x201c;Catalent Agreement&#x201d;), Ypsomed Agreement, and Lonza Agreement, all of which have been transferred to Cosette. As a result of the sale of Vyleesi to Cosette, the Company is still required to make certain payments for the manufacture and supply of Vyleesi.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The following table summarizes the contractual obligations under the Catalent Agreement and Ypsomed Agreement as of March 31, 2025:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Current&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;1 - 3 Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;4 - 5 Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Inventory purchase commitments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,101,800&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,101,800&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of March 31, 2025, the Company has $1,576,350 accrued within other current liabilities in the consolidated balance sheet related to estimated losses for firm commitment contractual obligations under these agreements. As of June 30, 2024, $944,150 and $1,032,300 was accrued within other current and long-term liabilities, respectively. Losses on these firm commitment contractual obligations are recognized based upon the terms of the respective agreement and similar factors considered for the write-down of inventory, including expected sales requirements as determined by internal sales forecasts.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The commitment contractual obligation amounts above are denominated in Swiss Francs and Euros and have been translated using period end exchange rates. The Company may experience a negative impact on future earnings and equity solely as a result of future foreign currency exchange rate fluctuations.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Contingencies&lt;/em&gt; - The Company accounts for litigation losses in accordance with ASC 450-20, &lt;em&gt;Loss Contingencies&lt;/em&gt;. In addition, the Company is subject to other contingencies, such as product liability, arising in the ordinary course of business. Loss contingency provisions are recorded for probable losses when management is able to reasonably estimate the loss. Any outcome upon settlement that deviates from the Company&#x2019;s best estimate may result in additional expense or in a reduction in expense in a future accounting period. The Company records legal expenses associated with such contingencies as incurred.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is involved, from time to time, in various claims and legal proceedings arising in the ordinary course of its business. The Company is not currently a party to any such claims or proceedings that, if decided adversely to it, would either individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1982">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Current&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;1 - 3 Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;4 - 5 Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Inventory purchase commitments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,101,800&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,101,800&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfInventoryPurchaseCommitmentsTableTextBlock>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_865"
      unitRef="USD">2101800</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2025-03-31_ptn_CurrentMember"
      decimals="0"
      id="fid_866"
      unitRef="USD">2101800</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2025-03-31_ptn_OneToThreeYearsMember"
      decimals="0"
      id="fid_867"
      unitRef="USD">0</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="AsOf2025-03-31_ptn_FourToFiveYearsMember"
      decimals="0"
      id="fid_2335"
      unitRef="USD">0</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_870"
      unitRef="USD">1576350</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_869"
      unitRef="USD">944150</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLongTermDebt
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_871"
      unitRef="USD">1032300</us-gaap:OtherLongTermDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_1950">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;(13) STOCKHOLDERS&#x2019; DEFICIENCY&lt;/strong&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Series A Convertible Preferred Stock&lt;/em&gt; &#x2013; As of March 31, 2025, 4,030 shares of Series A Convertible Preferred Stock were outstanding. Each share of Series A Convertible Preferred Stock is convertible at any time, at the option of the holder, into the number of shares of common stock equal to $100 divided by the Series A Conversion Price. As of March 31, 2025, the Series A Conversion Price was $60.33, and each share of Series A Convertible Preferred Stock is convertible into approximately 1.66 shares of common stock. The Series A Conversion Price is subject to adjustment, under certain circumstances, upon the sale or issuance of common stock for consideration per share less than either (i) the Series A Conversion Price in effect on the date of such sale or issuance, or (ii) the market price of the common stock as of the date of such sale or issuance. The Series A Conversion Price is also subject to adjustment upon the occurrence of a merger, reorganization, consolidation, reclassification, stock dividend or stock split which will result in an increase or decrease in the number of shares of common stock outstanding. Shares of Series A Convertible Preferred Stock have a preference in liquidation, including certain merger transactions, of $100 per share, or $403,000 in the aggregate as of March 31, 2025. Additionally, the Company may not pay a dividend or make any distribution to holders of any class of stock unless the Company first pays a special dividend or distribution of $100 per share to holders of the Series A Convertible Preferred Stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;em&gt;Financing Transactions &#x2013; &lt;/em&gt;On February 10, 2025, the Company entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000 shares of its common stock (or common stock equivalents in lieu thereof) in a registered direct offering (the &#x201c; February 2025 RD Offering&#x201d;) at a purchase price of $1.00 per share.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company also agreed to issue to the same investor in a concurrent private placement warrants to purchase up to an aggregate of 4,688,000 shares of common stock (the &#x201c;February 2025 Private Placement&#x201d; and, together with the February 2025 RD Offering, the &#x201c;February 2025 Offering&#x201d;). The warrants issued in the concurrent February 2025 Private Placement will have an exercise price of $1.00 per share, will be exercisable 181 days after their issuance and will expire approximately five and a half years from the date of issuance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The gross proceeds from the February 2025 Offering totaled $4,687,786, with net proceeds after deducting the placement agent fees and offering expenses amounting to $4,309,641.&#160;The Company intends to use the net proceeds from the Offering for general corporate purposes.&#160; The Company paid the placement agents a cash fee equal to 7.0% of the aggregate gross proceeds of the February 2025 Offering. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On January 29, 2024, the Company entered into a securities purchase agreement (the &#x201c;January 2024 Purchase Agreement&#x201d;) to sell in a registered direct offering (the &#x201c;January 2024 RD Offering&#x201d;), an aggregate of 1,831,503 shares of common stock of the Company. Pursuant to the January 2024 Purchase Agreement, the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the &#x201c;January 2024 Private Warrants&#x201d;) to purchase up to 1,831,503 shares of the Company&#x2019;s common stock (the &#x201c;January 2024 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;Private Offering&#x201d; and together with the January 2024 RD Offering, the &#x201c;January 2024 Offering&#x201d;). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The January 2024 Private Warrants are exercisable on the six-month anniversary of the issuance date for a period of four years from the issuance date, at an exercise price equal to $5.46 per January 2024 Private Warrant Share. The January 2024 Private Warrants are exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the January 2024 Private Warrant Shares issuable upon exercise of the January 2024 Private Warrants to or by the holder of such January 2024 Private Warrants is not in effect, on a cashless basis. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company paid the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds of the January 2024 Offering and for certain expenses and legal fees in connection with the January 2024 Offering. In addition, the Company also issued to the placement agent or its designees warrants (the &#x201c;2024 Placement Agent Warrants&#x201d;) to purchase up to 91,575 shares of the Company&#x2019;s common stock (the &#x201c;January 2024 Placement Agent Warrant Shares&#x201d;) as part of the compensation payable to the placement agent. The January 2024 Placement Agent Warrants have substantially the same terms as the January 2024 Private Warrants, except that the January 2024 Placement Agent Warrants have an exercise price of $6.825 per share.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On March 14, 2024, the Company filed a registration statement on Form S-1 to register the January 2024 Private Warrants and the January 2024 Placement Agent Warrants, which registration statement was declared effective on March 28, 2024 and a prospectus was filed on the same date.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The gross proceeds from the January 2024 Offering totaled $10,000,006, with net proceeds from the January 2024 Offering, after deducting the placement agent fees and offering expenses, amounting to $9,224,056. The Company intends to use the net proceeds received from the January 2024 Offering for general working capital purposes.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On October 20, 2023, the Company entered into a securities purchase agreement (the &#x201c;October 2023 Purchase Agreement&#x201d;) with a certain institutional investor, to sell in a registered direct offering (the &#x201c;October 2023 RD Offering&#x201d;), an aggregate of (i) 1,325,000 shares of common stock (the &#x201c;October 2023 Shares&#x201d;), of the Company and (ii) pre-funded warrants (the &#x201c;October 2023 Pre-Funded Warrants&#x201d;) to purchase up to 1,033,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Pre-Funded Warrant Shares&#x201d;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#x201c;October 2023 Private Warrants&#x201d;) to purchase up to 2,358,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;October 2023 Private Offering&#x201d; and together with the October 2023 RD Offering, the &#x201c;October 2023 Offering&#x201d;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The October 2023 Private Warrants are exercisable on the six-month anniversary of issuance for a period of five and one-half years from the issuance date, at an exercise price equal to $2.12 per October 2023 Private Warrant Share. The October 2023 Private Warrants will be exercisable for cash, or, solely during any period when a registration statement for the issuance or resale of the October 2023 Private Warrant Shares issuable upon exercise of the October 2023 Private Warrants to or by the holder of such October 2023 Private Warrants is not in effect, on a cashless basis.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The October 2023 Pre-Funded Warrants had an exercise price of $0.0001 per October 2023 Pre-Funded Warrant Share, were exercisable upon issuance, and during the three months ended December 31, 2023, the institutional investor exercised the outstanding October 2023 Pre-Funded Warrants to purchase 1,033,491 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The net proceeds from the October 2023 Offering, after deducting the placement agent fees and offering expenses, were $4,573,948.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The placement agent warrants were issued to non-employees in exchange for services related to the offering are accounted for in accordance with ASC 718 which requires the fair value of the warrants to be recognized as an offering expense. The placement agent warrants contain certain contingent cash settlement features that are not probable of occurring and not within the control of the Company, therefore the placement agent warrants are classified out of permanent equity.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On January 24, 2024, the Company and warrant holders amended the terms of warrants related to the October 2023 financings. As a result, all liability classified warrants were reclassified to additional paid-in capital.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On February 11, 2025, the Company entered into a sales agreement (the &#x201c;2025 Sales Agreement&#x201d;) with A.G.P./Alliance Global Partners (&#x201c;A.G.P.&#x201d;), pursuant to which the Company may, from time to time, sell shares of the Company&#x2019;s common stock at market prices by methods deemed to be an &#x201c;at-the-market offering&#x201d; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended(the &#x201c;Securities Act&#x201d;). The 2025 Sales Agreement and related prospectus is limited to sales of up to an aggregate maximum of $6.0 million of shares of the Company&#x2019;s common stock. The Company pays A.G.P. 3.0% of the gross proceeds as a commission.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;For the three months ended March 31, 2025, a total of 413,400 shares of common stock were sold through A.G.P. under the 2025 Sales Agreement for net proceeds of $271,037 after payment of commission fees of $7,837 and other related expenses of $164,054.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;During the three months ended March 31, 2025, the equity distribution agreement (the &#x201c;2023 Equity Distribution Agreement&#x201d;) that the Company entered into with Canaccord Genuity LLC (&#x201c;Canaccord&#x201d;) on April 12, 2023, was terminated.&#160; The 2023 Equity Distribution Agreement and related prospectus was limited to sales, from time to time in an &#x201c;at-the-market offering&#x201d; (as defined in Rule 415 promulgated under the Securities Act), of up to an aggregate maximum $50.0 million of shares of the Company&#x2019;s common stock. The Company paid Canaccord 3.0% of the gross proceeds as a commission.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Proceeds raised under the 2023 Equity Distribution Agreement are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;March 31, 2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Cumulative from&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;inception&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Gross proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;547,803&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,744,542&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Fees&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(16,434&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(52,336&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Expenses&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(126,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Net proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;531,369&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,565,406&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;No proceeds were raised under the 2023 Equity Distribution Agreement during the three and nine months ended March 31, 2025.&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Stock Warrants&lt;/em&gt; &#x2013; On December 13, 2024, the Company entered into a letter agreement (the &#x201c;December 2024 Inducement Letter&#x201d;) with a holder (the &#x201c;December 2024 Exercising Holder&#x201d;) of outstanding common stock purchase warrants that the Company issued on June 24, 2024, with an initial exercise price of $1.88, and October 24, 2023, with an initial exercise price of $2.12 (the &#x201c;December 2024 Existing Warrants&#x201d;). To induce the exercise of a portion of the December 2024 Existing Warrants by the December 2024 Exercising Holder, the Company agreed to adjust the exercise price of such portion of the December 2024 Existing Warrants to $0.875. Pursuant to the December 2024 Inducement Letter, the December 2024 Exercising Holder agreed to exercise, for cash, the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company&#x2019;s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock (the &#x201c;Series C Warrants&#x201d;) and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock (the &#x201c;Series D Warrants&#x201d; and together with the Series C Warrants, the &#x201c;December 2024 Inducement Warrants,&#x201d; and the shares issuable upon exercise of the December 2024 Inducement Warrants, the &#x201c;December 2024 Inducement Warrant Shares&#x201d;). The Company received aggregate gross proceeds of $3,419,219 from the exercise of the December 2024 Existing Warrants by the December 2024 Exercising Holder (the &#x201c;December 2024 Warrant Inducement&#x201d;). The incremental value of the December 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;On June 20, 2024, the Company entered into a letter agreement (the &#x201c;June 2024 Inducement Letter&#x201d;) with a holder (the &#x201c;June 2024 Exercising Holder&#x201d;) of outstanding common stock purchase warrants that the Company issued on November 2, 2022, and October 24, 2023 (the &#x201c;June 2024 Existing Warrants&#x201d;). Pursuant to the June 2024 Inducement Letter, the June 2024 Exercising Holder agreed to exercise, for cash, June 2024 Existing Warrants to purchase, in the aggregate, 3,233,277 shares of common stock in exchange for the Company&#x2019;s agreement to (i) lower the exercise price to $1.88 per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#x201c;June 2024 Series A Warrants&#x201d;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#x201c;June 2024 Series B Warrants&#x201d; and together with the June 2024 Series A Warrants, the &#x201c;June 2024 Inducement Warrants&#x201d;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the &#x201c;Warrant Inducement&#x201d;). As part of the agreement, 1,443,277 shares of common stock were held in abeyance on behalf of the June 2024 Exercising Holder. During the three months ended March 31, 2025, at the request of the June 2024 Exercising Holder, 1,443,277 shares were released from abeyance. The incremental value of the June 2024 Warrant Inducement was recorded as an offering expense against the proceeds received in additional paid-in capital. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;As of March 31, 2025, the Company had outstanding warrants for shares of common stock as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares of Common&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Exercise Price per&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Latest Expiration&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Stock&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;May 2022 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;66,666&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12.50&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;May 11, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;October 2022 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;90,909&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;October 31, 2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;October 2023 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;117,925&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;October 20, 2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 2024 Private Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,831,503&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.46&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 2024 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;91,575&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.83&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;June 2024 Series B Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,885,632&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;June24,2029*&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 2024 Series C Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,907,679&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 17, 2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 2024 Series D Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,953,839&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;**&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 2025 Series E Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,688,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;August 12, 2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="11" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance and the balance expire on June 24, 2029.&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="4" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;** 1,953,839 shares expire on the five year anniversary following stockholder approval of the warrant issuance.&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Stock Options &#x2013;&lt;/em&gt; For the three and nine months ended March 31, 2025, the Company recorded stock-based compensation related to stock options of $176,410 and $531,817, respectively. For the three and nine months ended March 31, 2024, the Company recorded stock-based compensation related to stock options of $205,176 and $615,716, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;A summary of stock option activity is as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Term in &lt;/strong&gt;&lt;strong&gt;Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding - June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,263,440&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.11&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.2&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(14,338&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4.50&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding - March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,249,102&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6.12&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7.5&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercisable at March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;937,894&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10.77&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;5.9&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Expected to vest at March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,311,208&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8.6&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Stock options granted to the Company&#x2019;s executive officers and employees generally vest over a 48-month period, while stock options granted to its non-employee directors vest over a 12-month period. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Included in the outstanding options in the table above are 418,945 and 88,911 unvested performance-based stock options granted to executive officers and other employees, respectively, which were granted in June 2020, 2021, 2022 and 2023. Grants in June 2021, 2022, 2023 and 2024 were 95,167, 60,566, 238,838 and 264,945, respectively. The performance-based stock options vest on annual performance criteria through the fiscal years ending June 30, 2028 relating to advancement of MC1r programs, including initiation of clinical trials and licensing of Vyleesi in additional countries or regions.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Restricted Stock Units &#x2013; &lt;/em&gt;For the three and nine months ended March 31, 2025, the Company recorded stock-based compensation related to restricted stock units of $171,281 and $513,852 respectively. For the three and nine months ended March 31, 2024, the Company recorded stock-based compensation related to restricted stock units of $185,019 and $555,057, respectively. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;A summary of restricted stock unit activity is as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,374,980&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Vested &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(232,941&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Expirations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,726&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,139,313&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Included in outstanding restricted stock units in the table above are 279,700 vested shares that have not been issued as of March 31, 2025, due to a provision in the restricted stock unit agreements to delay delivery.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Time-based restricted stock units granted to the Company&#x2019;s executive officers, other employees, and non-employee directors generally vest over 48 months, 48 months, and 12 months, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;Included in the outstanding restricted stock units in the table above are 274,549 and 59,842 unvested performance-based restricted stock units granted to executive officers and other employees, respectively, which were granted in June 2021, 2022, 2023, and 2024. Grants in June 2021, 2022, 2023 and 2024 were 22,343, 40,707, 152,432 and 184,443 restricted stock units, respectively. The performance-based restricted stock units vest on annual performance criteria through the fiscal years ending June 30, 2026 relating to advancement of MC1r programs, including initiation of clinical trials, and licensing of Vyleesi in additional countries or regions&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;In connection with the vesting of restricted share units during the nine months ended March 31, 2025, the Company withheld 54,691 shares, with an aggregate value of $99,482, in satisfaction of minimum tax withholding obligations.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_2704"
      unitRef="Shares">4030</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CashAvailableForDistributions
      contextRef="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_2708"
      unitRef="USD">100</us-gaap:CashAvailableForDistributions>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="INF"
      id="fid_2706"
      unitRef="USDPShares">60.33</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:DebtInstrumentConvertibleLiquidationPreferencePerShare
      contextRef="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="INF"
      id="fid_2707"
      unitRef="USDPShares">1.66</us-gaap:DebtInstrumentConvertibleLiquidationPreferencePerShare>
    <ptn:DistributableValueOfDividendPerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="fid_2710"
      unitRef="USDPShares">100</ptn:DistributableValueOfDividendPerShare>
    <ptn:AggregateValue
      contextRef="From2024-07-01to2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="0"
      id="fid_2705"
      unitRef="USD">403000</ptn:AggregateValue>
    <ptn:DividendAdditionalPerShare
      contextRef="AsOf2025-03-31_ptn_ConvertibleSeriesAPreferredStocksMember"
      decimals="INF"
      id="fid_2709"
      unitRef="USDPShares">100</ptn:DividendAdditionalPerShare>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-02-01to2025-02-10"
      decimals="0"
      id="fid_2767"
      unitRef="Shares">4688000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-02-10"
      decimals="INF"
      id="fid_2766"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-02-01to2025-02-10_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="fid_2770"
      unitRef="Shares">4688000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-10_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="fid_2771"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-02-01to2025-02-10"
      decimals="0"
      id="fid_2768"
      unitRef="USD">4687786</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <ptn:OfferingExpensesAmount
      contextRef="From2025-02-01to2025-02-10"
      decimals="0"
      id="fid_3202"
      unitRef="USD">4309641</ptn:OfferingExpensesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-01to2024-01-29"
      decimals="0"
      id="fid_2772"
      unitRef="Shares">1831503</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2024-01-01to2024-01-29_ptn_PrivateWarrantSharesMember"
      decimals="0"
      id="fid_2776"
      unitRef="Shares">1831503</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-29_ptn_PrivateWarrantSharesMember"
      decimals="INF"
      id="fid_2774"
      unitRef="USDPShares">5.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-31"
      decimals="INF"
      id="fid_2700"
      unitRef="USDPShares">5.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ptn:EquityIssuanceCostsPercentage
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="fid_3189"
      unitRef="Pure">0.070</ptn:EquityIssuanceCostsPercentage>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2025-03-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="0"
      id="fid_2716"
      unitRef="Shares">91575</ptn:SharesOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-03-31_ptn_TwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="fid_2717"
      unitRef="USDPShares">6.825</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2777"
      unitRef="USD">10000006</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CostsAndExpenses
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2699"
      unitRef="USD">9224056</us-gaap:CostsAndExpenses>
    <ptn:DescriptionOfSecuritiesPurchaseAgreement contextRef="From2023-10-01to2023-10-20" id="fid_2718">an aggregate of (i) 1,325,000 shares of common stock (the &#x201c;October 2023 Shares&#x201d;), of the Company and (ii) pre-funded warrants (the &#x201c;October 2023 Pre-Funded Warrants&#x201d;) to purchase up to 1,033,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Pre-Funded Warrant Shares&#x201d;). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the &#x201c;October 2023 Private Warrants&#x201d;) to purchase up to 2,358,491 shares of the Company&#x2019;s common stock (the &#x201c;October 2023 Private Warrant Shares&#x201d;) in a concurrent private placement (the &#x201c;October 2023 Private Offering&#x201d; and together with the October 2023 RD Offering, the &#x201c;October 2023 Offering&#x201d;). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199. The October 2023 Offering closed on October 24, 2023</ptn:DescriptionOfSecuritiesPurchaseAgreement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-10-20"
      decimals="INF"
      id="fid_2701"
      unitRef="USDPShares">2.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-10-20"
      decimals="INF"
      id="fid_2702"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <ptn:PurchaseOfWarrantShares
      contextRef="From2024-07-01to2025-03-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember"
      decimals="0"
      id="fid_2719"
      unitRef="USD">1033491</ptn:PurchaseOfWarrantShares>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-10-01to2023-10-20"
      decimals="0"
      id="fid_2712"
      unitRef="USD">4573948</us-gaap:CostsAndExpenses>
    <ptn:DescriptionOfSecuritiesPurchaseAgreement contextRef="From2023-04-01to2023-04-12" id="fid_2720">The 2025 Sales Agreement and related prospectus is limited to sales of up to an aggregate maximum of $6.0 million of shares of the Company&#x2019;s common stock. The Company pays A.G.P. 3.0% of the gross proceeds as a commission</ptn:DescriptionOfSecuritiesPurchaseAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-01to2025-03-31_ptn_TwoThousandTwentyFiveSalesAgreementMember"
      decimals="0"
      id="fid_2782"
      unitRef="Shares">413400</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-01-01to2025-03-31_ptn_TwoThousandTwentyFiveSalesAgreementMember"
      decimals="0"
      id="fid_2783"
      unitRef="USD">271037</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions
      contextRef="From2025-01-01to2025-03-31_ptn_TwoThousandTwentyFiveSalesAgreementMember"
      decimals="0"
      id="fid_2784"
      unitRef="USD">7837</us-gaap:PaymentsForCommissions>
    <us-gaap:OtherExpenses
      contextRef="From2025-01-01to2025-03-31_ptn_TwoThousandTwentyFiveSalesAgreementMember"
      decimals="0"
      id="fid_2785"
      unitRef="USD">164054</us-gaap:OtherExpenses>
    <ptn:PurchaseOfWarrantShares
      contextRef="From2025-01-01to2025-03-31_ptn_TwentyTwentyThreeEquityDistributionAgreementMember"
      decimals="-5"
      id="fid_2779"
      unitRef="USD">50000000.0</ptn:PurchaseOfWarrantShares>
    <ptn:ScheduleOfEquityDistributionAgreementTableTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_2105">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Nine Months Ended&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;March 31, 2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Cumulative from&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;inception&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Gross proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;547,803&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,744,542&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Fees&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(16,434&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(52,336&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Expenses&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(126,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;&lt;strong&gt;Net proceeds&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,027&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;531,369&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;721,061&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,565,406&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfEquityDistributionAgreementTableTextBlock>
    <ptn:EquityGrossProceedsShares
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2395"
      unitRef="Shares">217027</ptn:EquityGrossProceedsShares>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2394"
      unitRef="USD">547803</us-gaap:ProceedsFromOtherEquity>
    <ptn:EquityNetProceedsShares
      contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2403"
      unitRef="Shares">721061</ptn:EquityNetProceedsShares>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2408"
      unitRef="USD">1744542</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2397"
      unitRef="USD">16434</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2406"
      unitRef="USD">52336</us-gaap:ProceedsFromFeesReceived>
    <ptn:EquityExpensesProceeds
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2399"
      unitRef="USD">0</ptn:EquityExpensesProceeds>
    <ptn:EquityExpensesProceeds
      contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2404"
      unitRef="USD">-126800</ptn:EquityExpensesProceeds>
    <ptn:EquityNetProceedsShares
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2400"
      unitRef="Shares">217027</ptn:EquityNetProceedsShares>
    <ptn:EquityNetProceedsProceeds
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2401"
      unitRef="USD">531369</ptn:EquityNetProceedsProceeds>
    <ptn:EquityGrossProceedsShares
      contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2409"
      unitRef="Shares">721061</ptn:EquityGrossProceedsShares>
    <ptn:EquityNetProceedsProceeds
      contextRef="From2024-07-01to2025-03-31_ptn_CumulativeFromInceptionMember"
      decimals="0"
      id="fid_2402"
      unitRef="USD">1565406</ptn:EquityNetProceedsProceeds>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-12-13_ptn_StockWarrantsMember"
      decimals="INF"
      id="fid_2749"
      unitRef="USDPShares">1.88</us-gaap:SharesIssuedPricePerShare>
    <ptn:DescriptionOfExistingHolderPurchaseOfWarrants
      contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember"
      id="fid_2751">the Company agreed to adjust the exercise price of such portion of the December 2024 Existing Warrants to $0.875. Pursuant to the December 2024 Inducement Letter, the December 2024 Exercising Holder agreed to exercise, for cash, the December 2024 Existing Warrants to purchase an aggregate of 3,907,679 shares of common stock at the adjusted exercise price in exchange for the Company&#x2019;s agreement to issue to the December 2024 Exercising Holder Series C common stock purchase warrants to purchase 3,907,679 shares of common stock (the &#x201c;Series C Warrants&#x201d;) and Series D common stock purchase warrants to purchase 1,953,839 shares of common stock (the &#x201c;Series D Warrants&#x201d; and together with the Series C Warrants, the &#x201c;December 2024 Inducement Warrants,&#x201d; and the shares issuable upon exercise of the December 2024 Inducement Warrants, the &#x201c;December 2024 Inducement Warrant Shares&#x201d;)</ptn:DescriptionOfExistingHolderPurchaseOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-12-01to2024-12-13_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2753"
      unitRef="USD">3419219</us-gaap:ProceedsFromWarrantExercises>
    <ptn:WarrantsToPurchaseShares
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2714"
      unitRef="Shares">3233277</ptn:WarrantsToPurchaseShares>
    <ptn:DescriptionOfExistingHolderPurchaseOfWarrants
      contextRef="From2024-06-01to2024-06-20_ptn_StockWarrantsMember"
      id="fid_2723">(i) lower the exercise price to $1.88 per share for the 3,233,277 June 2024 Existing Warrants being exercised pursuant to the June 2024 Inducement Letter and (ii) issue to the June 2024 Exercising Holder an aggregate of 4,849,915 warrants to purchase shares of common stock, comprised of Series A common stock purchase warrants to purchase 2,727,273 shares of common stock (the &#x201c;June 2024 Series A Warrants&#x201d;) and Series B common stock purchase warrants to purchase 2,122,642 (of which 1,624,201 shares of common stock are subject to stockholder approval) shares of common stock (the &#x201c;June 2024 Series B Warrants&#x201d; and together with the June 2024 Series A Warrants, the &#x201c;June 2024 Inducement Warrants&#x201d;). The Company received aggregate gross proceeds of $6,078,561 from the exercise of the June 2024 Existing Warrants by the June 2024 Exercising Holder (the &#x201c;Warrant Inducement&#x201d;)</ptn:DescriptionOfExistingHolderPurchaseOfWarrants>
    <ptn:ExercisingHolderReleasedShares
      contextRef="From2024-07-01to2025-03-31_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2724"
      unitRef="Shares">1443277</ptn:ExercisingHolderReleasedShares>
    <ptn:ExercisingHolderReleasedShares
      contextRef="From2025-01-01to2025-03-31_ptn_StockWarrantsMember"
      decimals="0"
      id="fid_2786"
      unitRef="Shares">1443277</ptn:ExercisingHolderReleasedShares>
    <ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_2106">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Shares of Common&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Exercise Price per&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Latest Expiration&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Stock&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;May 2022 Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;66,666&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;12.50&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;May 11, 2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;October 2022 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;90,909&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;October 31, 2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;October 2023 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;117,925&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;October 20, 2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 2024 Private Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,831,503&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5.46&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;January 2024 Placement Agent Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;91,575&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.83&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;February 1, 2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;June 2024 Series B Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,885,632&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;June24,2029*&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 2024 Series C Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,907,679&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;December 17, 2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;December 2024 Series D Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,953,839&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;**&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;February 2025 Series E Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,688,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"&gt;August 12, 2030&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="11" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;* 1,624,201 shares expire on the five year anniversary following stockholder approval of the warrant issuance and the balance expire on June 24, 2029.&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="4" style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;** 1,953,839 shares expire on the five year anniversary following stockholder approval of the warrant issuance.&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</ptn:ScheduleOfStockPurchaseWarrantsTableTextBlock>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2025-03-31_ptn_MayTwoThousandTwentyTwoWarrantsMember"
      decimals="0"
      id="fid_2410"
      unitRef="Shares">66666</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2025-03-31_ptn_MayTwoThousandTwentyTwoWarrantsMember"
      decimals="INF"
      id="fid_2413"
      unitRef="USDPShares">12.50</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2025-03-31_ptn_MayTwoThousandTwentyTwoWarrantsMember"
      id="fid_2416">May 11, 2026</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"
      decimals="0"
      id="fid_2412"
      unitRef="Shares">90909</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"
      decimals="INF"
      id="fid_2415"
      unitRef="USDPShares">6.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoThousandTwentyTwoPlacementAgentWarrantsTwoMember"
      id="fid_2418">October 31, 2027</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"
      decimals="0"
      id="fid_2423"
      unitRef="Shares">117925</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"
      decimals="INF"
      id="fid_2422"
      unitRef="USDPShares">2.65</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2025-03-31_ptn_OctoberTwoZeroTwoThreePlacementAgentWarrantsMember"
      id="fid_2421">October 20, 2028</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"
      decimals="0"
      id="fid_2426"
      unitRef="Shares">1831503</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"
      decimals="INF"
      id="fid_2425"
      unitRef="USDPShares">5.46</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPrivateWarrantsMember"
      id="fid_2424">February 1, 2028</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"
      decimals="0"
      id="fid_2429"
      unitRef="Shares">91575</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="fid_2428"
      unitRef="USDPShares">6.83</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2025-03-31_ptn_JanuaryTwoZeroTwoFourPlacementAgentWarrantsMember"
      id="fid_2427">February 1, 2028</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2025-03-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"
      decimals="0"
      id="fid_2432"
      unitRef="Shares">1885632</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2025-03-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"
      decimals="INF"
      id="fid_2431"
      unitRef="USDPShares">1.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2025-03-31_ptn_JuneTwoThousandTwentyFourSerisBWarrantsMember"
      id="fid_2430">June24,2029</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2025-03-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember"
      decimals="0"
      id="fid_2411"
      unitRef="Shares">3907679</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2025-03-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember"
      decimals="INF"
      id="fid_2414"
      unitRef="USDPShares">0.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2025-03-31_ptn_DecemberTwoThousandTwentyFourSerisCWarrantsMember"
      id="fid_2417">December 17, 2029</ptn:LatestTerminationDate>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2025-03-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember"
      decimals="0"
      id="fid_2420"
      unitRef="Shares">1953839</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2025-03-31_ptn_DecemberToZeroTwoFourSeriesDWarrantsMember"
      decimals="INF"
      id="fid_2419"
      unitRef="USDPShares">0.88</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:SharesOfCommonStock
      contextRef="From2024-07-01to2025-03-31_ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember"
      decimals="0"
      id="fid_2764"
      unitRef="Shares">4688000</ptn:SharesOfCommonStock>
    <ptn:ExercisePricePerShareWarrantsOutstanding
      contextRef="From2024-07-01to2025-03-31_ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember"
      decimals="INF"
      id="fid_2763"
      unitRef="USDPShares">1.00</ptn:ExercisePricePerShareWarrantsOutstanding>
    <ptn:LatestTerminationDate
      contextRef="From2024-07-01to2025-03-31_ptn_FebruaryTwoZeroTwoFiveSeriesEWarrantsMember"
      id="fid_2765">August 12, 2030</ptn:LatestTerminationDate>
    <ptn:WarrantIssuanceShares
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2742"
      unitRef="Shares">1624201</ptn:WarrantIssuanceShares>
    <ptn:WarrantIssuance
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2743"
      unitRef="Shares">1953839</ptn:WarrantIssuance>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2744"
      unitRef="USD">176410</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2725"
      unitRef="USD">531817</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2745"
      unitRef="USD">205176</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2726"
      unitRef="USD">615716</us-gaap:StockOptionPlanExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_2107">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Weighted Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Term in &lt;/strong&gt;&lt;strong&gt;Years&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"&gt;&lt;strong&gt;Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding - June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,263,440&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6.11&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.2&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(14,338&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;4.50&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding - March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,249,102&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6.12&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;7.5&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Exercisable at March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;937,894&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10.77&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;5.9&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Expected to vest at March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,311,208&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8.6&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2433"
      unitRef="Shares">2263440</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance
      contextRef="From2024-07-01to2025-03-31"
      decimals="INF"
      id="fid_2436"
      unitRef="USDPShares">6.11</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2024-07-01to2025-03-31" id="fid_2444">P8Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-01to2025-03-31"
      decimals="INF"
      id="fid_2437"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-01to2025-03-31"
      decimals="INF"
      id="fid_2438"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-01to2025-03-31"
      decimals="INF"
      id="fid_2439"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-07-01to2025-03-31"
      decimals="INF"
      id="fid_2440"
      unitRef="USDPShares">4.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2453"
      unitRef="Shares">2249102</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance
      contextRef="From2024-07-01to2025-03-31"
      decimals="INF"
      id="fid_2441"
      unitRef="USDPShares">6.12</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2024-07-01to2025-03-31" id="fid_2445">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2450"
      unitRef="USD">0</ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExercisable>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2454"
      unitRef="Shares">937894</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumberEndingBalance3A>
    <ptn:shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice
      contextRef="From2024-07-01to2025-03-31"
      decimals="INF"
      id="fid_2442"
      unitRef="USDPShares">10.77</ptn:shareBasedCompensationArrangementByShareBasedPaymentsAwardOptionExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2024-07-01to2025-03-31" id="fid_2446">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2449"
      unitRef="USD">0</ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2455"
      unitRef="Shares">1311208</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpectedtovestNumberEndingBalance>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice
      contextRef="From2024-07-01to2025-03-31"
      decimals="INF"
      id="fid_2443"
      unitRef="USDPShares">2.80</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2024-07-01to2025-03-31" id="fid_2447">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2448"
      unitRef="USD">0</ptn:ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue>
    <ptn:UnvestedPerformanceBasedStockOptionsGranted
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2754"
      unitRef="Shares">418945</ptn:UnvestedPerformanceBasedStockOptionsGranted>
    <ptn:UnvestedPerformanceBasedStockOptionsGranted
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2727"
      unitRef="Shares">88911</ptn:UnvestedPerformanceBasedStockOptionsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-07-01to2021-06-30"
      decimals="0"
      id="fid_2728"
      unitRef="Shares">95167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-07-01to2022-06-30"
      decimals="0"
      id="fid_2729"
      unitRef="Shares">60566</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-07-01to2023-06-30"
      decimals="0"
      id="fid_2730"
      unitRef="Shares">238838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="fid_2731"
      unitRef="Shares">264945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits
      contextRef="From2025-01-01to2025-03-31"
      decimals="0"
      id="fid_2746"
      unitRef="USD">171281</ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits>
    <ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2732"
      unitRef="USD">513852</ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits>
    <ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits
      contextRef="From2024-01-01to2024-03-31"
      decimals="0"
      id="fid_2747"
      unitRef="USD">185019</ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits>
    <ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2733"
      unitRef="USD">555057</ptn:StockIssuedDuringPeriodValueShareBasedCompensationToRestrictedStockUnits>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_2109">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,374,980&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Vested &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(232,941&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:10pt"&gt;Expirations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,726&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"&gt;Outstanding at March 31, 2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,139,313&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="fid_2456"
      unitRef="Shares">1374980</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2457"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2458"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <ptn:RestrictedStockVestedInPeriod
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2459"
      unitRef="Shares">-232941</ptn:RestrictedStockVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2461"
      unitRef="Shares">2726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2460"
      unitRef="Shares">1139313</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber>
    <ptn:NumberOfOutstandingSharesOfRestrictedStockUnits
      contextRef="AsOf2025-03-31"
      decimals="0"
      id="fid_2734"
      unitRef="Shares">279700</ptn:NumberOfOutstandingSharesOfRestrictedStockUnits>
    <ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2735"
      unitRef="Shares">274549</ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits>
    <ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits
      contextRef="From2023-07-01to2024-03-31"
      decimals="0"
      id="fid_2736"
      unitRef="Shares">59842</ptn:UnvestedPerformanceBasedStockOptionsGrantedEstrictedStockUnits>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2020-07-01to2021-06-30"
      decimals="0"
      id="fid_2738"
      unitRef="Shares">22343</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2021-07-01to2022-06-30"
      decimals="0"
      id="fid_2739"
      unitRef="Shares">40707</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2022-07-01to2023-06-30"
      decimals="0"
      id="fid_2740"
      unitRef="Shares">152432</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="fid_2737"
      unitRef="Shares">184443</ptn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedRSU>
    <ptn:StockIssuedDuringPeriodValueRestrictedStockUnitshares
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2741"
      unitRef="Shares">54691</ptn:StockIssuedDuringPeriodValueRestrictedStockUnitshares>
    <ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmoun
      contextRef="From2024-07-01to2025-03-31"
      decimals="0"
      id="fid_2748"
      unitRef="USD">99482</ptn:WithholdingTaxesRelatedToRestrictedStockUnitsAmoun>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-07-01to2025-03-31" id="fid_2393">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;strong&gt;(14) SUBSEQUENT EVENTS&lt;/strong&gt; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;Sales Under 2025 Sales Agreement&lt;/em&gt; &#x2013; As disclosed in Note 13 above, the Company entered into the 2025 Sales Agreement. During the period from April 1, 2025 through and until May 14, 2025, the Company has sold 10,598,496 shares for gross proceeds of $2,296,532 under the at-the-market offering&#x201d; pursuant to the 2025 Sales Agreement and related prospectus.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;May 2025 Public Offering&lt;/em&gt; &#x2013; On May 8, 2025, the Company completed a public offering with participation from institutional and accredited investors of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the &#x201c;Series F Warrants&#x201c;), Series G warrants to purchase up to 7,324,119 shares of common stock (the &#x201c;Series G Warrants&#x201c;), and Series H warrants to purchase up to 7,324,119 shares of common stock (the &#x201c;Series H Warrants&#x201c;), at a combined public offering price of $0.15 per share of common stock and accompanying warrants (the &#x201c;Offering&#x201c;). The Offering was made pursuant to the Company&#x2019;s registration statement on Form S-1 (Registration No. 333-286280) previously filed with the SEC and declared effective on May 6, 2025.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Series F Warrants have an exercise price of $0.30 per share, are immediately exercisable and expire on the five-year anniversary of the original issuance date, subject to the certain terms as defined in such warrant. The Series G Warrants have an exercise price of $0.15 per share, are immediately exercisable and expire on the earlier of (i) the 24-month anniversary of the original issuance date or (ii) the expiration of the FDA Exercise Period (as such term is defined in the Series G Warrant). The Series H Warrants will be issuable to the holder upon their exercise of the Series G Warrants, will have an exercise price of $0.225 per share, will be immediately exercisable upon issuance and will expire on the 24-month anniversary of its issuance date.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;A.G.P. acted as lead placement agent and Laidlaw &amp;amp; Company (UK) Ltd., as co-placement agent in the Offering. The Company paid the placement agents a cash fee equal to 7.0% of the gross proceeds raised in the Offering and reimbursed the placement agents for out-of-pocket expenses, including the reasonable fees of legal counsel, in an amount equal to $85,000.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;The Company received aggregate net proceeds from the Offering of $931,715. The Company intends to use the net proceeds from the Offering primarily for working capital and general corporate purposes.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"&gt;&lt;em&gt;NYSE American Delisting&lt;/em&gt; &#x2013; On May 7, 2025, the Company announced that it has received a notice from the NYSE American LLC (&#x201c;NYSE American&#x201d;) stating that the NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Company&#x2019;s common stock. NYSE American commenced delisting proceedings in connection with the foregoing determination, and trading in the Company&#x2019;s common stock was suspended on May 7, 2025. Since May 8, 2025 the Company&#x2019;s common stock has traded on the Pink Market of the OTC Markets Group under the trading symbol &#x201c;PTNT&#x201d;. The Company has a right to a review of NYSE Regulation&#x2019;s determination to delist the Company&#x2019;s common stock by the Listings Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange. The Company is currently assessing the viability of such an appeal.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-04-01to2025-05-14_us-gaap_SubsequentEventMember_ptn_TwoThousandTwentyFiveSalesAgreementMember"
      decimals="0"
      id="fid_2787"
      unitRef="Shares">10598496</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2025-04-01to2025-05-14_us-gaap_SubsequentEventMember_ptn_TwoThousandTwentyFiveSalesAgreementMember"
      decimals="0"
      id="fid_2788"
      unitRef="USD">2296532</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ptn:DescriptionOfPublicOffering
      contextRef="From2025-05-01to2025-05-08_us-gaap_SubsequentEventMember"
      id="fid_2789">public offering with participation from institutional and accredited investors of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the &#x201c;Series F Warrants&#x201c;), Series G warrants to purchase up to 7,324,119 shares of common stock (the &#x201c;Series G Warrants&#x201c;), and Series H warrants to purchase up to 7,324,119 shares of common stock (the &#x201c;Series H Warrants&#x201c;), at a combined public offering price of $0.15 per share of common stock and accompanying warrants (the &#x201c;Offering&#x201c;)</ptn:DescriptionOfPublicOffering>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-08_us-gaap_SubsequentEventMember_ptn_SeriesFWarrantsMember"
      decimals="INF"
      id="fid_2759"
      unitRef="USDPShares">0.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-08_us-gaap_SubsequentEventMember_ptn_SeriesGWarrantsMember"
      decimals="INF"
      id="fid_2791"
      unitRef="USDPShares">0.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-08_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_2792"
      unitRef="USDPShares">0.225</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ptn:EquityIssuanceCostsPercentage
      contextRef="AsOf2025-05-08_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_3187"
      unitRef="Pure">0.070</ptn:EquityIssuanceCostsPercentage>
    <us-gaap:LegalFees
      contextRef="From2025-05-01to2025-05-08_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_2758"
      unitRef="USD">85000</us-gaap:LegalFees>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-05-01to2025-05-08_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_2760"
      unitRef="USD">931715</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
